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Summary 
Chikungunya virus (CHIKV) is a member of the genus alphavirus and 
family Togaviridae. CHIKV is transmitted in humans by mosquitoes and is 
responsible for a disease characterized by high fever, rash and arthritis. The 
viral genome has a positive polarity and encodes four non-structural and 
three structural proteins that are essential for the virus life cycle. In the past 
decade, the incidence of CHIKV infection has increased dramatically, 
affecting several million people worldwide. To date, there is no licensed 
vaccine or antiviral treatment available to mitigate this disease. A prominent 
feature of CHIKV pathogenesis is its capacity to massively replicate in 
infected patients and in vitro in mammalian cells. This work is focused on 
investigating a cellular response that CHIKV should evade to achieve a high 
level of replication, the unfolded protein response (UPR). The UPR pathways 
are responsible for sensing the accumulation of viral proteins during infection 
and limiting viral replication.  
Firstly, an in vitro CHIKV infection model was established 
demonstrating that HEK-293 cells are susceptible to alphavirus infection and 
support prolific CHIKV replication. An in vivo infection model was also 
characterized using IFNα/βR deficient (A-129) mice that display key human 
CHIKV pathologies, such as high viremia, inflammation and musculopathy.  
The interactions of CHIKV with three major branches of the UPR, i.e. 
ATF-6, IRE-1 and PERK were investigated using biochemical and molecular 
techniques to monitor protein transcription, translation and activation. This led 
to the discovery that CHIKV employed unique strategies to overcome cellular 
ER stress and UPR that are not used by the closely related Sindbis virus. 
Early during CHIKV replication, the ATF-6 pathway was activated, while the 
	   ix	  
activation of IRE-1 was delayed. Importantly, the PERK pathway of the UPR, 
which initiates protein translation arrest and apoptosis during ER stress, was 
suppressed during CHIKV replication. This occurred through suppression of 
the phosphorylation of PERK pathway component, eIF2α. A viral factor, nsP4, 
was shown to suppress the phosphorylation of eIF2α, even in the presence of 
ER stress-inducing drugs. Mechanistically, experiments utilizing selective 
UPR-specific drugs and employing sophisticated techniques, such as mass-
spectrometry and over-expression systems, suggests that CHIKV suppresses 
the phosphorylation of eIF2α by utilizing the cellular phosphatase complex 
CReP-PP1c, in conjunction with nsP4.  
Simultaneously, a cellular UPR-associated chaperone, HSP-90 was 
found to be pro-viral during CHIKV replication. HSP-90 was shown to play a 
significant role in CHIKV replication through its specific interactions with 
CHIKV replicase complex proteins, nsP3 and nsP4. Drugs targeting HSP-90 
were shown to be effective against CHIKV replication in cell culture. 
Furthermore, treatment of animals with HSP-90 inhibitors reduced CHIKV 
replication and also reduced CHIKV-induced inflammation and swelling in 
muscles.  
Overall, this study has shown that the host UPR pathway is integral to 
the successful replication of CHIKV and provides evidence that CHIKV 
establishes infection in the host by suppressing the host UPR machinery. The 
study also demonstrates that small molecule drugs targeting UPR 
components could potentially be used to limit CHIKV replication in human 
patients and reduce the long-term sequelae of infection, such as joint swelling 
and arthritis.  
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Chapter 1. Introduction  
1.1 Arboviral infections 
The term “arboviral infection” is used to define the arthropod-borne 
viral infections that are transmitted mainly by mosquitoes. Other vectors for 
arboviral transmission include biting flies, midges and ticks (Calisher, 1994). 
Arboviruses are classified according to their antigenicity, morphology and 
replicative mechanisms. Some of the most clinically significant arboviruses 
belong to the families of Togaviridae, Flaviviridae, Bunyaviridae and 
Reoviridae. 
1.2 Alphaviruses of the family Togaviridae 
There are 26 known alphaviruses, which have a wide host range. 
Antibodies against alphaviruses have been found in marsupials, rodents, 
reptiles, fish, birds, humans, horses and domestic pets (Fields et al., 2001).  
However, humans are almost exclusively incidental (dead-end) hosts for 
several of these viruses. In general, alphaviruses are divided into viruses that 
cause human diseases characterized by rash and arthritis that are primarily 
found in the ‘Old World’, such as Chikungunya (CHIKV), O’nyong-nyong 
(ONNV), Sindbis (SINV), Ross River (RRV), Barmah Forest (BFV) and 
Mayaro virus (MAYV), and viruses that cause encephalitis, which are 
primarily found in the ‘New World’ such as Western Equine Encephalitis virus 
(WEEV), Venezuelan Equine Encephalitis virus (VEEV) and Eastern Equine 
Encephalitis virus (EEEV) (Fields et al., 2001) (Table-1). The first ‘New World’ 
alphavirus to be cultured was WEEV in 1930 (Meyer et al., 1931). The virus 
was cultured from the central nervous system tissues of two horses involved 
in an epidemic of equine encephalitis that occurred in the San Joaquin valley 
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of California (Meyer et al., 1931). The first clear association of an alphavirus 
with arthritic disease was reported in 1953 when CHIKV was isolated from the 
blood of individuals in Tanzania with severe arthritis (Robinson, 1955; Ross, 
1956). 
 
Table-1: List of ‘Old World’ and ‘New World’ alphaviruses causing 
known human diseases (Table adapted from Fields Virology 4th edition) 
Alphaviruses Epidemics Disease caused Distribution 




‘Old World’ alphaviruses 
CHIKV Yes          +                     -                         - Africa, Asia, Europe 
ONNV Yes          +                     -                         - Africa 
SINV Yes          +                     -                         - Scandinavia 
RRV Yes          +                     -                         - Australia, Oceania 
SFV No          -                      +                        - Africa 
MAYV Yes          +                     -                         - South America 
BFV No          +                     -                         - Australia 
‘New World’ alphaviruses 
WEEV Yes          -                      -                        + North & South 
America 
EEEV Yes          -                      -                        + North & South 
America 
VEEV Yes          -                      +                        - South & Central 
America 
 
1.3 Chikungunya virus & its classification 
CHIKV belongs to the genus alphavirus and family Togaviridae. The 
name Chikungunya refers to the stooped posture (Bantu language of the 
Makonde tribe) that patients obtain due to the frequent and debilitating joint 
pain occurring during CHIKV infection (Enserink, 2006). CHIKV is a member 
of the Semliki Forest virus (SFV), (Eurasia) antigenic complex, which also 
includes ONNV (which has spread in Africa), MAYV (in South America) and 
RRV (in Australia). A phylogenetic divergence tree constructed from partial 
gene sequences from various ‘Old World’ and ‘New World’ alphaviruses is 
shown in Fig-1-1. Several of these viruses from the SFV antigenic complex, 
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including CHIKV, can cause acute or persistent arthralgia in humans (Powers 
et al., 2000).  
 
 
Fig-1-1: Phylogenetic analysis of ‘Old World’ and ‘New World’ 
alphaviruses. Partial gene sequences from E1 envelope glycoprotein from 
different alphaviruses were used to construct this evolutionary tree using a 
Neighbor-Joining program. This figure is adapted from (Powers et al., 2001). 
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1.3.1 Discovery, epidemiology and natural history 
CHIKV was first isolated from a febrile patient in Tanzania in 1952 
(Robinson, 1955). CHIKV is thought to have originated in Africa, where two 
phylogenetic groups with distinct genotypic and antigenic characteristics have 
been identified. These include the West African phylogenetic group and the 
East, Central, and Southern African (ECSA) phylogenetic group that also 
includes an Asian genotype (Powers et al., 2000). Since its first isolation, 
frequent CHIKV epidemics have occurred primarily in Africa and Asia. These 
epidemics were mainly transmitted by the mosquitos Aedes aegypti and, to a 
lesser extent, Aedes albopictus. One of the largest epidemics of CHIKV ever 
recorded occurred between 2004-2011 (Jaffar-Bandjee et al., 2010; Ng and 
Hapuarachchi, 2010; Schwartz and Albert, 2010) and this was associated 
with an emergence of a clade of virus that was efficiently transmitted by 
Aedes albopictus (Jaffar-Bandjee et al., 2010; Ng and Hapuarachchi, 2010; 
Schwartz and Albert, 2010). Over the past 30-40 years Aedes albopictus has 
dramatically expanded globally in its geographical distribution (Lambrechts et 
al., 2010). The 2004-2011 epidemic, which began in Kenya, swept through 
Indian Ocean islands to India (~1.4-6 million cases) reaching South East Asia 
in 2010 (Ng and Hapuarachchi, 2010; Schwartz and Albert, 2010). In the 
same epidemic in French Reunion islands in 2005-2006, ~266,000 cases 
(~38% of total local population) of CHIKV infections were reported (Renault et 
al., 2007). Outside the traditional endemic areas, the first transmission of 
CHIKV in Europe occurred in 2007 in Italy (Rezza et al., 2007) (>200 cases) 
and in France in 2010 (Grandadam et al., 2011). Due to international travel, 
CHIKV cases have now been reported in nearly 40 countries including 
Americas (Frank et al., 2011; Gibney et al., 2011; Mizuno et al., 2011; 
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Powers, 2011) (Fig-1-2). Since the first reported locally transmitted case of 
CHIKV infection in Saint Martins, the virus has now spread to 17 countries or 
territories in the Caribbean. In the second-quarter of year 2014, nearly 
100,000 suspected and tens of thousands of laboratory confirmed cases have 
been reported in Dominican Republic, Martinique, Guadeloupe, Haiti and 
Saint Martins (Charrel et al., 2014; Fischer et al., 2014; Leparc-Goffart et al., 
2014). Notably, this outbreak also signified the first endemic transmission of 
CHIKV within the United States. 
 
 
Fig-1-2: A map showing global distribution of CHIKV infections (source 
CDC website & information up to date as of July 2014). 
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1.3.2 Reservoirs and transmission cycle  
Human beings serve as the reservoir of CHIKV during epidemic 
periods. Normally, the main reservoirs are monkeys, rodents, bird’s etc. 
(Inoue et al., 2003; Wolfe et al., 2001). Primates, such as monkeys, develop 
viremia; however, they show no apparent clinical manifestations (Inoue et al., 
2003; Wolfe et al., 2001). This suggests that CHIKV may amplify in monkeys 
when the herd immunity is low and could potentially increase the chance of 
virus transmission in to humans. Two distinct transmission cycles for CHIKV 
have been proposed. The first is a sylvatic cycle in Africa that involves virus 
transmission between forest mosquitoes and non-human primates with 
accidental spill in to humans (Wolfe et al., 2001). The other transmission 
cycle, such as the one seen in Asia, Indian Ocean, Africa and Europe, 
involves mosquito-human-mosquito virus transmission (Rezza et al., 2007). 
1.3.3 Transmission vectors 
The main vectors for CHIKV in Asia and in the Indian Ocean region 
are Aedes aegypti and Aedes albopictus (Burt et al., 2012). A broader range 
of Aedes species (Aedes furcifer, Aedes vittatus, Aedes fulgens, Aedes 
luteocephalus, Aedes dalzieli, Aedes vigilax, Aedes camptorhynchites) 
transmit the virus in Africa, and Culex annulirostris, Mansonia uniformis, and 
Anopheles mosquitoes have also occasionally been implicated in 
transmission (Jupp and McIntosh, 1990; Jupp et al., 1981; Lam et al., 2001). 
In India, the dominant carrier of CHIKV is Aedes aegypti, which breeds mainly 
in stored fresh water in urban and semi-urban environments (Yergolkar et al., 
2006). The presence of Aedes albopictus in the Indian Ocean region is 
historically well-known (Enserink, 2006; Knudsen, 1995), and it is very difficult 
to avoid Aedes albopictus bites and also to control this mosquito species in 
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tropical, human-modified ecosystems with modern infrastructures, irrigation, 
and massive solid waste production (Knudsen, 1995). Moreover, Aedes 
albopictus has been imported to Europe and Americas through the trade in 
used tyres and of ornamental plants (Knudsen, 1995), suggesting a potential 
risk of CHIKV transmission in these regions.  
1.3.4 Genome microevolution 
During the largest CHIKV epidemic (2004-2011), viruses from the 
ECSA phylogenetic group dominated infections in Indian Ocean and Asia. 
Interestingly, at the beginning of outbreak in 2004-2005, CHIKV was 
transmitted to humans mainly by Aedes aegypti (Arankalle et al., 2007) but 
during the outbreak a mutation in the viral genome occurred at residue 226 of 
the membrane fusion glycoprotein E1 (E1 A226V, substitution of alanine with 
valine at 226 residue) (Schuffenecker et al., 2006). The A226V adaptive 
mutation in CHIKV has increased its transmissibility by the vector Aedes 
albopictus (Tsetsarkin et al., 2007) and at the same time viral fitness was 
marginally compromised in Aedes aegypti vector (Tsetsarkin et al., 2007; 
Vazeille et al., 2007). Despite its apparent high level of fitness and frequent 
epidemics, the CHIKV A226V adaptive mutation didn’t occur in all the CHIKV 
genetic backgrounds and appears to have been limited to the strains 
belonging to ECSA lineages (Tsetsarkin et al., 2011). Nevertheless, the 
demonstration that CHIKV adaptation can lead to explosive epidemics is a 
warning sign that counter measures need to be in place to limit virus spread. 
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1.3.5 Disease and symptoms 
The clinical symptoms during CHIKV infection have several similarities 
with Dengue fever. The incubation period ranges from an average of 2-4 
days, followed by abrupt febrile illness (temperature usually more than 
38.9ºC), poly-arthralgia (over 90% of the cases) and maculopapular rash (a 
form of microvasculitis) (Borgherini et al., 2007; Queyriaux et al., 2008). The 
viremic phase (average 107 virus/ml) lasts for 3-10 days after the onset of 
symptoms (Thiberville et al., 2013). Anti-alphavirus IgM antibodies have been 
reported to persist particularly for CHIKV compared to other acute viral 
infections. This could be an indicator of virus and/or viral antigenic 
persistence with continuing stimulation of the humoral response by 
mechanisms that have not yet been fully characterized (Calisher et al., 1986; 
Kurkela et al., 2005). High levels of IgM during SINV infections were also 
reported in more recent cohort studies (in over 30% of patients from 6 months 
up to 4 years) and some patients were found to be positive for autoimmune 
Rheumatoid Factor (RF) (Niklasson et al., 1988). More recently, the presence 
of high levels of anti-CHIKV IgM antibodies has been also reported in a cohort 
of Indian patients with post-CHIKV rheumatoid arthritis-like illness (Chopra et 
al., 2008).  
The pain associated with CHIKV-induced arthralgia can be 
excruciating and is usually symmetrical, involving more than one joint. 
Fingers, wrists, elbows, toes, ankles and knees are most commonly affected, 
as described for most of the other arthritogenic alphaviruses (Tesh, 1982). 
Swelling is a common feature and joints that are already damaged by 
underlying disorders, e.g. osteoarthritis, are particularly susceptible (Dupuis-
Maguiraga et al., 2012). Resolution of arthralgia occurs ~2 weeks after acute 
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onset of fever and most patients recover fully (Brighton et al., 1983). 
However, many patients also develop persistent arthralgia, which could 
persist for months or even years. Recently, many clinical studies have also 
concluded that a substantial proportion of people infected with CHIKV have 
persistent arthralgia and that most of these cases develop destructive arthritis 
over time (Borgherini et al., 2008; Bouquillard and Combe, 2009; Brighton et 
al., 1983; Malvy et al., 2009; Sissoko et al., 2009). It has also been reported 
that individuals with older ages (45 years and above) are significantly more 
susceptible to persistent arthralgia (Gerardin et al., 2013).   
The other symptoms of CHIKV infection include myalgia (muscle 
pain), headache, edema of the extremities and gastrointestinal complaints 
(Lakshmi et al., 2008). Skin lesions (vesciculobullous lesions with 
desquamation) are also found to be associated with CHIKV infection (Robin 
et al., 2010). Unusual complications such as hepatitis, pneumonia, mild 
hemorrhage, pre-renal failure, cardiologic manifestations (heart failure, 
myocarditis) and neurologic diseases were also reported from the 
hospitalized cohorts of patients and may be related to several underlying 
medical conditions (Sankari et al., 2008; Tandale et al., 2009). 
1.3.6 CHIKV is a major health concern 
Since the first recorded CHIKV epidemic (Robinson, 1955), human 
CHIKV infections have been documented in Burma, Thailand, Cambodia, 
Vietnam, India, Sri Lanka, and the Philippines (Mackenzie et al., 2001). 
Epidemics were reported in the Philippines in 1954, 1956, and 1968 and in 
south Sumatra, Java, Timor, Sulawesi, and the Moluccas Islands between 
1982 and 1985 (Mackenzie et al., 2001; Reiter et al., 2006) and also in 
Indonesia (Kosasih et al., 2013; Laras et al., 2005). CHIKV infection occurs in 
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West Africa, from Senegal (Diallo et al., 1999) to Cameroon (Kuniholm et al., 
2006), Democratic Republic of the Congo (Pastorino et al., 2004), Nigeria 
(Moore et al., 1974), Angola (Filipe and Pinto, 1973), Uganda (Kalunda et al., 
1985), Guinea, Malawi, Central African Republic, and also in southern Africa 
(Thiberville et al., 2013). CHIKV infections are affecting millions of people in 
the Indian subcontinent (Ravi, 2006). Imported CHIKV cases have also been 
reported in Germany, Switzerland, Italy, Norway, China and French Guyana 
(Thiberville et al., 2013). Earlier thought to be free from CHIKV infections, the 
Americas have now seen a massive surge in detection of CHIKV infections 
(Fischer et al., 2014). The vast scale and sudden emergence of CHIKV 
outbreaks in this region underlies how little we know about the biology and 
pathology of CHIKV. CHIKV infections are usually symptomatic and the 
proportion of people requiring medical attention is thought to be much higher 
than for other alphavirus infections. Recent seroprevalence studies suggest 
that the number of asymptomatic CHIKV cases is only between 3-9% 
(Thiberville et al., 2013). In children, CHIKV infection is associated with a high 
incidence of dermatological and neurological complications (Robin et al., 
2010; Sebastian et al., 2009). Pregnant women are also at risk of transmitting 
virus to their newborns and vertical transmission of CHIKV has been reported 
during recent Reunion outbreaks (Gerardin et al., 2008). The death rates 
associated with CHIKV infection have been estimated to be 1:1000, with most 
mortalities occurring in neonates, adults with underlying conditions and the 
elderly (Schwartz and Albert, 2010). Overall, the recent emergence of CHIKV 
in many parts of the world indicates that it is a growing health burden affecting 
large human populations.  
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1.3.6.1 Differential diagnosis  
As CHIKV and dengue virus (DENV) share common mosquito vectors, 
they are often found in same areas and incidences of dual infections have 
also been reported (Thein et al., 1992). CHIKV infection is often 
misdiagnosed as dengue fever due to overlap in many aspects of their early 
clinical presentations. The presence of rash, conjunctivitis, arthralgia and 
myalgia are common in both diseases. In Asia, the CHIKV affected areas 
overlap with DENV endemic areas and provide opportunities for mosquitoes 
to become infected with both the viruses (Mackenzie et al., 2001; Myers and 
Carey, 1967). Co-infections with DENV and CHIKV have been reported in 
Thailand, India (Chahar et al., 2009) and in a German traveler in 2009 
(Schilling et al., 2009). Subsequent serological investigations indicated that 
the two viruses could co-exist in the same human host (Leroy et al., 2009). 
Although there are enough cases reported to conclude that CHIKV-DENV co-
infections exist, based on limited data it is difficult to comment on whether 
there is increased severity of illness in patients with DENV-CHIKV co-
infections. Additional clinical information is needed to determine the influence 
of co-infections on clinical expression of CHIKV and DENV fever.  
1.3.7 Structure, genome organization and replication cycle 
The CHIKV virion has icosahedral symmetry where the capsid is 
enclosed within a lipid envelope and forms virus particles of ~60-70nm in 
diameter (Voss et al., 2010). The CHIKV virion is sensitive to desiccation and 
also to higher temperatures, such as ≥58ºC (Thiberville et al., 2013). The viral 
genome is a single-stranded RNA molecule of ~12kb in size and of positive 
polarity. The 5’ end of the RNA molecule has a 7-methyl-guanosine (7mG) 
cap and there is a poly-A tail at the 3’ end (Khan et al., 2002) (Fig-1-3). The 
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viral genome is read in two open reading frames (ORF) where the 5’ ORF is 
translated from the genomic RNA and codes for 4 non-structural proteins 
(nsPs): nsP1 contains methyl transferase and guanyl transferase activities; 
nsP2 is a helicase/protease; nsP3 is an accessory protein involved in RNA 
synthesis and nsP4 is the RNA-dependent RNA polymerase (Fig-1-3). The 3’ 
ORF is translated from a sub-genomic 26S RNA and encodes for Capsid (C), 
envelope glycoproteins (E1 & E2) and small peptides such as E3 and 6K 
(Simizu et al., 1984; Strauss and Strauss, 1994; Voss et al., 2010) (Fig-1-3).  
The translation of genomic RNA produces two different polyproteins 
P123 and P1234 (Jose et al., 2009). The translation read-through of an opal 
stop codon present between nsP3 and nsP4 results in the production of 
P1234 (Jose et al., 2009). The efficiency of this translation read-through 
varies between 10-20% among alphaviruses (Li and Rice, 1993). Therefore, 
the predominant polyprotein product is P123 compared to P1234 during 
alphavirus replication (Jose et al., 2009). These polyproteins are processed 
by a virus-encoded protease, which is located in the nsP2 protein (Ding and 
Schlesinger, 1989; Hardy and Strauss, 1989). The cleavage at the nsP1-nsP2 
site occurs in cis or trans in P12. However this site is cleaved only in trans in 
P123 or P1234. Similarly, the cleavage at the nsP2-nsP3 site occurs only in 
trans in P123 or P1234. The nsP3-nsP4 site in P1234 is cleaved efficiently in 
cis in P1234 but not in P34 (Shirako and Strauss, 1994). Due to these 
differential polyprotein processings during alphavirus replication P123 and 
free nsP4 are the major translation products in the early phase of replication 
(de Groot et al., 1990). In the late phase of replication P123 is processed 
rapidly and P34 is produced in excess compared to free nsP4 (de Groot et al., 
1990). This coupled with active degradation of nsP4 by the N-end rule 
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pathway keeps the free nsP4 levels very low in the late phase of the 
alphavirus replication cycle (de Groot et al., 1991; Shirako and Strauss, 
1994).  
Being a RNA-dependent RNA polymerase (RdRP) activity containing 
protein, alphavirus nsP4 also contains common GDD motifs, which are 
present in many other viral-encoded RdRPs (Kamer and Argos, 1984). It is 
believed that the C-terminus of alphavirus nsP4 is somewhat homologous to 
other viral RdRPs, but the N-terminus region is variable and not conserved 
(Hahn et al., 1989). The N-terminus of nsP4 is predicted to facilitate its 
interaction with other nsPs and also host factors during virus replication (Fata 
et al., 2002; Shirako et al., 2000). The nsP4 of alphavirus is also known to 
possess terminal adenylate transferase activity, which adds non-template 
adenines to the 3’ end of the acceptor RNA molecule, suggesting its role in 
the synthesis of the viral genomic poly-A tail (Tomar et al., 2006). 
Replication of alphaviruses occurs in cytoplasmic vacuoles, which are 
derived from membranes from the ER and lysosomes (Froshauer et al., 
1988). The viral non-structural proteins make the replicase complex, together 
with host factors (Barton et al., 1991; Kujala et al., 2001). In the early stages 
of the replication cycle, when P123 and free nsP4 are abundant, these 
proteins make a replicase complex, which synthesizes minus-strand viral 
RNA using genomic RNA as a template (Shirako and Strauss, 1990, 1994; 
Strauss et al., 1992). As the replication progresses, P123 is cleaved into 
individual nsPs, that form another replicase complex, together with the host 
factors (Strauss and Strauss, 1994). This replicase complex now efficiently 
synthesizes plus-strand viral RNA (Strauss and Strauss, 1994). It is 
suggested that a short-lived intermediate replicase complex could also exist 
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that contains nsP1, P23 and nsP4. The intermediary complex may synthesize 
both plus- and minus-strand viral RNAs during replication (Gorchakov et al., 
2008; Lemm et al., 1998; Wang et al., 1994). Both plus-strand and sub-
genomic viral RNA are synthesized exclusively during the late replication 
stage (Strauss and Strauss, 1994). The plus-strand RNA could be 
synthesized from either a genomic or a sub-genomic promoter. The sub-
genomic promoter yields ~3 times more sub-genomic RNA compared to the 
full length genomic RNA during replication (Raju and Huang, 1991) and codes 
for viral structural proteins C, E3, E2, 6K and E1. 
Alphavirus proteins serve diverse functions in both virus replication 
and in utilizing host cellular machinery. The list of known viral and host 
interacting protein functions described for various alphavirus proteins are 
presented in Table-2. 
 
Fig-1-3: Genome organization of CHIKV. The CHIKV genome reads in two 
ORFs and translation products are further processed by the viral-encoded 
protease or host proteases. The polyprotein processing results in the 
maturation of individual CHIKV proteins that assist in the formation of active 
viral replication complexes.  
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Known viral functions, 
acquired from (Strauss 
and Strauss, 1994). 
Other host functions 
nsP1 535 Capping of viral mRNA. Actin rearrangement for virus 
replication in SFV 
(Laakkonen et al., 1998). 
 
Translocation of virus 
replication complex to 
endosomal compartment in 
SFV (Salonen et al., 2003). 
nsP2 798 Capping of viral mRNA. 
 
Processing of viral 
polyprotein-1234. 
 
Possess Protease, NTPase 
and Helicase activities. 
Induction of cytotoxic effects 
in SINV & CHIKV (Fros et 
al., 2013; Garmashova et al., 
2006). 
 
Suppression of antiviral 
response in SINV & CHIKV 
(Frolova et al., 2002; Fros et 
al., 2010). 
nsP3 530 Synthesis of viral sub-
genomic mRNA. 
Inhibition of stress-granule 
assembly in SINV (Fros et 
al., 2012). 
nsP4 611 Synthesis of viral genomic 




Modulation of the Unfolded 
Protein Response in CHIKV 
(Rathore et al., 2013). 
 
Interaction with HSP-90 for 
virus replication in CHIKV 
(Rathore et al., 2014). 
 
Interaction with G3BP1 and 
G3BP2 for virus replication in 
SINV (Cristea et al., 2010). 
C 261 Viral genome encapsidation. Inhibition of cellular 
transcription in VEEV 
(Garmashova et al., 2007a). 
E3 64 Virus maturation. Not known 
E2 423 Virion assembly and viral 
budding together with E1. 
Not known 
6K 61 Virion assembly. Formation of ion channels in 
the cell membranes in RRV 
and BFV (Melton et al., 
2002). 
E1 439 Virion assembly and 
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Structurally, E1 and E2 are arranged in a heterodimeric form in the 
viral envelope for viral attachment and membrane fusion. E1 is a class-II 
fusion protein and is responsible for viral fusion to the cell membrane by a low 
pH triggered process of endosomal acidification. Upon acidification, E1 
trimers are inserted in the endosomal membrane through its hydrophobic 
fusion peptide and they refold to form a hairpin like structure. It is noteworthy 
that cholesterol is required for both cell membrane fusion (viral entry) and 
budding during the alphavirus infection cycle (Schwartz and Albert, 2010; 
Solignat et al., 2009). The translocation of the E3-E2-6K-E1 polyprotein to the 
ER and its cleavage at E3 and 6K are important for virus maturation (Lobigs 
et al., 1990; Sanz and Carrasco, 2001). 
In general, virus enters the host cell by receptor-mediated endocytosis 
where upon the acidic environment of the endosome triggers conformational 
changes in the viral envelope, thereby releasing the nucleocapsid in to the 
cytoplasm (1). Upon internalization, the RNA genome is translated into a 
precursor polypeptide and processed by viral and host proteases into mature 
non-structural proteins and their cleavage intermediates (2). These proteins 
help form the viral replication complex, where the synthesis of a full length 
negative-strand RNA intermediate occurs (3). This newly synthesized 
negative-strand RNA intermediate now serves as a template for synthesis of 
both sub-genomic (26S) and genomic  (49S) RNA (4). The sub-genomic RNA 
drives the synthesis of the C-pE2-6K-E1 polyprotein precursor that is further 
processed by autoproteolysis and serine proteases (5). Finally, synthesized 
glycoproteins mature in the ER and the virion buds out to plasma membrane 
through trans-Golgi network (6) (Schwartz and Albert, 2010) (Fig-1-4). 
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Fig-1-4: Life cycle (replication cycle) of CHIKV infection. The events in 
CHIKV life cycle include (1) virus entry, (2) processing of polyprotein, (3) 
assembly of replication complex, (4) synthesis of genomic and sub-genomic 
RNA, (5) translation and maturation of glycoproteins, and finally (6) budding 
of mature virion from the plasma membrane. The replication complex consists 
of virus non-structural proteins, nsP1, nsP2, nsP3 and nsP4. While nsP1, 
nsP2, nsP3 and nsP4 are all cytoplasmic in their sub-cellular localizations, 
nsP2 is also known to translocate in the nucleus. The information contained in 
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1.3.8 Pathogenesis 
1.3.8.1 Tissue tropism 
CHKV shows broad tissue tropism, affecting several tissues:  
• Skin – skin lesions, including vesiculobullous lesions with 
desquamation and aphthous like ulcers, are reported in CHIKV 
infected children (Robin et al., 2010; Valamparampil et al., 2009).  
• Brain – CHIKV infection is also reported to affect the central nervous 
system (Fig-1-5) and has been found to be associated with seizures, 
meningoencephalopathy, myelitis and choroiditis. Meningoencephalitis 
and deaths have been observed in neonates hospitalized with severe 
CHIKV infection (Economopoulou et al., 2009; Lewthwaite et al., 
2009).  
• Muscles and joints- CHIKV antigens have also been detected in 
human myogenic precursors such as satellite cells (Ozden et al., 
2007) (Fig-1-5). Indeed, another closely related alphavirus, RRV, was 
also shown to primarily target bone, joint and skeletal muscle tissues 
of hind limbs in the mouse model (Morrison et al., 2006). Also, RRV-
infected mice suffered extensive damage to striated muscles, 
eventually causing deaths (Murphy et al., 1973). 
 
Whether organs like the kidney, liver, heart etc. become infected 
during the CHIKV infection in humans is still not known. However, reports of 
unusual complications, such as mild hemorrhage, pre-renal failure and 
cardiologic manifestations (heart failure, myocarditis), suggest that these 
organs may be susceptible to CHIKV infection (Economopoulou et al., 2009). 
Unfortunately, the available information on virus tropism is still not sufficient to 
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fully understand the CHIKV target organs and this needs to be thoroughly 
studied to better understand the virus pathogenesis. 
1.3.8.2 Cellular tropism 
Evidence supports that CHIKV infection and replication can occur in 
several cell culture models, including fibroblasts (chick embryo fibroblast like 
cells, mouse L929 & human lung fibroblast, MRC-5 cells), epithelial cells 
(Vero, HeLa, HEp-2, BEAS-2B), hepatocytes (human HuH-7), a 
neuroblastoma cell line (SH-SY5Y) and melanocytes (human SK-MEL) 
(Hahon and Zimmerman, 1970; Schwartz and Albert, 2010; Sourisseau et al., 
2007). However, CHIKV could bind but not replicate in A549 human 
pneumocytes, highlighting the possibility of a robust antiviral mechanism in 
these cells (Sourisseau et al., 2007). CHIKV infection and activation of 
platelets and endothelial cells has also been reported and these events could 
be linked to the thrombocytopenia and microvasculitis (rash) that develop 
during the acute phase of infection (Sourisseau et al., 2007).      
Interestingly, immune cells are not permissive to CHIKV infection 
(Rinaldo et al., 1975), and this observation has been confirmed recently by 
experiments using lymphocytes, monocytes, dendritic cells (DCs), natural 
killer cells etc. (Sourisseau et al., 2007). This is in sharp contrast with RRV 
and VEEV, which are shown to infect and stimulate immune cells such as 
monocytes, cluster of differentiation-4+ (CD-4+) cells and DCs (Gardner et al., 
2008; Shabman et al., 2007). Primary macrophages were also found to be 
poorly infected with CHIKV and release only viral particles, which are possibly 
immature or non-infectious (Solignat et al., 2009; Sourisseau et al., 2007). 
CHIKV also replicates in human muscle satellite cells but not in differentiated 
myotubes (Ozden et al., 2007). The cellular tropism of alphaviruses (Fig-1-5) 
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is very sophisticated and probably is governed by many factors. For instance, 
RRV envelope glycoproteins allow infection of mouse DCs but not human 
DCs (Strang et al., 2005). Also, a single amino acid substitution in the E2 of 
SINV or VEEV can determine their infectivity in DCs (Gardner et al., 2000; 
MacDonald and Johnston, 2000). Other factors that regulate alphavirus tissue 
tropism and virulence are type-I interferon (IFN) such as in case of SFV and 


















Fig-1-5: A schematic showing tissue tropism of CHIKV infection in 
humans. CHIKV infection has been observed in brain, liver, joints, muscle 
and lymphoid tissues. The information contained in this figure is derived in 
part from (Schwartz and Albert, 2010). 
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1.3.8.3 Infection profile in vivo  
The first events of CHIKV infection are still poorly understood. Based 
on studies examining infection by CHIKV, as well as other closely related 
alphaviruses, in various mouse models, some understanding has been 
gained regarding the infection profile in vivo. CD-1 outbred mice showed 
symptoms that are consistent with human CHIKV-induced clinical pathology, 
such as loss of balance, difficulty walking, dragging of hind limbs, skin lesions 
and some deaths (Ziegler et al., 2008). In support, CD-1 and C57BL/6J mice 
infected with RRV have also been shown to produce similar signs of illness, 
reminiscent of humans, in RRV infection (Morrison et al., 2006). Notably, 
newborn and young mice are extremely sensitive to CHIKV infection, 
supporting high levels of CHIKV replication, leading to death. In a highly 
pathogenic mouse model where animals lack type-I IFN-receptors, animals 
have been found to be very susceptible to severe CHIKV disease and 
mortality. In these animals, CHIKV infection has been found in muscles, 
joints, and skin fibroblasts and also in the endothelial and epithelial layers of 
many organs including the liver, spleen and brain. Because of many apparent 
similarities to the human disease, these mice constitute a valuable animal 
model for studying CHIKV pathogenesis and particularly for screening 
antiviral drug candidates (Couderc et al., 2008; Rathore et al., 2014).  
Non-human primates have also been used for studying CHIKV-
associated pathologies. In two recent studies, CHIKV inoculation of 
macaques resulted in high viremia, transient acute lymphopenia and 
neutropenia. In particular, CHIKV targeted lymphoid tissues, the central 
nervous system, the liver, joints and muscles during the acute phase of 
infection. An increase in the number of monocytes and a pro-inflammatory 
	   22	  
response were also observed. Overall, the animals recapitulated the viral, 
clinical and pathological features observed in humans (Akahata et al., 2010; 
Labadie et al., 2010). Interestingly, persistent infection was also observed in 
splenic macrophages and endothelial cells (Labadie et al., 2010). Tissue 
derived from these animals at 44 days post-infection also carried low levels of 
replication competent virus (Labadie et al., 2010), suggesting the primate 
model exhibits persistence that may be analogous to the possible persistence 
of CHIKV in some human patients, as well. 
1.3.8.4 Virus dissemination 
Even if the patrolling host immune cells, such as skin-derived DCs and 
Langerhans cells (LCs), mount a response to control the virus in the skin 
dermis, the virus disseminates quite rapidly to the blood circulatory system. 
Different scenarios could account for this; first, Aedes mosquitos inject saliva 
during inoculation, which is known to contain immune modulators that may 
shield the virus against the first line of host immune defense. As observed in 
SINV, this saliva could potentiate viral infection (Schneider et al., 2004). 
Second, infected resident dermal cells, DCs, LCs or infiltrating cells such as 
macrophages or DCs, which are infected by newly produced CHIKV, may 
migrate to the draining lymph nodes. West Nile Virus (WNV) and SFV, which 
can infect mouse LCs, can induce migration of these cells to draining lymph 
nodes (Johnston et al., 2000). It has been shown that WNV infection in mice 
leads to a TLR-dependent inflammatory response, which modifies the blood-
brain barrier and facilitates virus penetration in the brain (Wang et al., 2004). 
However, these pathogenic mechanisms still need to be validated for CHIKV 
infection. 
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1.3.8.5 Virus clearance 
CHIKV viremia persists for between 3-7 days and, therefore, virus 
elimination occurs before the host can start to make high titer 
immunoglobulins (Igs) and as T-cell responses are only beginning (Fig-1-6). 
This clearance could be mainly due to the strong IFN-α/β responses induced 
by the virus. Moreover, it has been shown that CHIKV is very sensitive to 
action of type-I IFNs (Sourisseau et al., 2007). The detailed role of CD4+ and 
CD8+ cells in the CHIKV clearance has yet to be established. However, in the 
case of RRV (Morrison et al., 2006), the role of CD4+ and CD8+ cells in viral 
clearance has been well established, suggesting the possible role of these 
cells in CHIKV clearance, as well. 
 
 
Fig-1-6: CHIKV disease progression and pathogenesis. After a mosquito 
bite, the incubation period for virus is ~2-4 days, which is followed by high 
viremia and clinical presentation in infected patients. High viremia lasts for an 
average of 3-7 days before being completely cleared by the body’s innate and 
adaptive immune responses. At this point, the clinical manifestations have 
also resolved; however, a significant proportion of patients develop persistent 
arthralgia or arthritis that could last from several months to years.  
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1.3.8.6 Persistent Arthralgia 
There is a strong body of evidence that persistent joint manifestations 
are linked with persistence of alphaviruses. However, the mechanism of 
persistence is not well characterized (Rulli et al., 2007; Suhrbier et al., 2012). 
CHIKV infection also involves a chronic arthralgia/arthritis that can persist for 
several months (Schwartz and Albert, 2010). In case of RRV, the rheumatic 
synovial exudates from EPA (epidemic polyarthritis) are mainly composed of 
monocytes, vacuolated and phagocytic macrophages, T-cells, B-cells and 
natural killer cells (Rulli et al., 2007; Ryman and Klimstra, 2008). 
Macrophages are considered to be the major player in CHIKV-induced 
arthritis suggesting their role in persistent maintenance of infectious virus 
(Hoarau et al., 2010; Rulli et al., 2011). In case of RRV, it has been shown 
that RRV can persist in macrophages for long periods after infection (Way et 
al., 2002). More importantly it has been reported in RRV animal model that, 
treatment of mice with silica or carrageenan (macrophage toxic agents) prior 
to infection completely abrogated arthritis like disease symptoms (Lidbury et 
al., 2008). Complement component C3 was also shown to be important in 
contributing to inflammatory tissue destruction in the RRV mouse model 
(Morrison et al., 2007). It will be interesting to ascertain whether the 
mechanisms identified for some of these factors in related viral infections also 
stand true for CHIKV infection.   
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1.4 ER stress and the Unfolded Protein Response 
One host response that has the potential to limit virus replication is ER 
stress, which results in a coordinated unfolded protein response (UPR). In 
eukaryotic cells, ER is the sub-cellular organelle that is responsible for protein 
synthesis, modifications and their delivery to target sites such as in the 
secretory pathway and extracellular space by providing a unique oxidizing 
environment to the proteins. The ER is also involved in the synthesis of 
cellular lipids and sterols. In addition, ER is an important signal-transducing 
organelle that responds to environmental stimuli and is very sensitive to 
alterations in homeostasis. Different stimuli signal through several protein 
kinases to enhance the folding capacity of the ER. These stimuli include 
calcium depletion from the ER, inhibition of asparagine (N)-linked 
glycosylation, expression of mutant proteins, viral infections and reduction of 
disulfide bonds, etc. The diverse ER response signals or UPR, results in 
cellular adaptations to its fate towards survival or a death (Kaufman, 1999).  
1.4.1 Protein folding machinery 
Numerous protein-chaperones present in the ER facilitate the folding 
of various other proteins and protein complexes by assisting in two crucial 
ways. First, there are certain chaperones, such as protein disulfide isomerase 
or cis-trans prolyl isomerase (PDI), that catalyze the rate of protein-folding 
reactions (Gething and Sambrook, 1992). Second, several heat shock or 
glucose-regulated proteins (GRPs) maintain the protein in a stable folding-
competent state, although they do not actively catalyze protein folding 
(Gething and Sambrook, 1992). One of the best-characterized examples of 
the latter is glucose-regulated protein-78 (GRP-78) or immunoglobulin binding 
protein (BIP). BIP was identified in B-lymphocytes to bind to heavy chain Igs 
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and prevent their secretion in the absence of a light chain (Haas and Wabl, 
1983). BIP was also identified as a protein that is expressed at high levels in 
virally infected cells and also upon glucose deprivation. BIP maintains the 
quality control in the ER lumen by ensuring that only properly folded proteins 
exit the ER compartment (Hurtley and Helenius, 1989).  Other proteins that 
assist in protein folding include heat shock protein-90 (HSP-90) subunits α 
and β, HSP-90α, HSP-90β (GRP-94) and HSP-40 or DNAJ family proteins. In 
general, the ER responds to misfolded or unfolded proteins by (i) up-
regulating the folding capacity of the ER through increased expression of ER 
resident molecular chaperones and foldases, (ii) down-regulating the protein 
load of the ER by shutting off the protein synthesis at both the transcriptional 
and translational levels (Harding et al., 1999), and (iii) increased clearance of 
misfolded proteins from the ER through active engagement of the ER-
associated degradation (ERAD) pathway (Friedlander et al., 2000; Travers et 
al., 2000). 
As presented in Table-3, there are three major protein families that 
comprise the protein folding machinery: foldases, molecular chaperones and 
lectins. Foldases catalyze the rate of protein folding, for example, cis-trans 
peptidyl prolyl isomerases. Molecular chaperones facilitate protein folding, 
such as class HSP-70 chaperones (e.g. GRP-78) and class HSP-90 
chaperones (e.g. GRP-94). Lectins, such as calnexin and calreticulin, 
maintain the quality control of folded proteins in the ER secretory 
compartment.  
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Table-3: List of components involved in protein folding (adapted from 
(Schroder and Kaufman, 2005)). 
 
Foldases  
Foldases subclass,  
disulfide isomerases 
PDI, ERp72, ERp61, ERp57, ERp44, 
ERO1p/EROα/ERO1β 
Foldases subclass,  
FAD-dependent oxidases 
FMO1p 
Foldases subclass,  
peptidyl prolyl isomerase 
FKBP13, FKBP65, Cyclophillin-B, S-
Cyclophillin 
Lectins Calnexin, Calreticulin, EDEM 
Molecular Chaperones  
Chaperone, class HSP-70 BIP/GRP-78, GRP-170 
Chaperone, class GRP-E like BAP, GRPEL1, Sis1p 
Chaperones, class HSP-90 GRP-94/Endoplasmin 
Chaperone, class DNAJ or HSP-
40 
ERdj1, ERdj3, ERdj4, ERdj5, Sec63p 
 
1.4.2 BIP is a master sensor of UPR 
BIP has an ATPase domain in its N’ terminus and a peptide binding 
domain in its C’ terminus. In the ADP-bound state, BIP shows high affinity for 
protein substrates (Flynn et al., 1991). Studies using random peptides have 
shown that short hydrophobic peptides forming beta peptides are 
preferentially bound to BIP with weaker affinity, thereby allowing a broad 
spectrum of substrates to bind (Blond-Elguindi et al., 1993). Exchange of ADP 
with ATP releases the partially folded substrate from BIP and permits it to 
proceed further in its folding pathway. This cycle of energy consuming ADP-
ATP exchange through BIP helps in polypeptide folding and consumes 
energy. Consequently, folding of many secretory proteins can be inhibited by 
depletion of cellular ATP levels, such as when there is increased demand of 
cellular proteins during cancer or during viral replication (Braakman et al., 
1992; Dorner and Kaufman, 1994; Dorner et al., 1990). In stressed cells, co-
chaperone proteins regulate protein-folding reactions such as nucleotide 
exchange and ATP hydrolysis. For instance, DNAJ-like proteins Erdj1, Erdj3-
5 and Sec63p stimulate the ATPase activity of BIP and BIP-associated 
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protein (BAP) and Sis1p catalyzes the nucleotide exchange reaction. This 
regulation of nucleotide exchange and ATP-hydrolysis by co-chaperones is 
crucial for BIP to function in a cell (Kaufman, 1999). 
1.5 Signal transduction in UPR 
An unfolded protein signal across the ER membrane is transduced by 
three transmembrane proteins (Fig-1-7).  
A. PERK (dsRNA-activated protein kinase (PKR) like ER kinase or 
PEK (Liu et al., 2002; Shamu and Walter, 1996) (pancreatic 
eukaryotic translation initiation factor-2α kinase (eIF2α kinase).  
B. The type-I transmembrane proteins such as ER stress regulated 
oligomerization domains, including IRE-1 (inositol-requiring-1) or 
ERN1 (ER to nucleus signaling 1).  
C. A type-II transmembrane protein, activating transcription factor-6 
(ATF-6) (Shen et al., 2002).  
In its inactive state, luminal domains of IRE-1 and PERK are bound to 
BIP. However, upon ER stress or accumulation of unfolded proteins in the ER 
lumen, BIP dissociates from IRE-1 and PERK, which results in 
oligomerization and further activation of these proximal sensors (Liu et al., 
2002; Shamu and Walter, 1996). ATF-6 is also regulated by BIP in the same 
manner as IRE-1 and PERK, except that BIP also regulates the activity of two 
independent Golgi localization sequences, GLS1 and GSL2, on ATF-6. 
During ER stress when BIP is removed from ATF-6, GSL2 helps in the 
translocation of ATF-6 to the Golgi and allows its further activation (Shen et 
al., 2002). The mechanism of activation and targets of the three major UPR 
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Fig-1-7: A schematic showing signaling resulting from three branches 
of the UPR. During ER stress and UPR, the (A) PERK, (B) IRE-1 and (C) 
ATF-6 transduce signals across the ER to regain homeostasis in the cell. 
Upon activation of signaling, PERK, IRE-1 and ATF-6 regulate the 
transcription and translation of several UPR-associated genes. These 
proteins perform diverse functions during ER stress, ranging from assisting in 
the folding of unfolded proteins to protein degradation and triggering cell 




	   30	  
1.5.1 IRE-1 
The IRE-1 pathway transduces many signals in response to ER stress 
or UPR, including expansion of ER and induction of chaperones and ERAD. It 
encodes a type-I transmembrane protein kinase endoribonuclease, which is 
comprised of a cytosolic kinase, an endoribonuclease domain and an ER 
luminal dimerization domain. IRE-1 oligomerizes and activates its 
endoribonuclease domain by auto-phosphorylation (Shamu and Walter, 
1996). The mammalian system has two types of IRE-1, IRE-1α (Tirasophon 
et al., 1998) and IRE-1β (Wang et al., 1998). IRE-1α is ubiquitously 
expressed in all cell types. However, the expression of IRE-1β is only limited 
to the gut. Deletion of IRE-1α in mice resulted in embryonic lethal phenotype 
(Urano et al., 2000) while mice were viable after the deletion of IRE-1β, 
although the animals were found to be susceptible to dextran sodium sulfate-
induced colitis (Bertolotti et al., 2001). During UPR, activation of IRE-1 leads 
to the splicing of X-box binding protein-1 (XBP-1) mRNA and the further 
translation of the spliced product as a basic leucine zipper (bZIP) transcription 
factor (Kaufman, 1999) (Fig-1-7).  
IRE-1 targets: XBP-1 is a transcription factor that belongs to the 
ATF/cAMP response element-binding protein (CREB) family and regulates 
transcription of CRE (cAMP response element)-like element genes (Clauss et 
al., 1996) (Table-4). XBP-1 is also known to be essential for terminal B-cell 
differentiation (Reimold et al., 2001).  XBP-1 regulates a subset of UPR genes 
that promote ERAD of misfolded proteins and ER biogenesis (Lee et al., 
2003). IRE-1 can also act by alternative means. In mammals, recruitment of 
TRAF-2 (tumor necrosis factor receptor (TNFR)-associated factor-2) by 
phosphorylated IRE-1 allows it to signal to c-Jun N-terminal kinase (JNK) and 
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alter intracellular signaling (for example, resulting in insulin resistance (Ozcan 
et al., 2004)). The IRE-1-TRAF-2 complex has also been linked to caspase-
12 activation and cell death (Yoneda et al., 2001). In cultured Drosophila 
melanogaster cells, activated IRE-1 can promote the cleavage of various ER-
localized mRNAs, leading to their degradation (Hollien and Weissman, 2006). 
This IRE-1 dependent degradation of ER-localized mRNAs reduces the 
burden of misfolded proteins on the stressed ER and could potentially help in 
the reprograming of the protein folding machinery in the ER. However, the 
mechanisms by which of IRE-1 degrade these mRNAs are poorly understood. 
It is predicted that IRE-1 could directly cleave mRNA or could potentially 
promote mRNA decay by utilizing other host RNAses such as JNKK (JNK 
kinase) and JNKKK, (JNKK kinase).  
Table-4: List of genes targeted by the UPR. 
UPR 
branches 
Major target genes 
IRE-1 BIP, p58IPK, EDEM, ERdj4, PDI-P5, XBP-1, UBE2E1 
ATF-6 BIP, GRP-94 (HSP-90β), ERO1L, PDI-A4, CHOP, p58IPK 
PERK/ 
ATF-4 




In mammalian cells ATF-6 exists as two homologs: ATF-6α and ATF-
6β (Haze et al., 2001). Under conditions of ER stress, ATF-6 is released from 
the ER luminal domain and transported to Golgi where it is cleaved by Golgi 
resident proteases site-1 protease (S1P) and site-2 protease (S2P). The 
cleavages result in release of the cytosolic N-terminus part of ATF-6 (Chen et 
al., 2002; Haze et al., 1999). ATF-6 also encodes the bZIP transcription factor 
and binds to ATF/CRE element and to ER-stress responsive cis-acting 
elements (ERSE)-I & II (Kokame et al., 2001; Yoshida et al., 1998) (Fig-1-7). 
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Overexpression studies of both ATF-6α (Okada et al., 2002) & ATF-6β (Haze 
et al., 2001) have shown that they positively regulate ER-resident molecular 
chaperones and foldases. Intriguingly, heterodimeric complexes of ATF-6α & 
ATF-6β are transcriptional repressors of the BIP promoter (Thuerauf et al., 
2004).  
ATF-6 targets: ATF-6 regulates transcription of BIP, XBP-1, C/EBP 
homologous protein (CHOP), protein kinase inhibitor of 58kDa (p58IPK) and 
membrane protein homocysteine-responsive ER-resident ubiquitin-like 
domain member-1 protein (HERP) (Kokame et al., 2001; van Huizen et al., 
2003; Yoshida et al., 2000) (Table-4). ATF-6 also forms a heterodimeric 
complex with basic loop helix transcription factor sterol response element-
binding protein-2 (SREBP-2) (Zeng et al., 2004).  
1.5.3 PERK 
PERK is a type-I transmembrane protein kinase and is also activated 
(like IRE-1 & ATF-6) by the release of BIP from its ER luminal domain. Upon 
activation, PERK undergoes oligomerization and auto-phosphorylation 
whereby phosphorylated PERK phosphorylates its substrate eukaryotic 
translation initiation factor-2 alpha (eIF2α) subunit (Harding et al., 1999; Shi et 
al., 1999; Shi et al., 1998). Phosphorylation of eIF2α inhibits the complex 
formation of guanine nucleotide exchange factor, eukaryotic initiation factor-2 
(eIF2B). This complex is responsible for further recycling the eIF2α to its 
GTP-bound state. Reduced levels of active eIF2α result in decreased 
translation initiation, consequentially, reducing the load of newly translated 
proteins globally. In general, phosphorylation of eIF2α by PERK shuts off 
global protein translation in a cell (Harding et al., 1999) (Fig-1-7).  
	   33	  
It is important to note that other eIF2 kinases (RNA-activated protein 
kinase (PKR), Heme-regulated inhibitor kinase (HRI) and general control non-
derepressible-2 (GCN2)) can phosphorylate eIF2α independently of ER 
stress. Therefore, this portion of the UPR is termed as the integrated stress 
response (ISR) (Harding et al., 2000; Harding et al., 2003). Nevertheless, 
PERK-/- cells are sensitive to ER stress and could be partially rescued by 
translation inhibitors such as cyclohexamide (Harding et al., 2000). In addition 
to reducing protein load in the ER, phosphorylation of eIF2α also contributes 
to transcriptional activation in the UPR, which allows for preferential 
translation of mRNAs encoding several short upstream (5’-3’) ORFs (Harding 
et al., 2000; Scheuner et al., 2001). ATF-4 mRNA is regulated in this way and 
the translated ATF-4 then binds to amino acid response elements (Harding et 
al., 2000). ATF-4 regulates the transcription of CHOP, growth arrest and DNA 
damage-inducible protein-34 (GADD-34) and ATF-3 (Harding et al., 2000; 
Jiang et al., 2004; Ma et al., 2002). ATF-4 is also required for transcriptional 
activation of genes involved in amino acid import, glutathione biosynthesis 
and resistance to oxidative stress (Harding et al., 2003) (Table-4).  
1.6 UPR regulation and feedback mechanisms  
Translation attenuation by PERK is transient so as to allow rapid 
recovery to occur and to re-establish a homeostatic environment after 
exposure to stress. Also, sustained activation of PERK leads to uncontrolled 
UPR that finally leads to cell death (Kaufman, 1999). Therefore, it is 
imperative that a regulatory mechanism exists for the PERK pathway. 
Activation of ATF-6 during ER stress increases the expression of HSP-40 co-
chaperone p58IPK. p58IPK can inhibit PERK by binding to its kinase domain 
(van Huizen et al., 2003; Yan et al., 2002).  
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In normal cells, p58IPK associates with a HSP-40 and forms an 
inhibitory complex. Cellular stress or virus infection induces dissociation of 
p58IPK from HSP-40. Therefore, the released p58IPK can bind to PKR and 
disrupt its activity. It has also been shown that p58IPK can interact with PERK 
and inhibit its activity (van Huizen et al., 2003; Yan et al., 2002). 
Overexpression of p58IPK reduces eIF-2α phosphorylation, which is 
mediated by PERK in mouse embryonic stem cells (van Huizen et al., 2003). 
On the other hand, deletion of p58IPK increases eIF-2α phosphorylation and 
induction of CHOP and BIP. Moreover, p58IPK expression is induced by 
tunicamycin (chemical inducer of ER stress) as well; consistent with the 
observation that the p58IPK promoter bears an element that is commonly 
found in the promoter region of other genes induced by UPR (Lee et al., 1990, 
1992; Yan et al., 2002).  
Although it remains to be determined whether activation of the non-
catalytic region of tyrosine kinase (Nck-1), an amino acid phosphatase, could 
potentially limit the phosphorylation of eIF2α (Kebache et al., 2004). Other 
key regulators of eIF2α phosphorylation are GADD-34 and protein 
phosphatase-1 regulatory subunit-15B (CReP). Both regulate the 
phosphatase activity of protein phosphatase-1 (PP1) through their 
homologous C-terminal domains. It is established that PP1 accepts eIF2α as 
its substrate and de-phosphorylates the phosphorylated form of eIF2α 
(Connor et al., 2001; Jousse et al., 2003; Novoa et al., 2001). It is noteworthy 
that CReP is a constitutive regulator of PP1 (Jousse et al., 2003), whereas 
the expression of GADD-34 is induced by ATF-4 (Kojima et al., 2003; Ma and 
Hendershot, 2003; Novoa et al., 2003). Thus, activation of p58IPK and 
GADD-34 during ER stress acts as a negative feedback mechanism that 
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limits the shut off of protein synthesis through phosphorylation of eIF2α and 
PERK (Fig-1-7). 
1.6.1 Regulation of Apoptosis 
When UPR is unable to maintain homeostasis during ER stress, 
signaling events in the UPR trigger pathways that lead to cell death through 
apoptosis. An intrinsic pathway responds to intracellular signals (e.g. DNA 
damage) and an extrinsic pathway responds to external stimuli, such as 
during nutrient deprivation or viral infections.  
In general, the intrinsic pathway is controlled by a balance between 
pro-apoptotic proteins (BH3 only proteins- e.g. Bad, Bax & Bak) and anti-
apoptotic proteins (e.g. Bcl-2). During ER stress, Bak and Bax undergo 
conformational changes resulting in Ca2+ release from the ER lumen. 
Depletion of calcium pools in the ER then converts procaspase-12 to 
caspase-12 and initiates a cascade of caspase cleavage events through 
procaspase-9 and procaspase-3, resulting in apoptosis. Also the anti-
apoptotic effects of Bcl-2 are suppressed when its own transcription is 
reduced by activation of the transcription factor CHOP (Orrenius et al., 2003). 
TRAF-2, which is an IRE-1 regulated protein, responds to extrinsic 
pathway by forming a heterotrimeric complex with IRE-1, and c-Jun amino-
terminal inhibitory kinase. When activated, IRE-1 transmits a signal via Ask1 
(apoptosis signal-regulating kinase) and triggers caspase-12 activation and 
subsequent apoptosis (Urano et al., 2000; Yoneda et al., 2001). 
1.6.2 Regulation of a key chaperone HSP-90  
In eukaryotic cells, the response to UPR in the ER involves three 
distinct aspects (i) translational attenuation, which reduces the burden of 
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newly synthesized proteins to be folded by the ER; (ii) transcriptional 
induction of ER-resident molecular chaperones and related stress response 
proteins, including BIP/GRP-78 and HSP-90β/GRP-94; and (iii) removal of 
misfolded proteins from the ER by retrograde transport coupled to their 
degradation by proteasome (Kaufman, 1999; Mori, 2000). Indeed, the 
expression of HSP-90β or GRP-94 is regulated by both the ATF-6 and IRE-1 
arms of the UPR (Marcu et al., 2002; Yoshida et al., 1998) (Fig-1-7). 
Moreover, a number of key regulatory kinases, including the soluble 
serine/threonine kinases, Raf1 (Schulte et al., 1995), Akt (Sato et al., 2000), 
GCN2 (Donze and Picard, 1999), PKR (Donze et al., 2001), and the type-I 
transmembrane tyrosine kinase p185ErbB2 (Xu et al., 2001), depend on 
interactions with the molecular chaperone HSP-90 for their stability and 
function. It has also been shown that interference with this association by the 
HSP-90 binding drug geldanamycin (GA) results in their rapid destabilization 
and proteasome-mediated degradation (Mimnaugh et al., 1996). In 
mammalian cells, HSP-90s are a family of highly conserved molecular 
chaperones. These include two cytoplasmic isoforms, stress-induced HSP-
90α and constitutively expressed HSP-90β, the latter of which has an ER 
resident homologue, GRP-94, and a mitochondrial homologue, TRAP-1 
(Chen et al., 2005). The HSP-90 proteins form a homodimeric complex with 
each monomer consisting of a C-terminal dimerization domain, a middle 
domain and an N-terminal ATPase domain (Pearl and Prodromou, 2006). In 
general, HSP-90 is involved in maturation, localization, and turnover of its 
client proteins in a cell.  
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1.7 UPR in viral infections 
To circumvent the host cellular translational response, several viruses, 
such as respiratory syncytial virus, simian virus-5, Tula virus, African swine 
fever virus (ASFV), herpes simplex virus (HSV), cytomegalovirus (CMV), 
dengue virus (DENV) and hepatitis-C virus (HCV) have been shown to 
regulate UPR machinery (He, 2006). For example, in the case of HCV, the 
virus encoded NS5A phosphoprotein, inhibits PKR activation by direct 
protein-protein interaction (Gale et al., 1998). Likewise, the K3L gene product 
of vaccinia virus also binds to PERK and inhibits its activation (Davies et al., 
1993). Others, such as HSV, encode proteins that mimic host factors to 
regulate the protein synthesis trafficking (Cheng et al., 2005).  
1.7.1 Virus modulation of UPR 
The ER resident chaperone BIP is a master sensor of UPR, the 
expression of which is known to be up-regulated during ER stress. Although 
the effects of BIP induction on virus replication are not fully understood this 
phenotype becomes quite clear in paramyxoviral infections, such as by simian 
virus 5 or respiratory syncytial virus (Bitko and Barik, 2001; Peluso et al., 
1978), and also during other viral infections, for example the flavivirus family 
and hantavirus (Jordan et al., 2002; Li et al., 2005; Su et al., 2002). Recent 
studies on Influenza and HCV have also revealed that expression of BIP and 
HSP-90 family proteins are induced during viral infections (Liberman et al., 
1999). 
1.7.2 Virus modulation of PERK signaling 
Activation of the PERK pathway leads to global protein translation 
arrest and cell death. Therefore, several viruses have evolved to modulate or 
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regulate this pathway of UPR. For example, HSV utilizes GADD-34, in 
conjunction with its gamma134.5 protein, to rescue protein synthesis in HSV-
infected cells (Cheng et al., 2005; He et al., 1997). Similarly, in CMV infection, 
activation of PERK is delayed until very late during infection. When PERK is 
eventually phosphorylated, the phosphorylation of its substrate, eIF2α, does 
not occur.  This suggests the involvement of a viral component in this 
regulation process (Isler et al., 2005). However, the exact mechanism of this 
delay in PERK activation has not yet been determined.  
Another virus, an ASFV, doesn’t induce PERK activation and, 
moreover, its replication can also block chemically-induced ER stress and cell 
death (Netherton et al., 2004). In addition, a cytopathic strain of bovine viral 
diarrhea virus, a flavivirus that causes acute infection, has been shown to 
activate PERK and increase phosphorylation of eIF2α. PERK phosphorylation 
peaks in infected cells when the virus production is highest, which suggests 
the level of ER stress signaling increases as viral gene products accumulate 
during infection. As a consequence, infected cells undergo apoptosis with 
increased expression of CHOP and caspase-12. This phenotype is not 
associated with the non-cytopathic strain of bovine viral diarrhea virus, which 
tends to cause chronic infection (Jordan et al., 2002). Viruses also exploit 
inhibitory proteins such as p58IPK, which is a tetra-tri-co-peptide repeat 
(TPR) family of proteins and negatively regulates both PKR and PERK. 
p58IPK was originally characterized as an influenza virus-activated protein 
that interacts with the kinase domain of PKR and inhibits its activity (Lee et 
al., 1990). Thus, p58IPK is also a component of the system that regulates 
unfolded protein response during infection and is a target for viral modulation 
of the UPR. 
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1.7.3 Virus modulation of IRE-1 and ATF-6 signaling  
HCV replication has been shown to stimulate the ATF-6 pathway but 
suppress the IRE-1/XBP-1 pathway. These studies suggested that slow 
replicating HCV infections induce protein-folding chaperones and reduce 
protein degradation during viral assembly (Tardif et al., 2004; Tardif et al., 
2002). In contrast, CMV infection controls the level of BIP (downstream 
product of ATF-6), which regulates the onset of UPR (Isler et al., 2005). Other 
viruses, such as DENV activate both ATF-6 and IRE-1 during the late phase 
of their infection cycles (Pena and Harris, 2011). Also, replication of WNV 
triggers activation of the ATF-6 and IRE-1 branches of the UPR, whereas the 
PERK pathway is suppressed during WNV replication (Ambrose and 
Mackenzie, 2011, 2013). These observations show that individual viruses 
have adapted unique strategies for regulating the IRE-1/ATF-6 pathways 
during replication. 
1.7.4 Virus modulation of Apoptosis 
During UPR, CHOP is activated to facilitate cell death by apoptosis. 
CHOP-mediated apoptosis has been linked to pathways that suppress Bcl-2 
expression, to depletion of intracellular glutathione and to the increase of free 
radicals. Other pathways of apoptosis involve activation of IRE-1, TRAF-2 
and caspase-12. Infections by many different viruses induce apoptosis that is 
mediated by UPR. For instance, Japanese encephalitis virus exhibits CHOP-
mediated severe cell death, which is associated with apoptosis, and can be 
partially reversed by overexpressing Bcl-2 proteins (Su et al., 2002). Similarly, 
infection with Tula virus activates the JNK pathway that contributes to 
apoptosis during its infection (Li et al., 2005). In contrast, simian virus-5 
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infection has been shown to induce expression of BIP and GRP-94 without 
triggering apoptosis (Sun et al., 2004). 
1.7.5 Virus modulation of HSP-90 chaperone 
Viral proteins, like cellular proteins, also require chaperones for their 
proper folding and assembly and HSP-90 has been known to play an 
important role in the replication of many viruses. For example, HSP-90 assists 
in the reverse transcription reaction step during hepatitis-B virus replication 
(Hu and Anselmo, 2000). Similarly, HSP-90 also stabilizes the polymerase 
complex during influenza virus replication (Momose et al., 2002). 
Furthermore, HSP-90 is known to be involved in the replication processes of 
many other viruses, including α-HSV, CMV, HCV, and bunyavirus (Geller et 
al., 2012). The dependence of many viruses on HSP-90 for replication makes 
it an interesting potential broad-spectrum antiviral drug target. Geldanamycin 
and its derivatives, 17-allyl-17-demethoxygeldanamycin (17AAG) and 17-
desmethoxy- 17-N,N-dimethylaminoethylaminogeldanamycin (17DMAG) are 
some of the HSP-90  inhibitors that have shown antiviral activity in cell-lines, 
against range of DNA or RNA viruses (Geller et al., 2012).  
1.8 UPR in CHIKV and related alphaviruses 
Several studies have shown that alphavirus replication in mammalian 
cells usually results in severe cytopathicity, mainly caused by dramatic 
shutdown of host translation machinery (Barry et al., 2010; Bourai et al., 
2012; Garmashova et al., 2007b; Toribio and Ventoso, 2010). However, the 
mechanism by which these viruses maintain such a high replication rate in 
infected cells is poorly understood. Few studies have suggested the idea that 
alphaviruses, such as SFV or SINV, have certain translational enhancer 
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elements in their sub-genomic RNA, which makes obsolete the requirement 
of eIF2B for its translation in the late phase of infection when eIF2α is 
phosphorylated (McInerney et al., 2005; Ventoso et al., 2006).  However, the 
early events of alphavirus replication in context to the UPR and, in particular, 
the role of UPR in CHIKV infection is completely unknown.  
1.9 CHIKV Therapeutics 
To date, there are no approved vaccines or anti-viral therapies against 
CHIKV. Many groups are currently working to develop strategies to combat 
CHIKV infection, which fall broadly into the categories of therapeutic 
antibodies, vaccines and, the focus of this work, antiviral drugs. 
1.9.1 Neutralizing antibody as therapy 
Pathogen-specific polyclonal Igs purified from immunized donors have 
been used for prophylaxis of several infectious diseases (Sawyer, 2000). 
Human monoclonal antibodies (MAbs) have been used extensively in 
prophylactic as well as therapeutic settings (Keller and Stiehm, 2000). The 
development and characterization of anti-CHIKV neutralizing antibodies is 
promising and there are several lead candidates that have been recently 
identified (Goh et al., 2013; Pal et al., 2013; Pal et al., 2014; Selvarajah et al., 
2013).  
1.9.2 Vaccines 
Currently, many potential CHIKV vaccine candidates have been 
developed or tested in humans or animals with varying degree of success 
(Edelman et al., 2000; Garcia-Arriaza et al., 2014; Muthumani et al., 2008). 
The vaccines tested to date have primarily focused on chimeric virus strains, 
live attenuated strains and the use of DNA vaccine technology.   
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1.9.3 Antivirals 
 
In spite of the fact that CHIKV has recently dispersed widely 
throughout Africa and Asia causing substantial morbidity for millions of 
infected patients, there are currently no recognized antiviral therapies 
available to control this pathogen. Chloroquine was first reported to inhibit 
SINV and SFV infectivity in vitro more than three decades ago (Cassell et al., 
1984; Coombs et al., 1981; Helenius et al., 1982). Chloroquine was also 
found to be effective against CHIKV infection (Savarino et al., 2007) and has 
also been used to treat chronic CHIKV arthritis (Brighton, 1984). However, the 
several subsequent reports that have indicated chloroquine is ineffective for 
treating CHIKV in human patients have raised many questions regarding its 
applicability and cautioned against the use of chloroquine as an antiviral drug 
to treat CHIKV (De Lamballerie et al., 2008; Maheshwari et al., 1991).  
Another drug, Ribavirin shows wide in vitro inhibitory activity against 
RNA viruses with different modes of action characterized. In some cases it 
inhibits IMP dehydrogenase, depleting cellular GTP pools and in others it acts 
as a potent mutagen by inducing error catastrophe (Crotty et al., 2001; 
Severson et al., 2003). A combination of IFNα and Ribavirin showed a 
synergistic effect on the in vitro inhibition of CHIKV (Briolant et al., 2004). 
Whether Ribavirin is effective against CHIKV in vivo is not known. Moreover, 
several new potent anti-CHIKV compounds have also been demonstrated to 
be effective in recent years (Bourjot et al., 2012; Cruz et al., 2013; Delang et 
al., 2014; Gigante et al., 2014; Rathore et al., 2014) but there is a pressing 
need to understand the infectious cycle of CHIKV to understand the detailed 
mode of action of these drugs.  
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1.10 Thesis Aims 
The UPR is a cellular response that regulates the fate of misfolded or 
unfolded proteins in the ER and has the potential to limit virus replication. In 
previous studies of DENV by this group, the importance of UPR during viral 
replication was revealed. These studies showed that a detailed understanding 
of the UPR pathway not only could help predict disease severity but also 
could help design novel antivirals (Paradkar et al., 2011; Rathore et al., 2011; 
Umareddy et al., 2007). The role of the host UPR machinery during CHIKV 
infection is completely unknown and, indeed, very little is known about the 
role of UPR in other alphaviruses. Therefore, the specific aims stated below 
were proposed to acquire a detailed understanding of the physical and 
functional interactions between the CHIKV and host UPR component genes.  
Specific Aims: 
Aim-1: Study the mechanism of a robust CHIKV growth through an insight in 
‘Unfolded Protein Response’ (UPR).  
Aim-2: Identify the viral or host factors that modulate the UPR and support 
CHIKV replication.  
Aim-3: Validate key UPR drug targets obtained from Aim-1 or -2, either in 
vitro or in vivo. 
Results obtained from each of these Aims will expand the basic 
knowledge of the CHIKV replication cycle. In particular, this information 
should enhance our understanding of the mechanisms that CHIKV utilizes to 
evade the host cellular translational response machinery. The data obtained 
from the studies described herein may help in identifying new drug targets 
and designing novel antiviral strategies. 
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Cells and viruses 
Mosquito cells, Aedes albopictus clone (C6/36), and baby hamster 
kidney cells (BHK-21) were originally obtained from ATCC, USA. Human 
embryonic kidney cells (HEK-293 & HEK-293T) and human lung fibroblast 
cells (MRC-5) were obtained from Duke cell culture facility at Duke University, 
USA. Mouse embryonic fibroblast cells (MEFs) that were either wild type 
(WT) or mutant in GADD-34 were generously provided by Prof. Shirish 
Shenolikar’s laboratory at Duke-NUS Graduate Medical School, Singapore. 
  
CHIKV laboratory strain ‘Ross’, a human clinical isolate CHIKV EAS 
(East African lineage strain-DMERI09/08) and a laboratory strain of SINV, 
MRM-39, were a generous gift from Dr. Ooi Eng Eong (Duke-NUS Graduate 
Medical School, Singapore). 
2.1.2 Drugs 
The drugs tunicamycin and thapsigargin were used to induce ER 
stress in cells. Salubrinal and guanabenz were used as specific inhibitors of 
CReP and/or GADD-34 phosphatases. HS-10 and SNX-2112 were used as 
selective inhibitors of HSP-90 chaperone activity, whereas chloroquine and 
ribavirin were used as antiviral drugs (Table-5).  
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Table-5: List of drugs used in this study. 
Drug name Molecular 
weight 
Chemical structure Company  











































et al., 2009; 










et al., 2009; 
Hughes et al., 
2012). 















2.1.3 Primary & secondary antibodies 
2.1.3.1 Primary antibodies 
i. Anti-phosphorylated eIF2α (Ser 51) – Cell signaling, USA [#9721] 
ii. Anti-eIF2α (Total) – Cell signaling, USA [#9722] 
iii. Anti-phosphorylated PERK (Thr 981) – Santa Cruz Biotechnology, 
USA [#sc-32577] 
iv. Anti-HSP-90β – SABio, Singapore [#M1001] 
v. Anti-HSP-90α – SABio, Singapore [#M1002] 
vi. Anti-ATF-6 – Abcam, USA [#ab11909] 
vii. Anti-phosphorylated PERK (Thr 980) – Cell signaling, USA [#3179] 
viii. Anti-p58IPK – Cell signaling, USA [#2940] 
ix. Anti-HSP-90 Total – Cell signaling, USA [#4875] 
x. Anti-HSP-90α – Abcam, USA [#ab2928] 
xi. Anti-CHOP – Cell signaling, USA [#2895] 
xii. Anti-GFP – Abcam, USA [#ab6556] 
xiii. Anti-dsRNA clone J2 – SCICONS, Hungary 
xiv. Anti-BIP – Abcam, USA [#21685] 
xv. Anti-FLAG – SABio, Singapore [#M2001] 
xvi. Anti-β-actin – Sigma, USA [#A5316] 
xvii. Anti-GAPDH – Abcam, USA [#ab9484] 
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xviii. Anti-Puromycin – KeraFAST, USA [#EQ0001] 
xix. Anti-CHIKV E – Produced in-house, a polyclonal serum raised in 
rabbits after immunization with bacterially purified CHIKV-E1-DIII 
protein. 
xx. Anti-CHIKV antibodies, nsP1, nsP2, nsP3, nsP4 and Capsid were 
generously provided by Prof. Andres Merits at University of Tartu, 
Estonia. These polyclonal antibodies were raised in rabbits after 
immunization with bacterially expressed individual CHIKV proteins. 
2.1.3.2 Secondary antibodies 
i. Anti-mouse, HRP conjugated – Cell signaling, USA [#7076] 
ii. Anti-rabbit, HRP conjugated – GeneTex, USA [#GTX213110-01]  
iii. Anti-mouse Alexa 488 – Life Technologies, USA [#A-11001] 
iv. Anti-mouse Alexa 594 – Life Technologies, USA [#A-11005] 
v. Anti-rabbit Alexa 488 – Life Technologies, USA [#A-11034] 
vi. Anti-rabbit Alexa 594 – Life Technologies, USA [#A-11012]  
vii. DAPI for nuclear staining in the cells – Sigma-Aldrich, USA [#D9542] 
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2.1.4 Primers and siRNA sequences 
2.1.4.1 Primer sequences  
Nucleotide sequences of the primers used for cloning of GFP-tagged 
CHIKV genes, for the XBP-1 splicing assay, for amplification of HSP-90α and 
HSP-90β genes and for the real time RT-PCR assay are described below 
(Table-6). Primers were obtained from AITbiotech, Singapore and Integrated 
DNA Technologies Pte Ltd, Singapore.  
Table-6: List of primers sequences used in this study. 



















































 Real time RT-PCR primers 
18S F–TGTTCAAAGCAGGCCCGAG, R–
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CGGAACTACGACGGTATCTGATC 
GAPDH F–ACAGTCAGCCGCATCTTCTT, R–ACGACCAAATCCGTTGACTC 
Actin F–CAGGGGAACCGCTCATTGCCAATGG,  
R–TCACCACACACTGTGCCCATCTACGA 
HSP-90 F–ACTCTACTCTGTCTCTGGAA, R–TATAAATGGCTGCAGATCCT 
EDEM F–TCATCCGAGTTCCAGAAAGCAGTC,  
R–TTGACATAGAGTGG AGGGTCTCCT 
XBP-1 F–TCACCCCTCCAGAACATC TC, R–
ACTGGGTCCAAGTTGTCCAG 
CHOP F–TCT GATTGACCGAATGGTG, R–TCTGGGAAAGGTGGGTAGTG 






CReP F–CATCCCTTGCAAATTCTTCC, R–CAGACTCGGTACAGCGTGAC 
EIF2αK2 F–CCGTCAATTCTGTGTTTTGCT, R–
CCCAGATTTGACCTTCCTGA 
mActin F–ATGGAGGGGAATACAGCCC, R–TTCTTTGCAGCTCCTTCGTT 
















2.1.4.2 siRNA sequences 
Nucleotide sequences of each of the two siRNAs used to target a 
specific gene for validation of the gene products that were identified as 
interacting partners with CHIKV nsPs (by GFP-nsPs pull-down mass 
spectrometry proteomic screen) are provided in Table-7.  All the siRNAs were 
synthesized by SABio, Singapore. A Non-targeting siRNA control for human 
was used as negative control in the gene validation studies (#SN001-10D, 
SABio, Singapore). 
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Table-7: List of siRNAs used in gene-knockdown studies. 
Genes siRNAs (annealed) sequences used in this study  
PRKDC 1- Sense– CCUGGAAUCCUUUCUGAAAdTdT,  
Anti-sense– UUUCAGAAAGGAUUCCAGGdTdT 
2- Sense– CCAUGUACCAGCUCUAUAAdTdT,  
Anti-sense– UUAUAGAGCUGGUACAUGGdTdT 
GCN1L 1- Sense– GCUUGACUCUGCAUCGAUAdTdT,  
Anti-sense– UAUCGAUGCAGAGUCAAGCdTdT 
2- Sense– GCACCUGGAUCAGAUCAUUdTdT,  
Anti-sense– AAUGAUCUGAUCCAGGUGCdTdT 
PABPC 1- Sense– AGGCGAUGCUCUACGAGAAdTdT,  
Anti-sense– UUCUCGUAGAGCAUCGCCUdTdT 
2- Sense- CGAUGCUCUACGAGAAGUUdTdT, 
 Anti-sense– AACUUCUCGUAGAGCAUCGdTdT 
PPP2CA 1- Sense– GCGAGAAGGCUAAAGAAAUdTdT,  
Anti-sense– AUUUCUUUAGCCUUCUCGCdTdT 
2- Sense– GCAAAUCACCAGAUACAAAdTdT,  
Anti-sense– UUUGUAUCUGGUGAUUUGCdTdT 
LARS 1- Sense– GCUGCUAAAGCUGGAUCUUdTdT,  
Anti-sense– AAGAUCCAGCUUUAGCAGCdTdT 
2- Sense– GGGUUCGUCCUGAUAUGAAdTdT,  
Anti-sense– UUCAUAUCAGGACGAACCCdTdT 
TRAF-2 1- Sense– GCAUAUAUGAAGAAGGCAUdTdT,  
Anti-sense– AUGCCUUCUUCAUAUAUGCdTdT 
2- Sense– GGACCAAGACAAGAUUGAAdTdT,  
Anti-sense– UUCAAUCUUGUCUUGGUCCdTdT 
PRPF8 1- Sense– GCAGAUGGAUUGCAGUAUAdTdT,  
Anti-sense– UAUACUGCAAUCCAUCUGCdTdT 
2- Sense– CCGACUACAUGACAGCCAAdTdT,  
Anti-sense– UUGGCUGUCAUGUAGUCGGdTdT 
HSP-90 1- Sense– GAACACGUCUUGCUAAACUTT  
Anti-sense– AGUUUAGCAAGACGUGUUCTT 
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2.2 Methods 
2.2.1 Virus quantification by plaque assay 
Cells (BHK-21, 1x105 cells/well) were seeded in a 24-well plate (Nunc, 
USA) in 0.5ml of growth media and cultured to confluency (typically overnight) 
in an incubator at 37°C with 5% CO2. For infection, media from the cells was 
removed and replaced with serially diluted virus (virus stock serially diluted 
from 10-1 to 10-10 in serum-free RPMI 1640 media) in 200μl of media followed 
by an incubation for 1h at 37°C with gentle rocking at 15min intervals. After 
infection, the excess virus containing media was removed and the growth 
media (prepared in RPMI 1640 supplemented with 2% FBS, both from Gibco, 
USA) supplemented with 0.5ml of 1% (w/v) of carboxy-methyl-cellulose 
(Calbiochem, USA) was added to each well. At Day 3 post-infection, cells 
were fixed with 4% paraformaldehyde and stained using 1% crystal violet dye. 
Plates were thoroughly rinsed with water and air-dried. Finally, the plaques 
were counted visually (Rathore et al., 2011). 
2.2.2 Virus infections in vitro 
Cells (HEK-293, HEK-293T, MRC-5 & MEFs) were cultured overnight 
at 37ºC in a humidified incubator with 5% CO2 atmosphere. The next day, 
infections were performed using MOI of 1 of CHIKV-Ross or SINV followed by 
incubation for 1h at 37ºC. After incubation, excess virus containing media was 
removed and cells were washed twice using non-serum containing growth 
media and finally the media was replenished with complete growth media. At 
indicated times post-infection or treatment with drugs, media supernatants 
were collected for plaque assay and cells were harvested for RNA or protein 
analysis. 
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2.2.3 Cell viability test 
To measure the cytotoxicity of each test drug, cells were treated with 
varying concentrations of drugs and cell viability was measured using the Cell 
Titer-Glo Luminescent cell viability assay kit (Promega, USA), following the 
manufacturer’s instructions. Briefly, 20,000 cells/well (BHK-21 or HEK-293) 
were seeded in a clear bottom 96-well plate (Corning, USA) in 100μl of 
complete growth media and incubated for overnight at 37ºC. Next, the media 
from each well was removed and replaced with varying concentrations of test 
drugs or 2% final concentration of dimethyl sulfoxide (DMSO – Sigma-Aldrich, 
USA) prepared in 100μl of growth medium, followed by an incubation of 24-
48h at 37ºC. After incubation, cells were acclimatized to room temperature 
before addition of 100μl of Cell Titer-Glo reagent in each test well followed by 
mixing for 2min using a rocker (Labnet, USA). Plates were incubated at room 
temperature for 15min to stabilize the luminescent signal and finally the 
luminescence was measured in a plate reader (Tecan, Switzerland). The 50% 
cytotoxic concentration (CC50) was determined by measuring the 
luminescence signals for cells treated with the test drugs or treated with the 
maximum tolerated dose (2%) of DMSO and the graphs were plot using 
Graph-Pad prism software. 
2.2.4 RNA extraction and real-time RT-PCR  
Infection of cells (1×105 cells/well) was achieved using MOI of 1 of 
either CHIKV-Ross or SINV for 1h followed by mock or drug treatments for 
indicated times post-infection/treatments. At given time intervals, total RNA 
was extracted using the TRIzol (Life Technologies, USA). Briefly, cells from 
each well were lysed in 0.5ml of TRIzol and incubated at room temperature 
for 5min followed by an addition of 0.3ml of chloroform (Sigma-Aldrich, USA). 
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Chloroform mixed sample was incubated at room temperature for 2min before 
centrifuged at 11,800xg for 15min at 4ºC. After centrifugation, top layer (clear 
aqueous) was carefully transferred to a new 1.5ml eppendorf tube followed by 
an addition of 0.3ml of isopropanol (Sigma-Aldrich, USA) and mixing using a 
vortex (BOECO, Germany) for 10sec. This mix was then incubated for 10min 
at room temperature and centrifuged at 11,800xg for 10min at 4ºC. After 
centrifugation the supernatant was gently poured out and the pellet was 
washed with 0.5ml of 70% (v/v) of ethanol (Sigma-Aldrich, USA) and 
centrifuged at 11,800xg for 5min at 4ºC. Ethanol was carefully removed after 
washing and the pellet was air-dried for 10min at room temperature.  Finally, 
RNA pellet was dissolved in desired volume of nuclease free water (typically 
20μl) and stored in -80ºC freezer till further processing.  
For real time RT-PCR, total RNA that was extracted earlier was 
quantified using a Nano Drop spectrophotometer (Thermo Scientific, USA). 
Nearly, 1μg of the total RNA was converted to cDNA using ImProm-II reverse 
transcription system (Promega, USA), with oligo dT as primers.  
cDNA synthesis steps: 
Step 1– Total RNA and oligo dT primer were dissolved in 5μl of nuclease free 
water and incubated at 70ºC for 5min, followed by an incubation at 4ºC for 
5min. 
Step 2– Master mix (containing 5x-RT reaction buffer, MgCl2, dNTPs and 
reverse transcriptase enzyme, prepared in 15μl of nuclease free water) was 
added to the RNA and oligo dT primer mix. 
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Step 3– Reaction parameters 
25ºC for 5min 
42ºC for 60min (RT stage) 
70ºC for 15min (enzyme inactivation) 
-20ºC (storage until use) 
Following cDNA synthesis, a real time PCR detection reaction was 
set-up using ~50ng of cDNA and gene specific primers in an iQ-5 real time 
thermal cycler (Bio-Rad, USA) using the conditions described below. The 
expression of host and viral gene products was normalized to the levels of 
host mRNAs such as GAPDH, actin or 18S, as indicated, and also normalized 
to the expression levels at uninfected conditions. 
RT-PCR cycling conditions: 
Denaturation     5min at 95ºC 
PCR cycling and detection (45 cycles) 10sec at 95ºC 
      30sec at 48-60ºC  
(Data collection) 
      30sec at 72ºC 
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2.2.5 XBP-1 splicing assay 
The XBP-1 splicing assay was adapted from a published protocol 
(Umareddy et al., 2007). The XBP-1 mRNA has a 26bp intron that is removed 
during the splicing process (Fig-2-1). In this PCR based splicing assay the 





Fig-2-1: The schematic of a XBP-1 splicing assay. During the splicing of 
XBP-1 mRNA, a 26bp intron is removed. 
 
Briefly, total RNA from the CHIKV-, SINV-, or mock-infected cells was 
extracted and converted to cDNA, as described in Section 2.2.4, followed by 
PCR amplification of XBP-1 spliced gene products using XBP-1 splicing-
specific primers. Amplified products were further resolved in 2.5% agarose 
gel and visualized using a UV Image-Quant machine (GE Healthcare, USA). 
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Cycling conditions: 
cDNA synthesis    30min at 50ºC 
Denaturation     3min at 95ºC 
PCR cycling (40 cycles)   30sec at 95ºC 
      30sec at 65ºC 
      40sec at 68ºC 
Final extension     2min at 68ºC 
Storage     4ºC (until use) 
 
2.2.6 Sample preparation for SDS-PAGE and Western blotting 
For SDS-PAGE and Western blotting, total cell lysates were prepared 
from virus-infected or drug-treated cells at indicated time points. Lysis of cells 
was achieved using ice-cold NET lysis buffer (20mM Tris, 100mM NaCl & 
1mM EDTA, all from Sigma-Aldrich, USA) containing 0.1% Triton X-100 
(Sigma-Aldrich, USA) with protease inhibitor cocktail (Roche, USA) for 30min 
and with continuous shaking. Next, cell lysates were clarified by centrifugation 
at 13,000rpm for 10min at 4ºC. Following centrifugation, supernatants were 
collected and quantified using Quick-Start Bradford protein assay kit (Bio-
Rad, USA)) before being resolved (2-5μg of protein) on 12% SDS-PAGE and 
subjected to Western blotting or silver staining. 
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2.2.7 SDS-PAGE 
A mini gel assembly unit (Bio-Rad, USA) was used to assemble the 
glass plates of 1mm thickness. Twelve percent polyacrylamide gels (pH 8.8), 
with stacking gel of 5% (pH 6.8), were prepared using 30% 
acrylamide/bisacrylamide aqueous solution, SDS, APS and TEMED (All from 
Bio-Rad, USA). Equal amounts of total proteins (2-5μg) were quantified using 
a Quick-Start Bradford protein assay kit (Bio-Rad, USA). The samples were 
diluted in 10μl of laemmli buffer and resolved in a 12% SDS-PAGE gel at a 
constant voltage of 80volts. The gels were either silver stained or subjected to 
Western blotting. Silver staining of protein gels was performed using mass-
spectrometry compatible silver stain kit (Pierce, Thermo Scientific, USA) 
exactly following the manufacturer’s described protocol. 
2.2.8 Western blotting 
After transfer of proteins onto 0.45μm pore size nitro-cellulose 
membranes (Bio-Rad, USA), blots were blocked overnight using a blocking 
solution (2% Fish gelatin or 2% BSA (Sigma-Aldrich, USA) in 1x PBS). 
Finally, blots were probed using primary antibodies against various proteins. 
All the antibodies used were diluted in blocking solution. After incubating with 
secondary HRP-conjugated antibodies, blots were developed using ECL 
detection reagent (GE healthcare, USA) and exposed on Amersham hyper 
films (GE Healthcare, USA) prior to development or visualized using Image-
Quant chemiluminiscent machine (GE Healthcare, USA). Where required, 
image processing and quantifications were done using ImageJ software. 
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2.2.9 Puromycin labeling of newly translated proteins 
Cells (HEK-293T or MEFs, 2x105 cells/well) were seeded in a 12-well 
plate (Nunc, USA) and incubated overnight. Next, cells were mock infected or 
infected with CHIKV-Ross using MOI of 1 followed by mock-treatment or 
treatment with salubrinal or guanabenz (5μM) for 6, 12, 24 or 48h. At 
indicated time points, post-infection/treatments, cells were pulsed with 
puromycin (10μg/ml) (Sigma-Aldrich, USA) for 40min and washed once with 
ice-cold PBS. Cells were harvested in NET lysis buffer and total protein was 
quantified, as described above (Section 2.2.6). Roughly 10μg of each of the 
total protein lysates were resolved on 12% SDS-PAGE followed by Western 
blotting using an anti-puromycin antibody, as described above (Section 2.2.7 
& 2.2.8). Tunicamycin treatment at 2μg/ml for 2h was used to induce ER 
stress in mock- or CHIKV-infected cells. Cyclohexamide treatment at 22μg/ml 
for 1h was used to inhibit protein translation independent of ER stress. CHIKV 
infection of cells at indicated time points was probed using an anti-CHIKV 
capsid antibody and actin was used to demonstrate the loading control. 
2.2.10 Construction of pEGFP-CHIKV clones 
For construction of CHIKV clones, a mammalian expression vector 
pEGFP-C1 (Clontech, USA) containing a strong CMV promoter was used to 
clone all non-structural (nsP1, nsP2, nsP3 & nsP4) and major structural (C, 
E2 & E1) genes. Briefly, viral RNA was extracted using a QIAamp Viral RNA 
Mini Kit (Qiagen, USA) followed by an amplification of viral genes using 
specific primers employing Superscript-III one step RT PCR with platinum Taq 
kit (Invitrogen, USA) in a thermal cycler (Applied Biosystems, USA). Amplified 
genes products were resolved on 1% agarose gels and eluted using the 
QIAquick gel extraction kit (Qiagen, USA). Next, each of the purified PCR 
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products was cloned in the pEGFP-C1 vector using the cloneEZ PCR cloning 
kit (Genscript, USA), following the manufacturer’s recommendations. To 
promote restriction digestion analysis for screening positive clones, nsP1 was 
cloned between HindIII-PstI restriction sites and nsP2, nsP3 nsP4 and C were 
cloned between XhoI-KpnI restriction sites. Likewise, E1 and E2 were also 
cloned between HindIII-BamHI restriction sites. Enzymes for restriction 
analysis were obtained from New England Biolabs, Singapore. Furthermore, 
each of the PCR and restriction digest positive clones were sequence verified 
using capillary DNA sequencing service from AITbiotec, Singapore. 
2.2.11 Transfection of plasmids 
Transfection of plasmid DNA in cells (HEK-293, HEK293T and MRC-
5, 8x104 cells/well) was achieved using JetPRIME transfection reagent 
(Polyplus-transfection, France) in a 24-well plate following the manufacturer’s 
protocol. Equal amounts of plasmid DNA (1-2μg) of each plasmids such as 
GFP-only, GFP-nsP1, -nsP2, -nsP3, -nsP4, -C, -E1, -E2 and pcDNA, FLAG-
CReP or FLAG-GADD-34 (the latter generously given by Prof. Shirish 
Shenolikar at Duke-NUS Graduate Medical School, Singapore) were 
transfected in cells incubated for 24-48h post-transfection to allow for 
sufficient translation of viral proteins. Before harvest, cells were washed using 
1x PBS (Gibco, USA) followed by cell lysis in NET lysis buffer and Western 
blotting as described in Section 2.2.6-8. Rough estimation of the transfection 
efficiencies for each of the GFP-fused plasmids was done using an inverted 
fluorescence microscopic (Olympus IX7A, USA). Visual scoring of GFP 
positive cells established the transfection efficiency of each of the plasmids 
between 70-90%, except for GFP-nsP2, -E1 and -E2 for which increased 
transfection efficiency was achieved by doubling the amount of plasmid DNA 
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used for transfection to reach the 70-90% efficiency that was desired. No cell 
cytotoxicity was observed for any of the CHIKV plasmids until 48h post-
transfection. However, expression of FLAG-CReP and FLAG-GADD-34 led to 
significant cell death at 24h post-transfection. 
2.2.12 siRNA knockdowns 
For siRNA knockdown studies, 50nM of each of the gene specific 
siRNA duplexes  (SABio’s, Singapore) were transfected in the cells (HEK-
293T, 5x104 cells/well) in a 24-well plates using JetPRIME transfection 
reagent, following the manufacturer’s described protocol. At 48h post-
silencing, cells were either mock or CHIKV-Ross infected using MOI of 1 for a 
further 20h before being harvested for protein and RNA analysis. In the case 
of HSP-90-specific knockdowns, cells (HEK-293T) were seeded at the density 
of 8x104 cells/well in a 24-well plate. After overnight incubation, 100nM of 
each of the HSP-90 specific siRNAs was transfected in the cells for 24h, 
followed by a mock or CHIKV-Ross infection using MOI of 1 for a further 24h 
to see the effects of HSP-90 knockdown on CHIKV replication. The 
sequences for each of the siRNAs used in this study are provided in Table-7. 
2.2.13 Immunofluorescence microscopy 
For immunofluorescence microscopy, cells were seeded at ~70% 
confluency on glass coverslips in a 12-well plate. Following overnight 
incubation, the cells were transfected with plasmids, as described in Section 
2.2.11, or infected with CHIKV-Ross or SINV using MOI of 1. Next, cells were 
fixed at indicated times post-infection or transfection using (80% v/v) ice-cold 
acetone (Sigma-Aldrich, USA) for 10min and further incubated overnight at 
4°C with blocking buffer (5% BSA in 1x PBS or 2% fish gelatin). Both primary 
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and fluorescence-conjugated secondary antibodies used were diluted in 
blocking buffer. Finally, coverslips were mounted on glass slides using 
prolong gold anti-fade mounting media (Invitrogen, USA) containing DAPI. 
Images were visualized and captured using an inverted fluorescence 
microscope (Olympus IX71, USA) or upright confocal microscope (Zeiss, 
Germany). Where required, images were processed using ImageJ software or 
Zeiss image analysis software. 
2.2.14 Co-immunoprecipitation assay 
Cells (HEK-293T, 1x105 cells/well) were transfected with plasmids, 
such as the control GFP vector or CHIKV-nsPs, using the methods described 
in Section 2.2.11, or infected with CHIKV-Ross at MOI of 1. 
Transfected/infected cells were further cultured for 24h, washed once using 
cold PBS and lysed using NET lysis buffer (included protease inhibitor 
cocktail) for 1h with intermittent mixing at each 15min. The cell lysates were 
centrifuged at 14,000rpm for 30min at 4ºC and the supernatants were 
collected. Next, immunoprecipitations were performed using 2μg each of 
either the polyclonal anti-GFP antibody (Abcam, USA) or HSP-90α or HSP-
90β antibodies (SABio’s, Singapore). Antibodies were added in each of the 
clarified lysates that were further incubated overnight in a cold room using an 
end-over-end rotor/mixer (Barnstead Thermolyne, USA). The immune 
complexes formed were pulled out of solution using 50μl/reaction of protein 
A/G beads slurry (Pierce, USA). Before elution, beads were washed 3-times 
using 0.5ml of NET lysis buffer and immune complexes were eluted in 
laemmli buffer, followed by boiling of samples for 15min. Eluted samples were 
centrifuged at 14,000rpm before being analyzed by SDS-PAGE and Western 
blotting.  
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2.2.15 Sample preparation for mass-spectrometry 
For pull-down and mass-spectrometry sample preparation, cells (HEK-
293T, 5x106) were seeded in 150mm tissue culture dishes (Corning, USA) 
followed by transfection (10μg each) of plasmids containing individual GFP-
fused CHIKV-nsPs. At 24h post-transfection, cells were lysed in 200μl of lysis 
buffer (10mM Tris-HCl pH 7.5, 150mM NaCl, 0.5mM EDTA, 0.5% NP-40 
(Sigma, USA) and complete protease inhibitor cocktail (Roche, USA)) for 
30min with constant mixing. Lysates were further clarified at 20,000xg for 
10min and supernatants were collected and adjusted to a volume of 0.5ml 
using a dilution buffer (10mM Tris-HCl pH 7.5, 150mM NaCl, 0.5mM EDTA 
and complete protease inhibitor cocktail). Separately, GFP-TrapA beads 
(~30μl each, ChromoTek, Germany) were equilibrated in 0.5ml of dilution 
buffer for 15min. Next, equilibrated beads were added to clarified lysates 
followed by overnight incubation with constant mixing using an end-over-end 
rotor/mixer. After overnight incubation, beads were spun down at 2,500xg for 
2min and washed once with 0.5ml ice-cold wash buffer (10mM Tris-HCl pH 
7.5, 150mM NaCl, 0.5mM EDTA), once with 0.5% NP-40 in PBS and twice 
with 50mM ammonium bicarbonate. Finally, elution was done using 60μl of 
mass-spectrometry compatible elution buffer (0.25% Rapigest SF (Waters 
Corporation, USA) in 50mM ammonium bicarbonate) and subjected to in-
solution mass-spec analysis using LC/ESI/MS/MS mass-spectrometry at the 
Duke proteomic facility, USA. For mass-spectrometry data analysis, trypsin-
digested protein peptides were matched against the Swiss-Prot 2013x 
database using the ‘Mascot’ database search algorithm. The data analysis 
was performed using software (‘Scaffold’ version 4.3.2), using a peptide 
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threshold of min 95% and a protein threshold of min 99.9% (i.e. minimum four 
peptides).  
Pathway analysis of mass-spectrometric proteomic data using 
Ingenuity or KEGG software was kindly performed by Asst. Prof. Sujoy Ghosh 
at the Computational Biology center at Duke-NUS Graduate Medical School, 
Singapore. Pathway analysis of protein list uniquely interacting with nsP4 was 
done using online available tools ‘KEGG’ (http://www.genome.jp/kegg/) and 
InnateDB (http://www.innatedb.com). 
2.2.16 Animal infections in vivo 
All the animal work related to this study was performed at the BSL-2 
animal facility at Duke-NUS Graduate Medical School, Singapore, under an 
experimental protocol (IACUC#578) approved by the Animal Care & Ethics 
Committee at Singapore General Hospital. Mice (Sv/129 strain) that are 
deficient in type-I IFN receptors (A-129) were initially purchased from B&K 
Universal (UK). Virus was diluted in sterile PBS from frozen stocks. Infection 
of mice was achieved by injecting ~50-100pfu of CHIKV-Ross or -EAS in a 
20μl volume of saline, by the footpad-injection route. For drug treatments 
during infection, mice were either mock-treated or drug-treated with the 
indicated drug concentrations, starting from Day 0. Control mice were given 
maximum dose of DMSO (5%) diluted in saline as the vehicle control or 
“mock” treatment. Animals were euthanized at humane end points and blood 
or organs were collected at indicated time points for viremia, cross-sectioning 
of tissues for histological analysis and serum cytokine analysis.  
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2.2.16.1 Limb swelling measurements 
For measuring swelling in the infected limbs, animals were briefly held 
in a mouse restraint and the measurement was done using a standard flexible 
surgical ruler (Roboz surgical instruments, USA). 
2.2.16.2 Tissue processing 
Muscle tissues from infected/treated animals or controls were 
harvested and washed with ice-cold PBS before frozen in OCT compound 
(Tissue-Tek, USA) at -80ºC freezer. Next, tissues were frozen-sectioned to 
~10μm thickness using a cryostat (Leica, Germany). Following sectioning, 
tissues were fixed with cold acetone and air-dried before being subjected to 
immunostaining or H&E (Hematoxylin & Eosin) staining. For H&E staining, 
tissues were treated with 0.1% Mayers Hematoxylin (Sigma, USA) for 10min 
followed by a 5min wash with water. Sections were further treated with 0.5% 
Eosin (Sigma, USA) for 2min, washed with water and then sequentially 
dehydrated using 50%, 70%, 95% and 100% ethanol. The final dehydration 
step was done in xylene (Sigma, USA) and slides were mounted with 
permount (Bio-world, USA) for visualization and image capture. Image 
visualization and capturing was performed using an inverted fluorescence 
microscope (Olympus IX71, USA). For immunofluorescence staining of frozen 
sectioned tissues, the immunostaining protocol was followed as described 
earlier (Section 2.2.13) before being visualized using an upright confocal 
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2.2.16.3 Serum cytokine analysis 
For cytokine analysis, Quantikine ELISA kits (R&D systems, USA) 
were used following the manufacturer’s described protocol. Briefly, equal 
volumes of serum that had been obtained from each of the mice at a given 
time point were pooled for individual experimental groups and the 
concentrations of each of several pro-inflammatory cytokines were measured.  
2.2.17 Statistical tests 
Statistical comparison of results were performed by unpaired 
Student’s t-tests using GraphPad Prism 5.0 software or using Microsoft Excel 
software, with p<0.05 considered statistically significant. For more than two 
comparisons, one-way ANOVA was used. 
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Chapter 3. CHIKV infection modulates the Unfolded Protein Response 
3.0 Introduction 
ER stress is characterized by disequilibrium in the ER folding 
machinery due to excess accumulation of misfolded or unfolded proteins in 
the ER. In response to ER stress, cellular machinery reacts through UPR via 
three simple mechanisms. First, it reduces the burden of newly synthesized 
proteins that are translocated to the ER. Second, it increases the capacity of 
the ER to handle misfolded or unfolded proteins through transcriptional 
induction of UPR target genes that are components of the ER folding 
machinery. If homeostasis cannot be attained then a third mechanism of cell 
death is induced. Classically, UPR is known to be involved in maintaining 
cellular homeostasis linked to protein folding processes. Recent studies have 
expanded the role of UPR in various other cellular processes, including 
cholesterol metabolism, inflammation, cell differentiation and energy 
regulation (Rutkowski and Hegde, 2010; Wang and Kaufman, 2012). 
Furthermore, the roles of UPR during many diseases, including viral 
infections, have also been well described (He, 2006). This forms a good 
rationale to study UPR processes during CHIKV infection and to explore key 
UPR target proteins that could be used to treat CHIKV infections. The UPR 
transduces its signals through three transmembrane domains: IRE-1, ATF-6 
and PERK. IRE-1 and ATF-6 activation leads to transcriptional induction of 
chaperones and protein-degradation machinery proteins (Fig-3-1). However, 
activation of PERK leads to protein translation arrest and, eventually, cell 
death through apoptosis (Fig-3-1). Virus replication and translation in a cell 
results in ER stress, followed by UPR. Therefore, it is not surprising that many 
viruses have adapted to cope with the UPR machinery, as discussed in 
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Section-1.7. In this chapter, the growth rate of CHIKV in various mammalian 
cultured cells and the overall impact of CHIKV replication on UPR pathways 
have been studied. Responses in each of these pathways during CHIKV 
replication were benchmarked to SINV replication, which was known to 
induce protein translation arrest due to ER stress (Toribio and Ventoso, 
2010). These comparative response studies have revealed that the 
suppression of the PERK pathway and a delay in the activation of the IRE-1 
pathway occurs during CHIKV replication. Further characterization of the 
suppression of these processes was investigated by employing UPR-targeted 
chemical drugs, an over-expression system and a genetic knock-out cell line. 
The use of these tools has permitted mechanistic explorations into the role of 
cellular regulatory factors, CReP and GADD-34, which CHIKV utilizes to 
suppress the PERK pathway in the UPR.  
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Fig-3-1: Schematic illustration of the UPR. Three transmembrane proteins, 
IRE-1, ATF-6, and PERK are activated in response to ER stress. The 
dimerization and phosphorylation of PERK phosphorylates eIF2α and induces 
protein translation arrest and apoptosis through ATF-4. Similarly, dimerization 
and phosphorylation of IRE-1 lead to splicing in the XBP-1 mRNA, followed 
by transcriptional induction of protein degradation machinery proteins such as 
EDEM. Upon activation, ATF-6 is cleaved in the Golgi and acts as a 
transcription factor, which induces the transcription of protein folding 
machinery proteins, such as BIP, HSP-90 and p58IPK. The balance in UPR 
via IRE-1, PERK and ATF-6 is essential for maintaining cellular homeostasis 
during normal and diseased states. 
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3.1 Growth rate of CHIKV in various mammalian cell types 
Since the major focus of this study is to understand the mechanisms 
underlying the robust growth that is characteristic of CHIKV, the first aim of 
this project was to determine the infectivity and growth rate of CHIKV in 
various cultured mammalian cell types. For this, cells were infected with 
CHIKV at MOI of 1, followed by measurement of viral growth rate using real 
time RT-PCR for detecting viral RNA. A standard plaque assay technique was 
also used to measure the extracellular infectious virus particles. For real time 
RT-PCR detection of CHIKV RNA, a standard and published pair of primers 
for the nsP1 gene was used. The nsP1 gene can be used to quantify only 
genomic viral RNA (Hasebe et al., 2002). The results demonstrated that 
various mesenchymal cell types (human embryonic kidney cells (HEK-293), 
human lung fibroblast cells (MRC-5), human cervical epithelial cells (HeLa), 
and rat basophilic mast cell-like cells (RBL-2H3)) supported robust CHIKV 
replication (Fig-3-2). On the contrary, several key immune cells, such as 
peripheral blood monocytic cells (THP-1 & K562) and T lymphocytic cells 
(Jurkat) were poorly infected with CHIKV, suggesting that immune cells may 
not be the primary targets of CHIKV infection (Fig-3-2). These results not only 
describe a robust in vitro cell infection model system for CHIKV, but also 
emphasize the finding that immune cells are very weakly susceptible to 
CHIKV infections, which is consistent with previously published reports that 
examined monocyte-derived macrophages and T and B cells (Rinaldo et al., 
1975; Solignat et al., 2009; Sourisseau et al., 2007). 
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Fig-3-2: CHIKV growth rate in various mammalian cell types. Growth rate 
of CHIKV-Ross in various mammalian cell types are shown by real time RT-
PCR analysis of the CHIKV-nsP1 gene, normalized to 6h and actin or 
GAPDH mRNA. The error bars (± SD) are shown in blue on the graph. HEK-
293, MRC-5, HeLa, and RBL-2H3 cell lines support robust CHIKV replication, 
while THP-1, K562, and Jurkat cells only show limited CHIKV growth. This 
graph is representative of two independent experimental repeats.  
 
Very little is known about the status of UPR during alphavirus 
replication. Only limited studies have been published linking ER stress to 
apoptosis or innate immune responses, such as in the case of SFV and SINV 
infections, which utilize distinct mechanisms to avoid the host cellular 
response (McInerney et al., 2005; Ventoso et al., 2006). Therefore, this study 
investigates the impact of CHIKV replication on the UPR in comparison to its 
close relative, SINV. Based on the viral growth rate in various mammalian cell 
types (Fig-3-2), HEK-293 cells were chosen for the UPR studies as these 
cells support prolific CHIKV and SINV replication, reaching viral plaque assay 
titers of ~1011-12pfu/ml of cell supernatants and up to tens-of-thousands-fold 
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induction of viral RNA (Fig-3-3A & B). Although the kinetics of the release of 
viral particles was somewhat similar in both viral infections, the relative 
amount of viral RNA detected during SINV replication was much higher 
compared to CHIKV (Fig-3-3B). The explanation for this discrepancy lies in 
the fact that the detection primers used for SINV RNA (Sane et al., 2012), 
bind in the E2 gene and, thus, quantified both viral genomic and sub-genomic 
RNA. In comparison, the CHIKV primers used only detected genomic RNA. 
Also, it is important to note that alphaviruses synthesize excess sub-genomic 
RNA compared to genomic RNA, although only the viral genomic RNA is 
packaged inside the mature virus particles (Frolova et al., 1997; Strauss and 
Strauss, 1994). Nevertheless, these growth kinetic studies have identified 
HEK-293 cells as a relevant cell culture infection model that sustains robust 
CHIKV and SINV growth. HEK-293 cells have also been used prominently by 
other groups for studying molecular pathways including UPR (Lee et al., 
2003). Importantly, similar growth rate of CHIKV and SINV in HEK-293 cells 
also make this a relevant model for undertaking a comparative analysis of the 
UPR signaling. 
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Fig-3-3: HEK-293 cells support prolific replication of CHIKV and SINV. 
HEK-293 cells were infected with MOI of 1 of CHIKV-Ross or SINV and at 
indicated time points post-infection plaque assays were performed using cell 
supernatants to quantify the infectious virus particles produced (left Y-axis on 
the graphs) at each time point. Similarly, viral RNA was quantified at each 
time point using real time RT-PCR for CHIKV-nsP1 gene or SINV-E2 gene 
and normalized to 3h and actin mRNA (right Y-axis in the graphs). The error 
bars (± SD) are shown in blue on the graph. (A) CHIKV and (B) SINV display 
similar growth rate in HEK-293 cells. Thus, these cells present as a model to 
compare the UPR pathways activated during CHIKV and SINV infections. 
Data in this figure are representative of three independent experimental 
repeats. 
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3.2 ATF-6 signaling during CHIKV and SINV infections 
The excess translation of viral proteins during virus replication triggers 
the UPR. The UPR results in signaling through three integral domains in the 
ER, ATF-6, IRE-1 and PERK.  Therefore, both the overall and specific impact 
of CHIKV and SINV replication on each of these UPR signaling arms was 
investigated. Activation of ATF-6 induces the transcription of chaperones and, 
therefore, increases the protein folding capacity of the ER. This is quite a 
significant cellular response during viral replication since failure to do so could 
result in persistent ER stress. In order to achieve a proper comparison of the 
UPR between the two viruses it was confirmed that a homogenous infection 
was achieved during both viral infections when HEK-293 cells were infected 
using MOI of 1. The data obtained by staining the infected cells for dsRNA 
(an intermediary step in RNA virus replication) over a time course of 48h, 
followed by immunofluorescence microscopy, showed that ~90% of the cells 
were positive for dsRNA staining from 12h post-infection in both CHIKV- and 
SINV-infected cells (Fig-3-4).  
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Fig-3-4: Immunofluorescence microscopy confirming homogenous 
CHIKV and SINV replication in HEK-293 cells. Cells (HEK-293) were 
cultured on coverslips and were either mock-infected or CHIKV-Ross- or 
SINV-infected using MOI of 1. At indicated time points post-infection, cells 
were fixed and stained with dsRNA (red) to probe for virus replication. DAPI 
staining for nuclei (blue) was used as a background control and un-infected 
cells were used as a negative control. These images demonstrate that CHIKV 
and SINV have relatively similar growth rate in vitro with the majority of cells 
infected beginning 6h after infection.  
 
After establishing that homogenous infection was achieved by both 
CHIKV and SINV in HEK-293 cells, the next experiment was to compare ATF-
6 signaling responses during CHIKV and SINV replication. Cells were infected 
with equal doses (MOI-1) of either CHIKV or SINV. At various time points 
post-infection, including 0, 3, 6, 12, 24 and 48h, cells were harvested and 
analyzed for proteins using Western blotting and RNA using real time RT-
PCR. Activation of ATF-6 is marked by its translocation to the Golgi where it 
is proteolytically cleaved and further translocate to the nucleus to act as a 
transcription factor. The western blotting data showed that CHIKV infection 
induced both transmembrane ATF-6 protein (~100kDa) and its cleaved 
product, cytosolic (~36kDa) ATF-6 (Fig-3-5A). Cleaved ATF-6 acts as 
transcription factor and regulates the expression of protein folding 
chaperones such as BIP, HSP-90 and p58IPK. The data showed that CHIKV 
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infection significantly induced translation of BIP (6-fold) at 48h post-infection 
compared to un-infected (0h) cells (Figs-3-5A & B). Similarly, translation of 
protein folding chaperones, HSP-90 (~2 fold) and p58IPK (~1.5 fold) were 
significantly induced from 12h and 24h post-CHIKV infections compared to 
the un-infected (0h) control (Fig-3-5A & B). Here, it is noteworthy that p58IPK 
is a negative regulator of PERK signaling. In contrast to CHIKV, SINV 
infection did not result in translational induction of either transmembrane ATF-
6 or cleaved ATF-6 at any of the time points measured (Fig-3-5A). Similar to 
the levels of ATF-6, protein levels of BIP were also not altered at any time 
points measured for SINV infection (Fig-3-5A). Likewise, the translation of 
other chaperones, HSP-90 and p58IPK, was also not significantly altered 
during SINV infection (Fig-3-5A). Densitometry quantifications of Western 
blots discussed in Fig-3-5A are also provided in Fig-3-5B. Taken together, 
this data suggested that CHIKV infection significantly activates ATF-6 
signaling in the UPR, whereas SINV infection seems to weakly induce this 
branch of the UPR. 
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Fig-3-5: ATF-6 signaling responses during CHIKV and SINV replication. 
HEK-293 cells were mock- or CHIKV-Ross- or SINV-infected using MOI of 1. 
At each time point post-infection, cells were lysed in NET lysis buffer and total 
proteins were resolved on 12% SDS-PAGE, followed by Western blotting 
using antibodies specific to the ATF-6 pathway component proteins. Un-
infected cells were used as baseline control and actin was used as a loading 
control. (A) Western blots demonstrate induction of BIP, increased 
transmembrane (100kDa) and cytosolic (36kDa) ATF-6, and that there are 
increased HSP-90 and p58IPK levels over the course of CHIKV infection. In 
contrast, SINV infection does not result in increased levels of BIP, 
transmembrane or cytosolic ATF-6, HSP-90 or p58IPK. This suggests 
stronger activation of the ATF-6 pathway by CHIKV than SINV. (B) Quantified 
amounts of the proteins from panel (A) are displayed. Data in this figure are 
representative of two independent experimental repeats.  
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3.3 The IRE-1 signaling during CHIKV and SINV infections 
IRE-1 is a type-I transmembrane protein with a cytoplasmic kinase 
domain, a cytoplasmic endoribonuclease domain, and a luminal dimerization 
domain. During UPR, activation of IRE-1 leads to the splicing of XBP-1 
mRNA. The splicing of XBP-1 by IRE-1 removes 26 nucleotides from the 
spliced mRNA causing a frame-shift that results in translation of the spliced 
XBP-1 isoform (Yoshida et al., 2001). This form of XBP-1 is a potent bZIP 
transcription factor that binds to the UPRE and regulates the expression of 
ERAD machinery genes, including EDEM and Erdj4. To investigate IRE-1 
signaling during CHIKV and SINV infections, splicing of XBP-1 was examined 
using a widely-used PCR based XBP-1 splicing assay 
(http://ron.medschl.cam.ac.uk/protocols/XBP-1.splicing.04.09.16.pdf). For 
this, total RNA was extracted from CHIKV- or SINV-infected cells at various 
time points post-infection, followed by PCR amplification of the spliced XBP-1 
gene product. First, using virus-specific gene amplifications (nsP1 for CHIKV 
and E2 for SINV), it was demonstrated that comparable infection levels were 
attained at each of the time points during both CHIKV and SINV infections 
(Fig-3-6). Next, the XBP-1 splicing analysis showed that CHIKV replication 
weakly activated XBP-1 splicing, which could only be significantly detected at 
48h post-infection (Fig-3-6). As expected based on published studies (Back et 
al., 2006; Shang, 2005), a hybrid form of XBP-1, which is an artifact of the 
assay, was also detected (Fig-3-6). In contrast, SINV replication triggered 
more prominent splicing of XBP-1 and the spliced gene product was detected 
as early as 12h post-infection (Fig-3-6). In CHIKV infection, downstream 
effector genes such as XBP-1 and EDEM were also transcriptionally-induced 
at 48h post infection (Fig-3-7A). However, in case of SINV infection, 
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transcriptional induction of XBP-1 (starting at 3h) and EDEM (starting at 24h) 
further supported that SINV infection led to more profound activation of IRE-1 
starting early in the replication cycle compared to CHIKV (Fig-3-7B).  
 
 
Fig-3-6: Splicing of XBP-1 mRNA during CHIKV and SINV replication. 
Cells were infected at MOI of 1 with CHIKV-Ross or SINV and at indicated 
time points post-infection total RNA was extracted and converted to cDNA. 
Equal amounts of cDNA (1μg) were used for PCR amplification of the XBP-1 
spliced (s-XBP-1) form using specific primers against the spliced and un-
spliced (u-XBP-1) gene variants. Virus replication at each time point (in the 
same samples) was measured using PCR for the CHIKV-nsP1 gene or the 
SINV-E2 gene. Actin was amplified as the input RNA control and un-infected 
cells were used as a baseline control. On the gel, spliced products are lowest 
(444bp), the un-spliced product, u-XBP-1, is slightly higher (470bp) and a 
hybrid product formed during the assay (h-XBP-1) could also be detected 
(496bp). CHIKV infection delays IRE-1 activation compared to SINV infection, 
as evidenced by delayed splicing (48h) of XBP-1 mRNA. Data in this figure 
are representative of two independent experimental repeats.  
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Fig-3-7: Transcriptional analysis of IRE-1-targeted genes during CHIKV 
and SINV replication. In similar conditions and at the same time points 
described above in Fig-3-6 for the XBP-1 splicing assay, total RNA was 
extracted for real time RT-PCR amplification of IRE-1 effector genes, XBP-1 
and EDEM. Relative change in XBP-1 and EDEM transcripts during (A) 
CHIKV or (B) SINV infections are presented and normalized to actin mRNA 
and the un-infected control group. Error bars represented on the graphs are ± 
SD. Statistics were performed using unpaired Student’s t-test and considered 
significant if p<0.05. Significant results are indicated by *, whereas “ns” 
indicates “not significant”. CHIKV infection delayed transcriptional induction of 
IRE-1 effector genes compared to SINV infection. Data in this figure are 
representative of three independent experimental repeats.  
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3.4 PERK signaling during CHIKV and SINV infections 
Similar to IRE-1, PERK is also a type-I transmembrane protein with a 
cytoplasmic kinase domain. During UPR, activated PERK trans-
autophosphorylates at the threonine-980 (Thr-980) amino acid residue 
followed by the phosphorylation of its substrate eIF2α at its serine-51 (Ser-51) 
amino acid residue. The phosphorylated eIF2α limits translation initiation, 
causing global protein synthesis arrest. In general, PERK signaling in the 
UPR is critical during viral infections as it leads to global translation arrest and 
determines the fate of a cell during ER stress. Therefore, to investigate the 
effects of CHIKV and SINV replication on the PERK signaling branch of the 
UPR, the phosphorylation levels of PERK (Thr-980) and its effector protein 
eIF2α (Ser-51) were measured. Cells (HEK-293) were infected with CHIKV or 
SINV using MOI of 1 and at various time points post-infections total cell 
lysates were collected for Western blotting and total cells from the 
experimental duplicate wells were collected for real time RT-PCR analysis. 
The Western blotting data showed that CHIKV infection led to 
phosphorylation of PERK starting from 6h post-infection. However, the 
phosphorylation of eIF2α was not observed until 48h (Fig-3-8). This 
observation is rather intriguing because auto-phosphorylation of PERK should 
immediately phosphorylate its substrate eIF2α and result in global translation 
arrest. In addition to reducing protein load in the ER, phosphorylation of eIF2α 
also contributes to preferential translation of mRNAs encoding several short 
upstream (5’-3’ ORF) mRNAs such as ATF-4, which regulates the 
transcription of CHOP, eIF2αK and GADD-34. Both transcription and 
translation of CHOP and eIF2αK were unaltered during CHIKV infection and 
the transcription of GADD-34 was only induced at 48h post-infection (Figs-3-
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8, 3-9A). In contrast to CHIKV, SINV infection resulted in phosphorylation of 
PERK, followed by a dramatic increase in the phosphorylation levels of its 
substrate, eIF2α (Fig-3-8). Similarly, a significant increase in the protein 
levels of CHOP was observed starting 12h post-infection (Fig-3-8). SINV 
infection also resulted in transcriptional induction of CHOP, eIF2αK and 
GADD-34 genes (Figs-3-9B). Altogether, the data suggested that CHIKV 
infection modulated the PERK pathway signaling of the UPR by delaying the 
phosphorylation of eIF2α. SINV infection, in contrast, led to uncontrolled ER 
stress and early cell death that was characterized by induction of CHOP, an 
apoptotic marker protein. 
 
 
Fig-3-8: PERK signaling response during CHIKV and SINV replication. 
For kinetics of PERK signaling during CHIKV or SINV replication, cells (HEK-
293) were infected using MOI of 1 of CHIKV-Ross or SINV. At indicated time 
points post-infection, cells were lysed and analyzed by Western blotting using 
antibodies specific for PERK pathway component proteins. Activation of 
PERK signaling was determined by kinetic analysis of the phosphorylated 
forms of PERK and eIF2α. Actin was used as a loading control and un-
infected cells were used as a baseline control. Phosphorylation of PERK 
occurs at early time points in both CHIKV and SINV-infected cells; however, 
phosphorylation of eIF2α appears delayed in CHIKV-infected cells compared 
to SINV-infected cells. CHOP is also not induced in CHIKV-infected cells, in 
contrast to SINV-infected cells. These results are consistent with early 
induction of ER stress in SINV-infected cells that was not observed before 
48h in CHIKV-infected cells. Data in this figure are representative of two 
independent experimental repeats.  
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Fig-3-9: Transcriptional profile of genes targeted by PERK/ATF-4 during 
CHIKV and SINV replication. Relative changes in the transcript levels of 
PERK signaling effector genes such as eIF2αK, GADD-34 and CHOP were 
determined during (A) CHIKV or (B) SINV replication, using real time RT-PCR 
and normalized to actin and the un-infected control group. Error bars 
represented on the graphs are ± SD. Any change in the levels of mRNA was 
considered significant if p<0.05 by Students’ unpaired t-test. Significant 
results are indicated by *, whereas “ns” indicates “not significant”. CHIKV 
induced expression of GADD-34 only at the late time point of 48h, while SINV 
induced significant expression of eIF2αK, GADD-34 and CHOP at multiple 
early time points. This transcriptional activation profile is consistent with early 
activation of ER stress in SINV-infected cells, but only a partial and delayed 
(in the case of GADD-34) ER stress response in CHIKV-infected cells. Data in 
this figure are representative of three independent experimental repeats.  
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3.5 CHIKV infection suppress phosphorylation of eIF2α 
To investigate in detail the delayed phosphorylation of eIF2α that 
occurred during CHIKV infection (Fig-3-8), it was first confirmed that 
phosphorylation of eIF2α did not occur during early CHIKV replication using a 
secondary technique to Western blotting. For this, HEK-293 cells were grown 
on glass coverslips and infected with CHIKV or SINV using MOI of 1. At 24h 
post-infection, cells were fixed and stained for dsRNA to probe for virus 
replication and also probed for phosphorylated eIF2α. Immunofluorescence 
microscopy data confirm that during CHIKV replication the level of eIF2α 
phosphorylation was much reduced compared to during SINV replication and, 
indeed, appeared to be at the comparable levels to the un-infected control 
group (Fig-3-10).  
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Fig-3-10: Early CHIKV replication does not phosphorylate eIF2α. Cells 
(HEK-293) were cultured on tissue culture coverslips overnight, followed by 
mock-infection or infection with CHIKV-Ross or SINV using MOI of 1. At 24h 
post-infection for all groups, cells were fixed and prepared for 
immunofluorescence microscopy using antibodies specific for dsRNA (green) 
and the phosphorylated form of eIF2α (red). DAPI was used to stain nuclei in 
the cells. Upon phosphorylation, eIF2α also partially translocate to the 
nucleus, which is observed as an overlap (pink) with DAPI staining. CHIKV 
replication does not phosphorylate eIF2α compared to the SINV replication. 
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It was also confirmed that this phenotype (delay in the phosphorylation 
of eIF2α) during CHIKV replication was not limited to only HEK-293 cells. To 
replicate the data from Fig-3-8 in human lung fibroblast cells (MRC-5), cells 
were infected with CHIKV or SINV using MOI of 1 and, at indicated time 
points post-infection, total cells were collected for Western blotting. Cells in 
the duplicate experimental wells were fixed and immunostained for dsRNA to 
probe for virus replication. The microscopy images of immunostained cells 
confirmed that almost equal replication was achieved in MRC-5 cells during 
both the viral infections and nearly 95% of the cells were positive for dsRNA 
staining starting from 12h post-infections (Fig-3-11A). The Western blotting 
data in MRC-5 cells (Fig-3-11B) replicated the previously-obtained data in 
HEK-293 cells (Fig-3-8) and demonstrated that even though PERK was 
phosphorylated starting early (3h) in CHIKV replication, the phosphorylation 
of eIF2α did not occur until 48h post-infection (Fig-3-11B). On other hand, 
SINV replication triggered an increase in the phosphorylation of PERK, as 
well as induction in the phosphorylation of eIF2α at 6h post-infection (Fig-3-
11B). These data further confirmed the novel finding that CHIKV infection 
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Fig-3-11: CHIKV suppression of eIF2α phosphorylation in MRC-5 cells. 
MRC-5 cells were infected with MOI of 1 of CHIKV-Ross or SINV for 1h. At 
indicated time points post-infection, (A) cells were prepared for 
immunofluorescence microscopy or (B) lysed in NET lysis buffer for Western 
blotting. In (A), Infection of the cells at each time point is confirmed by 
immunofluorescence microscopy, using dsRNA staining (green) and a 
nuclear stain DAPI (blue) as a background control. Infection is observed to be 
homogenous for both CHIKV and SINV in MRC-5 cells. (B) For Western 
blotting, lysed samples were electrophoresed in a 12% SDS-PAGE followed 
by Western blotting using antibodies specific to phosphorylated-PERK 
(PERK-P, at Thr-980 residue), phosphorylated eIF2α (eIF2α-P, at Ser-51 
residue) and total eIF2α. Actin antibody was used to provide the loading 
control in Western blots. Un-infected cell controls are labeled 0h and were 
used as a baseline protein level control. PERK is activated early (starting at 
3h) during both the virus replications, but the eIF2α phosphorylation is 
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To interrogate whether modulation of the PERK pathway during 
CHIKV infection is due to the suppression of eIF2α phosphorylation, it was 
determined whether CHIKV infection could suppress phosphorylation of 
eIF2α in the presence of either thapsigargin or tunicamycin, the known 
inducers of UPR (Calfon et al., 2002; Treiman et al., 1998). Tunicamycin 
treatment blocks the N-linked glycosylation of newly-synthesized 
glycoproteins in the ER, which causes accumulation of misfolded proteins and 
UPR in the cell (Bassik and Kampmann, 2011). Thapsigargin has a different 
mode of action, as it inhibits the function of ER-resident calcium pumps, 
which, in turn, depletes the levels of calcium ions from the luminal side of the 
ER and triggers ER stress and UPR (Lytton et al., 1991). Using Western 
blotting, it was observed that treatment of cells with tunicamycin at a 0.5μg/ml 
dose for 6h was sufficient to induce UPR, which is shown by phosphorylation 











Fig-3-12: Tunicamycin induces ER stress. Cells (HEK-293) were treated 
with tunicamycin (0.5μg/ml) for 6h. Western blotting of cell lysates shows 
increased phosphorylation of eIF2α (eIF2α-P) and increased levels of BIP 
with drug treatment. CC stands for cell control in the experiment and was 
used as baseline control, whereas, GAPDH in the blot was probed as loading 
control. Tunicamycin treatment for 6h is sufficient to induce ER stress in cells.  
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 The optimal dose of thapsigargin treatment was chosen based on the 
published report that exposure of cells with thapsigargin at 0.1μM dose could 
induce phosphorylation of eIF2α (Kato et al., 2012). A 6h treatment time was 
selected for further experiments to rule out any potential undesired toxicity 
effects of these drugs during prolonged treatments. To assess the effects of 
CHIKV or SINV replication on thapsigargin- or tunicamycin-induced ER 
stress, cells (HEK-293) were infected with CHIKV or SINV using MOI of 1 for 
12h to allow for sufficient translation of viral proteins and were mock-treated 
or treated with thapsigargin (0.1μM) or tunicamycin (0.5μg/ml) for a further 
6h. Finally, cells were lysed for Western blotting analysis and the cell 
supernatants from each test were used for plaque assays.  
As expected, in presence of thapsigargin or tunicamycin, the levels of 
eIF2α phosphorylation were increased in un-infected cells compared to the 
mock-treated and un-infected control cells (Fig-3-13A & B), suggesting that 
the PERK pathway was activated in drug-treated cells. Consistent with the 
earlier data (Fig-3-8 and Fig-3-11B), CHIKV infection in the mock-treated 
cells, showed only baseline levels of eIF2α phosphorylation compared to the 
drug (thapsigargin or tunicamycin) -treated cells (Fig-3-13A & B). 
Interestingly, a significant reduction in the phosphorylation levels of eIF2α 
was noted in CHIKV-infected cells, even in the presence of thapsigargin or 
tunicamycin (Fig-3-13A & B). This data confirmed that, indeed, CHIKV 
replication suppresses the phosphorylation of eIF2α. In contrast, SINV 
infection showed increased phosphorylation of eIF2α in both mock- and 
thapsigargin- or tunicamycin-treated cells (Fig-3-13A & B). However, viral 
titers were reduced by thapsigargin or tunicamycin treatments in both CHIKV- 
and SINV-infected cells (Fig-3-14A & B
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Fig-3-13: CHIKV suppression of eIF2α phosphorylation in the presence 
of thapsigargin or tunicamycin. HEK-293 cells were mock-infected (CC) or 
infected with CHIKV-Ross or SINV using MOI of 1 for 12h to allow for viral 
proteins to translate, followed by treatment with (A) thapsigargin (0.1μM) or 
(B) tunicamycin (0.5μg/ml) for a further 6h. At 6h post-treatment, cells were 
lysed and Western blotting was performed to measure the phosphorylation 
levels of eIF2α in the experimental samples. Un-infected cells (CC) were 
used as a baseline level control. Total eIF2α was probed as another control to 
provide total eIF2α levels and (A) actin or (B) GAPDH were used as the 
loading controls. CHIKV infection suppresses thapsigargin and tunicamycin-
induced phosphorylation of eIF2α but SINV does not. Data in this figure are 
representative of two independent experimental repeats. 
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Fig-3-14: Thapsigargin or tunicamycin treatment reduces CHIKV and 
SINV infection. HEK-293 cells were mock-infected or infected with CHIKV-
Ross or SINV using MOI of 1 for 12h to allow for viral proteins to translate, 
followed by treatment with thapsigargin (0.1μM) for further 6h. At 6h post-
treatment, cell supernatants were collected for plaque assays to quantify the 
amounts of infectious virus particles released. Error bars represented on the 
graphs are ± SD. (A) Thapsigargin treatment significantly reduced CHIKV and 
SINV infections. (B) In an independent experiment, the mean viral titers of 
CHIKV and SINV were lower after tunicamycin treatment than mock 
treatment. However, this trend was only significant to a 90% confidence 
interval. The reduced viral titers after ER stress-inducing drug treatments 
suggest involvement of UPR in the replication cycles of both viruses. Data in 
this figure are representative of two independent experimental repeats. 
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3.6 Dissecting the role of phosphatases, GADD-34 and CReP in the 
suppression of eIF2α phosphorylation 
Key regulators of eIF2α phosphorylation are stress-induced GADD-34 
and endogenously expressed CReP. Both GADD-34 and CReP regulate the 
phosphatase activity of protein phosphatase-1c (PP1c) and de-phosphorylate 
eIF2α. In order to examine if either of these cellular phosphatases could have 
a direct or indirect role in de-phosphorylation of eIF2α during CHIKV or SINV 
infections, salubrinal, a specific chemical inhibitor that inactivates both the 
complexes formed by GADD-34 with PP1c and CReP with PP1c, was used. 
Salubrinal was first discovered as a selective inhibitor of eIF2α de-
phosphorylation and was shown to block the de-phosphorylation of eIF2α 
mediated by HSV replication (Boyce et al., 2005). The optimal dose (5μM) for 
salubrinal treatment was obtained from earlier published studies on HSV and 
dengue (Boyce et al., 2005; Umareddy et al., 2007). Next, to investigate the 
effects of salubrinal during CHIKV or SINV replication, cells (HEK-293) were 
infected with CHIKV or SINV using MOI of 1 or mock-infected for 1h, followed 
by treatment with a 5μM dose of salubrinal for 24h. After 24h post-infection 
and treatment, Western blotting was performed on cell lysates from each 
experimental group. Interestingly, the Western blotting data showed that 
salubrinal treatment increased the phosphorylation of eIF2α only in CHIKV-
infected cells, suggesting the involvement of CReP and/or GADD-34 in 
CHIKV-mediated de-phosphorylation of eIF2α (Fig-3-15). In SINV infection, 
salubrinal treatment did not result in any significant increase in the 
phosphorylation of eIF2α over mock-treated infected cells (Fig-3-15).  
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Fig-3-15: Salubrinal treatment influences CHIKV suppression of eIF2α 
phosphorylation. Cells (HEK-293) were mock-infected (CC) or infected with 
CHIKV-Ross or SINV using MOI of 1 for 1h, followed by treatment with a 5μM 
dose of salubrinal for 24h. At 24h post-infection/treatments, levels of the 
phosphorylated form of eIF2α (eIF2α-P, at residue Ser-51) were detected in 
each of the samples by Western blotting, using antibodies specific for eIF2α-
P, total eIF2α and actin. Salubrinal treatment increases phosphorylation of 
eIF2α during CHIKV infection, suggesting that the drug’s targets, CReP and 
GADD-34, are involved in CHIKV suppression of eIF2α phosphorylation. 
Salubrinal has no obvious effect on SINV infection, which already induces 
phosphorylation of eIF2α. 
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3.7 A significant role for CReP in the early phase of the CHIKV 
replication cycle 
Although comparison studies between CHIKV and SINV have 
revealed differential responses of alphaviruses towards UPR, the major focus 
of this study has been to understand the role of UPR in facilitating robust 
CHIKV growth. Thus, further investigation was focused only on CHIKV for 
mechanistic studies on the roles of CReP and GADD-34 during replication.  
To understand the detailed role of CReP and GADD-34 during CHIKV 
modulation of eIF2α phosphorylation, another drug, guanabenz, was used in 
subsequent experiments. Guanabenz is a selective inhibitor of the GADD-34-
PP1c phosphatase complex and also inhibits the de-phosphorylation of eIF2α 
during ER stress. Importantly, guanabenz does not affect the CReP-PP1c 
phosphatase complex, which maintains the homeostatic levels of eIF2α 
phosphorylation in the cell (Tsaytler et al., 2011). Because of their selective 
targets, salubrinal (GADD-34-PP1c & CReP-PP1c) and guanabenz (GADD-
34-PP1c) provide useful chemical tools that, used together, can differentiate 
the involvement of CReP and GADD-34 in CHIKV replication.  
Cells (HEK-293T) were infected with CHIKV using MOI of 1 for 1h, 
followed by a mock-treatment or treatment with a 5μM dose of either 
salubrinal or guanabenz) for 12h. At 12h post-infection or -treatment, cells 
were harvested for Western blotting to measure the levels of eIF2α 
phosphorylation and the amounts of viral protein synthesized. The data 
showed that salubrinal treatment increased the phosphorylation of eIF2α in 
both the un-infected and CHIKV-infected groups, compared to mock-treated 
group (Fig-3-16A & B). Guanabenz treatment, on the other hand, had no 
effect on the phosphorylation of eIF2α in both the un-infected and infected 
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groups compared to mock-treated groups (Fig-3-16A & B). Viral infection 
levels in each of the test groups were probed by using an antibody specific to 
the capsid protein of CHIKV. Interestingly, the level of capsid protein was 
reduced in the presence of salubrinal treatment compared to both mock- or 
guanabenz-treated infection groups (Fig-3-16A & B). This is a significant 
finding that suggests that salubrinal treatment resulted in increased levels of 
eIF2α phosphorylation during early (12h post-infection) CHIKV replication by 
targeting the CReP activity. Also, an increased level of eIF2α phosphorylation 
was correlated with a decrease in CHIKV capsid protein translation during 
salubrinal treatment (Fig-3-16A & B). The effect of guanabenz treatment on 
CHIKV capsid protein levels was minimal compared to the salubrinal, 
suggesting that CReP has a major impact on CHIKV replication, compared to 
GADD-34 (Fig-3-16A & B). Total eIF2α was probed to measure the baseline 
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Fig-3-16: Salubrinal and guanabenz treatment demonstrates a link 
between CReP and CHIKV suppression of eIF2α phosphorylation. HEK-
293T cells were infected with CHIKV-Ross using MOI of 1 for 1h and treated 
with salubrinal (5μM) and guanabenz (5μM) or mock-treated for 12h. (A) At 
12h post-infection/treatment, cells were collected for Western blotting using 
antibodies specific for total eIF2α, phosphorylated eIF2α (eIF2α-P) and actin. 
Salubrinal treatment of infected cells results in increased eIF2α-P and 
reduces the amounts of viral capsid protein compared to the mock- or 
guanabenz-treated groups. (B) The band intensities of eIF2α-P to total eIF2α 
are presented as a ratio of eIF2α-P over total eIF2α and normalized to un-
infected control group. Capsid protein was also quantified, normalized to the 
levels in the mock-treated infection control.  Band intensities were quantified 
using ImageJ software. Both salubrinal and guanabenz treatments reduce 
detection of viral proteins suggesting their influence on CHIKV replication; 
however, the stronger effect of salubrinal treatment reveals the role of CReP 
in early CHIKV replication. Data in this figure are representative of two 
independent experimental repeats. 
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Since phosphorylation of eIF2α leads to protein translation arrest in a 
cell, the amounts of newly synthesized proteins in both CHIKV-infected and 
salubrinal- or guanabenz-treated infected cells were measured. 
Cyclohexamide and tunicamycin treatments were used as experimental 
controls because cyclohexamide treatment blocks protein translation, 
independent of ER stress, and tunicamycin treatment induces translation 
arrest, mediated by ER stress. The amounts of newly-synthesized proteins 
were measured in each group by labeling the newly translated proteins using 
puromycin. The antibiotic puromycin is an analogue of the 3’ end of the 
aminoacyl-t-RNA and causes premature termination of protein translation by 
binding to the newly-synthesized polypeptide chains (Miyamoto-Sato et al., 
2000). Moreover, this incorporation of puromycin can be detected using an 
antibody against puromycin. Therefore, the amount of puromycin labeled 
corresponds to the rate of protein synthesis in the cell.  
Cells (HEK-293T) were infected with CHIKV using MOI of 1 for 1h, 
followed by mock-treatment or treatment with a 5μM dose of salubrinal or 
guanabenz for the indicated times post-infection (12, 24 and 48h). Cells were 
then pulsed with puromycin and, finally, harvested for Western blotting. The 
results showed that at both 12h and 24h post-infection almost equal amounts 
of new proteins were translated in the mock-treated CHIKV-infection group 
compared to the mock-treated un-infected group (Fig-3-17A & B Lanes-3, 4 & 
5). As expected and consistent with the initial data in Fig-3-8, at the time point 
when eIF2α was phosphorylated (48h), protein translation was also blocked 
in infected cells (Fig-3-17C, Lanes-3, 4 & 5). This set of data, again, validates 
that CHIKV replication suppresses phosphorylation of eIF2α early (12h & 
24h– Fig 3-17A & B) in its replication cycle for efficient translation of viral 
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proteins. Interestingly, salubrinal treatment resulted in protein translation 
arrest in both infected and, to some extent, in un-infected treated groups 
starting from 24h post-infection (Fig-3-17B, Lanes-11 & 13 and Fig-3-17C, 
Lanes-6 & 8). This suggested that CReP could have a role in the early phase 
of replication. Guanabenz treatment, on the other hand, resulted in protein 
translation arrest that was only prominent at 48h post-infection and not at 12 
or 24h post-infection/treatment, suggesting delayed (48h) involvement of 
GADD-34 in CHIKV replication (Fig-3-17A & B, Lanes-12 & 14, and Fig-3-
17C, Lanes-7 & 9). The levels of the viral protein, capsid, in each test group 
were probed using a capsid-specific antibody (Fig-3-17A, B & C). Salubrinal 
treatment resulted in a substantial reduction of viral protein being translated at 
24h and 48h post-infection, compared to mock- and guanabenz-treated 
infection groups (Fig-3-17B, C & D). Guanabenz treatment had overall milder 
effects on the phosphorylation of eIF2α and CHIKV protein translation (Fig-3-
17B, C & D). 
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Fig-3-17: Time course of protein labeling experiments revealed a role 
for CReP in the early phase of CHIKV replication. Cells (HEK-293T) were 
infected with CHIKV-Ross using MOI of 1 and mock-treated or salubrinal- or 
guanabenz-treated at the dose of 5μM for (A) 12h, (B) 24h and (C) 48h. At 
the indicated times post-infection and treatment, newly-translated proteins in 
the cells were labeled using puromycin, as described in detail in Section 
2.2.9. At indicated time points post-labeling, cells were lysed and proteins 
were extracted, followed by Western blotting using an antibody specific for 
puromycin. Tunicamycin treatment was used to provoke ER stress-induced 
translation arrest and cyclohexamide treatment was used as a positive control 
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for protein translation arrest. Total viral infection in all samples was probed 
using an antibody against CHIKV-capsid and probing for actin was used as a 
loading control. (D) Quantification of capsid protein was determined by 
densitometry from panels (B-C) and is presented in (D), after normalization to 
the CHIKV infection control group. Due to high background, the densitometry 
of capsid in panel (A) was not performed. Salubrinal treatment induces CReP- 
and GADD-34- mediated protein translation arrest and reduces viral protein 
translation. Guanabenz, which targets GADD-34, only has a lesser effect, 
emphasizing the importance of CReP during CHIKV replication. 
 
Next, the transcriptional profiles of UPR component genes, including 
GADD-34 and CReP, were investigated in salubrinal- and guanabenz-treated 
cells after CHIKV infection. Cells were infected with CHIKV using MOI of 1, 
followed by mock-treatment or salubrinal- or guanabenz-treatment (5μM). 
Finally, cells were harvested at the indicated times post-infection/treatment (6, 
12, 24 & 48h) for total RNA extraction and real time RT-PCR analysis of UPR 
genes was performed. The transcriptional kinetics data revealed that viral 
replication was significantly reduced during salubrinal treatment (6-48h) (Fig-
3-18). Although, the guanabenz treatment group showed an initial reduction in 
CHIKV replication (6h and 12h post-infection), there was a progressive 
increase in virus replication as infection progressed, peaking at 48h (Fig-3-
18). This may well be due to the short half-life of guanabenz in cell culture.  
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Fig-3-18: Time course of salubrinal and guanabenz suppression of 
CHIKV replication. HEK-293T cells were infected with CHIKV-Ross using a 
MOI of 1, followed by mock-treatment or treatment with salubrinal or 
guanabenz, each at a 5μM dose. At indicated time points post-infection or -
treatment, total RNA was extracted and converted to cDNA for real time RT-
PCR amplification of the CHIKV-nsP1 gene. Relative changes in viral RNA 
(nsP1 gene) are presented after normalization to actin mRNA and to the 
levels of the CHIKV infection control group. Salubrinal and guanabenz 
treatments both reduce early CHIKV replication, but salubrinal allows 
sustained reduction in viral replication through 48h post-infection. Error bars 
represented on the graph are ± SEM. Statistical analysis was performed by 
comparing each treatment group to the CHIKV mock-treated infection control 
group at each time point using Student’s un-paired t-test and considered 
significant if p<0.05 (indicated by *). This graph is representative of three 
independent experimental repeats. 
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The kinetics data also revealed that the levels of CReP were induced 
early in the infection, starting from 12h post-infection (Fig-3-19A). As 
expected (Boyce et al., 2005), salubrinal treatment showed the trend of 
reduction in the levels of CReP but a statistically significantly reduction in the 
levels of CReP was only obtained at 48h post-infection/treatment compared 
to the mock-treated or guanabenz-treated groups (Fig-3-19A). Guanabenz 
targets only the GADD-34-PP1c complex and, therefore, guanabenz 
treatment had no effect on the CReP mRNA levels (Fig-3-19A). Furthermore, 
consistent with the data presented in (Fig-3-9), the levels of GADD-34 were 
only significantly induced at 48h post-infection (Fig-3-19B). Also, the mild 
inhibitory effects of guanabenz on the levels of GADD-34 transcription were 
only observed significantly at 24h post-infection or treatment and GADD-34 
was further induced transcriptionally at 48h (Fig-3-19B). Salubrinal treatment 
did not show any significant effects on the levels of GADD-34 (Fig-3-19B). 
Cumulatively, these data demonstrate the effects of eIF2α phosphorylation on 
viral protein synthesis, which could be influenced by salubrinal treatment. 
Salubrinal treatment increased phosphorylation of eIF2α and reduced viral 
protein translation by mainly targeting CReP and also GADD-34, which may 
have a potential role later in the viral replication cycle.  
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Fig-3-19: CHIKV infection induces CReP transcription starting early in 
the virus replication cycle. HEK-293T cells were infected with CHIKV-Ross 
using a MOI of 1, followed by mock-treatment or treatment with salubrinal or 
guanabenz, each at a 5μM dose.  At the indicated time points post-infection 
or treatment, total RNA was extracted and converted to cDNA for real time 
RT-PCR amplification of the (A) CReP and (B) GADD-34 transcripts. Relative 
changes in the CReP and GADD-34 gene transcripts are presented after 
normalization to actin mRNA levels and to the expression levels of the un-
infected control group. Induction of CReP during CHIKV infection was 
trending higher at 12h, but not statistically significant until 24h and 48h. 
GADD-34 was only induced significantly at 48h post-infection. Error bars 
represented in the graphs are ± SEM. Statistical analysis was performed 
using Students un-paired t-test and considered significant if p<0.05 (indicated 
by *). CHIKV infection induces transcription of CReP starting early in the 
replication cycle. Salubrinal but not guanabenz treatment significantly reduces 
CReP transcript levels at 48h compared to the un-treated CHIKV infection 
group, but has no effect on GADD-34. Data in this figure are representative of 
two independent experimental repeats. 
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To further investigate the regulation of CHIKV mediated de-
phosphorylation of eIF2α by CReP and GADD-34, FLAG-tagged CReP or 
GADD-34 plasmids were used to over-express these proteins. Cells (HEK-
293T) were transfected with 1μg each of FLAG-CReP or FLAG-GADD-34 and 
at 2h post-transfection cells were infected with CHIKV at MOI of 1. Control 
cells were transfected with an equal amount of pcDNA plasmid and also 
infected. At indicated time points post-infection (6h &12h), cells were 
harvested for Western blotting and blots were probed to measure the levels of 
eIF2α phosphorylation.  
The Western blot data showed the expression of FLAG-CReP was 
significantly lower compared to the FLAG-GADD-34 at both time points (Fig-
3-20A, Lanes-2, 3, 8, & 9). Over-expression of CReP during CHIKV infection 
could still suppress the phosphorylation of eIF2α at 6h and 12h (Fig-3-20A, 
Lanes-5 &11 and Fig-3-20B). However, the over-expression of FLAG-GADD-
34 had shown only minimal effects on the levels of eIF2α phosphorylation 
during CHIKV infection at 6h (Fig-3-20A, Lane-6) compared to pcDNA-
infected group (Fig-3-20A, Lane-4), which diminished at 12h post-infection 
compared to the CReP expression group and pcDNA-infection control group 
(Fig-3-20A, Lane-10, 11 & 12 and Fig-3-20B). Indeed, probing for CHIKV 
infection using capsid antibody demonstrated that CReP over-expression 
leads to an increase in viral protein translation at 6h, with a substantial 
increase at 12h post-infection, compared to the levels of the GADD-34 over-
expression group or pcDNA-transfected infection control group (Fig-3-20A, 
Lanes-5 & 11 and Fig-3-20C).  
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Transfection of plasmids also induced some degree of stress in the 
un-infected cells that is seen by increased baseline levels of eIF2α 
phosphorylation in pcDNA-transfected control cells (Fig-3-20A, Lanes-1 & 7), 
compared to the levels in infected-pcDNA-transfected cells where CHIKV 
infection mediates the suppression in phosphorylation of eIF2α (Fig-3-20A, 
Lanes-4 & 10 and Fig-3-20B). CReP and GADD-34 over-expression studies 
were not performed beyond the 12h time point due to toxicity induced by over-
expression of these two proteins occurring by the 24h time point and 
onwards. Altogether, this data strongly suggested the role of CReP in 
mediating the de-phosphorylation of eIF2α in the early phase of CHIKV 
replication cycle. 
  





Fig-3-20: Influence of CReP or GADD-34 on early CHIKV replication 
determined by over-expression studies. (A) Cells (HEK-293T) were 
transfected with 1μg each of the pcDNA plasmid, FLAG-CReP or FLAG-
GADD-34. After 2h post-transfection, cells were infected with CHIKV-Ross 
using MOI of 1 for a further 6 and 12h. At indicated times post-infection, cells 
were collected for Western blotting using antibodies specific to 
phosphorylated eIF2α, total eIF2α, FLAG, CHIKV-capsid and actin, as a 
loading control. The ratio of band intensities of phosphorylated eIF2α to the 
total eIF2α for 6h and 12h was calculated from measurements obtained using 
ImageJ software and normalized to the levels at pcDNA control group and 
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presented (labeled PE/E & pcDNA). (B) The densitometry measurements for 
PE/E & pcDNA reported in panel (A) are also shown in graph format. (C) 
Similarly, densitometry quantifications of CHIKV-capsid were normalized to 
actin and to the capsid levels detected in the control plasmid-transfected 
infected (pcDNA+CHIKV) group. Over-expression of CReP reduces 
phosphorylation of eIF2α, resulting in increased translation of viral proteins at 
6 and 12h post-infection. GADD-34 over-expression did not have any 
significant effect on CHIKV protein translation. Data in this figure are 
representative of two independent experimental repeats. 
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3.8 Probing the importance of GADD-34 using genetic knock-out cells  
So far, the data investigating the mechanism of de-phosphorylation of 
eIF2α during CHIKV replication have shown an early role of CReP and 
implied the involvement of GADD-34 is delayed to later time points. The role 
of GADD-34 in CHIKV replication was further investigated in the context of 
GADD-34 deficiency using GADD-34 knock-out (GADD-34-/-) mouse 
embryonic fibroblasts (MEFs). These cells are spontaneously immortalized, in 
contrast to the conventional immortalization method using SV-40. These cells 
grew very slowly with doubling time more than a week. They also were 
extremely sensitive to CHIKV infection, with cell death starting 24h post-
infection. This limited the kinetic analysis of these cells to early time points of 
6, 12 and 24h post-infection. For this, WT and GADD-34-/- cells were infected 
with CHIKV using MOI of 1 and, at indicated time points post-infection, cells 
were harvested for Western blotting and real time RT-PCR. The Western 
blots (6, 12 & 24h) showed that at 24h post-infection the level of eIF2α 
phosphorylation in GADD-34-/- cells was significantly higher than in WT 
control cells (Fig-3-21A). Some degree of phosphorylation of eIF2α was also 
observed in WT infected cells (Fig-3-21A). Nevertheless, the CHIKV infection 
was significantly reduced (as measured by detection of CHIKV capsid protein) 
starting 6h post-infection in GADD-34-/- cells compared to the WT infected 
cells (Fig-3-21A). The eIF2α was probed to measure the total eIF2α in the 
cells and actin was used as a loading control. The quantitative real time RT-
PCR data showed that, indeed, the replication of CHIKV (nsP1 transcript) was 
much slower in GADD-34-/- cells compared to WT cells (Fig-3-21B). As 
expected from Fig-3-19A, the levels of CReP in the WT cells were 
significantly induced during CHIKV infection at 24h post-infection (Fig-3-21C). 
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Intriguingly, CHIKV infection in GADD-34-/- cells did not result in transcription 
induction of CReP (Fig-3-21C), suggesting that the GADD-34 deficiency may 
also influence CReP expression in cells.  
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Fig-3-21: GADD-34 deficiency demonstrates its contribution to the 
suppression of eIF2α phosphorylation and CHIKV replication.  Cells, 
both WT and GADD-34-/- MEFs were infected with CHIKV-Ross using MOI of 
1 for 6, 12 and 24h. At each time point post-infection, cells were collected for 
(A) Western blotting to probe for the levels of eIF2α phosphorylation and 
CHIKV-capsid (infection). Total eIF2α and actin were probed as baseline and 
loading controls. (B) At each time point post-infection (12 and 24h), total RNA 
was extracted from the test samples and used for real time PCR amplification 
of CHIKV-nsP1. Relative change in viral RNA (detected by nsP1 gene) is 
presented after normalization to actin mRNA at each time point and the nsP1 
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levels in the WT cells at the 12h time point.  (C) Transcription levels of CReP 
at 12 and 24h post-infection in WT and GADD-34-/- cells normalized to actin 
and un-infected control levels. Error bars represented on graphs are ± SEM. 
For panels (B-C), results were considered significant when p<0.05 (indicated 
by *), determined by Students un-paired t-test. GADD-34 deficiency increases 
phosphorylation of eIF2α and limits CHIKV replication. GADD-34-/- cells 
failure to induce CReP during CHIKV infection further implicates the role of 
GADD-34 in regulation of CReP. 
 
To understand if the decrease in CHIKV replication in GADD-34-/- 
cells was due to poor translation of viral proteins, puromycin labeling of 
newly-translated proteins was performed. Both WT and GADD-34-/- MEFs 
were infected with CHIKV using MOI of 1 and incubated for 12h. At 12h post-
infection, cells were pulsed with puromycin and the newly labeled proteins 
were detected using an antibody against puromycin. The data showed that 
CHIKV infection in WT cells had no effect on protein translation compared to 
un-infected control cells (Fig-3-22A). Interestingly, protein translation during 
CHIKV infection was reduced in GADD-34-/- cells compared to the un-
infected GADD-34-/- cells and WT-un-infected or -infected cells (Fig-3-22A, 
B). Similarly, the effect of tunicamycin and cyclohexamide treatments on the 
protein translation was much more pronounced in both un-infected or CHIKV-
infected GADD-34-/- cells compared to their WT counterparts (Fig-3-22A, B). 
Densitometry quantifications of capsid also showed reduced viral protein 
(capsid) translation in GADD-34-/- cells compared to WT cells (Fig-3-22C). 
Actin levels were used as the loading control and cyclohexamide treatment 
was used as a positive control in the assay. Together, this data showed a 
clear involvement of GADD-34 in CHIKV-mediated de-phosphorylation of 
eIF2α. The question of whether GADD-34 is involved in the early phase of the 
CHIKV replication cycle or has a role in the delayed phase of replication is still 
obscure.  
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Fig-3-22: GADD-34 deficiency negatively influences protein translation 
in cells. Cells, WT and GADD-34-/- were infected with CHIKV-Ross at MOI of 
1 followed by incubation for 12h. At 12h post-infection, cells were pulsed with 
puromycin at 10μg/ml to label newly synthesized proteins in the cell. The 
detailed procedure for puromycin labeling is described in section 2.2.9. (A & 
B) Western blotting was performed on cells harvested at 12h and newly-
translated proteins were detected using anti-puromycin antibody. Viral 
infection levels were probed using the CHIKV-capsid antibody and actin was 
used to demonstrate the loading control. Tunicamycin treatment (2μg/ml) for 
1h was used to induce UPR-mediated translation arrest. Cyclohexamide 
treatment (22μg/ml) for 1h was used to inhibit protein translation, independent 
of UPR and was used as a positive control in the assay. (C) Densitometry of 
capsid protein levels from panel (A) is presented after normalization to levels 
of the CHIKV infection control group (WT cells). GADD-34 deficiency affects 
cellular translation resulting in reduced CHIKV protein synthesis.  
  
C. 
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Overall the results presented in this chapter demonstrated the early 
(6, 12, 24h) suppression of eIF2α phosphorylation during CHIKV replication. 
Mechanistically, this occurs through homeostatic phosphatase CReP and 
stress-induced phosphatase GADD-34 during the early and late phases (48h) 
of CHIKV replication. The question of how CHIKV utilizes these phosphatases 
is addressed in Chapter-4. 
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Chapter 4. CHIKV nsP4 modulation of eIF2α phosphorylation  
4.0 Introduction 
In the previous chapter (Chapter-3) the impact of CHIKV replication on 
UPR was shown and data pertaining to the role of the cellular phosphatases, 
CReP and GADD-34, in mediating the suppression of eIF2α was presented. 
To address the question of how CHIKV utilizes these phosphatases, it was 
investigated whether any of the individual CHIKV-encoded proteins play a 
role in the suppression of phosphorylation of eIF2α. Many viral proteins are 
known to modulate UPR signaling for their successful replication. To do so, 
viral proteins either physically block the activation of PKR or PERK or make 
complexes with eIF2α-dephosphorylating regulatory phosphatases, CReP 
and GADD-34 (He, 2006). In the case of HCV infection, NS5A protein 
physically interacts with PKR in its dimerization domain, blocking its auto-
phosphorylation and, thereby, inhibiting the phosphorylation of eIF2α (Gale et 
al., 1998). Similarly, the E2 protein of HCV binds to PERK and inhibits the 
phosphorylation of eIF2α (Pavio et al., 2003). Overexpression of HCV E2 can 
even suppress tunicamycin- or thapsigargin-induced phosphorylation of eIF2α 
(Pavio et al., 2003). Another mechanism that viruses utilize to suppress 
phosphorylation of eIF2α is by forming complexes with cellular regulatory 
phosphatases. The gamma134.5 protein of HSV binds and makes protein 
complexes with PP1c and GADD-34 (Cheng et al., 2005; He et al., 1998). 
These protein complexes de-phosphorylate eIF2α during HSV infection 
(Cheng et al., 2005; Chou and Roizman, 1994). African swine flu virus (ASFV) 
protein DP71L also binds to PP1c and recruits GADD-34 for the de-
phosphorylation of eIF2α (Zhang et al., 2010). Over-expression of DP71L 
suppresses phosphorylation of eIF2α, even in the presence of tunicamycin 
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treatment (Zhang et al., 2010). Therefore, in light of these studies, the 
potential of CHIKV viral factors to suppress eIF2α phosphorylation was 
investigated.  
4.1 Cloning and expression of CHIKV-encoded proteins 
Individual CHIKV non-structural (nsP1, nsP2, nsP3 & nsP4) and 
structural (C, E1 & E2) genes were cloned into a CMV promoter-driven 
pEGFP-tagged vector (pEGFP-C1), in order to study the role of viral proteins 
in modulating eIF2α and also to obtain further mechanistic insight into the 
mode of suppression reported in this study (Rathore et al., 2013). The 
pEGFP-C1 vector has been optimized for enhanced expression of cloned 
proteins and contains kozak consensus translation initiation sequences 
flanking the EGFP gene (Kozak, 1987). This vector also codes for a red-shift 
variant of WT-GFP for brighter fluorescence for microscopic visualization 
purposes. CHIKV genes cloned in pEGFP-C1 are expressed as GFP-fused 
proteins with EGFP being fused at the N-terminus. The CHIKV RNA is 
~11.8kb in size, containing a 7mG cap at the 5’ end and a poly-A tail at the 3’ 
end (Fig-4-1A). The major virally encoded non-structural and structural 
proteins are separated by a sub-genomic promoter element (26S) present in 
the CHIKV RNA (Fig-4-1A). The viral RNA from a low passage virus stock of 
CHIKV-Ross (GenBank: HM045811.1) was extracted using a viral RNA 
extraction kit, followed by amplification of individual CHIKV-encoded genes 
directly from the viral RNA, using gene specific primers (Section-2.1.4.1) and 
employing a one-step RT-PCR kit. The schematic diagram in Fig 4-1B shows 
the map of the pEGFP-C1 expression vector with the sequence of the multiple 
cloning sites (MCS) shown. The PCR-amplified CHIKV gene fragments 
(Table-8) were cloned into the expression vector using restriction 
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endonuclease sites introduced in the forward and reverse primers used in the 
amplification (Section-2.1.4.1). The nsP1 gene was cloned between HindIII-
PstI restriction sites, while nsP2, nsP3, nsP4 and C were cloned between 
XhoI-KpnI restriction sites. Likewise, E1 and E2 were amplified, restriction 
endonuclease digested and cloned between HindIII-BamHI restriction sites 
(Table-8). Restriction analysis of pEGFP-nsP1, pEGFP-nsP2, pEGFP-nsP3, 
pEGFP-nsP4, pEGFP-C, pEGFP-E2 and pEGFP-E1 clones (after digesting 
with the respective enzymes used in the cloning) showed the correctly sized 
CHIKV fragments were released (Fig-4-1C).   
 
Table-8: List of CHIKV non-structural and structural genes that were 
cloned in a mammalian expression vector, pEGFP-C1. The molecular 
sizes of each of the CHIKV genes, along with its starting codon, are listed. 
The enzymatic restriction sites used for cloning are also listed. 
 
CHIKV-genes Molecular size 
(bp) 
Starting codon Restriction sites 
nsP1 1608 ATG (Met) HindIII-PstI 
nsP2 2391 ATA (Ile) XhoI-KpnI 
nsP3 1590 GCA (Ala) XhoI-KpnI 
nsP4 1833 TAT (Tyr) XhoI-KpnI 
Capsid 468 TGC (Cys) XhoI-KpnI 
E2 1212 CCA (Pro) HindIII-BamHI 
E1 1518 AGA (Arg) HindIII-BamHI 
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Fig-4-1: Construction of pEGFP-CHIKV clones. (A) Schematic organization 
of CHIKV mRNA. (B) A vector map of pEGFP-C1 used for cloning of 
individual CHIKV genes. (C) For restriction digestion analysis, plasmid 
pEGFP-nsP1 was digested with HindIII-PstI restriction enzymes, and pEGFP-
nsP2, -nsP3, -nsP4 and pEGFP-C were digested using XhoI-KpnI restriction 
enzymes. Similarly, pEGFP-E1 and E2 were digested with HindIII-BamHI 
restriction enzymes. Digested products were resolved on a 1% agarose gel to 
detect the release of the correctly sized CHIKV cloned fragments. The data 
together demonstrates the successful cloning of individual CHIKV non-
structural and structural genes. 
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To confirm the expression of the sequence-verified clones, 1-2μg of 
each of the plasmids were transfected into HEK-293 cells in a 24-well plate, 
followed by incubation for 24h to achieve sufficient translation of each of the 
plasmid-encoded proteins, as described in detail in Section-2.2.11. At 24h 
post-transfection, cells were harvested and expression of individual proteins 
was confirmed by resolving each of the transfected cell lysates on 12% SDS-
PAGE, followed by Western blotting using an anti-GFP antibody. Results 
shown in Fig-4-2 confirmed the expression of individual non-structural and 
structural proteins and that each protein migrated approximately according to 
the calculated molecular weights (Fig-4-2). Expression of GFP-E1 resulted in 
two extra bands, in addition to an expected band size of 87kDa. Potentially, 
the higher protein size band could be a multimeric form of E1 while the lower 
size band could merely be a degradation product (Fig-4-2).  
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Fig-4-2: Expression and characterization of pEGFP-CHIKV clones. Cells 
(HEK-293) were transfected with 1-2μg of CHIKV plasmids using the 
JetPRIME transfection reagent, followed by an incubation period of 24h. At 
24h post-transfection, cells were lysed and the lysates were separated on a 
12% SDS-PAGE. The samples were then subjected to Western blotting using 
an antibody specific to GFP protein. All the transfected CHIKV genes were 
expressed and resolved at expected band sizes for each of the GFP-fused 
CHIKV proteins. “CC,” indicates the mock-transfected cell control. All the non-
structural and structural proteins expressed from CHIKV gene fusion 
constructs migrate to the expected molecular weights in the gel. 
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4.2 Over-expression of CHIKV nsP4 suppresses phosphorylation of 
eIF2α 
To study the impact of individual CHIKV proteins on phosphorylation 
of eIF2α, the question whether expression of any of these CHIKV genes 
could suppress tunicamycin-induced phosphorylation of eIF2α was 
investigated. Tunicamycin is an inducer of ER stress and known to 
phosphorylate eIF2α (Novoa et al., 2003). Individual GFP-fused CHIKV non-
structural and structural genes were transfected in HEK-293 cells and allowed 
to translate for 24h. At 24h post-transfection, cells were treated with 0.5μg/ml 
of tunicamycin to induce phosphorylation of eIF2α in these cells. Tunicamycin 
treatment was performed for 24h before cells were fixed and visualized using 
immunofluorescence confocal microscopy or harvested for Western blotting. 
Interestingly, data using confocal microscopy shows that the expression of 
CHIKV nsP4 (a RNA-dependent RNA-polymerase) efficiently suppressed the 
phosphorylation of eIF2α, even in the presence of tunicamycin (Figs-4-3). 
Expression of other CHIKV proteins, such as nsP1, nsP2, nsP3, C, E2, E1 
and the GFP-only expression (as control) did not show any significant effect 
on the phosphorylation levels of eIF2α (Fig-4-3).  
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Fig-4-3: Confocal microscopy imaging reveals suppression of 
tunicamycin-induced eIF2α phosphorylation by CHIKV-nsP4. HEK-293 
cells were cultured on coverslips overnight, followed by transfection (1μg) of 
each of the GFP-tagged CHIKV gene plasmids for 24h to allow for the 
sufficient translation of each of the viral proteins tested. At 24h post-
transfection, cells were mock-treated or treated with a 0.5μg/ml dose of 
tunicamycin and further incubated for 24h for the induction of ER stress in 
tunicamycin-treated cells. Finally, cells were fixed and prepared for 
immunofluorescence microscopy imaging. A detailed method describing 
sample preparation for immunofluorescence microscopy is available in 
Section-2.2.13. Confocal microscopy images presented in this figure show a 
decrease in the levels of eIF2α-phosphorylation (red) only in GFP-nsP4 
expressed cells (green) and not in GFP-nsP1, -nsP2, -nsP3, -C, -E2 and -E1 
expression groups. Un-transfected and mock-treated cells were used to set 
the laser intensity at the background level for eIF2α-phosphorylation and un-
transfected but tunicamycin-treated cells were used as a positive control. The 
data demonstrates involvement of nsP4 in the suppression of eIF2α 
phosphorylation. 
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Experiments performed using a secondary technique of Western 
blotting further confirmed that, indeed, nsP4 expression suppresses 
tunicamycin-induced phosphorylation of eIF2α (Fig-4-4A, B). The eIF2α 
phosphorylation suppression by nsP4 ranged between 65-94% depending on 
the expression of nsP4 in various independent experiments (Fig-4-3A, B).  
 
 
Fig-4-4: Western blotting confirms the suppression of tunicamycin-
induced eIF2α phosphorylation by CHIKV-nsP4. HEK-293 cells were 
transfected with equal amounts (1μg) of (A) GFP-only and GFP-fused nsP2, 
nsP4, C or (B) GFP-fused nsP4, E2 or E1 for 24h and then further treated 
with tunicamycin (0.5μg/ml) for 24h. This was followed by Western blotting 
analysis using antibodies against the phosphorylated form of eIF2α, total 
eIF2α and GFP. Anti-GAPDH was used for the loading control. The changes 
in band intensities of phosphorylated eIF2α over total eIF2α were calculated 
using imageJ software and are presented as % eIF2α-P over total eIF2α. 
Significance was calculated using Student’s un-paired t-test and considered 
significant if p<0.05 (indicated by *). Western blots support that CHIKV nsP4 
suppresses the phosphorylation eIF2α. Data in this figure are representative 
of two independent experimental repeats. 
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To rule out any possibility of a cell-line specific effect in the result, 
GFP-CHIKV constructs were transfected into the MRC-5 fibroblast cell line. 
The results showed a similar trend of suppression of eIF2α phosphorylation 
when MRC-5 cells were transfected with GFP-nsP4 (Fig-4-5). Expression of 
other proteins such as GFP-nsP1, -nsP2 and GFP-only tested in the 
experiment did not affect the phosphorylation of eIF2α (Fig-4-5). Altogether, 
this data suggested a significant involvement of CHIKV nsP4 in mediating the 





Fig-4-5: CHIKV-nsP4 suppresses tunicamycin-induced phosphorylation 
of eIF2α in MRC-5 cells. MRC-5 cells were transfected with 1μg each of 
GFP only, GFP-nsP1, GFP-nsP2 or GFP-nsP4 for 24h and further treated 
with tunicamycin at 0.5μg/ml for 24h followed by Western blotting using 
antibodies against phosphorylated eIF2α, eIF2α (for total protein) and GFP. 
Actin was used to probe the loading control. Relative changes in band 
intensities of phosphorylated eIF2α were calculated using ImageJ software 
and are presented as % phosphorylation of eIF2α over total eIF2α.  
Significance was calculated using Student’s un-paired t-test and considered 
significant if p<0.05 (indicated by *). “ns” indicates “not significant”. CHIKV 
nsP4 suppresses eIF2α phosphorylation in MRC-5 cells.  
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4.3 Proteomic analysis of CHIKV nsPs pull-down by mass-spectrometry. 
The above data showed the role of CHIKV nsP4 in the suppression of 
eIF2α phosphorylation, indicating a wider involvement of host protein 
interactions that could be required to execute this suppression process. This 
coincided with the earlier described functions of cellular regulatory 
phosphatases, CReP and GADD-34, in the suppression of eIF2α 
phosphorylation during CHIKV infection (Section-3.7, 3.8). This is interesting 
because in the case of HSV and ASFV infections, virally-encoded proteins 
interact with PP1c (a substrate for CReP and GADD-34) and help recruit 
regulatory phosphatase complexes containing GADD-34 that de-
phosphorylate eIF2α (Cheng et al., 2005; Chou and Roizman, 1994; He et al., 
1997; Zhang et al., 2010). The question of whether these interactions also 
occur during CHIKV infection prompted the evaluation of viral-host protein 
interactions using a systems level approach. To explore the influence of 
individual CHIKV nsPs on host cellular proteins, GFP-tagged CHIKV plasmids 
(described above in Section-4.1) were used. Each of the GFP-tagged CHIKV 
nsPs were used to transfect HEK-293T cells and incubated for 24h at 37°C. 
The cell extracts were treated with GFP-TrapA beads in order to pull-down 
interacting protein partners, according to the method described in Section-
2.2.15.  
These pull-down samples were subjected to in-solution trypsin digest 
followed by LC/ESI/MS/MS mass-spectrometric analysis at the Duke 
University Proteomics Facility, Durham, NC, USA. The peptide sequences 
obtained after mass-spectrometry were matched against the Swiss-prot 
2013x database using the ‘Mascot’ database search algorithm. The software 
Scaffold 4.3.2 was used to validate MS/MS based peptide and protein 
	   128	  
identifications. Protein identifications were accepted if they could be 
established at greater than 99.9% probability. Similarly, peptide identifications 
were accepted only if they could be established at greater than 95% 
probability and contained at least 4 identified peptides. Peptide probabilities 
were assigned by the peptide prophet algorithm (Keller et al., 2002) and 
protein probabilities were assigned by protein prophet algorithm (Nesvizhskii 
et al., 2003). The data provided a comprehensive list of host proteins that 
potentially interact with CHIKV nsPs but not with GFP (full list is available in 
the Appendix-4.0). A summary of the data is shown in the form of Venn 
diagrams, obtained from Scaffold software, representing the numbers of 
proteins uniquely interacting or overlapping in their association with multiple 
GFP-nsPs (Fig-4-6).  
 
 
Fig-4-6: Venn diagrams showing total number of proteins that uniquely 
interacted with CHIKV-nsPs. Venn diagrams showing the total numbers of 
proteins that were found to interact with each of the GFP-pull-down proteins 
are shown. The mass-spectrometry data file was analyzed with Scaffold 
software, using a protein threshold of 99.9% and a peptide threshold of 95%. 
Several proteins uniquely interacting with each of the nsPs were identified 
that did not interact with the GFP-only control. Many identified proteins 
interacted with multiple CHIKV nsPs. 
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Table-9: List of host phosphatases identified by mass spectrometry 
from the CHIKV nsP4 pull-down 
 Protein-phosphatases Exclusive unique 
peptides matched# 
1. Serene/threonine protein phosphatase 2A, 
65kDa regulatory subunit A alpha, PPP2RA 
8 
2. Serene/threonine protein phosphatase 6 
regulatory subunit 3, PP6R3 
7 
3. Protein phosphatase 1G or PP1c 4 
#Data analysis was done using a peptide threshold of 95% and protein 
threshold of 99.9% with minimum peptide counts of 4. 
 
 
Data analysis of the proteins identified by mass-spectrometry revealed 
several protein phosphatases that were uniquely associated with CHIKV-
nsP4 pull-down (Table-9). A particularly interesting protein identified in this 
experiment was PP1c phosphatase (Table-9), since the protein PP1c forms a 
regulatory complex with both CReP and GADD-34 and mediates the de-
phosphorylation of eIF2α (Brush et al., 2003; Jousse et al., 2003). These 
interactions have not previously been reported for other alphaviruses and this 
suggests that they could be specific to CHIKV. To further confirm the 
interaction between nsP4 and PP1c in CHIKV-infected cells, biochemical pull-
down was performed. HEK-293T cells were mock-infected or infected with 
CHIKV-Ross using a MOI of 1. At 24h, cells were lysed using NET lysis buffer 
and pull-down was performed using a nsP4 specific antibody (Fig-4-7). As 
expected, Western blotting of pull-down samples using nsP4 and PP1c 
specific antibodies clearly demonstrated that PP1c was co-precipitated with 
CHIKV-nsP4 (Fig-4-7). This data confirms the physical interaction between 
nsP4 and PP1c during CHIKV replication in infected cells (Fig-4-7). 
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Fig.4-7: Co-immunoprecipitation of PP1c with nsP4 from CHIKV-infected 
cells. Western blotting on nsP4 pull-down samples from mock- or CHIKV-
infected cells, followed by detection of nsP4 and PP1c using specific 
antibodies. (A) Pull-down of 68kDa nsP4 from CHIKV-infected cells is shown. 
(B) nsP4 pull-down co-precipitated the 37kDa PP1c subunit. PP1c interacts 
with nsP4 in CHIKV-infected cells. 
 
 
To explore this further, the protein sequences of CHIKV-nsP4, GADD-
34 and CReP were compared (Fig-4-8) to determine if known motifs required 
for the assembly of high molecular weight protein phosphatase complexes 
required for de-phosphorylation of eIF2α are present in the nsP4. The 
sequence comparison indicates the presence of conserved charged residues 
(RRRA) in the C-terminus of nsP4 (Fig-4-8). These residues in nsP4 are 
similar to the Ala-Arg motifs that are required for the assembly of high 
molecular weight protein phosphatase complexes, which de-phosphorylate 
eIF2α during HSV infection (Cheng et al., 2001). The presence of the Ala-Arg 
motifs suggests that they aid in the formation of the protein phosphatase 
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complex, which include nsP4 and PP1c. There are two known binding sites 
for PP1c in the GADD-34 sequence, KVRF and RARA (Fig-4-8) (Brush et al., 
2003). Interestingly, another potential PP1c binding site in CHIKV-nsP4 could 
be FEKLRG, which is somewhat homologous compared to another reported 
PP1c binding site in CReP, FNRLQG (Fig-4-8) (Jousse et al., 2003). Although 
further detailed biochemical studies are merited to verify these predicted 
interaction sites, the sequence similarities may explain why PP1c was co-
precipitated by nsP4 pull-down (Table-9 and Fig-4-7). 
 
 
Fig-4-8: The C-terminus of CHIKV nsP4 contains potential PP1c binding 
sites. Sequence comparison of nsP4 with GADD-34 and CReP was obtained 
using the online available Clustal-Omega tool. Known PP1c binding sites in 
GADD-34 are KVRF and RARA (underlined green). A similar charged cluster 
is also highlighted in nsP4 (RRRA). Another potential binding site of PP1c in 
CReP is FNRLQG, which also contains homology to the sequence present in 
nsP4, FEKLRG (highlighted yellow). Identical residues in the alignment are 
denoted by (*) and (:) and (.) denotes conserved and semi-conservative 
substitutions, respectively. Sequence alignment suggests a potential binding 
site for PP1c in nsP4. 
 
Several of the proteins that appeared in the pull-down/mass 
spectrometry analysis have also been identified in earlier published studies 
that examined host protein interactions with CHIKV or related alphaviruses 
(Table-10), supporting the validity of the pull-down method used here. 
Examples of proteins identified here and in prior studies are G3BPs (GTPase 
activating protein (SH3 domain) binding protein), G3BP1 & G3BP2, and INT-9 
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(integrator complex subunit) (Table-10). G3BP1 was shown to interact with 
SINV proteins nsP2, nsP3 and nsP4 in various different studies (Atasheva et 
al., 2007; Cristea et al., 2006; Frolova et al., 2006; Varjak et al., 2013). 
Indeed, in the GFP-nsPs pull-down mass-spectrometry lists obtained here, 
G3BP1 was identified by CHIKV nsP2, nsP3 and nsP4 pull-down (Table-10), 
suggesting that these interactions may be conserved among alphaviruses. 
Similarly, G3BP2 and INT9 were exclusively identified in the nsP3 pull-down 
in this study and in previously published studies (Cristea et al., 2006; Frolova 
et al., 2006). The interactions of G3BP proteins with nsP3 have been shown 
to have functional consequences for CHIKV and SFV replication (Fros et al., 
2012; Panas et al., 2012). Another protein that was exclusively identified in 
the nsP2 pull-down sample was kinesin light chain-1 (KLC) (Table-10). KLC 
was also previously shown to interact specifically with CHIKV nsP2 using a 
yeast-2-hybrid screen (Bourai et al., 2012). Several other proteins that 
associated with CHIKV nsPs (Table-10), such as eukaryotic translation 
elongation factor (EF2), heat-shock protein-90 (HSP-90), glucose regulated 
protein-75 (GRP-75), 2’, 3’-cyclic nucleotide 3’ phosphodiesterase (CNP), 
ribosomal protein S25 (RS25) and ribosomal protein L36 (RL36), have also 
been reported to be significantly enriched during CHIKV infection (Abere et 
al., 2012).  Identification of proteins that are known to be enriched in virus-
infected cells further supported the relevance of the protein associations 
identified using the expression of individual CHIKV proteins to the context of 
CHIKV infection.  
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Table-10: List of selected proteins identified in the proteomics data and 
also reported by others to be associated with alphavirus replication. A 
list of selected proteins that were found to interact with GFP-tagged CHIKV-
nsPs in the protein pull-down mass-spectrometry data that were also reported 
in other interaction studies performed on alphaviruses. 
 
 GFP-nsPs pull-down  
Protein 
names 




TBB5 + + + + + SINV-nsP3 (Frolova et al., 
2006), SINV-nsP4 (Cristea 
et al., 2006) 
DHX9 + + + + - SINV-nsP3 (Cristea et al., 
2006) 
SFV-infection (Varjak et al., 
2013) 
EF2 + + + + + SINV-nsP3 (Cristea et al., 
2006), CHIKV-infection 
(Abere et al., 2012), SFV-




- - + + - SINV-nsP4 (Cristea et al., 
2006), CHIKV-infection 
(Abere et al., 2012), SFV-
infection (Varjak et al., 
2013) 
PABP + - + + - SINV-nsP2 (Atasheva et 
al., 2007), SFV-infection 
(Varjak et al., 2013) 
IRS4 - - + + - SINV-nsP4 (Cristea et al., 
2006), SFV-infection 
(Varjak et al., 2013) 
G3BP1 - + + + - SINV-nsP2 (Atasheva et 
al., 2007), SINV-nsP3 
(Cristea et al., 2006), 
(Frolova et al., 2006), 
SINV-nsP4 (Cristea et al., 
2006), SFV-infection 
(Varjak et al., 2013) 
G3BP2 - - + - - SINV-nsP3 (Cristea et al., 
2006), (Frolova et al., 
2006), SFV-infection 
(Varjak et al., 2013) 
RL10 - - + + - SINV-nsP3 (Frolova et al., 
2006) 
GRP-75 + + + + - CHIKV-infection (Abere et 
al., 2012), SFV-infection 
(Varjak et al., 2013) 
HNRL1 - + + - - SINV-nsP2 (Atasheva et 
al., 2007), SFV-infection 
(Varjak et al., 2013) 
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CNP - - + + - CHIKV-infection (Abere et 
al., 2012) 
RL32 - - + + - SINV-nsP3 (Cristea et al., 
2006) 
RS25 - - + + - CHIKV-infection (Abere et 
al., 2012) 
ACLY - + + - - SFV-infection (Varjak et al., 
2013) 
FBL - - + + - SINV-nsP4 (Cristea et al., 
2006) 
SERPH - - + + - SINV-nsP4 (Cristea et al., 
2006), SFV-infection 
(Varjak et al., 2013) 
PGK1 + + - - - SFV-infection (Varjak et al., 
2013) 
RL36 - - + + - CHIKV-infection (Wikan et 
al., 2014) 
PRS6B + + - + - SINV-nsP4 (Cristea et al., 
2006) 
LPRC + + - - - SFV-infection (Varjak et al., 
2013) 
INT9 - - + - - SINV-nsP3 (Cristea et al., 
2006) 
KLC4 - + - - - CHIKV-nsP2 (Bourai et al., 
2012) 
GRP-78 - - + - - SINV-nsP3 (Cristea et al., 
2006) 
SLC3A2 - - - + - SFV-infection (Varjak et al., 
2013) 
BAG-2 - - - + - SFV-infection (Varjak et al., 
2013) 
LASP1 - - + + - SINV-nsP3 (Cristea et al., 
2006) 




The obtained data also revealed many unique and novel potentially 
interacting partners of CHIKV nsP4 that were absent in pull-downs from other 
nsPs. Many of these proteins were translation machinery proteins such as 
spliciosome components and ribosome machinery components (Fig-4-9). 
Another interesting class of proteins that interacted uniquely with nsP4 was 
proteasome machinery components (Fig-4-10). These data substantially 
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expand the known specific interactions that can occur between CHIKV nsPs 
and host proteins to facilitate viral replication. 
 
Fig-4-9: Enrichment of ribosome-component proteins in CHIKV nsP4 
pull-down. The list of proteins that were found to interact with CHIKV-nsP4 in 
the pull-down mass-spectrometry data was submitted to the online pathway 
analysis tool ‘KEGG’. Proteins represented in red were enriched in the 
analysis output file and identified as known components of ribosome 
complexes. nsP4 associates with ribosomal component proteins. 
 






Fig-4-10: Enrichment of proteasome machinery component proteins by 
CHIKV nsP4 pull-down. The list of proteins that were only found to interact 
with CHIKV-nsP4 (and not GFP-only, nsP1, nsP2 and nsP3) in pull-down 
mass-spectrometry data was submitted to another online pathway analysis 
tool, ‘InnateDB’. This software analyses numbers of proteins from the query 
list that are representative of a particular molecular pathway in a cell and 
scores based on the coverage of that particular pathway. The red shaded 
proteins represent proteasome components that were enriched in the nsP4 
pull-down list. 
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4.4 siRNA validation of selected hits from mass-spectrometry proteomic 
screen  
In order to verify the host proteins that were pulled-down and identified 
by mass-spectrometry, some proteins were selected that are known to be 
associated with ER homeostasis or UPR signaling. For this, the list of nsP4-
interacting proteins was submitted to the Ingenuity pathway analysis tool. The 
output data demonstrate the top five canonical pathways that were 
significantly enriched using a list of proteins identified by nsP4 pull-down 
(Table-11). These pathways involved eIF2 signaling, regulation of eIF4 and 
p70S6K, mTOR signaling, the protein ubiquitination pathway and tRNA 
charging (Table-11).  
 
Table-11: List of top five canonical pathways that were enriched by 
nsP4 pull-down proteins using Ingenuity pathway analysis tool. The 
number of proteins enriched in a particular pathway determines the p-value 
and protein ratio for each pathway presented. 
 
 Canonical pathways P-value Protein 
Ratio 
eIF2 signaling 1.47e-46 55/181 
Regulation of eIF4 and p70S6K signaling 6.58e-19 29/158 
mTOR signaling 4.62e-14 27/189 
Protein ubiquitination pathway 8.23e-13 30/263 
tRNA charging 5.66e-11 12/38 
 
The following proteins identified by pull-down of nsPs were chosen for 
validation, using siRNA-mediated knock-down of the corresponding gene 
transcripts: (i) TRAF-2— a key regulator of the IRE-1 signaling arm of UPR, 
(ii) GCN1L— (general control of amino acid synthesis like 1) that, together 
with GCN2, regulates the phosphorylation of eIF2α, (iii) PPP2CA— a serene 
threonine protein phosphatase that de-phosphorylates proteins globally (iv) 
LARS— (leucyl tRNA synthetase), transcription of which is regulated by ATF-
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4 and CHOP (Han et al., 2013), (v) PABP— a poly A binding protein that has 
known functions in assisting replication of many viruses (Smith and Gray, 
2010), (vi) PRPF8— a pre-mRNA splicing factor that mediates the cellular 
translation process and (vii) PRKDC— a DNA-dependent protein kinase 
catalytic subunit that was the top hit in the mass-spec proteomic list.  
Cells (HEK-293T) were transfected with 50nM of each of the selected 
gene-specific siRNAs for 48h, as described in detail Section-2.2.12. At 48h 
post-transfection, cells were infected with CHIKV-Ross using MOI of 1 for a 
further 20h. Finally, total cells were harvested for RNA extraction and real 
time RT-PCR analysis and the cell supernatants were collected to measure 
the infectious virus particles released in knocked-down conditions. The real 
time RT-PCR data, combined with plaque assay, presented in Fig-4-11 
showed that the siRNA knockdown (left Y-axis, blue bars) of PABP (Fig-4-
11A), PPP2CA (Fig-4-11B), TRAF-2 (Fig-4-11C) and PRKDC (Fig-4-11D) 
resulted in significant reductions in the levels of CHIKV RNA (nsP1 transcript, 
red bars) (Fig-4-11A-D). Similarly, the amounts of infectious virus particles 
released in the cell supernatants (yellow bars) were also reduced in each of 
these knockdown conditions (Fig-4-11-A-D). Conversely, siRNA knockdown 
of GCN1L (Fig-4-11E) and PRPF8 (Fig-4-11F) resulted in increased levels of 
CHIKV RNA (Fig-4-11E, F). The amounts of infectious virus particles released 
were also increased in GCN1L and PRPF8 knockdown conditions (Fig-4-11E, 
F). The knockdown of LARS had no effect on the levels of either CHIKV RNA 
or infectious virus particles produced (Fig-4-11G). The data shown here 
confirmed that most of the host protein hits obtained from the mass-
spectrometry analysis (as interacting partners of CHIKV-nsPs) can directly 
influence CHIKV replication, either positively or negatively.  
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Fig-4-11A-G: Validation of CHIKV-nsPs pull-downs using gene-specific 
siRNA knockdowns. HEK-293T cells were transfected with 50nM each of 
siRNAs against (A) PABP, (B) PPP2CA, (C) TRAF-2, (D) PRKDC, (E) 
PRPF8, (F) GCN1L or (G) LARS for 48h, followed by infection with CHIKV-
Ross using MOI of 1 for a further 20h. For all panels, control cells were 
transfected with non-targeted siRNA (si-NT). At 20h post-infection, cells were 
collected for RNA extraction and cell-supernatants were collected for plaque 
assay. Knockdown of each of the target genes was validated using real time 
RT-PCR amplification of individual genes in all the test groups. CHIKV 
replication in each test sample was quantified using real time RT-PCR 
amplification of nsP1 gene and using plaque assays on cell supernatants. 
The left Y-axis on the graph represents relative change in mRNA of each 
target gene after normalization to actin and un-infected control (blue bars). 
The left Y-axis also represents the relative change in viral RNA (nsP1 gene) 
in both non-targeted and targeted siRNA treatments and was normalized to 
actin mRNA (red bars). The right Y-axis on the graph shows amounts of 
infectious virus particles produced in each of the test or control conditions 
(yellow bars). Error bars are ± SEM. Significance was calculated using 
Student’s un-paired t-test and considered significant if p<0.05 (indicated by *). 
The data shows that expression of PABP, PPP2CA, TRAF-2, and PRKDC 
positively influence CHIKV replication. However, expression of PRPF8 and 
GCN1L has a suppressive effect on CHIKV replication. Data in this figure are 
representative of two independent experimental repeats. 
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Overall, the data described in this chapter demonstrate a significant 
role of CHIKV-nsP4 in mediating the process of eIF2α de-phosphorylation, 
possibly in conjunction with CReP or GADD-34 during CHIKV replication. 
Furthermore, the pull-down mass-spectrometry data suggests that nsP4 of 
CHIKV is a highly networked protein with many interactions observed with 
various host cellular machinery proteins. Finally, siRNA knockdown of some 
of the selected proteins obtained by pull-down of individual GFP-nsPs 
demonstrated that these interactions are involved in the process of CHIKV 
replication.  
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Chapter 5. UPR as a drug target against CHIKV 
5.0 Introduction 
The cumulative studies so far have defined an important role for UPR 
in CHIKV replication. Cross talk between UPR component proteins and viral 
proteins were shown to be important for successful virus replication. From the 
results in Chapter-3 & -4, it was deduced that PERK signaling and, in 
particular, the two phosphatases (CReP & GADD-34) may be novel antiviral 
drug targets for reducing CHIKV replication. Equally promising as drug targets 
are the IRE-1 and ATF-6 signaling arms of the UPR based on prior results 
that CHIKV replication induces expression of protein folding chaperones (BIP, 
HSP-90 and p58IPK – Chapter-3, Fig-3-5) and an ERAD component protein 
EDEM (Chapter-3, Fig-3-7).  
Negative regulators of HSP-90 (ATF-6 induced) and ERAD machinery 
components (IRE-1 induced) are well described as an interesting class of 
antivirals against many RNA viruses (Geller et al., 2012; Noack et al., 2014). 
In view of the initial observation in Chapter-3 (Fig-3-5) that the level of HSP-
90 protein was significantly induced by CHIKV replication, exploration in detail 
whether HSP-90 could have a direct role in CHIKV replication was warranted. 
Importantly, HSP-90 was identified in the list of interacting proteins for 
CHIKV-nsPs in the mass-spectrometry proteomic data that was obtained from 
GFP-pull-down assays in Section-4.3. Moreover, HSP-90 is known to serve 
important functions in assisting the key steps of virus replication during 
influenza and HCV infections (Chase et al., 2008; Naito et al., 2007; Okamoto 
et al., 2006). HSP-90 is a validated drug target with many chemical inhibitors 
currently in various stages of clinical development (Neckers and Workman, 
2012). HSP-90 inhibitors have also been shown to reduce inflammation (Dello 
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Russo et al., 2006; Kim et al., 2009; Rice et al., 2008), because of the well-
documented role of HSP-90 in cellular inflammation, immunology, apoptosis 
and innate antiviral pathways (Joly et al., 2010; Tsan and Gao, 2009). Other 
advantages of HSP-90 inhibitors, as antivirals, include their minimal toxicity to 
the infected host and their ability to be refractory towards development of 
drug-resistance (Geller et al., 2007; Nakagawa et al., 2007). Recently, several 
studies have demonstrated the resistance-free antiviral activity of HSP-90 
inhibitors towards many viral infections, including poliovirus and RSV (Geller 
et al., 2013; Geller et al., 2007). The diverse functions of HSP-90 in cellular 
processes, along with its involvement during CHIKV infection, provides a 
good rationale to investigate in detail the role of HSP-90 in the CHIKV 
replication cycle and to measure the effectiveness of HSP-90 inhibitors 
against CHIKV. 
5.1 Drugs targeting HSP-90 reduce CHIKV infection 
The initial study to define the contributions of HSP-90 to CHIKV 
replication involved, using a HSP-90 inhibitor drug ‘geldanamycin’. 
Geldanamycin has a known mechanism of action: It binds to the ATP-binding 
site of HSP-90, which locks the protein in an open conformation (Stebbins et 
al., 1997). This is effective in inhibiting HSP-90 function since its chaperone 
activity requires the ATP-driven closed conformation (Ali et al., 2006). HEK-
293T cells were infected with CHIKV (at MOI of 1) and were either 
geldanamycin- or mock-treated for 24h. Virus production in the cells was 
monitored by plaque assay. In geldanamycin treated cells, the amount of 
infectious virus particles released in the cell supernatant was reduced by ~2.5 
log compared to mock-treated cells, suggesting a significant contribution of 
HSP-90 in the CHIKV infection cycle (Fig-5-1).  
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Fig-5-1: Geldanamycin treatment reduces CHIKV infection in cell 
culture. HEK-293T cells were infected with CHIKV-Ross using MOI of 1 for 
1h, followed by mock treatment or treatment with geldanamycin at a 1.5μM 
dose for 24h. At 24h, a plaque assay was carried out on cell supernatants to 
measure the amount of infectious virus particles released in the presence of 
drug. Error bars are ± SD. Statistics was performed using an un-paired 
Student’s t-test and considered significant if p<0.05 (indicated by *). 
Geldanamycin treatment significantly reduces CHIKV infection, suggesting a 
role of HSP-90 in the CHIKV infection cycle. This graph is representative of 
two independent experimental repeats. 
 
To support that any off-target effects of geldanamycin were not 
responsible for the above observations, two additional highly specific 
synthetic inhibitors of HSP-90, HS-10 and SNX-2112, were used  (Fig-5-2). 
Both HS-10 (Kd=3nM) (Barrott et al., 2013) and SNX-2112 (Kd=16nM) (Huang 
et al., 2009) have higher affinity towards HSP-90, compared to geldanamycin 
(Kd=1200nM) (Roe et al., 1999). 
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Fig-5-2: Chemical structures of HSP-90 inhibitors. Chemical structures of 
HSP-90 inhibitors including commercially available geldanamycin, clinical 
candidate, SNX-5422, and HS-10 and SNX-2112 that were used in this study. 
The Kd values of these inhibitors against HSP-90 are as follows, 
geldanamycin (Kd=1200nM), SNX-5422 (Kd=41nM), HS-10 (Kd=3nM) and 
SNX-2112 (Kd=16nM) respectively. Both HS-10 and SNX-2112 inhibitors used 
in this study are highly selective against HSP-90 and possess stronger affinity 
towards HSP-90 compared to geldanamycin and SNX-5422. 
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The two compounds, HS-10 and SNX-2112, are close structural 
analogues of the clinical candidate HSP-90 inhibitor SNX-5422 (Kd=41nM) 
(Fadden et al., 2010; Huang et al., 2009). SNX-5422 has been shown to be 
well tolerated during the treatment of malignancies in recent human clinical 
trials (Rajan et al., 2011; Reddy et al., 2013), suggesting that these close 
structural analogues (HS-10 & SNX-2112) may also have a good safety 
profile. Viability tests were first performed to ensure that these inhibitors were 
not cytotoxic to the cells, using two different cell viability assays (Fig-5-3). 
Cells were treated with varying concentrations of either HS-10 or SNX-2112 
for 24h, followed by counting of viable cells using trypan blue staining. The 
highest dose (25μM) used in this assay showed no cellular toxicity (Fig-5-3A). 
No cell death was also observed in cells infected with CHIKV (MOI of 1) for 
24h (Fig-5-3A). This was done as a control before starting infection and 
treatment assays to confirm that any small reduction in viral titers in the 
presence of drug was not due to virus-induced cell death. Similarly, no cellular 
cytotoxicity was observed, even for increased concentrations (100μM) of HS-
10 or SNX-2112, in a secondary experiment, using cell titer-Glo luminescent 
cell viability assay kit (method described in Section-2.2.3) (Fig-5-3B). These 
cell viability data confirmed that both HS-10 and SNX-2112 were not toxic to 
the cells up to the 100μM dose tested (Fig-5-3).  
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Fig-5-3: Both HS-10 and SNX-2112 are not toxic to cells. (A) Cells (HEK-
293T) were treated at various concentrations of either HS-10 or SNX-2112 for 
24h, followed by counting of viable cells using trypan blue stain using a cell-
counting chamber. (B) Cells (HEK-293T) were given increasing 
concentrations of HS-10 or SNX-2112 followed by incubation for 24h. At 24h 
post-treatment, the cytotoxicity of each drug was measured using cell titer-Glo 
cell viability assay kit. The luciferase activity (cell viability) demonstrates that 
both HS-10 and SNX-2112 are not toxic up to the 100μM concentration. The 
data from two different assays confirm that both HS-10 and SNX-2112 are not 
toxic to the cells at the maximum concentration (100μM) tested for 24h post-
treatment. Error bars are ± SD and the data are representative of two 
independent experimental repeats. 
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After establishing that the drugs, HS-10 and SNX-2112, were not toxic 
to cells, experiments were performed to determine their influence on CHIKV 
infection. HEK-293T cells were infected with CHIKV at MOI of 1 and, 
subsequently, treated with various concentrations of HS-10 or SNX-2112 for 
24h, followed by measurement of viral infection using a plaque assay. The 
data showed that both HS-10 and SNX-2112 treatments resulted in a dose-
dependent reduction in viral titers (Fig-5-4).  The reduction in viral titers could 
even be observed at sub-nano-molar concentrations of both HS-10 and SNX-
2112, suggesting the specific action of these compounds on CHIKV infection.  
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Fig-5-4: Dose-response curves of HSP-90 inhibitors HS-10 and SNX-
2112 against CHIKV infection. HEK-293T cells were infected with CHIKV-
Ross using MOI of 1 for 1h, followed by mock-treatment or treatment of cells 
with increasing concentrations of HS-10 or SNX-2112 for 24h. At 24h, a 
plaque assay was performed on cell supernatants and a sigmoidal dose-
response curve was plotted using GraphPad prism. In the graphs, dotted lines 
represent the error range. The log μM range of the X-axis represents drug 
concentrations tested in the experiment from 5pM to 5μM against CHIKV 
infection. HS-10 and SNX-2112 treatments show a dose-dependent reduction 
in viral titers, suggesting the specificity of these drugs towards CHIKV 
infection. Error bars are ± SD and the data are representative of two 
independent experimental repeats. 
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5.2 HSP-90 inhibitors HS-10 and SNX-2112 affect CHIKV replication 
To further confirm that both HS-10 and SNX-2112 reduced CHIKV 
infection, a secondary technique to the plaque assay (Fig-5-4) was used in 
Fig-5-5. Immunofluorescence microscopy was performed on CHIKV infected 
(MOI of 1) HEK-293T cells, followed by mock-treatment or treatment with 
HSP-90 inhibitors (HS-10 or SNX-2112) at a 2μM dose for 24h. The resulting 
images showed a dramatic reduction in CHIKV infection, which was probed 
using an anti-E antibody (Fig-5-5). However, less than 5% of cells were still 
positive for CHIKV infection in the HS-10 treatment group, suggesting that a 
higher drug treatment dose should be used to achieve more complete viral 
clearance (Fig-5-5). The toxicity data in in Fig-5-3, suggests that any dose up 
to 100μM could be used for both HS-10 and SNX-2112 treatments against 
CHIKV infection. 
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Fig-5-5: Immunofluorescence microscopy of infected cells after 
treatment with HS-10 or SNX-2112. HEK-293T cells were cultured on 
coverslips before infection with CHIKV-Ross at MOI of 1 for 1h followed by 
mock- or HS-10- or SNX-2112- (2μM) treatment for 24h. At 24h post-
infection/treatments, cells were fixed and immunostained using antibodies 
specific to the CHIKV-E protein (red) and total HSP-90 protein (green). DAPI 
staining for nuclei was used as a background control. Un-infected cells were 
used to probe for baseline levels of HSP-90 protein. Images were acquired 
using an up-right confocal microscope at 20x magnification. The images 
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Next, to determine if the inhibitory effects of HSP-90 inhibitors on 
CHIKV virus production were due to a direct influence on CHIKV replication, 
intracellular viral RNA production was examined at an early time point (12h) 
of infection in the presence of HSP-90 inhibitors (HS-10 & SNX-2112). HEK-
293T cells were infected with CHIKV (MOI of 1), followed by mock-treatment 
or treatment with a 10μM dose of HS-10 or SNX-2112. After 12h of infection 
and treatment, the amount of CHIKV viral RNA (nsP1 or E2 genes) was 
quantified by real time RT-PCR, as described in Section-2.2.4. The nsP1 and 
E2 genes were chosen to ascertain the effects of HS-10 or SNX-2112 on both 
genomic and sub-genomic RNA synthesis during CHIKV replication. The 
amounts of total HSP-90 mRNA and protein in the cells were also measured. 
The RT-PCR data showed a significant reduction (~50–100 fold) in the levels 
of both genomic (nsP1) and sub-genomic (E2) viral RNA after treatments with 
either HS-10 or SNX-2112 (Fig-5-6A & B). This data suggests that HSP-90 
protein is involved in the early stages of RNA replication during CHIKV 
infection. Detection of the CHIKV-E protein by Western blotting also revealed 
dramatic reductions in the levels of viral E protein as a result of drug 
treatments (Fig-5-6C). The mRNA and protein levels of HSP-90 remained 
unchanged during the treatment time of 12h (Fig-5-6B, C & D), suggesting 
that the drug action is specific to the chaperone function of HSP-90 protein.   
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Fig-5-6: HSP-90 inhibitors, HS-10 and SNX-2112, target CHIKV 
replication. (A) Real time RT-PCR of CHIKV-nsP1 or -E2 genes was 
performed on total RNA extracted from CHIKV-infected cells (CHIKV-Ross, 
MOI of 1), which were mock-treated or treated with a 10μM dose of HS-10 or 
SNX-2112. Relative change in the mRNA levels of nsP1 or E2 are normalized 
to actin mRNA and are presented over the mock-treated infection control 
(CHIKV) group. Error bars are ± SD. Statistical significance in the graph was 
determined using an un-paired Student’s t-test and considered significant if 
p<0.05 (indicated by *). (B) Amplified products from panel-A were also 
resolved on a 1.5% agarose gel. Visually striking reductions in the levels of 
the E2 gene are seen in both the drug (HS-10 & SNX-2112) treatments. (C) 
Western blotting was conducted on experimental duplicates of panel-A, using 
antibodies specific to CHIKV-E and total HSP-90 proteins. Actin was used to 
show the loading control. (D) Under similar experimental conditions described 
for panel-A above, transcriptional levels of HSP-90 were also tested using 
real time RT-PCR and are represented as mean Ct value. Actin was used to 
show the equal input of total RNA in the test. Altogether, data in Fig-5 
demonstrate that HSP-90 inhibitors, HS-10 and SNX-2112, target CHIKV at 
the virus replication stage. The levels of HSP-90 mRNA or protein remain 
unaffected during drug treatment time of 12h. Data in this figure are 
representative of two independent experimental repeats. 
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5.3 siRNA silencing of HSP-90 has detrimental effects on CHIKV 
replication 
To evaluate the contributions of HSP-90 protein to CHIKV replication, 
HSP-90 transcripts were silenced and, subsequently, CHIKV replication was 
measured. HSP-90 was knocked-down in cells (HEK-293T) using two specific 
siRNAs that target the HSP-90 mRNA. The efficiency of knockdown was 
validated using a real time RT-PCR at 24h post-siRNA treatments. For this, 
cells (HEK-293T) were transfected with 100nM of either non-targeted siRNA 
or HSP-90 specific, siRNA(1) or siRNA(2) and incubated for 24h. At 24h post-
transfection, cells were mock-infected or infected with CHIKV using MOI of 1 
for a further 24h, before being harvested for quantification of HSP-90 mRNA 
or viral mRNA. Cells from experimental duplicates were collected for Western 
blotting to measure the levels of viral protein or total HSP-90 protein in 
knocked-down cells. Similarly, cell supernatants from the experimental 
duplicate wells were also collected for the quantification of infectious virus 
particles produced during HSP-90 knocked-down conditions.  
The real time RT-PCR data demonstrated that treatment of cells with 
siRNA(2) resulted in a more prominent knockdown of HSP-90 mRNA levels, 
compared to siRNA(1)-treatment or the non-targeted siRNA control (Fig-5-7A 
& B). siRNA(2)-treatment also resulted in a greater reduction in HSP-90 
protein levels compared to siRNA(1)-treatment or non-targeted siRNA control 
(Fig-5-7C). Interestingly, compared to the control cells that had been infected 
after treatment with non-targeted siRNA, siRNA silencing of HSP-90 
transcripts using both the siRNAs (siRNA(1) & siRNA(2)) resulted in a 
substantial reduction in the levels of intracellular viral RNA (Fig-5-7A & B), a 
reduction of viral protein (Fig-5-7C), as well as a significantly reduced 
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production of infectious virus particles compared to the non-targeted siRNA-
treated infection group (Fig-5-7D). Since the HSP-90 knockdown efficiency of 
siRNA(2) was more prominent than siRNA(1), greater reductions in the levels 
of viral RNA and viral protein were observed in siRNA(2)-treated cells 
compared to siRNA(1)-treated cells or non-targeted infection control cells 
(Fig-5-7A, B, C). The amounts of infectious virus particles produced were also 
significantly reduced in the presence of siRNA(2)-treatment compared to 
siRNA(1)-treatment or non-targeted treatment infection controls (Fig-5-7D). 
Even though the HSP-90 knockdown levels differed between treatments with 
each of the two specific siRNAs, a significant reduction in CHIKV replication 
was observed for both (Fig-5-7). Thus, this siRNA knockdown data further 
supported the results obtained by HSP-90 inhibition using specific drugs (HS-
10 & SNX-2112, Fig-5-6) that inhibition of HSP-90 can block CHIKV 
replication. Furthermore, taken together, the results clearly established the 
critical role of HSP-90 in CHIKV replication. 
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Fig-5-7: siRNA knockdown of HSP-90 negatively influences CHIKV 
replication. (A) Cells (HEK-293T) were treated with 100nM each of the 
siRNAs (non-targted, NT & HSP-90 1, 2) for 24h, followed by an infection with 
CHIKV-Ross using MOI of 1 and incubated for a further 24h. At 24h, cells 
were harvested for validation of HSP-90 knockdown. Infection levels in the 
siRNA-treated samples were measured by amplification of the E2 gene. (B) 
Densitometry quantifications of bands shown in panel-A were performed 
using ImageJ and are presented as percent relative intensity of HSP-90 after 
normalization to the levels of actin and HSP-90 in the un-infected control. 
Similarly, percent relative intensity of E2 is presented after normalization to 
actin and non-targeted siRNA+CHIKV infection control. (C) Western blotting 
performed on experimental duplicates of panel-A using antibodies specific to 
total HSP-90 and CHIKV-E protein. Un-infected cells were used as a baseline 
level control and actin was used as a loading control. The densitometry 
quantification of HSP-90 (labeled as numbers in the image) in knocked-down 
conditions is represented as the ratio of total HSP-90 levels in siRNA(1) or 
siRNA(2) over un-infected control. (D) Under similar experimental conditions 
described above for panel-A, plaque assays were conducted on cell 
supernatants from siRNA knockdown conditions. Error bars are ± SD. 
Statistical analysis was done using Students un-paired t-test and considered 
significant if p<0.05 (indicated by *). The data, together, show that siRNA 
knockdown of HSP-90 limits CHIKV replication. Treatment of siRNA(2) more 
potently inhibits HSP-90 levels (mRNA and protein) and significantly reduces 
CHIKV replication (viral RNA, viral protein and infectious particles produced). 
This suggests the critical role of HSP-90 during the CHIKV replication cycle. 
Data are representative of two independent experimental repeats. 
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5.4 CHIKV nsP3 or nsP4 proteins interact with HSP-90β and/or HSP-90α 
subunits 
To further investigate the mechanism underlying HSP-90 function 
during CHIKV replication, it was hypothesized that HSP-90 protein may aid 
virus replication through direct physical interaction with one or more of the 
CHIKV non-structural proteins (nsPs). Each (1μg) of the GFP-fused CHIKV 
nsPs plasmids were transfected (detailed method of transfection is described 
in Section-2.2.11) into HEK-293T cells. At 24h post-transfection, fluorescent 
confocal microscopy imaging was utilized to determine any association of 
GFP-fusion CHIKV-nsPs with HSP-90, using an antibody specific to total 
HSP-90 protein. The confocal imaging data demonstrated that only two of the 
CHIKV-nsPs, nsP3 and nsP4, clearly co-localized with HSP-90 (Fig-5-8). 
CHIKV nsP2 also appeared to show some degree of co-localization visually 
(Fig-5-8). No co-localization of nsP1 or GFP-only with HSP-90 was observed, 
suggesting that the co-localization between HSP-90 and nsP4 and nsP3 was 
highly specific (Fig-5-8). Interaction between CHIKV nsP3 and HSP-90 is 
novel and has not been previously reported (Fig-5-8). 
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Fig-5-8: Co-localization of HSP-90 with GFP-tagged CHIKV-nsP3 and 
nsP4. Cells (HEK-293T) were grown on coverslips overnight, followed by 
transfection of cells with 1μg each of the GFP-tagged CHIKV-nsPs. At 24h 
post-transfection, cells were fixed and immunostained using an antibody that 
detects total HSP-90 (red). Images were captured using a 63x lens. The blue 
colored arrows indicate co-localization (yellow) of HSP-90 (red) with GFP-
nsP3 or nsP4 (green). Although GFP-nsP1 did not show any co-localization 
with HSP-90, GFP-nsP2 and GFP-only showed background laser channels 
bleed-through (orange). The data in this figure point to a novel interaction 
between CHIKV-nsP3 and HSP-90 and also show interaction of CHIKV-nsP4 
with HSP-90.  
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To confirm the specific association of HSP-90 with CHKV proteins, 
nsP3 and nsP4, reciprocal pull-downs were performed using an anti-GFP 
antibody. Cells (HEK-293T) were transfected with each of the CHIKV-nsPs, 
followed by incubation for 24h. At 24h post-transfection, cells were lysed and 
immunoprecipitations were performed using 2μg of the polyclonal anti-GFP 
antibody in each test group. The immune-complexes formed were further 
isolated using protein A/G beads, before being resolved on 12% SDS-PAGE, 
followed by Western blotting using total HSP-90 antibody. The Western blots 
showed strong and specific interactions between GFP-nsP3 or GFP-nsP4 
proteins with the HSP-90 protein (Fig-5-9). Similar to the microscopy co-
localization data, no interaction between nsP1, nsP2 or GFP-only with HSP-
90 was detected (Fig-5-9). Although nsP2 seemed to co-localize with HSP-90 
in Fig-5-8, this interaction could not be verified by subsequent pull-down 
assays (Fig-5-9). This lack of observed physical association between nsP2 
and HSP-90 also could not be attributed to the theoretical limitation of poor 
nsP2 expression because similar levels of expression of nsP2 and nsP4 were 
observed in transfected cells (Fig-5-9). These data clearly demonstrate the 
association between the CHIKV replication complex proteins, nsP3 and nsP4, 
with HSP-90 protein, suggesting HSP-90 could be stabilizing the viral 
replication complex.  
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Fig-5-9: Co-immunoprecipitation of HSP-90 with GFP-tagged CHIKV 
nsp3 and nsP4. Western blotting on pull-downs of GFP-fused CHIKV nsPs, 
followed by detection of HSP-90 shows co-precipitation of HSP-90 protein 
with GFP-nsP3 and GFP-nsP4 proteins. A detailed procedure for GFP-pull-
downs is described in Section 2.2.14. Immunoprecipitations from GFP-nsP1, 
nsP2 and GFP-only did not pull-down HSP-90 protein. These data support 
that both CHIKV-nsP3 and nsP4 interact with HSP-90 and that these 
interactions are highly specific. 
 
In mammalian cells, HSP-90 protein exists in two isomeric forms: a 
stress-induced cytoplasmic subunit (HSP-90α) and constitutively expressed, 
predominantly ER-associated subunit (HSP-90β) (Chen et al., 2005). The 
next investigation was to determine with which HSP-90 subunit CHIKV nsP3 
or nsP4 proteins specifically interact. GFP-tagged CHIKV-nsP3, -nsP4 or 
GFP-only were over-expressed in HEK-293T cells for 24h, followed by pull-
down of GFP-fused proteins using GFP-TrapA beads. The pull-down proteins 
were further separated on 12% SDS–PAGE and silver stained for 
visualization. The silver-stained gel showed minimal background interaction of 
host cellular proteins with GFP-only, yet many bands representing interacting 
proteins were seen in lanes corresponding to CHIKV nsP3 or nsP4 pull-
downs (Fig-5-10).  
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Fig-5-10: Immunoprecipitation of GFP-nsP3 and nsP4 using GFP-TrapA 
beads. Protein samples from GFP-nsP3 or GFP-nsP4 pull-downs performed 
using GFP-TrapA beads were separated on 12% SDS-PAGE followed by 
silver staining. The silver-stained gel shows several unique interacting 
proteins in GFP-nsP3 and GFP-nsP4 Lanes but not in GFP-only Lane. This 
suggests minimal background interactions in the pull-down samples. The 
arrows in the image indicate GFP-nsP3 or GFP-nsP4 proteins in the pull-
down samples, identified based on size and the degree of enrichment. This 
data clearly demonstrates that both CHIKV-nsP3 and nsP4 interact with 
several of the host cellular proteins, possibly to assist in their multifaceted 
roles during virus replication. 
 
To identify these interacting proteins, pull-down samples were further 
analyzed using LC/ESI/MS/MS mass-spectrometry. This technique revealed 
unique specific interactions between CHIKV GFP-nsP3 with the HSP-90β 
subunit (17 unique peptides matched) and GFP-nsP4 with the HSP-90α and 
HSP-90β subunits, respectively (16 and 13 unique peptides matched, 
respectively) (Fig-5-11, Table-12). The GFP-only control did not show any 
significant interaction with either HSP-90α or HSP-90β subunits (only 1 or 0 
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unique peptides matched, respectively) (Fig-5-11, Table-12). These data 
suggest that nsP3 interacts more specifically with HSP-90β while nsP4 
interacts with both HSP-90α and HSP-90β subunits. 
 
Fig-5-11: GFP-pull-down mass-spectrometry revealed GFP-nsP3 and 
GFP-nsP4 interactions with HSP-90 subunits. Pull-down samples from 
GFP-only, GFP-nsP3 and GFP-nsP4 were subjected to in-solution trypsin 
digest, followed by mass-spectrometry analysis. Peptide sequences released 
were matched against Swiss-prot 2013 database, using Mascot database 
search algorithm, and analyzed using Scaffold software. A minimum peptide 
threshold of 95% and a minimum protein threshold of 99.9% were used to 
determine the list of potential interacting proteins. Mass-spectrometry data 
analysis reveals unique strong interaction of GFP-nsP3 with HSP-90β sub-
unit (17 peptides matched) and weak interaction with HSP-90α subunit (only 
4 peptides matched). Similarly, novel and strong interactions of GFP-nsP4 
with HSP-90α (16 peptides matched) and HSP-90β (13 peptides matched) 
are observed. The GFP-only control does not show any significant interaction 
with either of the HSP-90 subunits. This data further solidifies the importance 
of HSP-90 during CHIKV replication.  
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Table-12: Tabulation of GFP pull-down mass-spectrometry analysis for 





















HSP-90α 84663.20 100% 16 43.60% 
 HSP-90β 83267.30 100% 13 45.20% 
GFP-
nsP3 
HSP-90α 84663.20 100% 4 16.80% 
 HSP-90β 83267.30 100% 17 48.60% 
GFP-
only 
HSP-90α 84663.20 100% 0 0 
 HSP-90β 83267.30 100% 1 5.39% 
 
Next, to verify the mass-spectrometry findings, GFP-pull-down 
proteins were separated by SDS-PAGE, followed by Western blotting using 
specific antibodies against HSP-90α and HSP-90β. Consistent with the mass-
spectrometry data, it was observed that HSP-90α had co-precipitated with 
over-expressed GFP-nsP4 while HSP-90β co-precipitated with over-
expressed GFP-nsP3 (Fig-5-12). In this Western blot data, the interaction of 
GFP-nsP4 with HSP-90β, which was earlier observed in mass-spectrometry 
(Fig-5-11), was not confirmed. This difference could be attributed to lower 
sensitivity of the Western blotting compared to mass-spectrometry or may be 
due to the difference in binding affinities for the HSP-90 subunit specific 
monoclonal antibodies that were used. Nevertheless, neither of the HSP-90 
subunits co-precipitated with GFP alone (Fig-5-12), suggesting that HSP-90 
subunit interactions were highly specific to CHIKV nsP3 or nsP4 proteins. 
	   167	  
 
Fig-5-12: Co-immunoprecipitation of HSP-90β with GFP-nsP3 or HSP-
90α with GFP-nsP4. GFP-only and GFP-nsP3 and GFP-nsP4 plasmids were 
transfected in HEK-293T cells for 24h. At 24h, cells were lysed and pull-
downs were done using GFP-TrapA beads. Western blotting performed on 
pull-down samples using antibodies specific to GFP, HSP-90α and HSp-90β 
shows that HSP-90β co-precipitated with GFP-nsP3 protein and HSP-90α co-
precipitated with GFP-nsP4 protein. GFP-only is unable to precipitate with 
either the HSP-90α or HSP-90β subunit. The arrows on the left panel 
Western blot (labeled W.B. anti GFP) point to pull-down of GFP-only, GFP-
nsP3 and GFP-nsP4 proteins. The arrow on the middle panel Western blot 
(labeled W.B. anti HSP-90β) points to detection of HSP-90β in the GFP-nsP3 
pull-down lane and the arrow on the right panel Western blot (labeled W.B. 
anti-HSP-90α) points to detection of HSP-90α in GFP-nsP4 pull-down Lane. 
This immunoprecipitation data further confirms the mass-spectrometry data 
that CHIKV-nsP3 strongly interacts with the HSP-90β subunit and CHIKV-
nsP4 strongly interacts with the HSP-90α subunit.  
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To validate that these interactions also occur in the context of CHIKV 
infection, reverse pull-downs using antibodies specific to HSP-90α or HSP-
90β subunits were done. Briefly, cells (HEK-293T) were infected with CHIKV 
using MOI of 1 and incubated for 24h. At 24h post-infection, pull-downs were 
performed using antibodies specific to either HSP-90α or HSP-90β, as 
described in Section-2.2.14. After Western blotting, these pull-downs were 
probed for CHIKV nsP3 or nsP4 proteins. Indeed, the results showed that 
pull-down using an HSP-90β-specific antibody co-precipitated CHIKV-nsP3 
protein and pull-down using an HSP-90α-specific antibody co-precipitated 
CHIKV-nsP4 (Fig-5-13). The data showed clear association of CHIKV-nsP4 
with the HSP-90α subunit and CHIKV-nsP3 with the HSP-90β subunit during 
viral infection, suggesting these interactions are highly consequential for 
CHIKV replication. 
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Fig-5-13: Co-immunoprecipitation of nsP3 with HSP-90β and nsP4 with 
HSP-90α, from CHIKV-infected cell lysates. Cells (HEK-293T) were mock-
infected or infected with CHIKV-Ross using MOI of 1 for 24h. At 24h, cells 
were lysed and co-immunoprecipitations were done using 2μg each of the 
HSP-90α or HSP-90β antibodies. Immunoprecipitated samples were 
electrophoresed in 12% SDS-PAGE followed by Western blotting using 
antibodies specific to CHIKV-nsP3, CHIKV-nsP4, HSP-90α or HSP-90β. 
Western blotting data shows that CHIKV-nsP3 co-precipitated with the HSP-
90β subunit (arrow) and CHIKV-nsP4 co-precipitated with the HSP-90α 
subunit (arrow). This data demonstrates that HSP-90 subunit interactions with 
CHIKV-nsP3 and nsP4 also occur during CHIKV infection and suggest that 
these interactions are important for CHIKV replication. 
 
To further verify the importance of these specific interactions of CHIKV 
proteins with unique HSP-90 subunits, a siRNA knockdown method was 
used. Cells HEK-293T were treated with 100nM each of non-targeted siRNA, 
siRNA(1) or siRNA(2) for 24h, followed by infection with CHIKV using MOI of 
1 for a further 24h. At 24h post-infection, cells were harvested for total RNA 
extraction and cDNA synthesis using the conditions described in Section-
2.2.4. Equal amounts of cDNA (50ng) per reaction were used for PCR 
amplification of HSP-90α or HSP-90β subunits from each test sample. Viral 
infection was also measured by amplification of the CHIKV-E2 gene from 
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each of the test conditions. Amplification of actin was used as an input RNA 
control. The PCR data showed that siRNA(1) moderately silenced both the 
HSP-90α and HSP-90β subunits (Fig-5-14), while siRNA(2) only suppressed 
the HSP-90α but not the HSP-90β transcript (Fig-5-14). These findings 
suggested that siRNA(2) was specific to the HSP-90α subunit, allowing the 
dissection of the roles of each of the individual HSP-90 subunits during 
CHIKV replication. As expected from the siRNA knockdown data in Fig-5-7, 
knockdown of both HSP-90 subunits using siRNA(1), resulted in viral RNA 
reduction compared to the non-targeted siRNA infection control group (Fig-5-
14). Interestingly, CHIKV infection in the presence of siRNA(2), which only 
targeted HSP-90α subunit and did not affect the HSP-90β subunit, resulted in 
a greater reduction in viral RNA compared to both the siRNA(1) treatment 
group and the non-targeted siRNA control infection group (Fig-5-14). This 
data shows for the first time that, in addition to HSP-90β, HSP-90α plays an 
essential role in CHIKV replication. Importantly, the substantial reduction in 
viral RNA in the presence of HSP-90α-targeting siRNA suggests that the 
interaction between CHIKV-nsP4 and HSP-90α might be critical for assembly 
of the viral replication complex. 
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Fig-5-14: siRNA knockdown of HSP-90α has a more profound effect on 
CHIKV replication than knockdown of HSP-90β. (A) HEK-293T cells were 
transfected with 100nM of each of the siRNAs (NT, HSP-90 siRNA(1) & HSP-
90 siRNA(2)) for 24h, followed by mock- or CHIKV- infection (CHIKV-Ross, 
MOI of 1) for a further 24h. At 24h post-infection, total RNA was extracted and 
converted to cDNA for PCR amplification of the CHIKV-E2 gene (305bp), the 
HSP-90α gene (2196bp) or the HSP-90β gene (2172bp). Actin was used as 
an input RNA control. (B) Densitometry quantification of panel-A, normalized 
to the levels of actin and un-infected control (for HSP-90α and HSP-90β) and 
NT-siRNA+CHIKV control (for CHIKV-E2). Knockdown of HSP-90α and HSP-
90β both reduce CHIKV replication, but HSP-90α knockdown has a greater 
impact on CHIKV replication.  
 
 
Alphavirus replication occurs in the cytoplasm in close proximity to the 
rough ER (Froshauer et al., 1988; Strauss and Strauss, 1994). All the CHIKV 
nsPs are predominantly cytoplasmic in their sub-cellular localizations, with an 
exception of CHIKV-nsP2, which also translocates to the nucleus (Peranen et 
al., 1990; Strauss and Strauss, 1994). Also HSP-90α is UPR-induced and 
predominantly cytosolic. Therefore, it was further confirmed in this study that 
interaction with HSP-90α was only specific to CHIKV-nsP4 (and not other 
nsPs) during CHIKV replication. For this, cells (BHK-21) were infected with 
CHIKV using MOI of 1 for 24h. At 24h post-infection, cells were fixed and 
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prepared for confocal immunofluorescence microscopy using antibodies 
specific to HSP-90α and each of the CHIKV-nsPs. The immunofluorescence 
microscopy images clearly demonstrated the co-localization of CHIKV-nsP4 
with the HSP-90α subunit (Fig-5-15). The other CHIKV-nsPs, nsP1, nsP2 and 
nsP3, did not show any co-localization with the HSP-90α subunit (Fig-5-15), 
suggesting that interaction between HSP-90α and CHIKV-nsP4 is highly 
specific and HSP-90α may help in the stabilization of CHIKV-nsP4 protein in 
the virus replication complex. 
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Fig-5-15: Co-localization of HSP-90α with nsP4 during CHIKV infection. 
Cells (BHK-21) were grown on glass coverslips, followed by an infection with 
CHIKV-Ross at an MOI of 1 for 24h and further processed for 
immunofluorescence microscopy using antibodies specific to nsP1, nsP2, 
nsP3, nsP4 and HSP-90α. The figure shows strong co-localization (yellow, 
also denoted by blue arrows) of CHIKV nsP4 (red) with HSP-90α protein 
(green). CHIKV-nsP1, nsP2 and nsP3 did not show co-localization with the 
HSP-90α protein. Un-infected cells are used as baseline control for HSP-90α 
and DAPI staining is used to identify individual cells. The images were 
acquired at 40x magnification. This data confirms the specific interaction of 
CHIKV-nsP4 with the HSP-90α subunit in CHIKV-infected cells. 
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5.5 Characterization of a severe CHIKV disease model for in vivo 
studies 
In order to assess the effectiveness of HSP-90-targeted drugs against 
CHIKV in vivo, a mouse infection model was first characterized. The CHIKV-
orchestrated events occurring during the disease progression, the 
subsequent pathological manifestations, and the host immune response to 
viral infection are all still vaguely understood. Being an emerging virus that is 
gaining importance, very few studies have been published on the pathology 
and stepwise events in the disease progression of CHIKV infection in vivo. 
Some research groups have used wild-type inbred (Balb/c, C57B/6) (Gardner 
et al., 2010; Morrison et al., 2011) and outbred (CD1, ICR, NIH-Swiss) 
(Ziegler et al., 2008) mouse models as infection models. Unfortunately, due to 
lack of disease symptoms and a poor infection profile, these mouse models 
could not recapitulate or explain all the aspects of CHIKV pathogenesis. 
Notably, wild-type mice do not support CHIKV replication kinetics that 
approximate human infection (Couderc et al., 2008). In this study, A-129 mice 
that are deficient in type-I interferon (IFNα & IFNβ) receptors and are highly 
susceptible to CHIKV infection were used. Infection in A-129 mice also 
mimics the high viremia and disease severity that is observed during the 
natural course of CHIKV infection in humans.  
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5.5.1 CHIKV-infected A-129 mice develop high viremia and die from 
infection  
To establish CHIKV infection in A-129 mice (n=5), mice were infected 
with ~50pfu of virus via two different injection routes. Footpad (FP) injection 
was chosen to mimic the sub-cutaneous delivery of virus by a mosquito and 
intra-peritoneal (IP) delivery of virus was used to achieve immediate and 
systemic virus infection. The clinical isolate strain of CHIKV-EAS was used to 
increase the translational relevance of the in vivo studies. After virus 
inoculation (~50pfu/20μl in the case of FP injections or ~50pfu/50μl in the 
case of IP injections), mice were bled at every 12h time interval until 96h 
post-infection and plaque assays were performed on the collected sera. 
Control group animals (n=2 each) were also injected with either 20μl or 50μl 
of saline through FP or IP injection routes, respectively.  
The survival curve analysis demonstrated that IP-injected animals 
died one day earlier than the animals in the FP-injected group (Fig-5-16A). 
Viremia was measured by plaque assay and showed that infected animals in 
both groups supported prolific CHIKV replication, although IP-injected animals 
developed significantly higher viremia at 48h than the FP-injected group (Fig-
5-16B). Altogether, this data suggests that A-129 mice are highly susceptible 
to CHIKV infection and that a viral dose equivalent to a natural infectious 
inoculum (~50pfu) can result in severe viremia and, finally, death in these 
animals. For all further experiments the FP route was selected to mimic the 
natural sub-cutaneous delivery of virus by a mosquito and to allow longer 
survival so as to measure the impact of antiviral drugs. 
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Fig-5-16: Survival and viral growth rate in vivo. Mice (A-129) were given 
50pfu of CHIKV-EAS through two different injection routes (FP & IP). The 
mice were bled every 12h and serum was isolated to perform plaque assay 
analysis. (A) Survival curves for infected animals are shown, which were 
statistically analyzed using the log-rank (Mantel-Cox) test. (B) Viremia in mice 
over the course of disease spread is presented (with error bars in red), as 
determined by plaque assay. Both the FP and IP inoculation routes result in 
uniformly severe infection and outcomes. 
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5.5.2 CHIKV infection profile in A-129 mice  
To understand the spread of CHIKV from a site of sub-cutaneous 
injection, mice (n=5) were injected with ~50pfu of virus via the FP route and 
organs were harvested after euthanasia on each day until Day 5 post-
infection. Harvested organs included the brain, heart, lung, liver, kidney, 
spleen and muscle. These were processed to extract RNA for PCR detection 
of viral RNA using standard E2 gene-specific primers. 18S RNA was used as 
the input RNA control. The data showed that CHIKV infection was initially 
detected in liver and muscle on Day 2 and further spread to the spleen by 
Day 3 (Fig-5-17). Day 4 and onwards, CHIKV infection in mice became 
systemic and could be detected in all harvested organs (Fig-5-17). On Day 5, 
the amount of viral RNA detected in the spleen was notably reduced 
compared to Day 4 levels (Fig-5-17). This could potentially reflect some 
degree of viral clearance in this organ by Day 5. These data suggest that liver 
and muscle are the primary target organs of CHIKV infection in A-129 mice.  
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Fig-5-17: Infection profile of CHIKV in A-129 mice. Mice were infected with 
~50pfu of CHIKV-EAS by the FP injection route and total RNA was extracted 
from the tissues harvested at indicated time points. Standard CHIKV 
detection primers against the E2 gene (~305bp) were used to amplify the viral 
RNA from each of the tissues and 18S amplified from the same samples was 
used to demonstrate the input RNA control. The infection kinetics revealed 
liver and muscle as early CHIKV infection target organs that maintain high 
levels of infection.  
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5.5.3 CHIKV-infected A-129 mice develop inflammation and swelling in 
their limbs 
Arthralgia, or persistent arthritis, occurs in the majority of CHIKV 
infections and represents the most significant pathological complication in 
human patients. To model this human disease pathology, the CHIKV-infected 
A-129 mice were tested for the development of inflammation or arthralgia-like 
disease symptoms, such as limb swelling or musculopathy. As before, A-129 
mice (n=3) were infected with ~50pfu of CHIKV in their right rear FPs followed 
by measurement of limb size (see methods Section-2.2.16). Control group 
animals were injected with an equal volume of saline. Swelling in the limbs 
was observed as early as 48h (Day 2) post-infection with dramatic swelling or 
inflammation observed at Day 4 post-infection (Fig-5-18A & B). Furthermore, 
muscle cross-sections at Day 4, stained with methylene blue, showed 
massive infiltration of mononuclear cells, suggesting their involvement in 
muscle inflammation and swelling (Fig-5-18C).  
To assess the levels of immune products that are associated with 
inflammation, quantitative real time RT-PCR analysis of viral and cytokine 
genes from total RNA extracted from muscle tissues showed a sharp increase 
in viral replication from Day 2 post-infection that was significantly higher at 
Day 5 post-infection. Levels of pro-inflammatory cytokine genes, such as 
TNFα and IL-23α, were significantly increased on Day 3. Similarly, expression 
of immune suppressive cytokine genes, such as IL-10 and SOCS-3, was also 
induced, suggesting a highly inflammatory environment persisted in the 
muscle tissues of CHIKV-infected animals (Fig-5-18D). 
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Fig-5-18: CHIKV-infected A-129 mice develop swelling and inflammation 
in their limbs. Mice (n=3) were infected with CHIKV-EAS (~50pfu) through 
rear FPs by subcutaneous injection. Control mice were given an equal volume 
of saline (20μl). Animals were observed for swelling in their limbs. Panel (A) 
shows massive swelling in a representative limb of an infected animal 
compared to mock-infection. (B) Thickness of the inflamed limbs of infected 
animals and control animals was measured using a standard precision ruler 
and is presented. Significance was determined by Student’s un-paired t-test. 
(C) Microscopic images of muscle tissue sections, stained by methylene blue 
at Day 4 show infiltration of mononuclear cells (indicated by arrows) in the 
infected muscle tissue. (D) Real time RT-PCR amplification of selected 
cytokine genes was done using RNA extracted from muscle tissues that were 
harvested at the indicated days post-infection. Relative changes in the 
transcripts are presented after normalization to the levels of 18S and Day 1 
mRNA or virus nsP1 gene levels. 
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5.5.4 A-129 mice as a model to assess efficacy of anti-CHIKV drugs 
To establish whether A-129 mice could be used to assess the efficacy 
of anti-CHIKV drugs chloroquine (CHQ) and ribavirin (RBV) were used. As 
mentioned in Section-1.9, CHQ & RBV are anti-viral drugs that have been 
shown to limit CHIKV replication in cell culture (Briolant et al., 2004; Khan et 
al., 2010). Mice (n=5) were infected with ~50pfu of virus via the FP route and 
were treated for 4 days with a 15mg/kg/mouse dose of each drug. Infected 
animals were then bled from Day 1 to Day 3 for viremia analysis and further 
followed for survival analysis. The survival of CHQ-treated animals could only 
be extended by 1 day beyond the survival of the mock-treated animals (Fig-5-
19A), which was statistically significant for CHQ treatment group, but not for 
the RBV treatment group. However, RBV and CHQ treatments both 
significantly reduced viremia in animals (Fig-5-19B). Although both the drugs 
CHQ and RBV have significant antiviral effects on CHIKV, the dosage and 
frequency of these drugs used for this study may need further optimization.  A 
caveat is that CHIKV is highly sensitive to IFNs and since A-129 mice lack a 
functional IFN system, it may be difficult to establish a survival model for 
antiviral testing. The data suggested that viremia in A-129 mice could be 
effectively used to measure the efficacy of anti-CHIKV drugs. 
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Fig-5-19: CHQ and RBV treatments in A-129 mice reduce CHIKV viremia 
without influencing survival. Mice (n=5) were infected with CHIKV-EAS 
(~50pfu) and either mock-treated or treated with CHQ or RBV at a 
15mg/kg/mouse dose for 4 days. (A) Survival of mice was followed post-
infection/treatment. Significance is calculated using the log-rank (Mantel-Cox) 
test and is significant for CHQ treatment group, but not for the RBV group. (B) 
Serum from infected/treated animals was collected on Days 2 and 3 post-
infection for plaque assay. Panel-B shows reduced viremia at Days 2 and 3 
post-infection after treatment with either CHQ or RBV, as determined by 
ANOVA. Viremia is a more sensitive measure of antiviral efficacy in the A-129 
mouse model than survival. Error bars are ± SD and the data are 
representative of two independent experimental repeats. 
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5.6 HSP-90 inhibitors reduce CHIKV viremia and inflammation in vivo 
The effectiveness and specificity of HSP-90-targeted drugs against 
CHIKV, revealed in cell culture, combined with the findings of specific 
biochemical interactions occurring between HSP-90 subunits and viral nsPs, 
prompted the evaluation of the efficacy of these drugs in vivo. The CHIKV 
mouse model of lethal infection and inflammation (characterized in Section-
5.5) was used. A-129 mice were infected in rear FPs with 100pfu of a clinical 
isolate of CHIKV (CHIKV-EAS) and either mock- or HS-10- or SNX-2112-
treated via the IP injection route, at a dose of 10mg/kg, twice a day, for 3 
days. For both HS-10 and SNX-2112 treatment groups, serum viremia levels 
on Day 2 (~48h post-infection) were significantly reduced compared to the 
mock-treated group (Fig-5-20).  
 
 
Fig-5-20: Treatment of mice with HS-10 or SNX-2112 reduces CHIKV 
viremia. Mice (n=6) were injected with CHIKV-EAS (~100pfu) via the FP 
route and either mock- or HS-10- or SNX-2112-treated at a dose of 
10mg/kg/mouse, twice a day, for 3 days. Serum from mice was harvested at 
48h (Day 2) for plaque assay. Plaque assay data showed a significant 
reduction in the viremia of animals that were treated with HS-10 or SNX-2112 
compared to the mock-treated group. HSP-90 inhibitors are effective CHIKV 
antivirals. Error bars are ± SD and the data are representative of two 
independent experimental repeats. 
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That CHIKV infection was reduced in the muscles of infected animals 
was also verified for one of the two HSP-90 inhibitor drugs. SNX-2112 was 
selected for this verification since it is the analogue of the clinical candidate, 
SNX-5422. Viral infection in the limb muscles of animals that were either 
mock- or SNX-2112-treated was quantified, using real time RT-PCR for the 
CHIKV-E2 gene, at the indicated times post-infection/treatments. Consistent 
with the viremia data (Fig-5-20), there was a significant reduction of viral 
burden in the muscles of animals treated with SNX-2112, compared to the 
mock-treated animals at 24h and 48h post-infection (Fig-5-21). However, 
since CHIKV infection of A-129 mice is lethal due to the absence of the host 
IFN-response pathways, no difference in the levels of CHIKV RNA was 
observed between the mock- and SNX-2112-treated animals at 72h post-
infection (Fig-5-21).  
 
Fig-5-21: Treatment of mice with SNX-2112 lowers CHIKV infection in 
the muscle tissues. Real time RT-PCR analysis of the viral E2 gene was 
performed from the total RNA extracted from the muscle tissues of CHIKV-
infected animals (CHIKV-EAS, ~100pfu). Animals had been either mock- or 
SNX-2112-treated, at the dose of 10 mg/kg twice daily. Statistical analysis 
was performed using Student’s un-paired t-test and considered significant if 
p<0.05. HSP-90 inhibitor SNX-2112 reduces viral replication in the muscles of 
CHIKV-infected animals during the first 48h of infection. Error bars 
represented in graphs are ± SD and the data are representative of two 
independent experimental repeats. 
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Since the inflammatory events surrounding CHIKV infection are 
central to its pathogenesis, the question of whether the drug treatments had 
any effect on inflammation, in addition to the observed influence on CHIKV 
replication, was raised.  The harvested muscle tissues from animals from 
treated and mock-treated groups obtained at Day 3 post-infection were used 
for histological analysis.  Muscle tissues were cryosectioned, followed by 
staining with Hematoxylin and Eosin (H&E). H&E-stained muscle sections 
showed substantial infiltration of mononuclear cells and considerable tissue 
damage to the muscle fibers in mock-treated infected animals (Fig-5-22). In 
comparison to the mock-treated animals, tissue damage and infiltration of 
mononuclear cells into the muscles of mice treated with either HS-10 or 
SNX2112 was significantly reduced (Fig-5-22).  
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Fig-5-22: HS-10 or SNX-2112 treatment in CHIKV-infected mice blocks 
infiltration of mononuclear cells into muscle tissues. After CHIKV 
infection and treatments with drugs, as described in Fig-5-20, muscle tissues 
were harvested on Day 3 (72h) and sectioned for histology. H&E-stained 
muscle tissue sections show dramatic infiltration of mononuclear cells and 
extensive tissue damage in mock-treated but infected animals. Treatment 
with either of the drugs resulted in a significant reduction in tissue damage 
and infiltration of mononuclear cells. Arrows indicates areas with severe 
infiltration of cells. HSP-90 inhibitors block infiltration of cells into muscle 
tissues and limits tissue damage. 
 
Data relating to limb swelling was collected by measuring the width 
and thickness of the limbs (as described in Section-2.2.16) of infected 
animals that were mock-treated or treated with either HS-10 or SNX-2112. 
Results showed that CHIKV-induced inflammation (measured by thickness 
and width of the limb) was significantly reduced in animals upon treatment 
with either HS-10 or SNX-2112 compared to the mock-treated animals (Fig-5-
23A & B).  
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Fig-5-23: Treatment of HS-10 or SNX-2112 reduces limb swelling in 
CHIKV-infected mice. (A) Mice (n=6) were inoculated with ~100pfu/20μl of 
CHIKV-EAS through the FP route and the control mice were injected with an 
equal volume of saline. Mice were either mock- or HS-10- or SNX-2112-
treated at a 10mg/kg dose, twice a day, for 3 days. The representative 
pictures were taken at 72h and show that mock-treated mice developed 
greater swelling in their infected limbs. Swelling in the limbs of animals from 
both HS-10 and SNX-2112 treatment groups is significantly reduced. The 
swelling is measured in terms of both width and thickness (shown by arrows), 
using a standard surgical ruler. (B) This panel shows the measurements of 
swelling (thickness or width) at Day 2 and 3 from limbs of infected/treated 
mice. The data shows that treatment of CHIKV infected mice with either HS-
10 or SNX-2112 significantly reduces swelling and inflammation in their 
muscles. Error bars are ± SEM and the data are representative of two 
independent experimental repeats. 
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To better understand how the inflammatory response during CHIKV is 
modulated by HSP-90 inhibitors, HS-10 or SNX-2112, the concentrations of 
selected cytokines in the serum were measured, including IL-6, IL-12, IFN-γ, 
and TNF-α. These cytokines were chosen because they have been 
associated with inflammation during CHIKV infection in humans (Hoarau et 
al., 2010). The resulting data revealed that the levels of cytokines IL-12 and 
IFN-γ were significantly reduced in the serum of infected and HS-10- or SNX-
2112-treated mice, compared to the levels in the serum of infected but mock-
treated animals (Fig-5-24). Interestingly, the drugs evoked slightly different 
inflammatory responses since the levels of IL-6 and TNF-α were higher in the 
SNX-2112-treated animals, compared to untreated or to the HS-10 treatment 
group (Fig-5-24). Taken together, the results support further development of 
HSP-90 inhibitors as a potential therapeutic to reduce CHIKV replication, 
while also limiting the inflammation that is characteristic of CHIKV infection 
and pathology.  
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Fig-5-24: Treatment of mice with HS-10 or SNX-2112 reduces secretion 
of pro-inflammatory cytokines during CHIKV infection. Mice (n=6) were 
infected with CHIKV-EAS 100pfu/20ul and either mock-treated or treated with 
HS-10 or SNX-2112 at the dose of 10mg/kg/mouse, twice a day, for 3 days. 
At each day post-infection or treatment until Day 3, mice were bled and serum 
was isolated to quantify the levels of pro-inflammatory cytokines using 
ELISAs. Levels of some of these pro-inflammatory cytokines, such as IL-12 
and IFNγ, are significantly reduced in animals upon treatment with HS-10 or 
SNX-2112. 
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Chapter-6 Discussion 
 The life cycle of a mammalian virus is comprised of series of events 
beginning with virus entry and followed by un-coating and release of the viral 
genome, genome replication and virus morphogenesis, leading to egress of 
virus from the host cell. Since viruses are fundamentally intracellular 
parasites, they require the use of the host’s cellular machinery and energy 
resources to complete a life cycle. RNA viruses must synthesize dsRNA 
intermediates to replicate their genomic material and must produce viral 
proteins, including both structural proteins and non-structural proteins to 
assist with replication within host cells. Accordingly, viral replication elicits 
cellular responses, which are the first lines of host defense against invading 
pathogens. These responses include the dsRNA-stimulated antiviral response 
and the ER stress-induced UPR (He, 2006). dsRNA activates 2’-5’ 
oligoadenylate synthetase (OAS), which limits virus replication by degradation 
of single-stranded RNA molecules (Player and Torrence, 1998). Similarly, the 
activation of PKR by dsRNA stimulates type-I IFN signaling against viral 
infections (Wu and Kaufman, 1997). Activated PKR also phosphorylates 
eIF2α, leading to global protein translation arrest in a cell (Lu et al., 1995; 
Williams, 1997).  
Recent studies have demonstrated the importance of UPR during viral 
infections (Baltzis et al., 2004; Chan, 2014; Dimcheff et al., 2004; Jheng et al., 
2014; Smith, 2014). The ER is central to the replication of RNA viruses. ER-
associated membranes support virus replication hot spots (Froshauer et al., 
1988; Salonen et al., 2005) and the ER machinery is an absolute requirement 
for viral protein folding and for post-translational modifications (Hebert and 
Molinari, 2007). This dependency of viruses on ER machinery triggers ER 
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stress, followed by the UPR. The UPR during viral replication shapes the fate 
of a viral infection and also contributes to viral pathogenesis (Lin et al., 2008).  
Alphaviruses are capable of prolific replication and infections usually 
result in high viremia and high fever in patients (Strauss and Strauss, 1994). 
To maintain a robust replication-rate these viruses must overcome the 
resistance triggered by the host cellular UPR and interferon responses. 
Indeed, as discussed in Section 1.7, several other viruses, such respiratory 
syncytial virus, simian virus, HSV, CMV, and HCV are known to overcome the 
defensive responses of their cellular hosts that have the purpose of inhibiting 
or limiting viral replication (He, 2006). Alphaviruses, such as SFV and SINV, 
are known to possess translational enhancer elements in their sub-genomic 
RNA (McInerney et al., 2005; Ventoso et al., 2006). These translational 
enhancer elements are suggested to help in translation initiation of viral 
proteins, independent of the requirement of eIF2B (Ventoso et al., 2006). 
Whether these translational enhancer elements are functional in the CHIKV 
genome has yet to be discovered. CHIKV and SINV have been shown to 
modulate the host cellular interferon and apoptotic machinery during 
replication (Fros et al., 2010; Krejbich-Trotot et al., 2011). However, very little 
is known about the role of UPR in alphavirus replication and, in particular, the 
UPR during CHIKV replication is completely unknown. This study investigated 
the mechanisms behind robust CHIKV growth by examining the cellular UPR 
signaling during CHIKV replication.  
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6.1 Robust replication of CHIKV  
 CHIKV growth rate measured in various cultured mammalian cells  
(Fig-3-2) showed that HeLa, HEK-293 (epithelium origin) and MRC-5 
(fibroblast origin) could support robust CHIKV replication. This data is 
consistent with the similar observations in earlier reported studies (Solignat et 
al., 2009; Sourisseau et al., 2007). RBL-2H3, a basophilic mast cell line that 
was shown to be less permissive to dengue virus infection (St John et al., 
2011) also supported robust CHIKV replication. The findings here suggest 
that mesenchymal cell types are highly susceptible to CHIKV infection. 
Indeed, HEK-293 supported prolific CHIKV and SINV replication with tens-of-
thousands-fold induction of viral RNA and reaching plaque assay titers up to 
~1011 infectious units/ml of cell supernatants (Fig-3-3). HEK-293 cells have 
also been used prominently by other groups to study molecular pathways, 
including UPR (Li et al., 2008).  
Surprisingly, several of the key immune cells such as THP-1, K562 
(monocytic origin) and Jurkat cells (lymphocytic origin) supported poor CHIKV 
replication (Fig-3-2), suggesting immune cells may not be the primary targets 
of CHIKV infection. Indeed, various studies have demonstrated the resistance 
of hematopoietic immune cells towards CHIKV infection (Rinaldo et al., 1975; 
Schilte et al., 2010; Solignat et al., 2009; Sourisseau et al., 2007). In contrast, 
a recent study has also suggested that immune cells are the targets of CHIKV 
infection (Her et al., 2010). Therefore, further studies are warranted to 
ascertain the degree to which CHIKV replicates in immune cells. 
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 CHIKV infection in vivo in mice also recapitulates some of the 
features of human clinical infection. For example, CD-1 outbred mice show 
signs of illness, such as loss of balance, difficulty walking, dragging of hind 
limbs, skin lesions and some deaths (Ziegler et al., 2008). In contrast, wild-
type C57BL/6J mice do not support CHIKV replication kinetics that 
approximate human infection (Couderc et al., 2008). In this study, A-129 mice 
that are deficient in type-I interferon (IFNα & IFNβ) receptors and are highly 
susceptible to CHIKV infection were used. The in vivo infection studies using 
a human clinical isolate of CHIKV demonstrated that footpad inoculation of 
mice with a dose of ~50-100 infectious units of CHIKV, resulted in very high 
viremia and, finally, led to death (Fig-5-16). Virus infection profiles in various 
organs have demonstrated that muscle and liver are the primary target 
organs of CHIKV infection in A-129 mice (Fig-5-17). Furthermore, it was 
shown that CHIKV-infected A-129 mice develop inflammation or arthralgia-
like disease symptoms, such as limb swelling or musculopathy (Fig-5-18). 
Infection in A-129 mice mimics the high viremia and disease severity that is 
observed during the natural course of CHIKV infection in humans.  
6.2 The UPR during CHIKV replication 
Viral RNA replication and protein translation induces ER stress in 
cells. Induction of ER stress results in activation of UPR, which limits the virus 
replication and maintains homeostasis in a cell. As discussed in Section-1.5, 
activation of UPR is characterized by signal transduction events in three 
transmembrane proteins, IRE-1, PERK and ATF-6 (Fig-6-1) (Kaufman, 1999). 
In initial studies, the impact of CHIKV and SINV infections on UPR signaling 
was compared. These comparisons were made because it had been 
previously shown that SINV infection induces cellular translation arrest 
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(McInerney et al., 2005), which is mediated by phosphorylation of eIF2α. This 
cellular translation arrest is a characteristic marker of ER stress and UPR 




Fig-6-1: Schematic illustration of findings in the thesis. CHIKV enters the 
cell and starts to replicate and translate its non-structural and structural 
proteins. Viral RNA replication and protein translation trigger ER stress and 
UPR. The UPR transduces its signal through three transmembrane proteins, 
PERK, IRE-1 and ATF-6. BIP is the master sensor of UPR and activates all 
three UPR signaling arms. Upon activation, auto-phosphorylation of PERK 
phosphorylates its substrate eIF2α. Phosphorylation of eIF2α leads to global 
protein translation arrest and selective translation of ATF-4, which induces the 
transcription of apoptotic protein marker CHOP. CHIKV replication 
suppresses the phosphorylation of eIF2α through the CReP/GADD-34-PP1c 
phosphatase complex. These phosphatase complexes could be further 
inhibited by drugs salubrinal and guanabenz. Expression of viral protein nsP4 
also suppresses the phosphorylation of eIF2α likely in conjunction with 
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CReP/GADD-34-PP1c complex. Since this pathway is suppressed, it is 
represented in the diagram by short dotted lines. Activation of IRE-1 triggers 
its auto-phosphorylation and further splicing of the XBP-1 mRNA. The XBP-1 
spliced gene-product then acts as transcription factor and induces the 
transcription of ERAD machinery proteins EDEM and XBP-1. CHIKV 
replication delays the splicing of XBP-1 mRNA and delays the induction of its 
downstream effector genes XBP-1 and EDEM until the late phase of viral 
replication (48h post-infection). This delayed IRE-1 signaling is represented in 
the diagram using a thick dotted line. CHIKV replication almost 
instantaneously triggers the activation of ATF-6. Activated transmembrane 
ATF-6 is then cleaved to release its cytosolic product by S1P and S2P 
proteases in the Golgi. Cleaved ATF-6 further acts as transcription factor and 
induces the transcription of protein-folding chaperones, BIP, HSP-90 and 
p58IPK. Increased expression of HSP-90 is critical for CHIKV replication. 
HSP-90 physically interacts with CHIKV nsP3 and nsP4 proteins. The 
functions of HSP-90 during CHIKV replication could be blocked by using 
inhibitors, HS-10 and SNX-2112. 
 
BIP, the master regulator of UPR, is targeted by several viruses that 
have been shown to stimulate its transcription and translation (Liberman et 
al., 1999; Peluso et al., 1978). The role of BIP induction in viral infection is not 
fully known. Recent studies have suggested that BIP is involved in virion 
assembly and maturation during CMV and JEV infections (Buchkovich et al., 
2008; Wu et al., 2011). Another glucose-regulated protein that is induced 
during UPR is the HSP-90 family chaperone protein (Liberman et al., 1999). 
HSP-90 is also known to assist in forming the replication complex of influenza 
virus, HCV, CMV, α-HSV and bunyavirus (Geller et al., 2012), suggesting the 
critical nature of this UPR protein in viral replication.  
CHIKV infection was observed to result in the induction of ER-resident 
chaperones, such as BIP, p58IPK and HSP-90 (Fig-3-5). These proteins 
presumably assist in the folding of unfolded or misfolded proteins in order to 
relieve the ER stress caused by the high level of translation during CHIKV 
infection. These heightened translation levels are probably necessary to 
achieve the high virus titers that are observed here in cell culture and in vivo. 
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The translation induction of BIP, p58IPK and HSP-90 did not occur during 
SINV infection (Fig-3-5). 
The expression of both BIP and HSP-90 is regulated by activation of 
ATF-6. This association led to the hypothesis that levels of ATF-6 protein or 
its cleaved product could be altered during CHIKV and/or SINV infection. 
When this was evaluated (Fig-3-5), similar to BIP and HSP-90, protein levels 
of transmembrane ATF-6 and cytosolic cleaved ATF-6 were significantly 
induced during CHIKV replication. This finding suggests the direct activation 
of the ATF-6 branch of the UPR during CHIKV infection. However, during 
SINV infection, as hypothesized, the levels of both transmembrane and 
cytosolic ATF-6 were not induced. Since ATF-6 regulates their transcription, 
this could explain why the levels of BIP, p58IPK and HSP-90 remained 
unaltered during SINV infection. These chaperones play a key role in 
assisting the folding of viral proteins and, therefore, failure to induce them 
could lead to an early build up of ER stress during viral replication.  
The IRE-1 branch of the UPR was examined next (Fig-6-1). Activation 
of IRE-1 results in the expansion of the ER and the induction of ERAD 
machinery proteins, EDEM and XBP-1. During ER stress, activation of IRE-1 
leads to the splicing of XBP-1 mRNA that regulates the transcription of CRE 
and ERAD genes (Lee et al., 2003). The results (Fig-3-6 & -3-7) showed that 
during CHIKV replication, splicing of XBP-1 mRNA was delayed and could 
only be detected 48h post-infection. Similarly, the downstream effector genes, 
EDEM and XBP-1, were induced transcriptionally only at 48h post-infection. 
This is a significantly delayed splicing event during CHIKV replication 
because infection of SFV (related alphavirus) has been shown to induce 
splicing of XBP-1 mRNA as early as 9h post-infection (Barry et al., 2010). In 
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contrast to CHIKV but similar to SFV infection, SINV replication resulted in 
more pronounced splicing of XBP-1 mRNA that could be easily detected 
starting 12h post-infection (Fig-3-6). Thus, SINV infection leads to more 
profound activation of IRE-1, starting early in the replication cycle compared 
to CHIKV. This is an important finding, which indicates that ER stress build-up 
begins early during SINV replication.  
Presumably, IRE-1 activation occurs at this early time due to excess 
accumulation of viral RNA or unfolded viral proteins in the cell. Transcriptional 
induction of XBP-1 and the ERAD machinery protein, EDEM, during SINV 
replication (Fig-3-7) suggests that there is a need to degrade unfolded viral 
proteins in the ER. IRE-1 activation also results in mRNA decay through the 
regulated IRE-1 dependent decay (RIDD) pathway (Hollien et al., 2009). The 
roles of RIDD in degradation of viral RNA have been recently discussed 
(Bhattacharyya, 2014), which highlights a second mechanism (in addition to 
IRE-1 mediated ERAD machinery induction) through which ER stress could 
limit SINV infection. Delayed activation of IRE-1 during CHIKV replication, 
which is reflected by delayed splicing of XBP-1 mRNA and late transcriptional 
induction of EDEM, clearly suggests the modulation of UPR during the CHIKV 
replication cycle. This could suggest that the modulation of IRE-1 during 
CHIKV replication surmounts the ERAD and RIDD responses, which would 
allow heighted viral RNA replication and protein translation. 
Regaining homeostasis during ER stress results from balancing the 
integrated responses of the three different arms of the UPR. If homeostasis 
cannot be re-established, cell death occurs. The PERK branch of UPR plays 
a critical role in deciding the fate of a stressed cell. Upon activation, PERK 
undergoes oligomerization and auto-phosphorylation, whereby 
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phosphorylated PERK phosphorylates its substrate eIF2α (Fig-6-1). 
Phosphorylation of eIF2α by PERK shuts-off global protein translation in a cell 
and allows selective translation of only short mRNAs such as ATF-4 (Harding 
et al., 2000; Scheuner et al., 2001). ATF-4 regulates the transcription of 
GADD-34 and an apoptotic protein, CHOP (Harding et al., 2000). The 
influence of PERK signaling in deciding the fate of a cell raised the question 
of whether PERK is activated during CHIKV or SINV infections. The data (Fig-
3-8) showed that for both viral infections, phosphorylation of PERK was 
observed but, intriguingly, the kinetics of the concomitant phosphorylation of 
eIF2α was markedly different between the two. At early time points following 
CHIKV infection, the phosphorylation of eIF2α was not detected, in contrast to 
SINV infection where phosphorylation of eIF2α was an early event, 
immediately following phosphorylation of PERK. This suggested a breakdown 
in the PERK pathway between PERK and eIF2α phosphorylation during 
CHIKV infection. Also, the levels of CHOP and eIF2αK were unaltered during 
CHIKV infection. Interestingly, the transcription of GADD-34 was only induced 
at 48h post-infection (Fig-3-9). In the case of SINV infection, however, 
significant increases in the levels of CHOP, eIF2αK and GADD-34 were 
observed much earlier, starting 12h post-infection (Fig-3-9). This data 
demonstrates that CHIKV infection modulates the PERK pathway of the UPR 
by delaying the phosphorylation of eIF2α. SINV infection, in contrast, results 
in unobstructed PERK pathway activation, involving eIF2α phosphorylation. 
This leads to uncontrolled ER stress and early cell death that is characterized 
by induction of CHOP and apoptosis. The early (6h) phosphorylation of eIF2α 
was previously shown to mediate translation arrest, followed by cell death in 
SINV-infected cells (Toribio and Ventoso, 2010). Similarly to SINV, SFV 
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infection was also shown to induce expression of CHOP and to induce cell 
death by apoptosis (Barry et al., 2010). Altogether, the data from comparative 
monitoring of UPR pathways during CHIKV and SINV infection revealed that 
CHIKV infection regulates the UPR. SINV infection, in contrast, leads to 
unrestricted ER stress, followed by cell death. Comparing the data in Fig-3-8 
with the existing literature, it could also be deduced that both SINV and SFV 
behave similarly during their infection cycles, which both lead to massive 
cytopathy in their infected hosts. The UPR responses in the early phase of 
CHIKV replication are unique, compared to SINV and SFV infections, and 
could help establish successful replication and sustained viral growth. 
6.3 CHIKV suppression of the PERK pathway 
The observation (described above) that CHIKV modulates PERK 
signaling through delayed phosphorylation of eIF2α led to the hypothesis that 
CHIKV replication must actively suppress phosphorylation of eIF2α. Two 
drugs were used to test this hypothesis, thapsigargin (0.1μM) and 
tunicamycin (0.5μg/ml), which are known to induce phosphorylation of eIF2α 
(Calfon et al., 2002; Treiman et al., 1998). In an initial experiment, cells were 
infected, followed by treatment with either thapsigargin or tunicamycin. 
Interestingly, a significant reduction in the phosphorylation of eIF2α in CHIKV-
infected cells was observed, even in the presence of thapsigargin or 
tunicamycin treatment, compared to mock-infected treated cells (Fig-3-13). 
This experiment also supported the initial observation that CHIKV replication 
on its own did not induce phosphorylation of eIF2α compared to SINV 
infection (Fig-3-8). These findings clearly demonstrate that CHIKV infection 
suppresses the phosphorylation of eIF2α and is able to do so even in the 
presence of known eIF2α-phosphorylation-inducing drugs. Indeed, other 
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viruses also suppress phosphorylation of eIF2α. For instance, influenza virus 
replication induces expression of p58IPK (Melville et al., 1999). p58IPK is a 
negative regulator of both PKR- and PERK-induced phosphorylation of eIF2α 
during influenza virus infection (Goodman et al., 2007). It is noteworthy that 
expression of p58IPK was also induced during CHIKV infection (Fig-3-5), 
suggesting a potential involvement of p58IPK in negative regulation of eIF2α 
phosphorylation. In contrast, during SINV replication, infected cells showed 
much higher levels of eIF2α phosphorylation in both mock and tunicamycin or 
thapsigargin treatments, supporting that there is no suppression of this 
branch of the UPR (Fig-3-13). Again, this confirms that SINV infection leads 
to irreversible ER stress and, finally, cell death. 
To ascertain the mechanism behind CHIKV-mediated suppression of 
the phosphorylation of eIF2α, the role of regulatory cellular phosphatases 
CReP and GADD-34 were investigated in this process. Both CReP and 
GADD-34 make regulatory complexes with PP1c and could independently de-
phosphorylate eIF2α (Fig-6-2). It is noteworthy here that CReP is 
endogenously expressed and GADD-34 is only expressed during the 
condition of stress. So far, limited studies have defined the role of GADD-34 
during some viral infections (He et al., 1997, 1998; Umareddy et al., 2007). 
However, whether CReP could also have a function in viral replication has not 
yet been addressed. To determine if these phosphatases are involved in the 
de-phosphorylation of eIF2α during CHIKV replication, a UPR-specific drug, 
salubrinal, was used. Salubrinal is a specific chemical inhibitor that targets 
PP1c complex formation with CReP or GADD-34. Intriguingly, the data (Fig-3-
15) showed that salubrinal treatment increased the phosphorylation of eIF2α 
only in CHIKV-infected cells, suggesting the involvement of CReP and/or 
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GADD-34 in CHIKV suppression of eIF2α phosphorylation. 
 
Fig-6-2: A schematic showing eIF2α dephosphorylating regulatory 
complex.  Stress-induced GADD-34 and constitutively expressed CReP 
forms regulatory complexes with PP1c phosphatase subunit and de-
phosphorylates its substrate eIF2α-P. Salubrinal inhibits both GADD-34-PP1c 
and CReP-PP1c complexes. Guanabenz selectively targets the GADD-34-
PP1c phosphatase complex.  
 
 
Multiple techniques were used to delineate the roles of CReP and 
GADD-34 during CHIKV replication. These include specific inhibitors, an over-
expression system and genetic knock-out cells. The early infection time point 
(12h) data (Fig-3-16) showed that salubrinal treatment increased the 
phosphorylation of eIF2α in both mock-infected and CHIKV-infected cells. 
However, guanabenz treatment had no effect on the phosphorylation of eIF2α 
in both infected and mock-infected cells. Since guanabenz is a specific 
inhibitor of GADD-34-PP1c and this complex is only induced during ER 
stress, this data, again, clearly demonstrated that ER stress is suppressed 
during CHIKV replication. The phosphorylation of eIF2α during salubrinal 
treatment also suggests that the viral protein translation must be affected in 
infected and drug-treated cells. Indeed, the levels of viral protein were 
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significantly reduced during salubrinal treatment compared to both the mock- 
and guanabenz- treatment groups (Fig-3-16). Although a minor reduction in 
the level of viral protein during guanabenz treatment could also be observed, 
the effect of guanabenz on CHIKV protein translation was not significant. 
Since phosphorylation of eIF2α blocks protein synthesis, amounts of newly 
synthesized proteins in the cells were measured in the presence of infection 
or drug treatments. Time course kinetic analysis of protein labeling in infected 
and salubrinal- or guanabenz-treated cells (Fig-3-17) demonstrated that the 
rate of protein translation was not altered in CHIKV-infected cells until 24h. 
Also, the effects of salubrinal or guanabenz treatments on protein translation 
during CHIKV replication were not significantly different at 12h. However, at 
24h a significant reduction in the protein translation was observed in the 
salubrinal treatment group compared to the mock- or guanabenz-treated 
infection groups. As observed previously, guanabenz treatment also had a 
somewhat milder effect on protein translation during CHIKV replication. At 
48h post-infection, CHIKV resulted in protein translation arrest, possibly due 
the phosphorylation of eIF2α at 48h. These results were consistent with 
earlier experiments (Fig-3-8) in this study and are also consistent with the 
current literature that in the late phase of CHIKV replication, protein 
translation is attenuated (Strauss and Strauss, 1994). Although protein 
labeling data only provides a qualitative measurement of protein translation, it 
still presents as a valuable support for the argument that salubrinal treatment 
during CHIKV replication leads to protein translation arrest through 
phosphorylation of eIF2α, likely in conjunction with the activities of CReP and 
GADD-34.  
The kinetics of CHIKV replication was measured in greater detail in 
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the presence of salubrinal or guanabenz treatment by quantification of viral 
RNA and GADD-34 or CReP mRNA (Fig-3-18). The kinetic data revealed that 
salubrinal treatment significantly reduced viral RNA synthesis, throughout the 
time course tested. Guanabenz treatment reduced CHIKV replication at early 
time points but, at 48h, the levels of viral RNA in the guanabenz-treated group 
were equivalent to the levels in the mock-treated infected group, suggesting 
the loss of drug function, possibly due to its short half-life. In a recently 
published study (Clavarino et al., 2012), pre-treatment of cells with 
guanabenz also resulted in increased CHIKV infection. This was 
demonstrated to be the result of IFN-β inhibition by guanabenz treatment 
(Clavarino et al., 2012). This accessory effect (inhibition of IFN-β production) 
may also explain why the level of CHIKV infection was increased here at the 
late time point in guanabenz-treated cells.  
The comparative measurements of CReP and GADD-34 mRNA (Fig-
3-19) showed that CReP is induced early in the CHIKV replication cycle 
compared to GADD-34. Overall, these data suggest that CReP has a more 
significant role in the early phase of the CHIKV replication cycle compared to 
GADD-34, which may also be involved. To specifically investigate the 
influence of CReP and GADD-34 on de-phosphorylation of eIF2α during 
CHIKV replication, FLAG-CReP and FLAG-GADD-34 were ectopically 
expressed. Although the expression of FLAG-CReP was less compared to 
FLAG-GADD-34, over-expression of FLAG-CReP during CHIKV replication 
resulted in the suppression of eIF2α phosphorylation. Conversely the levels of 
viral capsid protein in the same test samples were induced, suggesting that 
CReP expression could enhance viral protein translation by suppression of 
eIF2α phosphorylation. Over-expression of GADD-34 did not result in the 
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suppression of eIF2α phosphorylation and also levels of viral protein were not 
altered in the GADD-34 expression group. These data solidify the role of 
CReP in CHIKV suppression of eIF2α phosphorylation. 
The role of GADD-34 in CHIKV replication was further addressed 
using genetically knock-out GADD-34 (GADD-34-/-) MEFs. The protein kinetic 
data (Fig-3-21) showed that at 24h post-infection the level of eIF2α 
phosphorylation in GADD-34-/- cells was significantly higher than in WT 
control cells. Conversely, CHIKV infection was significantly reduced in GADD-
34-/- cells compared to the WT infected cells. The quantitative viral RNA 
infection data also correlated with the Western blotting data and showed that, 
indeed, the replication of CHIKV was much slower in GADD-34-/- cells 
compared to WT cells. This result was expected since knockdown of GADD-
34 function (which involves de-phosphorylation of eIF2α) should result in 
increased phosphorylation of eIF2α and induction of ER stress in cells. A 
reduction in the CHIKV infection levels in GADD-34-/- cells was observed 
because of the global translation attenuation that is triggered by the 
phosphorylation of eIF2α during CHIKV replication. Indeed, a protein-labeling 
experiment using puromycin clearly demonstrated that the global protein 
translation during CHIKV infection was reduced in GADD-34-/- cells 
compared to the WT control cells.  
The transcriptional levels of CReP were also measured in both WT 
and GADD-34-/- infected cells. As expected from the data in Fig-3-19, the 
levels of CReP in the WT cells were significantly induced during CHIKV 
infection (Fig-3-21). Intriguingly, CHIKV infection in GADD-34-/- cells did not 
result in transcriptional induction of CReP, suggesting that GADD-34 
deficiency may also influence CReP expression in these knock-out cells (Fig-
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3-21). Since the transcriptional induction of CReP was negatively influenced 
in GADD-34 deficiency, its contribution to the viral reduction in GADD-34-/- 
cells could not be ruled out. Altogether, it can be concluded that the influence 
of GADD-34 during CHIKV replication was only observed to be moderate, 
However, experimental evidence obtained using salubrinal or guanabenz 
treatments and the data obtained from over-expression of FLAG-CReP or 
FLAG-GADD-34, strongly suggest the crucial involvement of CReP in the de-
phosphorylation of eIF2α and maintenance of viral protein synthesis during 
the CHIKV replication cycle. 
6.4 Involvement of a viral protein, nsP4, in the modulation of UPR 
 The role of host cellular phosphatases, CReP and GADD-34 in the de-
phosphorylation of eIF2α during CHIKV replication is discussed above but the 
role of viral proteins in mediating this process could not be ignored as a 
possibility. Several viruses encode proteins that have modulatory functions in 
the suppression of eIF2α phosphorylation. In case of HCV infection, viral 
proteins NS5A and E2 inhibit PKR or PERK, which phosphorylates eIF2α 
leading to protein translation arrest (Gale et al., 1997; Taylor et al., 1999).  
Other examples of these suppression mechanisms include the E3L 
protein of vaccinia virus that contains a C-terminus dsRNA-biding domain, 
which prevents the activation of PKR and inhibits phosphorylation of eIF2α 
(Chang et al., 1992). The K3L gene product of vaccinia virus also acts as 
pseudo-substrate for both PKR and PERK and blocks the phosphorylation of 
eIF2α (Langland and Jacobs, 2002; Sood et al., 2000). Similarly, other 
viruses that inhibit PKR or PERK include HSV (Mulvey et al., 2007; Mulvey et 
al., 2003), influenza (Lu et al., 1995) and HPV (Spangle and Munger, 2010). 
In light of these studies, the role of CHIKV proteins in modulation of eIF2α 
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phosphorylation was investigated. For this, all the major non-structural (nsP1, 
nsP2, nsP3 & nsP4) and structural (C, E2 & E1) proteins of CHIKV were 
cloned and expressed as GFP-fusion proteins. These proteins were then 
over-expressed to address the hypothesis that one or more of the CHIKV 
proteins could suppress chemically-induced phosphorylation of eIF2α. Cells 
transfected with GFP-CHIKV plasmids were allowed to translate individual 
viral proteins, followed by induction of ER stress using tunicamycin (Fig-4-3, -
4-4, -4-5). Intriguingly, it was observed that the over-expression of CHIKV-
nsP4 (a RNA-dependent RNA-polymerase) could efficiently suppress 
tunicamycin-induced phosphorylation of eIF2α. Over-expression of all the 
other viral proteins that were tested had no influence on the phosphorylation 
of eIF2α. These data demonstrate the involvement of CHIKV nsP4 in the 
suppression of eIF2α phosphorylation. 
To understand the global effects of individual CHIKV non-structural 
proteins on host cellular translational machinery, a systems level approach 
was used to identify potential physical interactions between CHIKV and host 
proteins. Recently, several studies have reported the use of global protein 
analysis using mass-spectrometric proteomic approaches to identify proteins 
that are influenced (up-regulated or down-regulated) during CHIKV infection 
(Abere et al., 2012; Issac et al., 2014; Thio et al., 2013). These studies have 
provided a comprehensive list of host proteins that are modulated during 
CHIKV infection. However, the associations of individual CHIKV proteins with 
host cellular proteins remained unknown. Therefore, to address this gap, 
GFP-fused CHIKV non-structural proteins were over-expressed, followed by 
pull-down. The pull-down samples were then subjected to mass-spectrometric 
analysis. This proteomic data provided a complete list of host-proteins (~700 
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total proteins) that interacted with individual CHIKV-nsPs (Fig-4-6).  
Interestingly, several of the proteins identified in these lists (Table-10) 
had been earlier reported to interact with nsPs of other alphaviruses, such as 
SFV, SINV or CHIKV (Bourai et al., 2012). Some of these proteins include 
INT-9, G3BP1 and G3BP2, which specifically interacted with nsP3 and nsP4 
proteins in this mass-spectrometric proteomic list as well as in the recently 
published literature (Cristea et al., 2006; Frolova et al., 2006). The 
consistency of these findings with prior reports provided greater confidence in 
the pull-down proteomics and also revealed that some protein interactions are 
not only specific to CHIKV, but are used by other members of the alphavirus 
family. Intriguingly, the data obtained from ‘KEGG or Ingenuity’ pathway 
analysis showed enrichment of translation machinery ribosomal proteins in 
the nsP4 pull-down (Fig-4-8). Since nsP4 is a viral polymerase, it is possible 
that this protein recruits ribosomal proteins to help support viral protein 
translation in a cell. Ribosomal machinery component proteins are known to 
be utilized by many DNA or RNA viruses in their replication process (Walsh 
and Mohr, 2011).  
Another pathway that was enriched by nsP4 pull-down was the 
proteasome pathway (Fig-4-10). Alphavirus nsP4 is unstable during the late 
phase of viral replication and degrades through the proteasomal degradation 
machinery (de Groot et al., 1991; Takkinen et al., 1991; Vasiljeva et al., 
2003); therefore, it is not very surprising that the proteasomal pathway was 
enriched. Inefficiency of the proteasome machinery during viral replication 
should theoretically lead to ER stress and UPR in infected cells. Therefore, it 
would be interesting to ascertain if nsP4 recruits proteasome component 
proteins during CHIKV replication to help ease accumulation of misfolded 
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proteins in the ER and subsequent UPR.  
Perhaps the most intriguing class of proteins enriched by nsP4 pull-
down was phosphatases. Three protein phosphatases, PPP2RA, PP6R3 and 
PP1c, exclusively interacted with CHIKV-nsP4 and not with any other nsPs 
(Table-9). Here, it is interesting to remember that the PP1c catalytic subunit is 
a substrate for both CReP and GADD-34 and de-phosphorylates eIF2α. A 
well-known example for a similar protein function is the γ134.5 protein, 
encoded by HSV. During HSV infection, γ134.5 recruits the PP1c subunit and 
de-phosphorylates eIF2α along with GADD-34 (Cheng et al., 2005). Indeed, 
over-expression of γ134.5 suppresses the phosphorylation of eIF2α, even in 
the presence of thapsigargin or DTT, the known inducers of ER stress (Cheng 
et al., 2005). Similarly, a protein (DP71L) encoded by ASFV binds to the PP1c 
subunit and de-phosphorylates eIF2α during ASFV infection (Zhang et al., 
2010). Over-expression of DP71L could also de-phosphorylate chemically-
induced phosphorylation of eIF2α (Zhang et al., 2010). Thus, many viruses 
encode proteins that target PP1c in order to de-phosphorylate eIF2α. 
The question of whether CHIKV nsP4 could also form protein 
complexes with PP1c, CReP and or GADD-34 was addressed by comparing 
the protein sequences of nsP4 with GADD-34 and CReP (Fig-4-8). Sequence 
comparisons have revealed the presence of Ala-Arg motifs in nsP4. These 
motifs in nsP4 are similar to the Ala-Arg motifs present in the γ134.5 protein of 
HSV (Cheng et al., 2001). These motifs are required for the assembly of high 
molecular weight protein phosphatase complexes including GADD-34, PP1c 
and γ134.5, which de-phosphorylate eIF2α during HSV infection (Cheng et al., 
2001). Although further detailed biochemical studies are warranted to verify 
these predicted interaction sites, the sequence similarities may explain why 
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PP1c was co-precipitated by nsP4 pull-down (Table-9 & Fig-4-7). Altogether 
the data here shows a significant involvement of CHIKV nsP4 in the 
suppression of eIF2α phosphorylation in plausible association with the CReP-
PP1c and GADD-34-PP1c complexes (Fig-6-1). 
In order to further verify the mass-spectrometric proteomic pull-down 
data, selected proteins were chosen for siRNA knockdown analysis. The 
proteins were chosen based on having higher peptide scores by mass 
spectrometry analysis and also based on their relevance to the UPR 
machinery. A list of proteins, including TRAF-2, GCN1L, PPP2CA, LARS, 
PABP, PRPF8 and PRKDC were subjected to siRNA knockdown in cells. The 
importance of these individual proteins during CHIKV replication was 
measured by measuring the levels of viral RNA and the numbers of infectious 
particles produced in each of the gene knockdown conditions (Fig-4-11). The 
data showed that siRNA knockdown of PABP, TRAF-2, PPP2CA and PRKDC 
resulted in significant reduction in CHIKV replication. PABP is known to be 
involved in the replication of many RNA and DNA viruses (Smith and Gray, 
2010). PABP is an RNA-binding protein that binds to poly-A tail of mRNA and 
stimulates protein translation.  Therefore, it is possible that PABP assists in 
CHIKV replication and translation by binding to the poly-A tail of viral RNA 
through its recruitment by viral nsPs. TRAF-2 is a key regulator of the IRE-1 
signaling arm of the UPR and its knockdown also resulted in reduced CHIKV 
replication. TRAF-2 has been shown to physically interact with NS5A of HCV 
(Park et al., 2002). This interaction was shown to block NF-κB activation 
during HCV infection (Park et al., 2002). The knockdowns of PPP2CA and 
PRKDC also resulted in reduced CHIKV replication, suggesting that these 
proteins have a positive impact on CHIKV replication. PPP2CA is known to be 
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associated with replication of HCV (Georgopoulou et al., 2006) and WNV 
infections (Hunt et al., 2007). The siRNA knockdown of PPP2CA during WNV 
infection has been shown to reduce virus replication (Hunt et al., 2007). On 
the contrary, knockdown of GCN1L and PRPF8 resulted in induction of 
CHIKV replication. GCN1L together with GCN2 kinase regulates the 
phosphorylation of eIF2α (Sattlegger and Hinnebusch, 2000). Knockdown of 
GCN1L could theoretically suppress the phosphorylation of eIF2α and, 
therefore, could result in increased viral protein translation and infection. 
Although the precise role of PRPF8 in viral replication is unknown, it was 
identified as a critical factor required for influenza replication using a genome-
wide siRNA screen (Karlas et al., 2010). The mechanisms by which these 
proteins assist in CHIKV replication are yet to be determined. Altogether, 
these siRNA knockdown studies have confirmed the functional relevance of 
several proteins that were shown to interact with CHIKV-nsPs. The list of host 
interacting proteins obtained by pull-down mass-spectrometry data contains 
cellular proteins that can influence CHIKV replication either positively or 
negatively.  
 
6.5 HSP-90: a potential drug target during CHIKV replication 
The data discussed so far show the relevance of UPR during CHIKV 
replication and reveal the key interplay of viral nsP4 with UPR that facilitates 
robust viral replication. HSP-90 is induced upon activation of the ATF-6 
pathway of UPR and is known to serve critical functions in assisting the key 
steps of virus replication, such as in cases of influenza and HCV infections 
(Geller et al., 2012). The observations in this thesis build upon a growing 
body of literature showing that HSP-90 facilitates various aspects of virus 
replication during many different viral infections (Geller et al., 2012). Following 
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the rationale that HSP-90 is key for CHIKV replication, drugs were used in 
these studies that block HSP-90 function. The results showed that drugs 
targeting HSP-90 have profound effects on CHIKV replication. The feasibility 
of this approach is bolstered by the advantage that HSP-90 is considered a 
highly “druggable” target and, to date, many structurally diverse specific 
pharmacological inhibitors have been identified. Most of these inhibitors bind 
to and block the ATP binding site in the HSP-90 protein. Both of the HSP-90 
inhibitors used in this study, HS-10 and SNX-2112, reduced CHIKV infection 
in a dose-dependent manner (Fig-5-4,). The data support that these inhibitors 
block CHIKV infection at the replication stage (Fig-5-6). Furthermore, 
knockdown of HSP-90 transcription resulted in a dramatic reduction in virus 
replication (Fig-5-7), supporting the crucial role of HSP-90 during CHIKV 
replication.  
The mechanistic requirement of HSP-90 during CHIKV replication was 
addressed by hypothesizing that the viral non-structural proteins must interact 
with the HSP-90 protein to complete its function in the CHIKV replication 
cycle. The biochemical pull-down of CHIKV nsPs (Fig-5-9) showed that 
CHIKV-nsP4 physically interacts with HSP-90. A similar interaction has been 
shown for SINV-nsP4 using a Flag-tagged protein and also by yeast-2-hybrid 
interaction analysis (Bourai et al., 2012; Cristea et al., 2006). Using the co-
immunoprecipitation system, CHIKV-nsP3 was identified as a novel HSP-90-
interacting partner in this study (Fig-5-9). Furthermore, the results also 
showed that, while nsP4 primarily associates with HSP90α, nsP3 primarily 
associates with HSP90β (Fig-5-12). Since HSP-90α is predominantly 
cytosolic (Lees-Miller and Anderson, 1989), it may assist in the stabilization of 
CHIKV nsP4 and in the formation of the CHIKV replication complex. 
	   213	  
Alphavirus replication complexes have been shown to include several host 
proteins, as revealed by extensive studies in SFV and SINV infections 
(Cristea et al., 2006; Varjak et al., 2013). This notion that HSP-90α could 
participate in the CHIKV replication complex is supported by data 
demonstrating that siRNA knockdown of the HSP-90α subunit resulted in 
greater inhibition of viral replication than targeting the HSP-90β subunit (Fig-
5-14).  
Interestingly, a growing body of literature suggests that the viral 
polymerases are the major clients of HSP-90 protein. For instance, the 
reverse transcriptase enzyme of human hepatitis B virus requires HSP-90 for 
the initiation of reverse transcription and nucleocapsid assembly (Hu et al., 
2004). Similarly, interaction of HSP-90 with influenza polymerase complex 
proteins, PB1 and PB2, stimulates viral RNA polymerase activity and 
increases viral RNA synthesis (Momose et al., 2002). The translation of RNA 
polymerase protein from Nodaviridae flock house virus also depends on its 
interaction with HSP-90 (Kampmueller and Miller, 2005). It will be interesting 
to ascertain whether interaction of CHIKV nsP4 with HSP-90 is important for 
viral polymerase activity. Overall, this data establishes a pivotal role for HSP-
90α subunit and a possible ancillary role for HSP-90β subunit in facilitating 
CHIKV replication. The contributions of HSP-90 to CHIKV replication may 
underlie its effectiveness as a host therapeutic target during CHIKV infection.  
The effectiveness of HSP-90 inhibitor drugs was measured in the A-
129 model of severe CHIKV infection and pathogenesis. Both the drugs, HS-
10 and SNX-2112, significantly reduced viral titers on Day 2 in these infected 
mice (Fig-5-20). However, likely due to the lack of any IFN response in these 
animals, viremia in all the treated animals further increased to the levels that 
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were not significantly different from the levels in the untreated control group 
on Day 3 (Fig-5-21).  Recent studies have discussed the role of HSP-90 in 
contributing to innate immunity and have highlighted the importance of 
extracellular or membrane-bound HSP-90 in immune functions (Donze et al., 
2001; Joly et al., 2010; Yang et al., 2006). Similarly, HSP-90 has been shown 
to be associated with inflammation and drugs targeting HSP-90 are known to 
reduce inflammation in vivo (Dello Russo et al., 2006; Kim et al., 2009; Rice 
et al., 2008). It is, therefore, also possible that the increased suppression in 
the levels of some of the inflammatory cytokines, combined with the use of a 
severe immune-compromised animal model could provide a second 
explanation why the viral titers in the drug-treated animals were increased at 
Day 3, aside from the direct role of IFN on viral clearance. Importantly, unlike 
untreated CHIKV-infected mice, none of the animals treated with either HS-10 
or SNX-2112 developed swelling in their limbs during the course of infection 
(Fig-5-23). HS-10- or SNX-2112-treated mice also did not develop substantial 
inflammation during infection, based on histologic analysis of cross-sections 
of muscle tissues (Fig-5-22) and also by measuring the serum concentrations 
of pro-inflammatory cytokines (IL-6, IL-12, IFN-γ, and TNF-α) (Fig-5-24). 
These results clearly demonstrated the ability of HSP-90-targeting drugs to 
suppress CHIKV-induced inflammation in mice. It is possible that, in vivo, 
multiple mechanisms of action could explain the influence of HSP-90 on both 
infection and inflammation. Cumulatively, these studies demonstrated the 
importance of UPR during CHIKV replication, an important aspect of which is 
the role of HSP-90 protein during CHIKV replication. Finally, it is also shown 
that drugs targeting HSP-90 can significantly reduce CHIKV replication and 
inflammation in infected animals.  
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6.6 Concluding remarks 
 
The findings presented in this thesis provide fundamental knowledge 
on CHIKV replication and the regulation of host translational processes that 
this virus triggers for establishing its successful infection in a cell. First, it was 
established that CHIKV utilizes different strategies to overcome cellular ER 
stress and UPR compared to its close family member SINV. CHIKV infection 
activated the ATF-6 pathway starting early in the replication cycle so that 
ATF-6-transcribed chaperone proteins, such as BIP, HSP-90 and p58IPK, 
can assist in viral protein folding. Simultaneously, the activation of IRE-1 was 
delayed. The advantage of delayed IRE-1 activation would be to avoid viral 
protein and RNA degradation by ERAD and RIDD signaling. Interestingly, the 
PERK pathway of the UPR was suppressed during CHIKV replication through 
suppression in the phosphorylation of eIF2α. Regulating the PERK pathway is 
a very significant step for a replicating virus since it decides the fate of a cell 
through protein translation arrest and apoptosis. Mechanistically, it was 
shown that CHIKV suppresses phosphorylation of eIF2α by utilizing the 
cellular phosphatase complex CReP-PP1c, in conjunction with viral nsP4 
protein. Since replication of CHIKV is reduced in GADD-34-deficient cells, 
there is a possibility that GADD-34 also contributes to CHIKV replication, but 
a definitive role for this protein has not yet been established. The findings that 
CHIKV-nsP4 influences host translational machinery by interacting with key 
cellular phosphatases including PP1c, ribosomal machinery proteins and 
proteasome pathway components, emphasizes the multifunctional nature of 
this protein.  
CHIKV nsP4 is the first viral protein to be proteolytically cleaved from 
the nascent viral polyprotein, P1234 (Shirako and Strauss, 1994). nsP4 
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(which has RNA-dependent RNA-polymerase activity) together, with host 
factors and P123, assembles into a replicase complex that synthesizes 
negative-strand viral RNA. Subsequently, P123 is cleaved in to nsp1 and 
P23, which, together with nsP4, helps in the synthesis of both positive- and 
negative-strand viral RNAs (Jose et al., 2009; Shirako and Strauss, 1994). 
Because of this preferential RNA synthesis and differential polyprotein 
processing, nsP4 is the major translation product in the early phase of virus 
replication (de Groot et al., 1990). This abundance of nsP4 in the early 
infection cycle suggests that it must serve accessory functions in modulating 
the host machinery along with its involvement in viral replication. Indeed, the 
data presented in this study demonstrate that CHIKV nsP4 engages with the 
cellular UPR machinery proteins in the early phase of the replication cycle to 
help establish successful viral infection. In the late phase of the replication 
cycle, the levels of P34 surpass the levels of free nsP4 in infected cells and 
P34 preferentially helps in the synthesis of positive-strand viral RNA (Lemm 
and Rice, 1993). Moreover, alphavirus nsP4 is unstable and degrades rapidly 
by proteasomal degradation in infected cells (de Groot et al., 1991). 
Therefore, this instability of nsP4 in the later phase of the virus replication 
cycle may justify why infected cells have restored phosphorylation of eIF2α in 
the late phase of CHIKV infection.  
Further experiments were performed with an aim to identify a host 
UPR factor that assists in CHIKV replication. This was coupled with an 
interest to demonstrate that drugs targeting UPR components could be useful 
as antivirals. HSP-90, an ATF-6-induced protein, was identified as an 
interaction partner for both CHIKV nsP3 and nsP4 proteins. These studies 
revealed the specific interactions of HSP-90α with CHIKV nsP4 and HSP-90β 
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with CHIKV nsP3 in both an ectopic expression system, as well as during 
CHIKV infection. Mechanistically, it was demonstrated that the interaction 
between HSP-90α and CHIKV nsP4 was highly consequential for CHIKV 
replication. Moreover, drugs targeting HSP-90 were effective against CHIKV 
replication in cell culture. Treatment of animals with specific HSP-90 inhibitors 
not only reduced CHIKV replication in mice but also reduced CHIKV-induced 
inflammation and swelling in their limbs. This suggests that HSP-90 inhibitor 
drugs may be used to treat CHIKV replication, as well as its associated 
pathology (polyarthralgia, musculopathy) in vivo. Overall, findings presented 
in this thesis (Fig-6-1) expand our basic knowledge of the CHIKV replication 
cycle and provide evidence how CHIKV establishes its infection in the host by 
suppressing the host UPR machinery. Furthermore, CHIKV infection exploits 
the host translational machinery proteins and also utilizes UPR-associated 
HSP-90 protein for its replication. This study also establishes innovative drug 
targets against CHIKV infection. Mechanistic insights in the action of 
salubrinal and HSP-90 inhibitors against CHIKV replication have the potential 
to open new avenues towards development of anti-CHIKV interventions. 
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6.7 Future studies 
In follow-up studies, it will be important to ascertain if nsP4 forms a 
part of the CReP-PP1c or GADD-34-PP1c phosphatase complexes. 
Mutational studies at the potential PP1c binding site in nsP4, followed by 
biochemical pull-down will demonstrate the exact contact site of PP1c in 
nsP4. This could be further used as a tool to demonstrate the influence of 
mutations or disruption of nsP4-PP1c complex formation in the suppression of 
eIF2α phosphorylation. The involvement of GADD-34 during the late phase of 
CHIKV replication when ER stress is induced could be further explored. Since 
nsP4 showed very specific interactions with two other phosphatases 
(PPP2RA and PP6R3), it will be interesting to investigate if either of these two 
phosphatases forms regulatory complexes with nsP4 and if they could also be 
involved in the de-phosphorylation of eIF2α. Similarly, the list of host proteins 
identified to interact with CHIKV-nsPs by pull-down and mass-spectrometry 
could provide a basis to further investigate the functions of some of these 
individual proteins in the CHIKV replication cycle, including the mechanisms 
they potentially use to modulate replication. Several of the UPR proteins, such 
as TRAF-2, PABP and GCN1L were identified by proteomic analysis and 
have already been validated to contribute to CHIKV replication. The question 
of whether these protein interactions occur in the early phase of the CHIKV 
replication cycle is also compelling since the early phase of replication is 
when cleaved nsP4 is abundant in infected cells, presumably to establish 
replication. UPR-induced HSP-90 plays a critical role in CHIKV replication 
and, therefore, HSP-90 inhibitor drugs are good candidates for further 
development as antiviral therapies against CHIKV. Their potential as antiviral 
targets is compounded by the observation that HSP-90 inhibitors reduce 
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inflammation and swelling during CHIKV infection in vivo. This suggests that 
HSP-90 inhibitor drugs could be used to treat both viremia and pathology 
during CHIKV infections. Further pre-clinical studies could be performed to 
optimize the most effective dose of HS-10 or SNX-2112 against CHIKV 
infections and determine if they are effective treatments for human CHIKV 
patients. 
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Appendices 
1.0 Cell culture media 
1.1 Growth medium for C6/36 and BHK-21 cells 
RPMI-1640 containing L-glutamine (Gibco, USA) 
10% FBS (heat inactivated, Gibco, USA) 
25mM HEPES (Gibco, USA) 
1x Penicillin Streptomycin (Gibco, USA) 
1.2 Maintenance medium for C6/36 and BHK-21 cells 
RPMI-1640 containing L-glutamine (Gibco, USA) 
5% FBS (heat inactivated, Gibco, USA) 
25mM HEPES (Gibco, USA) 
1.3 Growth medium for HEK-293 and HEK-293T cells 
DMEM containing L-glutamine, 4.5g/L of D-glucose & 110mg/L of sodium 
pyruvate (Gibco, USA) 
10% FBS (heat inactivated, Gibco, USA) 
1x Penicillin Streptomycin (Gibco, USA) 
1.4 Growth medium for MEFs 
DMEM containing L-glutamine, 4.5g/L of D-glucose & 110mg/L of sodium 
pyruvate (Gibco, USA) 
10% FBS (heat inactivated, Gibco, USA) 
1x Penicillin Streptomycin (Gibco, USA) 
1x Non essential amino acids (Gibco, USA) 
2μl of 2-mercaptoethanol (Sigma, USA) per 0.5L of media 
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2.0 Buffers 
2.1 50x-TAE Agarose running buffer 
2M Tris 
1M Glacial acetic acid 
0.05M EDTA 
pH range 8.1-8.3 
2.2 4x-Laemmli buffer 
40% Glycerol 
240mM Tris-HCl, pH-6.8 
8% SDS 
0.04% Bromophenol blue 
5% Beta-mercaptoethanol 





pH range 8.1-8.3 
2.4 1x-Western Transfer buffer 
25mM Tris 
192mM Glycine 
20% Methanol (v/v) 
pH range 8.1-8.3 
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pH adjusted to 7.4 





pH adjusted to 7.5 
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3.0 Protocols 
3.1 Hematoxylin and Eosin staining for frozen tissue sections 
i. Frozen cut samples were air dried for several minutes to remove 
moisture. 
ii. Sections were stained with freshly filtered 0.1% Mayers 
Hematoxylin (Sigma, USA) in the dark for 10min using a glass 
coplin staining jar. 
iii. Sections were rinsed in cool running ddH2O for 5min before being 
stained with 0.5% Eosin by dipping slides 12 times in the glass 
coplin jar containing 0.5% Eosin. 
iv. Sections were washed in ddH2O until Eosin stops streaking (~3-
5min). 
v. Sections were sequentially dehydrated with 50% ethanol by 
dipping 10 times followed by dipping in 70% ethanol, 10 times. 
vi. Final stages of dehydration involves treatment in 95% ethanol for 
30sec, followed by treatment with 100% ethanol for 1min before 
being treated with xylene for 1min. 
vii. Sections were mounted using a permount (Bio-World, USA) and 
coverslip. 
 
3.2 Silver staining 
i. After running a SDS-PAGE, the gel was washed twice in ddH2O 
for 5min each before being fixed in a fixing solution (30% ethanol 
and 10% acetic acid) for 15min at room temperature.  
ii. The gel was washed twice using 100% ethanol for 5min each, 
followed by washing using ddH2O for 5min. 
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iii. The gel was incubated with silver stain sensitizer (1:500 dilution in 
ddH2O) for 1min. 
iv. The gel was quickly washed by two changes of ddH2O for 20sec 
each, followed by incubation with silver stain enhancer (1:100 
dilution in silver stain solution provided in the kit) for 5min. 
v. The gel was washed by two changes of ddH2O for 20sec each 
before being treated with silver stain developer solution (1:100 
dilution of enhancer in developer solution provided in the kit) until 
the bands started to appear (~2-3min). 
vi. The developing reaction was finally stopped using a stop solution 
(5% acetic acid in ddH2O). 
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4.0 Mass-spectrometry proteomics list 
 
Parameters: 
3511_082313_Condensed, Protein report created on 09/14/2014   
Experiment: 3511_082313_Condensed      
Peak List Generator: unknown       
Version: unknown         
Charge States Calculated: unknown       
Deisotoped: unknown        
Textual Annotation: unknown        
Database Set: 2 Databases        
Database Name: unknown        
Version: unknown         
Taxonomy: All Entries         
Number of Proteins: 0         
Database Name: the SwissProt_2013x database     
Version: unknown         
Taxonomy: All Entries         
Number of Proteins: 540732        
Explain Database w/ < 1000 entries:       
Does database contain common contaminants?: unknown    
Search Engine Set: 2 Search Engines      
Search Engine: IdentityE        
Version: Unknown         
Samples: Plate_3511_C1_ID11122_01_UCA195_3511_080913, 
Plate_3511_C2_ID11123_01_UCA195_3511_080913, 
Plate_3511_C3_ID11124_01_UCA195_3511_080913    
Fragment Tolerance: 0.025 Da (Monoisotopic)     
Parent Tolerance: 0.0100 Da (Monoisotopic)     
Fixed Modifications: +57 on C (Carbamidomethyl)     
Variable Modifications: -1 on  (Amidation+C-TERM), +1 on NQ (Deamidated), 
+16 on M (Oxidation), +98 on STY (Phosphoryl STY)    
Database: null (unknown version, 0 entries)      
Digestion Enzyme: Trypsin        
Max Missed Cleavages: 2        
Probability Model:          
Plate_3511_C1_ID11122_01_UCA195_3511_080913: LFDR Model, No 
Classifier [all charge states]        
Plate_3511_C2_ID11123_01_UCA195_3511_080913: LFDR Model, No 
Classifier [all charge states]        
Plate_3511_C3_ID11124_01_UCA195_3511_080913: LFDR Model, No 
Classifier [all charge states]        
Search Engine: Mascot        
Version: 2.2.04         
Samples: QC_02_UCA195_3511_080913.raw (F039515)    
Fragment Tolerance: 0.040 Da (Monoisotopic)     
Parent Tolerance: 10.0 PPM (Monoisotopic)      
Fixed Modifications: +57 on C (Carbamidomethyl)     
Variable Modifications: +1 on NQ (Deamidated), +16 on M (Oxidation)  
Database: the SwissProt_2013x database (unknown version, 540732 entries) 
Digestion Enzyme: Trypsin       
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Max Missed Cleavages: 2        
Probability Model:          
QC_02_UCA195_3511_080913.raw (F039515): Peptide Prophet with Delta 
Mass Correction (No decoys found) [all charge states]    
Scaffold: Version: Scaffold_4.3.2       
Modification Metadata Set: 1541 modifications     
Source: C:\Program Files\Scaffold 4\parameters\unimod.xml   
Comment:           
Protein Grouping Strategy: Experiment-wide grouping with protein cluster 
analysis          
Peptide Thresholds: 95.0% minimum       
Protein Thresholds: 99.9% minimum and 4 peptides minimum   
Peptide FDR: 0.0% (Decoy)        
Protein FDR: 0.0% (Decoy)  
 












ADH QC POTE ankyrin domain family member E OS=Homo sapiens GN=POTEE PE=1 SV=3 POTEE_HUMAN 0 2.14%
ADH QC Alcohol dehydrogenase 1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / 
S288c) GN=ADH1 PE=1 SV=5
ADH1_YEAST 9 28.20%
ADH QC Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 VIME_HUMAN 1 4.08%
ADH QC Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 ACTB_HUMAN 0 6.13%
ID11122 (nsP4) Phosphoglycolate phosphatase OS=Homo sapiens GN=PGP PE=1 SV=1 PGP_HUMAN 8 34.00%
ID11122 (nsP4) Thioredoxin-dependent peroxide reductase, mitochondrial OS=Homo sapiens 
GN=PRDX3 PE=1 SV=3
PRDX3_HUMAN 7 42.20%
ID11122 (nsP4) Signal transducer and activator of transcription 1-alpha/beta OS=Homo sapiens 
GN=STAT1 PE=1 SV=2
STAT1_HUMAN 10 18.10%
ID11122 (nsP4) 26S proteasome non-ATPase regulatory subunit 14 OS=Homo sapiens GN=PSMD14 
PE=1 SV=1
PSDE_HUMAN 6 36.80%
ID11122 (nsP4) Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 K22E_HUMAN 15 38.80%
ID11122 (nsP4) Coatomer subunit beta' OS=Homo sapiens GN=COPB2 PE=1 SV=2 COPB2_HUMAN 13 19.60%
ID11122 (nsP4) Trifunctional purine biosynthetic protein adenosine-3 OS=Homo sapiens GN=GART 
PE=1 SV=1
PUR2_HUMAN 23 35.10%
ID11122 (nsP4) ADP-ribosylation factor 4 OS=Homo sapiens GN=ARF4 PE=1 SV=3 ARF4_HUMAN 3 50.60%
ID11122 (nsP4) Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 TEBP_HUMAN 4 32.50%
ID11122 (nsP4) F-actin-capping protein subunit alpha-2 OS=Homo sapiens GN=CAPZA2 PE=1 SV=3 CAZA2_HUMAN 3 21.70%
ID11122 (nsP4) Isochorismatase domain-containing protein 2, mitochondrial OS=Homo sapiens 
GN=ISOC2 PE=1 SV=1
ISOC2_HUMAN 7 53.20%
ID11122 (nsP4) Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 NPM_HUMAN 5 25.90%
ID11122 (nsP4) Uncharacterized protein C7orf50 OS=Homo sapiens GN=C7orf50 PE=1 SV=1 CG050_HUMAN 2 22.20%
ID11122 (nsP4) Serine-threonine kinase receptor-associated protein OS=Homo sapiens GN=STRAP 
PE=1 SV=1
STRAP_HUMAN 5 19.70%
ID11122 (nsP4) Importin-7 OS=Homo sapiens GN=IPO7 PE=1 SV=1 IPO7_HUMAN 5 7.23%
ID11122 (nsP4) Radixin OS=Homo sapiens GN=RDX PE=1 SV=1 RADI_HUMAN 4 7.55%
ID11122 (nsP4) Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 SV=3 EF1G_HUMAN 11 30.00%
ID11122 (nsP4) Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens GN=DDX5 PE=1 
SV=1
DDX5_HUMAN 11 32.90%
ID11122 (nsP4) 60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 RL23A_HUMAN 6 32.70%
ID11122 (nsP4) Mitochondrial inner membrane protein OS=Homo sapiens GN=IMMT PE=1 SV=1 IMMT_HUMAN 10 18.20%
ID11122 (nsP4) Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2
PAIRB_HUMAN 3 12.00%
ID11122 (nsP4) Hypoxanthine-guanine phosphoribosyltransferase OS=Homo sapiens GN=HPRT1 
PE=1 SV=2
HPRT_HUMAN 7 39.40%
ID11122 (nsP4) 40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 RS2_HUMAN 10 41.00%
ID11122 (nsP4) 60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 SV=1 RL7_HUMAN 14 49.60%
ID11122 (nsP4) Cytosol aminopeptidase OS=Homo sapiens GN=LAP3 PE=1 SV=3 AMPL_HUMAN 3 8.09%
ID11122 (nsP4) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 OS=Homo 
sapiens GN=RPN2 PE=1 SV=3
RPN2_HUMAN 9 27.70%
ID11122 (nsP4) T-complex protein 1 subunit zeta-2 OS=Homo sapiens GN=CCT6B PE=1 SV=4 TCPW_HUMAN 3 16.20%
ID11122 (nsP4) Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 HS90A_HUMAN 16 43.60%
ID11122 (nsP4) Ketosamine-3-kinase OS=Homo sapiens GN=FN3KRP PE=1 SV=2 KT3K_HUMAN 5 18.40%
ID11122 (nsP4) Exosome component 10 OS=Homo sapiens GN=EXOSC10 PE=1 SV=2 EXOSX_HUMAN 6 9.94%
ID11122 (nsP4) 40S ribosomal protein S29 OS=Homo sapiens GN=RPS29 PE=1 SV=2 RS29_HUMAN 2 33.90%
ID11122 (nsP4) F-actin-capping protein subunit beta OS=Homo sapiens GN=CAPZB PE=1 SV=4 CAPZB_HUMAN 9 41.20%
ID11122 (nsP4) 60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 SV=1 RLA2_HUMAN 8 93.90%
ID11122 (nsP4) L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 LDHB_HUMAN 4 16.20%
ID11122 (nsP4) Nascent polypeptide-associated complex subunit alpha OS=Homo sapiens GN=NACA 
PE=1 SV=1
NACA_HUMAN 5 32.60%
ID11122 (nsP4) 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 RS3_HUMAN 17 72.80%
ID11122 (nsP4) Structural maintenance of chromosomes protein 4 OS=Homo sapiens GN=SMC4 
PE=1 SV=2
SMC4_HUMAN 11 10.60%
ID11122 (nsP4) Developmentally-regulated GTP-binding protein 1 OS=Homo sapiens GN=DRG1 
PE=1 SV=1
DRG1_HUMAN 8 30.00%
ID11122 (nsP4) Protein NipSnap homolog 1 OS=Homo sapiens GN=NIPSNAP1 PE=1 SV=1 NIPS1_HUMAN 3 13.40%
ID11122 (nsP4) Proteasome subunit beta type-1 OS=Homo sapiens GN=PSMB1 PE=1 SV=2 PSB1_HUMAN 7 38.60%
ID11122 (nsP4) Serpin H1 OS=Homo sapiens GN=SERPINH1 PE=1 SV=2 SERPH_HUMAN 1 2.63%
ID11122 (nsP4) Methionyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=MARS PE=1 SV=2 SYMC_HUMAN 9 14.90%
ID11122 (nsP4) 60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=1 SV=2 RL7A_HUMAN 11 37.20%
ID11122 (nsP4) Glutathione reductase, mitochondrial OS=Homo sapiens GN=GSR PE=1 SV=2 GSHR_HUMAN 7 20.90%
ID11122 (nsP4) Trifunctional enzyme subunit beta, mitochondrial OS=Homo sapiens GN=HADHB 
PE=1 SV=3
ECHB_HUMAN 8 19.40%
ID11122 (nsP4) Glycyl-tRNA synthetase OS=Homo sapiens GN=GARS PE=1 SV=2 SYG_HUMAN 4 8.53%
ID11122 (nsP4) Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 HSP7C_HUMAN 27 54.20%
ID11122 (nsP4) Zinc finger CCCH-type antiviral protein 1-like OS=Homo sapiens GN=ZC3HAV1L 
PE=1 SV=2
ZCCHL_HUMAN 5 32.70%
ID11122 (nsP4) Exosome complex exonuclease RRP45 OS=Homo sapiens GN=EXOSC9 PE=1 SV=3 EXOS9_HUMAN 3 7.74%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens GN=HNRNPH1 PE=1 
SV=4
HNRH1_HUMAN 4 30.10%
ID11122 (nsP4) Protein phosphatase 1G OS=Homo sapiens GN=PPM1G PE=1 SV=1 PPM1G_HUMAN 4 11.00%
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ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1 
SV=1
HNRPK_HUMAN 13 41.00%
ID11122 (nsP4) NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial 
OS=Homo sapiens GN=NDUFA9 PE=1 SV=2
NDUA9_HUMAN 4 14.60%
ID11122 (nsP4) 60S ribosomal protein L10 OS=Homo sapiens GN=RPL10 PE=1 SV=4 RL10_HUMAN 10 46.70%
ID11122 (nsP4) E3 ubiquitin/ISG15 ligase TRIM25 OS=Homo sapiens GN=TRIM25 PE=1 SV=1 TRI25_HUMAN 14 32.90%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 
SV=6
HNRPU_HUMAN 21 29.20%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein H2 OS=Homo sapiens GN=HNRNPH2 
PE=1 SV=1
HNRH2_HUMAN 4 26.90%
ID11122 (nsP4) Leucine-rich repeat-containing protein 47 OS=Homo sapiens GN=LRRC47 PE=1 
SV=1
LRC47_HUMAN 5 11.30%
ID11122 (nsP4) Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 K1C14_HUMAN 1 11.70%
ID11122 (nsP4) Splicing factor U2AF 65 kDa subunit OS=Homo sapiens GN=U2AF2 PE=1 SV=4 U2AF2_HUMAN 6 29.50%
ID11122 (nsP4) Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 K2C5_HUMAN 5 18.50%
ID11122 (nsP4) Mitochondrial 2-oxoglutarate/malate carrier protein OS=Homo sapiens GN=SLC25A11 
PE=1 SV=3
M2OM_HUMAN 8 29.90%
ID11122 (nsP4) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 
OS=Homo sapiens GN=DDOST PE=1 SV=4
OST48_HUMAN 8 27.40%
ID11122 (nsP4) 26S proteasome non-ATPase regulatory subunit 1 OS=Homo sapiens GN=PSMD1 
PE=1 SV=2
PSMD1_HUMAN 11 20.10%
ID11122 (nsP4) Protein arginine N-methyltransferase 3 OS=Homo sapiens GN=PRMT3 PE=1 SV=2 ANM3_HUMAN 5 10.40%
ID11122 (nsP4) Pre-mRNA-processing factor 19 OS=Homo sapiens GN=PRPF19 PE=1 SV=1 PRP19_HUMAN 5 12.10%
ID11122 (nsP4) 2',3'-cyclic-nucleotide 3'-phosphodiesterase OS=Homo sapiens GN=CNP PE=1 SV=2 CN37_HUMAN 11 30.90%
ID11122 (nsP4) Trifunctional enzyme subunit alpha, mitochondrial OS=Homo sapiens GN=HADHA 
PE=1 SV=2
ECHA_HUMAN 11 22.80%
ID11122 (nsP4) Argininosuccinate synthase OS=Homo sapiens GN=ASS1 PE=1 SV=2 ASSY_HUMAN 8 28.20%
ID11122 (nsP4) 26S protease regulatory subunit 6B OS=Homo sapiens GN=PSMC4 PE=1 SV=2 PRS6B_HUMAN 9 31.60%
ID11122 (nsP4) Transcription intermediary factor 1-beta OS=Homo sapiens GN=TRIM28 PE=1 SV=5 TIF1B_HUMAN 22 41.80%
ID11122 (nsP4) 40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 RS15A_HUMAN 4 30.80%
ID11122 (nsP4) 26S proteasome non-ATPase regulatory subunit 13 OS=Homo sapiens GN=PSMD13 
PE=1 SV=1
PSD13_HUMAN 8 26.30%
ID11122 (nsP4) Mitochondrial dicarboxylate carrier OS=Homo sapiens GN=SLC25A10 PE=1 SV=2 DIC_HUMAN 9 46.70%
ID11122 (nsP4) 26S protease regulatory subunit 8 OS=Homo sapiens GN=PSMC5 PE=1 SV=1 PRS8_HUMAN 14 50.50%
ID11122 (nsP4) 60S ribosomal protein L18a OS=Homo sapiens GN=RPL18A PE=1 SV=2 RL18A_HUMAN 6 35.20%
ID11122 (nsP4) Tubulin beta-2B chain OS=Homo sapiens GN=TUBB2B PE=1 SV=1 TBB2B_HUMAN 4 60.00%
ID11122 (nsP4) 40S ribosomal protein S15 OS=Homo sapiens GN=RPS15 PE=1 SV=2 RS15_HUMAN 6 57.20%
ID11122 (nsP4) 28S ribosomal protein S22, mitochondrial OS=Homo sapiens GN=MRPS22 PE=1 
SV=1
RT22_HUMAN 5 20.80%
ID11122 (nsP4) 40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 SV=3 RS18_HUMAN 9 44.70%
ID11122 (nsP4) Cell division protein kinase 1 OS=Homo sapiens GN=CDK1 PE=1 SV=2 CDK1_HUMAN 9 40.40%
ID11122 (nsP4) F-actin-capping protein subunit alpha-1 OS=Homo sapiens GN=CAPZA1 PE=1 SV=3 CAZA1_HUMAN 7 50.30%
ID11122 (nsP4) Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1 SV=5 DDX21_HUMAN 9 16.30%
ID11122 (nsP4) Replication factor C subunit 5 OS=Homo sapiens GN=RFC5 PE=1 SV=1 RFC5_HUMAN 4 13.80%
ID11122 (nsP4) Nicalin OS=Homo sapiens GN=NCLN PE=1 SV=2 NCLN_HUMAN 5 11.20%
ID11122 (nsP4) 60S ribosomal protein L38 OS=Homo sapiens GN=RPL38 PE=1 SV=2 RL38_HUMAN 4 35.70%
ID11122 (nsP4) Small nuclear ribonucleoprotein Sm D3 OS=Homo sapiens GN=SNRPD3 PE=1 SV=1 SMD3_HUMAN 3 31.70%
ID11122 (nsP4) 60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 RL6_HUMAN 13 38.20%
ID11122 (nsP4) Protein RCC2 OS=Homo sapiens GN=RCC2 PE=1 SV=2 RCC2_HUMAN 11 27.00%
ID11122 (nsP4) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Homo 
sapiens GN=RPN1 PE=1 SV=1
RPN1_HUMAN 8 16.80%
ID11122 (nsP4) BolA-like protein 2 OS=Homo sapiens GN=BOLA2 PE=1 SV=1 BOLA2_HUMAN 4 61.60%
ID11122 (nsP4) 40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 RS14_HUMAN 7 38.40%
ID11122 (nsP4) Erlin-2 OS=Homo sapiens GN=ERLIN2 PE=1 SV=1 ERLN2_HUMAN 6 24.20%
ID11122 (nsP4) Serine/threonine-protein phosphatase PGAM5, mitochondrial OS=Homo sapiens 
GN=PGAM5 PE=1 SV=2
PGAM5_HUMAN 4 15.90%
ID11122 (nsP4) 26S proteasome non-ATPase regulatory subunit 12 OS=Homo sapiens GN=PSMD12 
PE=1 SV=3
PSD12_HUMAN 8 23.90%
ID11122 (nsP4) Activated RNA polymerase II transcriptional coactivator p15 OS=Homo sapiens 
GN=SUB1 PE=1 SV=3
TCP4_HUMAN 5 44.90%
ID11122 (nsP4) 60S ribosomal protein L19 OS=Homo sapiens GN=RPL19 PE=1 SV=1 RL19_HUMAN 2 13.30%
ID11122 (nsP4) Medium-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Homo sapiens 
GN=ACADM PE=1 SV=1
ACADM_HUMAN 6 19.00%
ID11122 (nsP4) Calcium-binding mitochondrial carrier protein Aralar2 OS=Homo sapiens 
GN=SLC25A13 PE=1 SV=2
CMC2_HUMAN 12 40.70%
ID11122 (nsP4) Leucyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=LARS PE=1 SV=2 SYLC_HUMAN 17 18.50%
ID11122 (nsP4) Transforming protein RhoA OS=Homo sapiens GN=RHOA PE=1 SV=1 RHOA_HUMAN 4 26.90%
ID11122 (nsP4) Serine/arginine-rich splicing factor 3 OS=Homo sapiens GN=SRSF3 PE=1 SV=1 SRSF3_HUMAN 4 28.70%
ID11122 (nsP4) Double-stranded RNA-specific adenosine deaminase OS=Homo sapiens GN=ADAR 
PE=1 SV=3
DSRAD_HUMAN 5 5.71%
ID11122 (nsP4) Structural maintenance of chromosomes protein 3 OS=Homo sapiens GN=SMC3 
PE=1 SV=2
SMC3_HUMAN 2 1.97%
ID11122 (nsP4) Replication factor C subunit 4 OS=Homo sapiens GN=RFC4 PE=1 SV=2 RFC4_HUMAN 5 19.80%
ID11122 (nsP4) Ras GTPase-activating protein-binding protein 1 OS=Homo sapiens GN=G3BP1 
PE=1 SV=1
G3BP1_HUMAN 8 29.60%
ID11122 (nsP4) DNA replication licensing factor MCM4 OS=Homo sapiens GN=MCM4 PE=1 SV=5 MCM4_HUMAN 10 16.50%
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ID11122 (nsP4) Eukaryotic translation initiation factor 2 subunit 2 OS=Homo sapiens GN=EIF2S2 
PE=1 SV=2
IF2B_HUMAN 4 18.90%
ID11122 (nsP4) Complement component 1 Q subcomponent-binding protein, mitochondrial OS=Homo 
sapiens GN=C1QBP PE=1 SV=1
C1QBP_HUMAN 5 32.60%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein A3 OS=Homo sapiens GN=HNRNPA3 
PE=1 SV=2
ROA3_HUMAN 8 20.90%
ID11122 (nsP4) Bifunctional aminoacyl-tRNA synthetase OS=Homo sapiens GN=EPRS PE=1 SV=5 SYEP_HUMAN 29 25.70%
ID11122 (nsP4) 40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 RS3A_HUMAN 11 47.70%
ID11122 (nsP4) Small nuclear ribonucleoprotein Sm D2 OS=Homo sapiens GN=SNRPD2 PE=1 SV=1 SMD2_HUMAN 3 25.40%
ID11122 (nsP4) 60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 SV=3 RL5_HUMAN 10 38.70%
ID11122 (nsP4) Flap endonuclease 1 OS=Homo sapiens GN=FEN1 PE=1 SV=1 FEN1_HUMAN 9 37.60%
ID11122 (nsP4) Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 PCNA_HUMAN 10 60.20%
ID11122 (nsP4) Cellular nucleic acid-binding protein OS=Homo sapiens GN=CNBP PE=1 SV=1 CNBP_HUMAN 3 24.90%
ID11122 (nsP4) 60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 PE=1 SV=2 RL30_HUMAN 5 58.30%
ID11122 (nsP4) Delta-1-pyrroline-5-carboxylate synthase OS=Homo sapiens GN=ALDH18A1 PE=1 
SV=2
P5CS_HUMAN 12 19.60%
ID11122 (nsP4) Peptidyl-prolyl cis-trans isomerase FKBP8 OS=Homo sapiens GN=FKBP8 PE=1 
SV=2
FKBP8_HUMAN 4 14.80%
ID11122 (nsP4) Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 SV=1 MEP50_HUMAN 5 27.80%
ID11122 (nsP4) 60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 RL11_HUMAN 4 24.70%
ID11122 (nsP4) Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4 PDIA3_HUMAN 4 11.90%
ID11122 (nsP4) GFP|GFP GFP|GFP 13 63.90%
ID11122 (nsP4) Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 SV=2 GRP75_HUMAN 8 16.80%
ID11122 (nsP4) Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 
SV=3
G3P_HUMAN 5 23.00%
ID11122 (nsP4) 60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 SV=1 RLA0_HUMAN 8 40.40%
ID11122 (nsP4) Tricarboxylate transport protein, mitochondrial OS=Homo sapiens GN=SLC25A1 
PE=1 SV=2
TXTP_HUMAN 6 24.10%
ID11122 (nsP4) U5 small nuclear ribonucleoprotein 200 kDa helicase OS=Homo sapiens 
GN=SNRNP200 PE=1 SV=2
U520_HUMAN 14 8.99%
ID11122 (nsP4) 60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 RL18_HUMAN 6 38.30%
ID11122 (nsP4) Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM2 PE=1 SV=4 KPYM_HUMAN 18 46.50%
ID11122 (nsP4) DnaJ homolog subfamily A member 3, mitochondrial OS=Homo sapiens GN=DNAJA3 
PE=1 SV=1
DNJA3_HUMAN 7 14.80%
ID11122 (nsP4) Calcium-binding mitochondrial carrier protein Aralar1 OS=Homo sapiens 
GN=SLC25A12 PE=1 SV=2
CMC1_HUMAN 5 17.80%
ID11122 (nsP4) Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens GN=AIFM1 PE=1 SV=1 AIFM1_HUMAN 19 43.40%
ID11122 (nsP4) NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial OS=Homo sapiens 
GN=NDUFS1 PE=1 SV=3
NDUS1_HUMAN 7 15.10%
ID11122 (nsP4) Actin, alpha cardiac muscle 1 OS=Homo sapiens GN=ACTC1 PE=1 SV=1 ACTC_HUMAN 2 37.70%
ID11122 (nsP4) 40S ribosomal protein S27 OS=Homo sapiens GN=RPS27 PE=1 SV=3 RS27_HUMAN 2 39.30%
ID11122 (nsP4) Coatomer subunit gamma OS=Homo sapiens GN=COPG PE=1 SV=1 COPG_HUMAN 5 12.50%
ID11122 (nsP4) Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 ENPL_HUMAN 4 7.35%
ID11122 (nsP4) 60S ribosomal protein L17 OS=Homo sapiens GN=RPL17 PE=1 SV=3 RL17_HUMAN 7 38.00%
ID11122 (nsP4) Structural maintenance of chromosomes protein 2 OS=Homo sapiens GN=SMC2 
PE=1 SV=2
SMC2_HUMAN 2 1.84%
ID11122 (nsP4) Phosphoenolpyruvate carboxykinase [GTP], mitochondrial OS=Homo sapiens 
GN=PCK2 PE=1 SV=3
PCKGM_HUMAN 4 7.81%
ID11122 (nsP4) Tubulin beta-6 chain OS=Homo sapiens GN=TUBB6 PE=1 SV=1 TBB6_HUMAN 4 34.30%
ID11122 (nsP4) Putative heat shock protein HSP 90-beta 2 OS=Homo sapiens GN=HSP90AB2P 
PE=1 SV=2
H90B2_HUMAN 2 22.60%
ID11122 (nsP4) Protein SEC13 homolog OS=Homo sapiens GN=SEC13 PE=1 SV=3 SEC13_HUMAN 6 26.70%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens 
GN=HNRNPA2B1 PE=1 SV=2
ROA2_HUMAN 12 45.90%
ID11122 (nsP4) Acylglycerol kinase, mitochondrial OS=Homo sapiens GN=AGK PE=1 SV=2 AGK_HUMAN 11 32.70%
ID11122 (nsP4) Acetyl-CoA acetyltransferase, mitochondrial OS=Homo sapiens GN=ACAT1 PE=1 
SV=1
THIL_HUMAN 6 19.70%
ID11122 (nsP4) tRNA (cytosine-5-)-methyltransferase NSUN2 OS=Homo sapiens GN=NSUN2 PE=1 
SV=2
NSUN2_HUMAN 14 27.10%
ID11122 (nsP4) Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 PRDX2_HUMAN 6 46.00%
ID11122 (nsP4) ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X PE=1 SV=3 DDX3X_HUMAN 13 28.50%
ID11122 (nsP4) 26S protease regulatory subunit 7 OS=Homo sapiens GN=PSMC2 PE=1 SV=3 PRS7_HUMAN 10 35.30%
ID11122 (nsP4) 2'-5'-oligoadenylate synthase 3 OS=Homo sapiens GN=OAS3 PE=1 SV=2 OAS3_HUMAN 0 0.00%
ID11122 (nsP4) Serine hydroxymethyltransferase, mitochondrial OS=Homo sapiens GN=SHMT2 
PE=1 SV=3
GLYM_HUMAN 6 17.30%
ID11122 (nsP4) Glutaminyl-tRNA synthetase OS=Homo sapiens GN=QARS PE=1 SV=1 SYQ_HUMAN 10 17.40%
ID11122 (nsP4) Matrin-3 OS=Homo sapiens GN=MATR3 PE=1 SV=2 MATR3_HUMAN 5 8.38%
ID11122 (nsP4) ATP-dependent RNA helicase A OS=Homo sapiens GN=DHX9 PE=1 SV=4 DHX9_HUMAN 25 27.20%
ID11122 (nsP4) Ubiquitin/ISG15-conjugating enzyme E2 L6 OS=Homo sapiens GN=UBE2L6 PE=1 
SV=4
UB2L6_HUMAN 5 49.00%
ID11122 (nsP4) Nuclease-sensitive element-binding protein 1 OS=Homo sapiens GN=YBX1 PE=1 
SV=3
YBOX1_HUMAN 2 25.00%
ID11122 (nsP4) 40S ribosomal protein S17 OS=Homo sapiens GN=RPS17 PE=1 SV=2 RS17_HUMAN 7 50.40%
ID11122 (nsP4) RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=1 SV=3 RUVB2_HUMAN 20 42.50%
ID11122 (nsP4) Calumenin OS=Homo sapiens GN=CALU PE=1 SV=2 CALU_HUMAN 12 47.00%
ID11122 (nsP4) 60S ribosomal protein L37a OS=Homo sapiens GN=RPL37A PE=1 SV=2 RL37A_HUMAN 4 41.30%
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ID11122 (nsP4) Protein transport protein Sec16A OS=Homo sapiens GN=SEC16A PE=1 SV=3 SC16A_HUMAN 21 15.70%
ID11122 (nsP4) Cold-inducible RNA-binding protein OS=Homo sapiens GN=CIRBP PE=1 SV=1 CIRBP_HUMAN 3 20.90%
ID11122 (nsP4) SUMO-activating enzyme subunit 1 OS=Homo sapiens GN=SAE1 PE=1 SV=1 SAE1_HUMAN 5 24.00%
ID11122 (nsP4) 40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 RS26_HUMAN 4 44.30%
ID11122 (nsP4) Translational activator GCN1 OS=Homo sapiens GN=GCN1L1 PE=1 SV=6 GCN1L_HUMAN 13 5.99%
ID11122 (nsP4) Isoleucyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=IARS PE=1 SV=2 SYIC_HUMAN 14 13.40%
ID11122 (nsP4) Adenylate kinase isoenzyme 6 OS=Homo sapiens GN=TAF9 PE=1 SV=1 KAD6_HUMAN 4 29.70%
ID11122 (nsP4) Protein arginine N-methyltransferase 1 OS=Homo sapiens GN=PRMT1 PE=1 SV=2 ANM1_HUMAN 6 24.40%
ID11122 (nsP4) Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 ILF2_HUMAN 7 36.20%
ID11122 (nsP4) Glutaredoxin-3 OS=Homo sapiens GN=GLRX3 PE=1 SV=2 GLRX3_HUMAN 10 35.80%
ID11122 (nsP4) RNA-binding protein 14 OS=Homo sapiens GN=RBM14 PE=1 SV=2 RBM14_HUMAN 2 3.14%
ID11122 (nsP4) Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 COF1_HUMAN 8 48.80%
ID11122 (nsP4) Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1 TBA1C_HUMAN 5 62.40%
ID11122 (nsP4) 26S proteasome non-ATPase regulatory subunit 11 OS=Homo sapiens GN=PSMD11 
PE=1 SV=3
PSD11_HUMAN 8 20.40%
ID11122 (nsP4) Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 PHB_HUMAN 3 11.80%
ID11122 (nsP4) T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 PE=1 SV=4 TCPG_HUMAN 28 58.20%
ID11122 (nsP4) SAM domain and HD domain-containing protein 1 OS=Homo sapiens GN=SAMHD1 
PE=1 SV=2
SAMH1_HUMAN 15 30.00%
ID11122 (nsP4) T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=1 SV=4 TCPQ_HUMAN 31 58.20%
ID11122 (nsP4) 60S ribosomal protein L27 OS=Homo sapiens GN=RPL27 PE=1 SV=2 RL27_HUMAN 5 42.60%
ID11122 (nsP4) ADP-ribosylation factor 1 OS=Homo sapiens GN=ARF1 PE=1 SV=2 ARF1_HUMAN 2 44.80%
ID11122 (nsP4) Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 H4_HUMAN 7 52.40%
ID11122 (nsP4) Isocitrate dehydrogenase [NADP], mitochondrial OS=Homo sapiens GN=IDH2 PE=1 
SV=2
IDHP_HUMAN 7 18.80%
ID11122 (nsP4) Keratin, type II cytoskeletal 3 OS=Homo sapiens GN=KRT3 PE=1 SV=2 K2C3_HUMAN 4 11.60%
ID11122 (nsP4) Retinol dehydrogenase 11 OS=Homo sapiens GN=RDH11 PE=1 SV=2 RDH11_HUMAN 1 3.77%
ID11122 (nsP4) ATP-binding cassette sub-family E member 1 OS=Homo sapiens GN=ABCE1 PE=1 
SV=1
ABCE1_HUMAN 4 9.85%
ID11122 (nsP4) Eukaryotic translation initiation factor 2 subunit 1 OS=Homo sapiens GN=EIF2S1 
PE=1 SV=3
IF2A_HUMAN 7 33.00%
ID11122 (nsP4) Mitochondrial import inner membrane translocase subunit TIM44 OS=Homo sapiens 
GN=TIMM44 PE=1 SV=2
TIM44_HUMAN 4 11.30%
ID11122 (nsP4) 60S ribosomal protein L36 OS=Homo sapiens GN=RPL36 PE=1 SV=3 RL36_HUMAN 4 30.50%
ID11122 (nsP4) RNA 3'-terminal phosphate cyclase OS=Homo sapiens GN=RTCD1 PE=1 SV=1 RTC1_HUMAN 2 6.56%
ID11122 (nsP4) Small nuclear ribonucleoprotein Sm D1 OS=Homo sapiens GN=SNRPD1 PE=1 SV=1 SMD1_HUMAN 2 20.20%
ID11122 (nsP4) 60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 RL4_HUMAN 14 38.20%
ID11122 (nsP4) Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 NUCL_HUMAN 18 25.50%
ID11122 (nsP4) Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 RINI_HUMAN 16 53.60%
ID11122 (nsP4) DnaJ homolog subfamily C member 7 OS=Homo sapiens GN=DNAJC7 PE=1 SV=2 DNJC7_HUMAN 5 13.00%
ID11122 (nsP4) Activator of 90 kDa heat shock protein ATPase homolog 1 OS=Homo sapiens 
GN=AHSA1 PE=1 SV=1
AHSA1_HUMAN 7 28.40%
ID11122 (nsP4) GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 RAN_HUMAN 8 38.00%
ID11122 (nsP4) THO complex subunit 4 OS=Homo sapiens GN=THOC4 PE=1 SV=3 THOC4_HUMAN 2 8.17%
ID11122 (nsP4) Pyridoxal phosphate phosphatase OS=Homo sapiens GN=PDXP PE=1 SV=2 PLPP_HUMAN 4 17.20%
ID11122 (nsP4) Serine/arginine-rich splicing factor 1 OS=Homo sapiens GN=SRSF1 PE=1 SV=2 SRSF1_HUMAN 6 24.60%
ID11122 (nsP4) 60S ribosomal protein L26 OS=Homo sapiens GN=RPL26 PE=1 SV=1 RL26_HUMAN 7 34.50%
ID11122 (nsP4) GTP-binding protein 1 OS=Homo sapiens GN=GTPBP1 PE=1 SV=3 GTPB1_HUMAN 6 12.90%
ID11122 (nsP4) Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 K1C9_HUMAN 18 41.10%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein D0 OS=Homo sapiens GN=HNRNPD PE=1 
SV=1
HNRPD_HUMAN 5 19.70%
ID11122 (nsP4) Plastin-3 OS=Homo sapiens GN=PLS3 PE=1 SV=4 PLST_HUMAN 9 25.10%
ID11122 (nsP4) ATP-dependent RNA helicase DDX39 OS=Homo sapiens GN=DDX39 PE=1 SV=2 DDX39_HUMAN 7 23.90%
ID11122 (nsP4) Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens 
GN=ATP1A1 PE=1 SV=1
AT1A1_HUMAN 13 19.80%
ID11122 (nsP4) Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 TBB5_HUMAN 3 67.30%
ID11122 (nsP4) ATPase family AAA domain-containing protein 3B OS=Homo sapiens GN=ATAD3B 
PE=1 SV=1
ATD3B_HUMAN 2 6.02%
ID11122 (nsP4) Thioredoxin domain-containing protein 5 OS=Homo sapiens GN=TXNDC5 PE=1 
SV=2
TXND5_HUMAN 7 19.70%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens GN=HNRNPA1 
PE=1 SV=5
ROA1_HUMAN 11 33.30%
ID11122 (nsP4) 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1433Z_HUMAN 4 30.60%
ID11122 (nsP4) Succinyl-CoA ligase [GDP-forming] subunit alpha, mitochondrial OS=Homo sapiens 
GN=SUCLG1 PE=1 SV=4
SUCA_HUMAN 4 15.00%
ID11122 (nsP4) Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 PRDX1_HUMAN 13 70.40%
ID11122 (nsP4) Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 EF2_HUMAN 23 34.00%
ID11122 (nsP4) Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2 IMB1_HUMAN 13 20.80%
ID11122 (nsP4) DNA-binding protein A OS=Homo sapiens GN=CSDA PE=1 SV=4 DBPA_HUMAN 2 16.40%
ID11122 (nsP4) FACT complex subunit SSRP1 OS=Homo sapiens GN=SSRP1 PE=1 SV=1 SSRP1_HUMAN 1 1.55%
ID11122 (nsP4) Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 ENOA_HUMAN 13 52.50%
ID11122 (nsP4) Eukaryotic initiation factor 4A-III OS=Homo sapiens GN=EIF4A3 PE=1 SV=4 IF4A3_HUMAN 3 14.10%
ID11122 (nsP4) RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE=1 SV=1 RUVB1_HUMAN 16 49.80%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein R OS=Homo sapiens GN=HNRNPR PE=1 
SV=1
HNRPR_HUMAN 8 26.50%
ID11122 (nsP4) DNA replication licensing factor MCM3 OS=Homo sapiens GN=MCM3 PE=1 SV=3 MCM3_HUMAN 22 36.00%
ID11122 (nsP4) 40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 RS25_HUMAN 6 32.00%
	   270	  
 
ID11122 (nsP4) Threonyl-tRNA synthetase, mitochondrial OS=Homo sapiens GN=TARS2 PE=1 SV=1 SYTM_HUMAN 1 1.81%
ID11122 (nsP4) 116 kDa U5 small nuclear ribonucleoprotein component OS=Homo sapiens 
GN=EFTUD2 PE=1 SV=1
U5S1_HUMAN 7 10.30%
ID11122 (nsP4) Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 K2C6B_HUMAN 3 21.10%
ID11122 (nsP4) Beta-enolase OS=Homo sapiens GN=ENO3 PE=1 SV=4 ENOB_HUMAN 3 20.30%
ID11122 (nsP4) 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 1433E_HUMAN 8 42.40%
ID11122 (nsP4) Cytochrome b-c1 complex subunit 2, mitochondrial OS=Homo sapiens GN=UQCRC2 
PE=1 SV=3
QCR2_HUMAN 10 35.10%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein A0 OS=Homo sapiens GN=HNRNPA0 
PE=1 SV=1
ROA0_HUMAN 5 19.30%
ID11122 (nsP4) Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 TBA1B_HUMAN 4 62.30%
ID11122 (nsP4) ATP synthase subunit gamma, mitochondrial OS=Homo sapiens GN=ATP5C1 PE=1 
SV=1
ATPG_HUMAN 7 31.20%
ID11122 (nsP4) Testin OS=Homo sapiens GN=TES PE=1 SV=1 TES_HUMAN 7 21.40%
ID11122 (nsP4) E3 ISG15--protein ligase HERC5 OS=Homo sapiens GN=HERC5 PE=1 SV=2 HERC5_HUMAN 6 7.32%
ID11122 (nsP4) Long-chain fatty acid transport protein 4 OS=Homo sapiens GN=SLC27A4 PE=1 
SV=1
S27A4_HUMAN 2 3.11%
ID11122 (nsP4) Interferon-induced, double-stranded RNA-activated protein kinase OS=Homo sapiens 
GN=EIF2AK2 PE=1 SV=2
E2AK2_HUMAN 4 9.44%
ID11122 (nsP4) Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A PE=1 SV=2 RS27A_HUMAN 5 42.30%
ID11122 (nsP4) Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 PABP1_HUMAN 6 24.50%
ID11122 (nsP4) 6-phosphofructokinase type C OS=Homo sapiens GN=PFKP PE=1 SV=2 K6PP_HUMAN 18 34.60%
ID11122 (nsP4) Nicotinamide phosphoribosyltransferase OS=Homo sapiens GN=NAMPT PE=1 SV=1 NAMPT_HUMAN 6 19.80%
ID11122 (nsP4) DNA replication licensing factor MCM7 OS=Homo sapiens GN=MCM7 PE=1 SV=4 MCM7_HUMAN 19 35.90%
ID11122 (nsP4) Exosome complex exonuclease RRP44 OS=Homo sapiens GN=DIS3 PE=1 SV=2 RRP44_HUMAN 22 31.40%
ID11122 (nsP4) 60S ribosomal protein L3 OS=Homo sapiens GN=RPL3 PE=1 SV=2 RL3_HUMAN 15 39.20%
ID11122 (nsP4) Splicing factor 3B subunit 3 OS=Homo sapiens GN=SF3B3 PE=1 SV=4 SF3B3_HUMAN 0 0.00%
ID11122 (nsP4) Coatomer subunit beta OS=Homo sapiens GN=COPB1 PE=1 SV=3 COPB_HUMAN 14 23.30%
ID11122 (nsP4) TAR DNA-binding protein 43 OS=Homo sapiens GN=TARDBP PE=1 SV=1 TADBP_HUMAN 4 13.50%
ID11122 (nsP4) Nucleosome assembly protein 1-like 1 OS=Homo sapiens GN=NAP1L1 PE=1 SV=1 NP1L1_HUMAN 4 24.60%
ID11122 (nsP4) 26S protease regulatory subunit 4 OS=Homo sapiens GN=PSMC1 PE=1 SV=1 PRS4_HUMAN 10 34.10%
ID11122 (nsP4) UPF0027 protein C22orf28 OS=Homo sapiens GN=C22orf28 PE=1 SV=1 CV028_HUMAN 13 39.20%
ID11122 (nsP4) T-complex protein 1 subunit epsilon OS=Homo sapiens GN=CCT5 PE=1 SV=1 TCPE_HUMAN 32 69.70%
ID11122 (nsP4) Coatomer subunit epsilon OS=Homo sapiens GN=COPE PE=1 SV=3 COPE_HUMAN 7 28.20%
ID11122 (nsP4) Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 K2C1_HUMAN 21 33.90%
ID11122 (nsP4) Cystathionine beta-synthase OS=Homo sapiens GN=CBS PE=1 SV=2 CBS_HUMAN 8 26.70%
ID11122 (nsP4) 40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 RS9_HUMAN 12 41.20%
ID11122 (nsP4) Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=3 EF1B_HUMAN 2 14.70%
ID11122 (nsP4) 3-hydroxyacyl-CoA dehydratase 3 OS=Homo sapiens GN=PTPLAD1 PE=1 SV=2 HACD3_HUMAN 3 12.40%
ID11122 (nsP4) Putative RNA-binding protein Luc7-like 2 OS=Homo sapiens GN=LUC7L2 PE=1 SV=2 LC7L2_HUMAN 3 11.50%
ID11122 (nsP4) ATPase family AAA domain-containing protein 3A OS=Homo sapiens GN=ATAD3A 
PE=1 SV=2
ATD3A_HUMAN 2 7.73%
ID11122 (nsP4) T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=1 SV=2 TCPH_HUMAN 22 52.30%
ID11122 (nsP4) DNA replication licensing factor MCM6 OS=Homo sapiens GN=MCM6 PE=1 SV=1 MCM6_HUMAN 6 9.99%
ID11122 (nsP4) Protein unc-45 homolog A OS=Homo sapiens GN=UNC45A PE=1 SV=1 UN45A_HUMAN 5 6.78%
ID11122 (nsP4) Exosome complex exonuclease RRP46 OS=Homo sapiens GN=EXOSC5 PE=1 SV=1 EXOS5_HUMAN 2 11.10%
ID11122 (nsP4) Spermidine synthase OS=Homo sapiens GN=SRM PE=1 SV=1 SPEE_HUMAN 6 25.80%
ID11122 (nsP4) Phenylalanyl-tRNA synthetase beta chain OS=Homo sapiens GN=FARSB PE=1 SV=3 SYFB_HUMAN 12 22.20%
ID11122 (nsP4) RNA-binding protein 4 OS=Homo sapiens GN=RBM4 PE=1 SV=1 RBM4_HUMAN 6 29.70%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein G OS=Homo sapiens GN=RBMX PE=1 
SV=3
HNRPG_HUMAN 4 15.10%
ID11122 (nsP4) DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC 
PE=1 SV=3
PRKDC_HUMAN 67 21.80%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein Q OS=Homo sapiens GN=SYNCRIP PE=1 
SV=2
HNRPQ_HUMAN 8 22.20%
ID11122 (nsP4) Pyruvate dehydrogenase E1 component subunit beta, mitochondrial OS=Homo 
sapiens GN=PDHB PE=1 SV=3
ODPB_HUMAN 8 31.50%
ID11122 (nsP4) Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 K1C10_HUMAN 22 51.70%
ID11122 (nsP4) Methylthioribose-1-phosphate isomerase OS=Homo sapiens GN=MRI1 PE=1 SV=1 MTNA_HUMAN 3 9.49%
ID11122 (nsP4) ATP-binding cassette sub-family F member 2 OS=Homo sapiens GN=ABCF2 PE=1 
SV=2
ABCF2_HUMAN 15 27.30%
ID11122 (nsP4) Aspartyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=DARS PE=1 SV=2 SYDC_HUMAN 15 37.50%
ID11122 (nsP4) Proteasome subunit alpha type-7 OS=Homo sapiens GN=PSMA7 PE=1 SV=1 PSA7_HUMAN 7 39.90%
ID11122 (nsP4) Coatomer subunit delta OS=Homo sapiens GN=ARCN1 PE=1 SV=1 COPD_HUMAN 11 28.00%
ID11122 (nsP4) Arginyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=RARS PE=1 SV=2 SYRC_HUMAN 13 22.90%
ID11122 (nsP4) 60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 PE=1 SV=1 RL24_HUMAN 6 31.80%
ID11122 (nsP4) Insulin-like growth factor 2 mRNA-binding protein 3 OS=Homo sapiens GN=IGF2BP3 
PE=1 SV=2
IF2B3_HUMAN 3 10.50%
ID11122 (nsP4) 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 RS8_HUMAN 10 54.80%
ID11122 (nsP4) Cytochrome b-c1 complex subunit 1, mitochondrial OS=Homo sapiens GN=UQCRC1 
PE=1 SV=3
QCR1_HUMAN 6 21.90%
ID11122 (nsP4) Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 TBB3_HUMAN 1 37.30%
ID11122 (nsP4) Glutaryl-CoA dehydrogenase, mitochondrial OS=Homo sapiens GN=GCDH PE=1 
SV=1
GCDH_HUMAN 5 17.80%
ID11122 (nsP4) ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=1 SV=4 ADT3_HUMAN 6 49.30%
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ID11122 (nsP4) Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 PARP1_HUMAN 6 8.19%
ID11122 (nsP4) T-complex protein 1 subunit zeta OS=Homo sapiens GN=CCT6A PE=1 SV=3 TCPZ_HUMAN 15 44.60%
ID11122 (nsP4) Phospholipid hydroperoxide glutathione peroxidase, mitochondrial OS=Homo sapiens 
GN=GPX4 PE=1 SV=3
GPX4_HUMAN 4 29.90%
ID11122 (nsP4) Four and a half LIM domains protein 1 OS=Homo sapiens GN=FHL1 PE=1 SV=4 FHL1_HUMAN 8 33.40%
ID11122 (nsP4) Proteasome subunit alpha type-5 OS=Homo sapiens GN=PSMA5 PE=1 SV=3 PSA5_HUMAN 5 30.30%
ID11122 (nsP4) Aspartyl aminopeptidase OS=Homo sapiens GN=DNPEP PE=1 SV=1 DNPEP_HUMAN 4 10.90%
ID11122 (nsP4) Phosphorylase b kinase gamma catalytic chain, testis/liver isoform OS=Homo sapiens 
GN=PHKG2 PE=1 SV=1
PHKG2_HUMAN 11 49.50%
ID11122 (nsP4) 3-hydroxyacyl-CoA dehydrogenase type-2 OS=Homo sapiens GN=HSD17B10 PE=1 
SV=3
HCD2_HUMAN 5 32.20%
ID11122 (nsP4) Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial 
OS=Homo sapiens GN=PDHA1 PE=1 SV=3
ODPA_HUMAN 5 12.60%
ID11122 (nsP4) 40S ribosomal protein S23 OS=Homo sapiens GN=RPS23 PE=1 SV=3 RS23_HUMAN 5 42.70%
ID11122 (nsP4) Zinc finger CCCH domain-containing protein 15 OS=Homo sapiens GN=ZC3H15 
PE=1 SV=1
ZC3HF_HUMAN 5 17.10%
ID11122 (nsP4) mRNA turnover protein 4 homolog OS=Homo sapiens GN=MRTO4 PE=1 SV=2 MRT4_HUMAN 2 9.62%
ID11122 (nsP4) Reticulocalbin-2 OS=Homo sapiens GN=RCN2 PE=1 SV=1 RCN2_HUMAN 7 27.10%
ID11122 (nsP4) Serine/threonine-protein phosphatase 6 catalytic subunit OS=Homo sapiens 
GN=PPP6C PE=1 SV=1
PPP6_HUMAN 4 18.00%
ID11122 (nsP4) 26S proteasome non-ATPase regulatory subunit 6 OS=Homo sapiens GN=PSMD6 
PE=1 SV=1
PSMD6_HUMAN 6 19.50%
ID11122 (nsP4) NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 OS=Homo 
sapiens GN=NDUFA13 PE=1 SV=3
NDUAD_HUMAN 5 41.00%
ID11122 (nsP4) POLNCHIKS|POLNCHIKS POLNCHIKS|POL
NCHIKS
50 28.00%
ID11122 (nsP4) 60S ribosomal protein L13a OS=Homo sapiens GN=RPL13A PE=1 SV=2 RL13A_HUMAN 6 25.10%
ID11122 (nsP4) Macrophage migration inhibitory factor OS=Homo sapiens GN=MIF PE=1 SV=4 MIF_HUMAN 6 89.60%
ID11122 (nsP4) ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=6 ADT2_HUMAN 6 45.60%
ID11122 (nsP4) Mitochondrial import inner membrane translocase subunit TIM50 OS=Homo sapiens 
GN=TIMM50 PE=1 SV=2
TIM50_HUMAN 4 16.10%
ID11122 (nsP4) Polyadenylate-binding protein 4 OS=Homo sapiens GN=PABPC4 PE=1 SV=1 PABP4_HUMAN 4 22.00%
ID11122 (nsP4) 40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 RS16_HUMAN 5 33.60%
ID11122 (nsP4) Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Homo 
sapiens GN=DHX15 PE=1 SV=2
DHX15_HUMAN 8 11.70%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein D-like OS=Homo sapiens GN=HNRPDL 
PE=1 SV=3
HNRDL_HUMAN 6 17.60%
ID11122 (nsP4) Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 PARK7_HUMAN 8 61.90%
ID11122 (nsP4) Probable ATP-dependent RNA helicase DDX17 OS=Homo sapiens GN=DDX17 PE=1 
SV=1
DDX17_HUMAN 18 42.50%
ID11122 (nsP4) T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 SV=4 TCPD_HUMAN 24 63.10%
ID11122 (nsP4) Glutamate-rich WD repeat-containing protein 1 OS=Homo sapiens GN=GRWD1 PE=1 
SV=1
GRWD1_HUMAN 5 21.30%
ID11122 (nsP4) 40S ribosomal protein S13 OS=Homo sapiens GN=RPS13 PE=1 SV=2 RS13_HUMAN 6 40.40%
ID11122 (nsP4) Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase 
OS=Homo sapiens GN=GNE PE=1 SV=1
GLCNE_HUMAN 0 0.00%
ID11122 (nsP4) Destrin OS=Homo sapiens GN=DSTN PE=1 SV=3 DEST_HUMAN 4 19.40%
ID11122 (nsP4) Protein transport protein Sec23A OS=Homo sapiens GN=SEC23A PE=1 SV=2 SC23A_HUMAN 6 11.90%
ID11122 (nsP4) GDP-mannose 4,6 dehydratase OS=Homo sapiens GN=GMDS PE=1 SV=1 GMDS_HUMAN 5 20.70%
ID11122 (nsP4) Hydroxysteroid dehydrogenase-like protein 2 OS=Homo sapiens GN=HSDL2 PE=1 
SV=1
HSDL2_HUMAN 5 19.10%
ID11122 (nsP4) Zinc finger CCCH-type antiviral protein 1 OS=Homo sapiens GN=ZC3HAV1 PE=1 
SV=3
ZCCHV_HUMAN 10 20.70%
ID11122 (nsP4) Reticulocalbin-1 OS=Homo sapiens GN=RCN1 PE=1 SV=1 RCN1_HUMAN 7 33.80%
ID11122 (nsP4) Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 IF4A1_HUMAN 6 38.70%
ID11122 (nsP4) 60S ribosomal protein L14 OS=Homo sapiens GN=RPL14 PE=1 SV=4 RL14_HUMAN 5 27.00%
ID11122 (nsP4) Proteasome subunit alpha type-6 OS=Homo sapiens GN=PSMA6 PE=1 SV=1 PSA6_HUMAN 7 34.10%
ID11122 (nsP4) Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform 
OS=Homo sapiens GN=PPP2R2A PE=1 SV=1
2ABA_HUMAN 6 18.80%
ID11122 (nsP4) Sideroflexin-1 OS=Homo sapiens GN=SFXN1 PE=1 SV=4 SFXN1_HUMAN 9 43.80%
ID11122 (nsP4) 60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE=1 SV=1 RL23_HUMAN 8 52.90%
ID11122 (nsP4) Cell division protein kinase 5 OS=Homo sapiens GN=CDK5 PE=1 SV=3 CDK5_HUMAN 3 12.70%
ID11122 (nsP4) 40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 RS7_HUMAN 8 52.10%
ID11122 (nsP4) Splicing factor U2AF 35 kDa subunit OS=Homo sapiens GN=U2AF1 PE=1 SV=3 U2AF1_HUMAN 5 20.80%
ID11122 (nsP4) 60S ribosomal protein L32 OS=Homo sapiens GN=RPL32 PE=1 SV=2 RL32_HUMAN 7 43.00%
ID11122 (nsP4) ATP synthase subunit d, mitochondrial OS=Homo sapiens GN=ATP5H PE=1 SV=3 ATP5H_HUMAN 4 28.00%
ID11122 (nsP4) Eukaryotic translation initiation factor 2 subunit 3 OS=Homo sapiens GN=EIF2S3 
PE=1 SV=3
IF2G_HUMAN 9 28.20%
ID11122 (nsP4) Monocarboxylate transporter 1 OS=Homo sapiens GN=SLC16A1 PE=1 SV=2 MOT1_HUMAN 4 9.00%
ID11122 (nsP4) Poly(rC)-binding protein 2 OS=Homo sapiens GN=PCBP2 PE=1 SV=1 PCBP2_HUMAN 3 30.70%
ID11122 (nsP4) Estradiol 17-beta-dehydrogenase 12 OS=Homo sapiens GN=HSD17B12 PE=1 SV=2 DHB12_HUMAN 8 24.70%
ID11122 (nsP4) ATP synthase subunit O, mitochondrial OS=Homo sapiens GN=ATP5O PE=1 SV=1 ATPO_HUMAN 3 17.40%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens GN=HNRNPF PE=1 
SV=3
HNRPF_HUMAN 8 37.80%
ID11122 (nsP4) Proteasome subunit beta type-5 OS=Homo sapiens GN=PSMB5 PE=1 SV=3 PSB5_HUMAN 8 42.60%
ID11122 (nsP4) 26S protease regulatory subunit 10B OS=Homo sapiens GN=PSMC6 PE=1 SV=1 PRS10_HUMAN 11 36.20%
ID11122 (nsP4) Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 CYTB_HUMAN 4 55.10%
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ID11122 (nsP4) Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 
OS=Homo sapiens GN=PPP2R1A PE=1 SV=4
2AAA_HUMAN 8 20.00%
ID11122 (nsP4) 60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 RL13_HUMAN 6 28.40%
ID11122 (nsP4) Interferon-induced protein with tetratricopeptide repeats 2 OS=Homo sapiens 
GN=IFIT2 PE=1 SV=1
IFIT2_HUMAN 4 11.70%
ID11122 (nsP4) Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform OS=Homo 
sapiens GN=PPP2CA PE=1 SV=1
PP2AA_HUMAN 7 33.30%
ID11122 (nsP4) D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 SERA_HUMAN 12 27.20%
ID11122 (nsP4) Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 UBA1_HUMAN 6 8.32%
ID11122 (nsP4) CTP synthase 1 OS=Homo sapiens GN=CTPS PE=1 SV=2 PYRG1_HUMAN 21 48.90%
ID11122 (nsP4) Ubiquitin carboxyl-terminal hydrolase 10 OS=Homo sapiens GN=USP10 PE=1 SV=2 UBP10_HUMAN 5 9.40%
ID11122 (nsP4) Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 OS=Homo sapiens 
GN=ATP2A2 PE=1 SV=1
AT2A2_HUMAN 4 11.40%
ID11122 (nsP4) Insulin-like growth factor 2 mRNA-binding protein 1 OS=Homo sapiens GN=IGF2BP1 
PE=1 SV=2
IF2B1_HUMAN 13 32.80%
ID11122 (nsP4) 40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 RS6_HUMAN 7 30.90%
ID11122 (nsP4) DnaJ homolog subfamily B member 11 OS=Homo sapiens GN=DNAJB11 PE=1 SV=1 DJB11_HUMAN 4 14.20%
ID11122 (nsP4) 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 1433B_HUMAN 2 20.70%
ID11122 (nsP4) Coatomer subunit gamma-2 OS=Homo sapiens GN=COPG2 PE=1 SV=1 COPG2_HUMAN 3 7.00%
ID11122 (nsP4) NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial OS=Homo 
sapiens GN=NDUFS3 PE=1 SV=1
NDUS3_HUMAN 7 28.80%
ID11122 (nsP4) DNA replication licensing factor MCM5 OS=Homo sapiens GN=MCM5 PE=1 SV=5 MCM5_HUMAN 20 37.60%
ID11122 (nsP4) Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=1 SV=2 PCBP1_HUMAN 5 32.90%
ID11122 (nsP4) Exportin-1 OS=Homo sapiens GN=XPO1 PE=1 SV=1 XPO1_HUMAN 2 3.55%
ID11122 (nsP4) rRNA 2'-O-methyltransferase fibrillarin OS=Homo sapiens GN=FBL PE=1 SV=2 FBRL_HUMAN 7 23.10%
ID11122 (nsP4) CAD protein OS=Homo sapiens GN=CAD PE=1 SV=3 PYR1_HUMAN 53 35.40%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein A/B OS=Homo sapiens GN=HNRNPAB 
PE=1 SV=2
ROAA_HUMAN 4 17.20%
ID11122 (nsP4) Profilin-2 OS=Homo sapiens GN=PFN2 PE=1 SV=3 PROF2_HUMAN 5 36.40%
ID11122 (nsP4) 40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 RSSA_HUMAN 8 41.00%
ID11122 (nsP4) ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1 
SV=1
ATPA_HUMAN 14 35.40%
ID11122 (nsP4) 40S ribosomal protein S12 OS=Homo sapiens GN=RPS12 PE=1 SV=3 RS12_HUMAN 6 53.80%
ID11122 (nsP4) Guanine nucleotide-binding protein-like 3 OS=Homo sapiens GN=GNL3 PE=1 SV=2 GNL3_HUMAN 4 11.50%
ID11122 (nsP4) Histone-binding protein RBBP7 OS=Homo sapiens GN=RBBP7 PE=1 SV=1 RBBP7_HUMAN 3 9.41%
ID11122 (nsP4) Serine/threonine-protein phosphatase 6 regulatory subunit 3 OS=Homo sapiens 
GN=PPP6R3 PE=1 SV=2
PP6R3_HUMAN 7 10.90%
ID11122 (nsP4) Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 IPO9_HUMAN 4 6.53%
ID11122 (nsP4) Mitochondrial intermembrane space import and assembly protein 40 OS=Homo 
sapiens GN=CHCHD4 PE=1 SV=1
MIA40_HUMAN 4 45.80%
ID11122 (nsP4) 26S protease regulatory subunit 6A OS=Homo sapiens GN=PSMC3 PE=1 SV=3 PRS6A_HUMAN 12 37.60%
ID11122 (nsP4) Gephyrin OS=Homo sapiens GN=GPHN PE=1 SV=1 GEPH_HUMAN 3 5.30%
ID11122 (nsP4) 26S proteasome non-ATPase regulatory subunit 4 OS=Homo sapiens GN=PSMD4 
PE=1 SV=1
PSMD4_HUMAN 5 26.80%
ID11122 (nsP4) Long-chain-fatty-acid--CoA ligase 3 OS=Homo sapiens GN=ACSL3 PE=1 SV=3 ACSL3_HUMAN 4 7.92%
ID11122 (nsP4) RNA-binding protein FUS OS=Homo sapiens GN=FUS PE=1 SV=1 FUS_HUMAN 7 18.40%
ID11122 (nsP4) 60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 SV=2 RL10A_HUMAN 11 38.70%
ID11122 (nsP4) General transcription factor 3C polypeptide 4 OS=Homo sapiens GN=GTF3C4 PE=1 
SV=2
TF3C4_HUMAN 6 10.70%
ID11122 (nsP4) 6-phosphofructokinase, muscle type OS=Homo sapiens GN=PFKM PE=1 SV=2 K6PF_HUMAN 7 17.70%
ID11122 (nsP4) Lysyl-tRNA synthetase OS=Homo sapiens GN=KARS PE=1 SV=3 SYK_HUMAN 4 10.20%
ID11122 (nsP4) Inorganic pyrophosphatase OS=Homo sapiens GN=PPA1 PE=1 SV=2 IPYR_HUMAN 10 58.10%
ID11122 (nsP4) T-complex protein 1 subunit beta OS=Homo sapiens GN=CCT2 PE=1 SV=4 TCPB_HUMAN 23 53.30%
ID11122 (nsP4) ES1 protein homolog, mitochondrial OS=Homo sapiens GN=C21orf33 PE=1 SV=3 ES1_HUMAN 6 44.40%
ID11122 (nsP4) 40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 SV=3 RS11_HUMAN 7 46.80%
ID11122 (nsP4) Cullin-associated NEDD8-dissociated protein 1 OS=Homo sapiens GN=CAND1 PE=1 
SV=2
CAND1_HUMAN 4 4.07%
ID11122 (nsP4) FAS-associated factor 2 OS=Homo sapiens GN=FAF2 PE=1 SV=2 FAF2_HUMAN 6 24.50%
ID11122 (nsP4) Proteasome subunit beta type-4 OS=Homo sapiens GN=PSMB4 PE=1 SV=4 PSB4_HUMAN 5 24.60%
ID11122 (nsP4) Elongation factor Tu, mitochondrial OS=Homo sapiens GN=TUFM PE=1 SV=2 EFTU_HUMAN 24 61.30%
ID11122 (nsP4) Exosome complex exonuclease RRP4 OS=Homo sapiens GN=EXOSC2 PE=1 SV=2 EXOS2_HUMAN 4 20.80%
ID11122 (nsP4) Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 LG3BP_HUMAN 6 15.70%
ID11122 (nsP4) 60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 RL31_HUMAN 4 31.20%
ID11122 (nsP4) Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 FAS_HUMAN 53 30.20%
ID11122 (nsP4) 60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 PE=1 SV=2 RL22_HUMAN 6 67.20%
ID11122 (nsP4) Tubulin beta-2C chain OS=Homo sapiens GN=TUBB2C PE=1 SV=1 TBB2C_HUMAN 2 63.40%
ID11122 (nsP4) 60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=1 RL9_HUMAN 12 67.20%
ID11122 (nsP4) Polypyrimidine tract-binding protein 1 OS=Homo sapiens GN=PTBP1 PE=1 SV=1 PTBP1_HUMAN 6 17.30%
ID11122 (nsP4) 60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 SV=1 RL12_HUMAN 6 54.50%
ID11122 (nsP4) 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 1433G_HUMAN 3 24.70%
ID11122 (nsP4) Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial OS=Homo sapiens 
GN=DUT PE=1 SV=3
DUT_HUMAN 4 18.30%
ID11122 (nsP4) 40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 RS4X_HUMAN 9 38.00%
ID11122 (nsP4) Proteasome subunit alpha type-4 OS=Homo sapiens GN=PSMA4 PE=1 SV=1 PSA4_HUMAN 6 41.40%
ID11122 (nsP4) Coatomer subunit alpha OS=Homo sapiens GN=COPA PE=1 SV=2 COPA_HUMAN 24 29.70%
ID11122 (nsP4) 60S ribosomal protein L21 OS=Homo sapiens GN=RPL21 PE=1 SV=2 RL21_HUMAN 6 33.10%
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ID11122 (nsP4) 26S proteasome non-ATPase regulatory subunit 3 OS=Homo sapiens GN=PSMD3 
PE=1 SV=2
PSMD3_HUMAN 14 32.60%
ID11122 (nsP4) Far upstream element-binding protein 3 OS=Homo sapiens GN=FUBP3 PE=1 SV=2 FUBP3_HUMAN 7 23.40%
ID11122 (nsP4) Cell division protein kinase 3 OS=Homo sapiens GN=CDK3 PE=1 SV=1 CDK3_HUMAN 3 18.00%
ID11122 (nsP4) DNA polymerase delta catalytic subunit OS=Homo sapiens GN=POLD1 PE=1 SV=2 DPOD1_HUMAN 2 1.99%
ID11122 (nsP4) 40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 RS5_HUMAN 9 39.70%
ID11122 (nsP4) KH domain-containing, RNA-binding, signal transduction-associated protein 1 
OS=Homo sapiens GN=KHDRBS1 PE=1 SV=1
KHDR1_HUMAN 3 9.71%
ID11122 (nsP4) 60S ribosomal protein L27a OS=Homo sapiens GN=RPL27A PE=1 SV=2 RL27A_HUMAN 7 37.80%
ID11122 (nsP4) Leucine-rich repeat-containing protein 59 OS=Homo sapiens GN=LRRC59 PE=1 
SV=1
LRC59_HUMAN 6 26.70%
ID11122 (nsP4) GMP synthase [glutamine-hydrolyzing] OS=Homo sapiens GN=GMPS PE=1 SV=1 GUAA_HUMAN 5 11.80%
ID11122 (nsP4) Vacuolar protein sorting-associated protein 35 OS=Homo sapiens GN=VPS35 PE=1 
SV=2
VPS35_HUMAN 1 1.88%
ID11122 (nsP4) Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 HSP71_HUMAN 22 59.30%
ID11122 (nsP4) 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 GRP78_HUMAN 4 11.90%
ID11122 (nsP4) Phenylalanyl-tRNA synthetase alpha chain OS=Homo sapiens GN=FARSA PE=1 
SV=3
SYFA_HUMAN 7 22.80%
ID11122 (nsP4) Poly(U)-binding-splicing factor PUF60 OS=Homo sapiens GN=PUF60 PE=1 SV=1 PUF60_HUMAN 5 15.00%
ID11122 (nsP4) Adenosylhomocysteinase OS=Homo sapiens GN=AHCY PE=1 SV=4 SAHH_HUMAN 10 31.70%
ID11122 (nsP4) HCLS1-associated protein X-1 OS=Homo sapiens GN=HAX1 PE=1 SV=2 HAX1_HUMAN 4 16.50%
ID11122 (nsP4) Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 PRDX6_HUMAN 5 31.20%
ID11122 (nsP4) Protein-L-isoaspartate(D-aspartate) O-methyltransferase OS=Homo sapiens 
GN=PCMT1 PE=1 SV=3
PIMT_HUMAN 11 63.90%
ID11122 (nsP4) 60S ribosomal protein L15 OS=Homo sapiens GN=RPL15 PE=1 SV=2 RL15_HUMAN 4 26.00%
ID11122 (nsP4) RING finger protein 114 OS=Homo sapiens GN=RNF114 PE=1 SV=1 RN114_HUMAN 3 18.90%
ID11122 (nsP4) Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 HS90B_HUMAN 13 45.20%
ID11122 (nsP4) Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens 
GN=GNB2L1 PE=1 SV=3
GBLP_HUMAN 15 73.20%
ID11122 (nsP4) Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 OS=Homo sapiens 
GN=ATP2A1 PE=1 SV=1
AT2A1_HUMAN 1 6.99%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNPC 
PE=1 SV=4
HNRPC_HUMAN 7 22.50%
ID11122 (nsP4) Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens GN=HNRNPM PE=1 
SV=3
HNRPM_HUMAN 14 25.60%
ID11122 (nsP4) Galactokinase OS=Homo sapiens GN=GALK1 PE=1 SV=1 GALK1_HUMAN 5 19.10%
ID11122 (nsP4) 6-phosphofructokinase, liver type OS=Homo sapiens GN=PFKL PE=1 SV=6 K6PL_HUMAN 14 35.10%
ID11122 (nsP4) C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens GN=MTHFD1 PE=1 
SV=3
C1TC_HUMAN 19 29.30%
ID11122 (nsP4) Insulin receptor substrate 4 OS=Homo sapiens GN=IRS4 PE=1 SV=1 IRS4_HUMAN 22 27.00%
ID11122 (nsP4) Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 K1C16_HUMAN 2 18.40%
ID11122 (nsP4) 40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 SV=1 RS20_HUMAN 3 22.70%
ID11122 (nsP4) Carbonyl reductase [NADPH] 1 OS=Homo sapiens GN=CBR1 PE=1 SV=3 CBR1_HUMAN 6 34.30%
ID11122 (nsP4) Mitochondrial ribonuclease P protein 1 OS=Homo sapiens GN=RG9MTD1 PE=1 
SV=2
MRRP1_HUMAN 2 7.44%
ID11122 (nsP4) Far upstream element-binding protein 2 OS=Homo sapiens GN=KHSRP PE=1 SV=3 FUBP2_HUMAN 7 12.70%
ID11122 (nsP4) DnaJ homolog subfamily A member 2 OS=Homo sapiens GN=DNAJA2 PE=1 SV=1 DNJA2_HUMAN 11 39.10%
ID11122 (nsP4) Phosphate carrier protein, mitochondrial OS=Homo sapiens GN=SLC25A3 PE=1 
SV=2
MPCP_HUMAN 7 19.30%
ID11122 (nsP4) Protein arginine N-methyltransferase 5 OS=Homo sapiens GN=PRMT5 PE=1 SV=4 ANM5_HUMAN 15 33.40%
ID11122 (nsP4) Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 PPIA_HUMAN 11 66.70%
ID11122 (nsP4) Mitochondrial glutamate carrier 1 OS=Homo sapiens GN=SLC25A22 PE=1 SV=1 GHC1_HUMAN 3 13.00%
ID11122 (nsP4) Dynamin-like 120 kDa protein, mitochondrial OS=Homo sapiens GN=OPA1 PE=1 
SV=3
OPA1_HUMAN 7 10.50%
ID11122 (nsP4) ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 SV=3 ATPB_HUMAN 12 34.20%
ID11122 (nsP4) 14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1 1433T_HUMAN 2 20.80%
ID11122 (nsP4) Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 THIO_HUMAN 6 51.40%
ID11122 (nsP4) T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 SV=1 TCPA_HUMAN 30 69.60%
ID11122 (nsP4) Proteasome subunit alpha type-1 OS=Homo sapiens GN=PSMA1 PE=1 SV=1 PSA1_HUMAN 4 20.50%
ID11122 (nsP4) Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 OS=Homo 
sapiens GN=AIMP1 PE=1 SV=2
AIMP1_HUMAN 9 44.60%
ID11122 (nsP4) Interleukin enhancer-binding factor 3 OS=Homo sapiens GN=ILF3 PE=1 SV=3 ILF3_HUMAN 17 26.30%
ID11122 (nsP4) Dolichol-phosphate mannosyltransferase OS=Homo sapiens GN=DPM1 PE=1 SV=1 DPM1_HUMAN 5 28.10%
ID11122 (nsP4) Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1 CSK21_HUMAN 10 34.00%
ID11122 (nsP4) Importin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=1 IMA2_HUMAN 3 10.00%
ID11122 (nsP4) 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 CH60_HUMAN 16 45.50%
ID11122 (nsP4) Double-stranded RNA-binding protein Staufen homolog 1 OS=Homo sapiens 
GN=STAU1 PE=1 SV=2
STAU1_HUMAN 8 18.50%
ID11122 (nsP4) Putative ATP-dependent RNA helicase DHX30 OS=Homo sapiens GN=DHX30 PE=1 
SV=1
DHX30_HUMAN 6 7.54%
ID11122 (nsP4) Protein FAM98B OS=Homo sapiens GN=FAM98B PE=1 SV=1 FA98B_HUMAN 3 10.90%
ID11122 (nsP4) Protein disulfide-isomerase A6 OS=Homo sapiens GN=PDIA6 PE=1 SV=1 PDIA6_HUMAN 13 45.50%
ID11122 (nsP4) Crk-like protein OS=Homo sapiens GN=CRKL PE=1 SV=1 CRKL_HUMAN 13 54.10%
ID11122 (nsP4) Chaperone activity of bc1 complex-like, mitochondrial OS=Homo sapiens GN=CABC1 
PE=1 SV=1
ADCK3_HUMAN 4 9.27%
ID11122 (nsP4) DnaJ homolog subfamily A member 1 OS=Homo sapiens GN=DNAJA1 PE=1 SV=2 DNJA1_HUMAN 8 37.50%
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ID11122 (nsP4) Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 ANXA2_HUMAN 7 30.40%
ID11122 (nsP4) 26S proteasome non-ATPase regulatory subunit 2 OS=Homo sapiens GN=PSMD2 
PE=1 SV=3
PSMD2_HUMAN 11 20.40%
ID11122 (nsP4) 60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 RL8_HUMAN 7 36.20%
ID11122 (nsP4) ATP-dependent RNA helicase DDX1 OS=Homo sapiens GN=DDX1 PE=1 SV=2 DDX1_HUMAN 12 23.80%
ID11122 (nsP4) 40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 SV=2 RS19_HUMAN 9 43.40%
ID11122 (nsP4) Mannosyl-oligosaccharide glucosidase OS=Homo sapiens GN=MOGS PE=1 SV=5 MOGS_HUMAN 5 8.84%
ID11122 (nsP4) Casein kinase II subunit beta OS=Homo sapiens GN=CSNK2B PE=1 SV=1 CSK2B_HUMAN 6 41.90%
ID11122 (nsP4) BAG family molecular chaperone regulator 2 OS=Homo sapiens GN=BAG2 PE=1 
SV=1
BAG2_HUMAN 8 44.50%
ID11123 (nsP3) E3 ISG15--protein ligase HERC5 OS=Homo sapiens GN=HERC5 PE=1 SV=2 HERC5_HUMAN 8 9.08%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens GN=HNRNPA1 
PE=1 SV=5
ROA1_HUMAN 9 28.50%
ID11123 (nsP3) Acetyl-CoA acetyltransferase, mitochondrial OS=Homo sapiens GN=ACAT1 PE=1 
SV=1
THIL_HUMAN 5 17.10%
ID11123 (nsP3) F-actin-capping protein subunit alpha-2 OS=Homo sapiens GN=CAPZA2 PE=1 SV=3 CAZA2_HUMAN 3 21.70%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein A0 OS=Homo sapiens GN=HNRNPA0 
PE=1 SV=1
ROA0_HUMAN 4 21.00%
ID11123 (nsP3) DNA replication licensing factor MCM7 OS=Homo sapiens GN=MCM7 PE=1 SV=4 MCM7_HUMAN 21 37.80%
ID11123 (nsP3) Ubiquitin carboxyl-terminal hydrolase 10 OS=Homo sapiens GN=USP10 PE=1 SV=2 UBP10_HUMAN 10 19.50%
ID11123 (nsP3) C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens GN=MTHFD1 PE=1 
SV=3
C1TC_HUMAN 16 25.20%
ID11123 (nsP3) 60S ribosomal protein L3 OS=Homo sapiens GN=RPL3 PE=1 SV=2 RL3_HUMAN 17 40.00%
ID11123 (nsP3) DNA replication licensing factor MCM6 OS=Homo sapiens GN=MCM6 PE=1 SV=1 MCM6_HUMAN 8 11.60%
ID11123 (nsP3) Protein FAM98B OS=Homo sapiens GN=FAM98B PE=1 SV=1 FA98B_HUMAN 3 14.50%
ID11123 (nsP3) Putative RNA-binding protein Luc7-like 1 OS=Homo sapiens GN=LUC7L PE=1 SV=1 LUC7L_HUMAN 2 17.80%
ID11123 (nsP3) Developmentally-regulated GTP-binding protein 1 OS=Homo sapiens GN=DRG1 
PE=1 SV=1
DRG1_HUMAN 11 43.60%
ID11123 (nsP3) NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial OS=Homo sapiens 
GN=NDUFS1 PE=1 SV=3
NDUS1_HUMAN 8 18.30%
ID11123 (nsP3) Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 EF2_HUMAN 24 34.50%
ID11123 (nsP3) 60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 RL4_HUMAN 20 46.10%
ID11123 (nsP3) 40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 RS4X_HUMAN 15 56.30%
ID11123 (nsP3) Serine/arginine-rich splicing factor 7 OS=Homo sapiens GN=SRSF7 PE=1 SV=1 SRSF7_HUMAN 3 17.60%
ID11123 (nsP3) Coatomer subunit beta' OS=Homo sapiens GN=COPB2 PE=1 SV=2 COPB2_HUMAN 19 31.10%
ID11123 (nsP3) Sodium/potassium-transporting ATPase subunit alpha-4 OS=Homo sapiens 
GN=ATP1A4 PE=1 SV=3
AT1A4_HUMAN 2 7.29%
ID11123 (nsP3) 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 RS3_HUMAN 20 76.50%
ID11123 (nsP3) Plastin-3 OS=Homo sapiens GN=PLS3 PE=1 SV=4 PLST_HUMAN 3 10.60%
ID11123 (nsP3) Mannosyl-oligosaccharide glucosidase OS=Homo sapiens GN=MOGS PE=1 SV=5 MOGS_HUMAN 3 4.78%
ID11123 (nsP3) E3 ubiquitin/ISG15 ligase TRIM25 OS=Homo sapiens GN=TRIM25 PE=1 SV=1 TRI25_HUMAN 16 37.90%
ID11123 (nsP3) Signal transducer and activator of transcription 1-alpha/beta OS=Homo sapiens 
GN=STAT1 PE=1 SV=2
STAT1_HUMAN 11 20.90%
ID11123 (nsP3) Cold-inducible RNA-binding protein OS=Homo sapiens GN=CIRBP PE=1 SV=1 CIRBP_HUMAN 4 22.70%
ID11123 (nsP3) Centromere protein V OS=Homo sapiens GN=CENPV PE=1 SV=1 CENPV_HUMAN 4 25.50%
ID11123 (nsP3) Protein arginine N-methyltransferase 3 OS=Homo sapiens GN=PRMT3 PE=1 SV=2 ANM3_HUMAN 4 8.85%
ID11123 (nsP3) Protein unc-45 homolog A OS=Homo sapiens GN=UNC45A PE=1 SV=1 UN45A_HUMAN 0 0.00%
ID11123 (nsP3) Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4 PDIA3_HUMAN 2 4.36%
ID11123 (nsP3) Exportin-1 OS=Homo sapiens GN=XPO1 PE=1 SV=1 XPO1_HUMAN 6 9.15%
ID11123 (nsP3) DnaJ homolog subfamily A member 2 OS=Homo sapiens GN=DNAJA2 PE=1 SV=1 DNJA2_HUMAN 9 26.50%
ID11123 (nsP3) H/ACA ribonucleoprotein complex subunit 4 OS=Homo sapiens GN=DKC1 PE=1 
SV=3
DKC1_HUMAN 4 11.50%
ID11123 (nsP3) DnaJ homolog subfamily A member 1 OS=Homo sapiens GN=DNAJA1 PE=1 SV=2 DNJA1_HUMAN 10 43.60%
ID11123 (nsP3) 40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 RS14_HUMAN 7 39.10%
ID11123 (nsP3) 40S ribosomal protein S13 OS=Homo sapiens GN=RPS13 PE=1 SV=2 RS13_HUMAN 8 43.70%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein A3 OS=Homo sapiens GN=HNRNPA3 
PE=1 SV=2
ROA3_HUMAN 7 20.90%
ID11123 (nsP3) Splicing factor U2AF 65 kDa subunit OS=Homo sapiens GN=U2AF2 PE=1 SV=4 U2AF2_HUMAN 4 17.90%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens 
GN=HNRNPA2B1 PE=1 SV=2
ROA2_HUMAN 12 45.60%
ID11123 (nsP3) Splicing factor U2AF 35 kDa subunit OS=Homo sapiens GN=U2AF1 PE=1 SV=3 U2AF1_HUMAN 5 25.40%
ID11123 (nsP3) 60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 PE=1 SV=2 RL22_HUMAN 6 57.80%
ID11123 (nsP3) 60S ribosomal protein L21 OS=Homo sapiens GN=RPL21 PE=1 SV=2 RL21_HUMAN 7 38.70%
ID11123 (nsP3) Exosome component 10 OS=Homo sapiens GN=EXOSC10 PE=1 SV=2 EXOSX_HUMAN 2 2.60%
ID11123 (nsP3) Glutaredoxin-3 OS=Homo sapiens GN=GLRX3 PE=1 SV=2 GLRX3_HUMAN 5 18.50%
ID11123 (nsP3) Nucleosome assembly protein 1-like 1 OS=Homo sapiens GN=NAP1L1 PE=1 SV=1 NP1L1_HUMAN 8 32.70%
ID11123 (nsP3) Fragile X mental retardation syndrome-related protein 2 OS=Homo sapiens GN=FXR2 
PE=1 SV=2
FXR2_HUMAN 4 10.10%
ID11123 (nsP3) Fragile X mental retardation syndrome-related protein 1 OS=Homo sapiens GN=FXR1 
PE=1 SV=3
FXR1_HUMAN 5 11.40%
ID11123 (nsP3) NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial OS=Homo 
sapiens GN=NDUFS3 PE=1 SV=1
NDUS3_HUMAN 6 26.10%
ID11123 (nsP3) Zinc finger CCCH domain-containing protein 15 OS=Homo sapiens GN=ZC3H15 
PE=1 SV=1
ZC3HF_HUMAN 5 18.10%
ID11123 (nsP3) ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=1 SV=4 ADT3_HUMAN 5 42.60%
ID11123 (nsP3) Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Homo 
sapiens GN=DHX15 PE=1 SV=2
DHX15_HUMAN 12 18.70%
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ID11123 (nsP3) Ubiquitin/ISG15-conjugating enzyme E2 L6 OS=Homo sapiens GN=UBE2L6 PE=1 
SV=4
UB2L6_HUMAN 5 56.90%
ID11123 (nsP3) Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1 SV=5 DDX21_HUMAN 19 29.10%
ID11123 (nsP3) RNA-binding protein FUS OS=Homo sapiens GN=FUS PE=1 SV=1 FUS_HUMAN 6 14.30%
ID11123 (nsP3) Ras GTPase-activating protein-binding protein 2 OS=Homo sapiens GN=G3BP2 
PE=1 SV=2
G3BP2_HUMAN 10 34.00%
ID11123 (nsP3) Phosphate carrier protein, mitochondrial OS=Homo sapiens GN=SLC25A3 PE=1 
SV=2
MPCP_HUMAN 7 24.30%
ID11123 (nsP3) Threonyl-tRNA synthetase, mitochondrial OS=Homo sapiens GN=TARS2 PE=1 SV=1 SYTM_HUMAN 4 6.27%
ID11123 (nsP3) Ras GTPase-activating protein-binding protein 1 OS=Homo sapiens GN=G3BP1 
PE=1 SV=1
G3BP1_HUMAN 20 61.40%
ID11123 (nsP3) ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1 
SV=1
ATPA_HUMAN 11 29.50%
ID11123 (nsP3) Glutaminyl-tRNA synthetase OS=Homo sapiens GN=QARS PE=1 SV=1 SYQ_HUMAN 16 28.00%
ID11123 (nsP3) 40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 RS16_HUMAN 6 33.60%
ID11123 (nsP3) 40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 RS5_HUMAN 6 27.50%
ID11123 (nsP3) DnaJ homolog subfamily C member 7 OS=Homo sapiens GN=DNAJC7 PE=1 SV=2 DNJC7_HUMAN 2 5.47%
ID11123 (nsP3) Interferon-induced, double-stranded RNA-activated protein kinase OS=Homo sapiens 
GN=EIF2AK2 PE=1 SV=2
E2AK2_HUMAN 3 6.53%
ID11123 (nsP3) 40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 RSSA_HUMAN 5 29.80%
ID11123 (nsP3) Coatomer subunit gamma OS=Homo sapiens GN=COPG PE=1 SV=1 COPG_HUMAN 17 31.10%
ID11123 (nsP3) Methylthioribose-1-phosphate isomerase OS=Homo sapiens GN=MRI1 PE=1 SV=1 MTNA_HUMAN 4 12.20%
ID11123 (nsP3) Elongator complex protein 1 OS=Homo sapiens GN=IKBKAP PE=1 SV=3 ELP1_HUMAN 4 4.58%
ID11123 (nsP3) Sideroflexin-1 OS=Homo sapiens GN=SFXN1 PE=1 SV=4 SFXN1_HUMAN 7 36.60%
ID11123 (nsP3) Putative ribosomal RNA methyltransferase NOP2 OS=Homo sapiens GN=NOP2 
PE=1 SV=2
NOP2_HUMAN 4 6.28%
ID11123 (nsP3) Long-chain-fatty-acid--CoA ligase 3 OS=Homo sapiens GN=ACSL3 PE=1 SV=3 ACSL3_HUMAN 8 14.20%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein Q OS=Homo sapiens GN=SYNCRIP PE=1 
SV=2
HNRPQ_HUMAN 5 15.60%
ID11123 (nsP3) DnaJ homolog subfamily A member 3, mitochondrial OS=Homo sapiens GN=DNAJA3 
PE=1 SV=1
DNJA3_HUMAN 7 22.50%
ID11123 (nsP3) Polypyrimidine tract-binding protein 1 OS=Homo sapiens GN=PTBP1 PE=1 SV=1 PTBP1_HUMAN 7 20.30%
ID11123 (nsP3) Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 K1C10_HUMAN 22 52.90%
ID11123 (nsP3) 40S ribosomal protein S15 OS=Homo sapiens GN=RPS15 PE=1 SV=2 RS15_HUMAN 5 55.90%
ID11123 (nsP3) U5 small nuclear ribonucleoprotein 200 kDa helicase OS=Homo sapiens 
GN=SNRNP200 PE=1 SV=2
U520_HUMAN 23 14.80%
ID11123 (nsP3) Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 THIO_HUMAN 6 51.40%
ID11123 (nsP3) Structural maintenance of chromosomes protein 3 OS=Homo sapiens GN=SMC3 
PE=1 SV=2
SMC3_HUMAN 5 5.26%
ID11123 (nsP3) 60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE=1 SV=1 RL23_HUMAN 8 66.40%
ID11123 (nsP3) ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=6 ADT2_HUMAN 6 31.20%
ID11123 (nsP3) Isochorismatase domain-containing protein 2, mitochondrial OS=Homo sapiens 
GN=ISOC2 PE=1 SV=1
ISOC2_HUMAN 6 48.30%
ID11123 (nsP3) Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 OS=Homo sapiens 
GN=ATP2A2 PE=1 SV=1
AT2A2_HUMAN 2 3.93%
ID11123 (nsP3) 60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 RL6_HUMAN 15 38.90%
ID11123 (nsP3) Mitochondrial glutamate carrier 1 OS=Homo sapiens GN=SLC25A22 PE=1 SV=1 GHC1_HUMAN 4 16.10%
ID11123 (nsP3) KH domain-containing, RNA-binding, signal transduction-associated protein 1 
OS=Homo sapiens GN=KHDRBS1 PE=1 SV=1
KHDR1_HUMAN 4 13.10%
ID11123 (nsP3) Protein NipSnap homolog 1 OS=Homo sapiens GN=NIPSNAP1 PE=1 SV=1 NIPS1_HUMAN 4 21.80%
ID11123 (nsP3) 60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 SV=3 RL5_HUMAN 12 36.70%
ID11123 (nsP3) Coatomer subunit gamma-2 OS=Homo sapiens GN=COPG2 PE=1 SV=1 COPG2_HUMAN 12 19.30%
ID11123 (nsP3) THO complex subunit 4 OS=Homo sapiens GN=THOC4 PE=1 SV=3 THOC4_HUMAN 4 26.80%
ID11123 (nsP3) NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 OS=Homo 
sapiens GN=NDUFA13 PE=1 SV=3
NDUAD_HUMAN 3 23.60%
ID11123 (nsP3) rRNA 2'-O-methyltransferase fibrillarin OS=Homo sapiens GN=FBL PE=1 SV=2 FBRL_HUMAN 7 29.30%
ID11123 (nsP3) Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 NPM_HUMAN 5 25.90%
ID11123 (nsP3) Casein kinase I isoform alpha OS=Homo sapiens GN=CSNK1A1 PE=1 SV=2 KC1A_HUMAN 5 15.70%
ID11123 (nsP3) 6-phosphofructokinase, liver type OS=Homo sapiens GN=PFKL PE=1 SV=6 K6PL_HUMAN 18 43.60%
ID11123 (nsP3) Mitochondrial import inner membrane translocase subunit TIM44 OS=Homo sapiens 
GN=TIMM44 PE=1 SV=2
TIM44_HUMAN 4 11.90%
ID11123 (nsP3) Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 HSP71_HUMAN 16 42.00%
ID11123 (nsP3) Leucyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=LARS PE=1 SV=2 SYLC_HUMAN 27 31.00%
ID11123 (nsP3) ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 SV=3 ATPB_HUMAN 10 25.70%
ID11123 (nsP3) F-actin-capping protein subunit alpha-1 OS=Homo sapiens GN=CAPZA1 PE=1 SV=3 CAZA1_HUMAN 4 33.60%
ID11123 (nsP3) 40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 RS7_HUMAN 7 51.50%
ID11123 (nsP3) Mitochondrial ribonuclease P protein 1 OS=Homo sapiens GN=RG9MTD1 PE=1 
SV=2
MRRP1_HUMAN 8 28.50%
ID11123 (nsP3) 40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 RS6_HUMAN 8 32.10%
ID11123 (nsP3) Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 HS90A_HUMAN 4 16.80%
ID11123 (nsP3) Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 ILF2_HUMAN 7 30.50%
ID11123 (nsP3) Glutathione reductase, mitochondrial OS=Homo sapiens GN=GSR PE=1 SV=2 GSHR_HUMAN 3 8.43%
ID11123 (nsP3) Calcium-binding mitochondrial carrier protein Aralar2 OS=Homo sapiens 
GN=SLC25A13 PE=1 SV=2
CMC2_HUMAN 15 48.10%
ID11123 (nsP3) Calcium-binding mitochondrial carrier protein Aralar1 OS=Homo sapiens 
GN=SLC25A12 PE=1 SV=2
CMC1_HUMAN 4 17.00%
ID11123 (nsP3) Protein disulfide-isomerase A6 OS=Homo sapiens GN=PDIA6 PE=1 SV=1 PDIA6_HUMAN 13 41.60%
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ID11123 (nsP3) 40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 SV=3 RS11_HUMAN 8 43.00%
ID11123 (nsP3) Serine/threonine-protein phosphatase PGAM5, mitochondrial OS=Homo sapiens 
GN=PGAM5 PE=1 SV=2
PGAM5_HUMAN 8 30.80%
ID11123 (nsP3) UPF0027 protein C22orf28 OS=Homo sapiens GN=C22orf28 PE=1 SV=1 CV028_HUMAN 13 35.40%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein R OS=Homo sapiens GN=HNRNPR PE=1 
SV=1
HNRPR_HUMAN 4 12.60%
ID11123 (nsP3) Serpin H1 OS=Homo sapiens GN=SERPINH1 PE=1 SV=2 SERPH_HUMAN 14 36.10%
ID11123 (nsP3) 40S ribosomal protein S17 OS=Homo sapiens GN=RPS17 PE=1 SV=2 RS17_HUMAN 8 52.60%
ID11123 (nsP3) 3-hydroxyacyl-CoA dehydratase 3 OS=Homo sapiens GN=PTPLAD1 PE=1 SV=2 HACD3_HUMAN 6 21.80%
ID11123 (nsP3) Cytochrome b-c1 complex subunit 2, mitochondrial OS=Homo sapiens GN=UQCRC2 
PE=1 SV=3
QCR2_HUMAN 11 39.10%
ID11123 (nsP3) Poly(rC)-binding protein 2 OS=Homo sapiens GN=PCBP2 PE=1 SV=1 PCBP2_HUMAN 4 33.70%
ID11123 (nsP3) 60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 RL8_HUMAN 9 47.10%
ID11123 (nsP3) 60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 PE=1 SV=1 RL24_HUMAN 6 31.80%
ID11123 (nsP3) ATP-dependent RNA helicase DDX1 OS=Homo sapiens GN=DDX1 PE=1 SV=2 DDX1_HUMAN 24 45.00%
ID11123 (nsP3) 60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 SV=1 RL7_HUMAN 16 50.40%
ID11123 (nsP3) Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 EF1A1_HUMAN 17 54.80%
ID11123 (nsP3) tRNA (cytosine-5-)-methyltransferase NSUN2 OS=Homo sapiens GN=NSUN2 PE=1 
SV=2
NSUN2_HUMAN 4 6.39%
ID11123 (nsP3) ATPase family AAA domain-containing protein 3A OS=Homo sapiens GN=ATAD3A 
PE=1 SV=2
ATD3A_HUMAN 3 9.94%
ID11123 (nsP3) Nucleosome assembly protein 1-like 4 OS=Homo sapiens GN=NAP1L4 PE=1 SV=1 NP1L4_HUMAN 3 17.60%
ID11123 (nsP3) Tubulin beta-2C chain OS=Homo sapiens GN=TUBB2C PE=1 SV=1 TBB2C_HUMAN 3 67.20%
ID11123 (nsP3) Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 PHB_HUMAN 4 16.20%
ID11123 (nsP3) Transcription intermediary factor 1-beta OS=Homo sapiens GN=TRIM28 PE=1 SV=5 TIF1B_HUMAN 24 43.80%
ID11123 (nsP3) Phosphorylase b kinase gamma catalytic chain, testis/liver isoform OS=Homo sapiens 
GN=PHKG2 PE=1 SV=1
PHKG2_HUMAN 0 0.00%
ID11123 (nsP3) Eukaryotic translation initiation factor 2 subunit 1 OS=Homo sapiens GN=EIF2S1 
PE=1 SV=3
IF2A_HUMAN 12 49.80%
ID11123 (nsP3) Long-chain fatty acid transport protein 4 OS=Homo sapiens GN=SLC27A4 PE=1 
SV=1
S27A4_HUMAN 6 13.40%
ID11123 (nsP3) RNA-binding protein 14 OS=Homo sapiens GN=RBM14 PE=1 SV=2 RBM14_HUMAN 5 10.50%
ID11123 (nsP3) 40S ribosomal protein S12 OS=Homo sapiens GN=RPS12 PE=1 SV=3 RS12_HUMAN 7 53.80%
ID11123 (nsP3) T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=1 SV=4 TCPQ_HUMAN 10 25.70%
ID11123 (nsP3) 40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 RS9_HUMAN 10 34.50%
ID11123 (nsP3) Exosome complex exonuclease RRP44 OS=Homo sapiens GN=DIS3 PE=1 SV=2 RRP44_HUMAN 25 34.40%
ID11123 (nsP3) Importin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=1 IMA2_HUMAN 4 12.10%
ID11123 (nsP3) 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 RS8_HUMAN 9 54.30%
ID11123 (nsP3) Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform 
OS=Homo sapiens GN=PPP2R2A PE=1 SV=1
2ABA_HUMAN 9 30.60%
ID11123 (nsP3) Nuclease-sensitive element-binding protein 1 OS=Homo sapiens GN=YBX1 PE=1 
SV=3
YBOX1_HUMAN 3 28.70%
ID11123 (nsP3) Exosome complex exonuclease RRP4 OS=Homo sapiens GN=EXOSC2 PE=1 SV=2 EXOS2_HUMAN 4 19.10%
ID11123 (nsP3) Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 HS90B_HUMAN 17 48.60%
ID11123 (nsP3) Interleukin enhancer-binding factor 3 OS=Homo sapiens GN=ILF3 PE=1 SV=3 ILF3_HUMAN 13 18.90%
ID11123 (nsP3) Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 PRDX1_HUMAN 11 60.80%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens GN=HNRNPH1 PE=1 
SV=4
HNRH1_HUMAN 4 27.80%
ID11123 (nsP3) Splicing factor 3B subunit 3 OS=Homo sapiens GN=SF3B3 PE=1 SV=4 SF3B3_HUMAN 12 12.80%
ID11123 (nsP3) 40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 SV=2 RS19_HUMAN 9 43.40%
ID11123 (nsP3) Protein-L-isoaspartate(D-aspartate) O-methyltransferase OS=Homo sapiens 
GN=PCMT1 PE=1 SV=3
PIMT_HUMAN 9 62.10%
ID11123 (nsP3) 40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 SV=3 RS18_HUMAN 10 43.40%
ID11123 (nsP3) 40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 RS15A_HUMAN 4 30.80%
ID11123 (nsP3) 60S ribosomal protein L27 OS=Homo sapiens GN=RPL27 PE=1 SV=2 RL27_HUMAN 7 45.60%
ID11123 (nsP3) ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X PE=1 SV=3 DDX3X_HUMAN 12 27.50%
ID11123 (nsP3) 60S ribosomal protein L26 OS=Homo sapiens GN=RPL26 PE=1 SV=1 RL26_HUMAN 7 40.00%
ID11123 (nsP3) Leucine-rich repeat-containing protein 47 OS=Homo sapiens GN=LRRC47 PE=1 
SV=1
LRC47_HUMAN 3 7.03%
ID11123 (nsP3) ATP-citrate synthase OS=Homo sapiens GN=ACLY PE=1 SV=3 ACLY_HUMAN 12 16.40%
ID11123 (nsP3) Argininosuccinate synthase OS=Homo sapiens GN=ASS1 PE=1 SV=2 ASSY_HUMAN 7 21.60%
ID11123 (nsP3) 60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=1 RL9_HUMAN 12 71.90%
ID11123 (nsP3) Aspartyl aminopeptidase OS=Homo sapiens GN=DNPEP PE=1 SV=1 DNPEP_HUMAN 3 9.47%
ID11123 (nsP3) Reticulocalbin-1 OS=Homo sapiens GN=RCN1 PE=1 SV=1 RCN1_HUMAN 0 0.00%
ID11123 (nsP3) Replication factor C subunit 5 OS=Homo sapiens GN=RFC5 PE=1 SV=1 RFC5_HUMAN 5 17.40%
ID11123 (nsP3) ATPase family AAA domain-containing protein 3B OS=Homo sapiens GN=ATAD3B 
PE=1 SV=1
ATD3B_HUMAN 2 6.79%
ID11123 (nsP3) Cellular nucleic acid-binding protein OS=Homo sapiens GN=CNBP PE=1 SV=1 CNBP_HUMAN 5 36.20%
ID11123 (nsP3) Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 ANXA2_HUMAN 0 0.00%
ID11123 (nsP3) Cytosol aminopeptidase OS=Homo sapiens GN=LAP3 PE=1 SV=3 AMPL_HUMAN 4 11.40%
ID11123 (nsP3) 6-phosphofructokinase type C OS=Homo sapiens GN=PFKP PE=1 SV=2 K6PP_HUMAN 22 46.90%
ID11123 (nsP3) ATP-dependent RNA helicase A OS=Homo sapiens GN=DHX9 PE=1 SV=4 DHX9_HUMAN 25 26.50%
ID11123 (nsP3) Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 K22E_HUMAN 12 44.40%
ID11123 (nsP3) BolA-like protein 2 OS=Homo sapiens GN=BOLA2 PE=1 SV=1 BOLA2_HUMAN 4 61.60%
ID11123 (nsP3) Thioredoxin-dependent peroxide reductase, mitochondrial OS=Homo sapiens 
GN=PRDX3 PE=1 SV=3
PRDX3_HUMAN 5 30.50%
ID11123 (nsP3) Phosphoenolpyruvate carboxykinase [GTP], mitochondrial OS=Homo sapiens 
GN=PCK2 PE=1 SV=3
PCKGM_HUMAN 5 10.80%
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ID11123 (nsP3) Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 PRDX2_HUMAN 6 40.40%
ID11123 (nsP3) Glutamate-rich WD repeat-containing protein 1 OS=Homo sapiens GN=GRWD1 PE=1 
SV=1
GRWD1_HUMAN 5 24.70%
ID11123 (nsP3) TBC1 domain family member 4 OS=Homo sapiens GN=TBC1D4 PE=1 SV=2 TBCD4_HUMAN 13 13.30%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein H2 OS=Homo sapiens GN=HNRNPH2 
PE=1 SV=1
HNRH2_HUMAN 4 24.30%
ID11123 (nsP3) SUMO-activating enzyme subunit 1 OS=Homo sapiens GN=SAE1 PE=1 SV=1 SAE1_HUMAN 2 12.10%
ID11123 (nsP3) 26S proteasome non-ATPase regulatory subunit 2 OS=Homo sapiens GN=PSMD2 
PE=1 SV=3
PSMD2_HUMAN 0 0.00%
ID11123 (nsP3) Elongation factor Tu, mitochondrial OS=Homo sapiens GN=TUFM PE=1 SV=2 EFTU_HUMAN 24 61.90%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 
SV=6
HNRPU_HUMAN 17 27.50%
ID11123 (nsP3) Vacuolar protein sorting-associated protein 35 OS=Homo sapiens GN=VPS35 PE=1 
SV=2
VPS35_HUMAN 4 5.65%
ID11123 (nsP3) Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 K1C14_HUMAN 3 24.80%
ID11123 (nsP3) Nicotinamide phosphoribosyltransferase OS=Homo sapiens GN=NAMPT PE=1 SV=1 NAMPT_HUMAN 10 30.30%
ID11123 (nsP3) Structural maintenance of chromosomes protein 2 OS=Homo sapiens GN=SMC2 
PE=1 SV=2
SMC2_HUMAN 10 10.90%
ID11123 (nsP3) Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens GN=DDX5 PE=1 
SV=1
DDX5_HUMAN 14 40.70%
ID11123 (nsP3) 60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 SV=1 RLA0_HUMAN 11 56.80%
ID11123 (nsP3) DnaJ homolog subfamily B member 11 OS=Homo sapiens GN=DNAJB11 PE=1 SV=1 DJB11_HUMAN 2 7.82%
ID11123 (nsP3) RNA-binding protein 39 OS=Homo sapiens GN=RBM39 PE=1 SV=2 RBM39_HUMAN 5 11.50%
ID11123 (nsP3) 60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 SV=2 RL10A_HUMAN 11 41.00%
ID11123 (nsP3) Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 PCNA_HUMAN 7 38.30%
ID11123 (nsP3) CTP synthase 1 OS=Homo sapiens GN=CTPS PE=1 SV=2 PYRG1_HUMAN 17 36.20%
ID11123 (nsP3) 60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 PE=1 SV=2 RL30_HUMAN 7 58.30%
ID11123 (nsP3) GFP|GFP GFP|GFP 13 63.90%
ID11123 (nsP3) 116 kDa U5 small nuclear ribonucleoprotein component OS=Homo sapiens 
GN=EFTUD2 PE=1 SV=1
U5S1_HUMAN 7 9.16%
ID11123 (nsP3) ATP synthase subunit gamma, mitochondrial OS=Homo sapiens GN=ATP5C1 PE=1 
SV=1
ATPG_HUMAN 4 15.10%
ID11123 (nsP3) Isoleucyl-tRNA synthetase, mitochondrial OS=Homo sapiens GN=IARS2 PE=1 SV=2 SYIM_HUMAN 11 13.60%
ID11123 (nsP3) Single-stranded DNA-binding protein, mitochondrial OS=Homo sapiens GN=SSBP1 
PE=1 SV=1
SSBP_HUMAN 5 43.20%
ID11123 (nsP3) Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial 
OS=Homo sapiens GN=CHCHD3 PE=1 SV=1
CHCH3_HUMAN 4 25.60%
ID11123 (nsP3) F-actin-capping protein subunit beta OS=Homo sapiens GN=CAPZB PE=1 SV=4 CAPZB_HUMAN 9 47.30%
ID11123 (nsP3) Mitochondrial import inner membrane translocase subunit TIM50 OS=Homo sapiens 
GN=TIMM50 PE=1 SV=2
TIM50_HUMAN 3 13.00%
ID11123 (nsP3) NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial OS=Homo sapiens 
GN=NDUFV1 PE=1 SV=4
NDUV1_HUMAN 5 15.10%
ID11123 (nsP3) Exosome complex exonuclease RRP46 OS=Homo sapiens GN=EXOSC5 PE=1 SV=1 EXOS5_HUMAN 4 30.60%
ID11123 (nsP3) GDP-mannose 4,6 dehydratase OS=Homo sapiens GN=GMDS PE=1 SV=1 GMDS_HUMAN 2 7.53%
ID11123 (nsP3) Reticulocalbin-2 OS=Homo sapiens GN=RCN2 PE=1 SV=1 RCN2_HUMAN 2 9.78%
ID11123 (nsP3) RUN and FYVE domain-containing protein 1 OS=Homo sapiens GN=RUFY1 PE=1 
SV=2
RUFY1_HUMAN 4 7.91%
ID11123 (nsP3) Double-stranded RNA-binding protein Staufen homolog 1 OS=Homo sapiens 
GN=STAU1 PE=1 SV=2
STAU1_HUMAN 12 26.90%
ID11123 (nsP3) Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial OS=Homo sapiens 
GN=IDH3B PE=1 SV=2
IDH3B_HUMAN 5 14.80%
ID11123 (nsP3) Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 CYTB_HUMAN 4 55.10%
ID11123 (nsP3) Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 K1C16_HUMAN 7 37.00%
ID11123 (nsP3) Cystathionine beta-synthase OS=Homo sapiens GN=CBS PE=1 SV=2 CBS_HUMAN 3 5.81%
ID11123 (nsP3) Structural maintenance of chromosomes protein 4 OS=Homo sapiens GN=SMC4 
PE=1 SV=2
SMC4_HUMAN 13 12.90%
ID11123 (nsP3) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Homo 
sapiens GN=RPN1 PE=1 SV=1
RPN1_HUMAN 8 17.10%
ID11123 (nsP3) Monofunctional C1-tetrahydrofolate synthase, mitochondrial OS=Homo sapiens 
GN=MTHFD1L PE=1 SV=1
C1TM_HUMAN 6 8.18%
ID11123 (nsP3) 60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 SV=1 RLA2_HUMAN 11 100.00%
ID11123 (nsP3) T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 SV=1 TCPA_HUMAN 14 33.60%
ID11123 (nsP3) Cell division protein kinase 5 OS=Homo sapiens GN=CDK5 PE=1 SV=3 CDK5_HUMAN 4 21.20%
ID11123 (nsP3) Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1 CSK21_HUMAN 5 18.70%
ID11123 (nsP3) UPF0568 protein C14orf166 OS=Homo sapiens GN=C14orf166 PE=1 SV=1 CN166_HUMAN 4 22.10%
ID11123 (nsP3) 40S ribosomal protein S23 OS=Homo sapiens GN=RPS23 PE=1 SV=3 RS23_HUMAN 5 42.70%
ID11123 (nsP3) POLNCHIKS|POLNCHIKS POLNCHIKS|POL
NCHIKS
40 20.30%
ID11123 (nsP3) Galactokinase OS=Homo sapiens GN=GALK1 PE=1 SV=1 GALK1_HUMAN 4 16.60%
ID11123 (nsP3) Carbonyl reductase [NADPH] 1 OS=Homo sapiens GN=CBR1 PE=1 SV=3 CBR1_HUMAN 8 43.00%
ID11123 (nsP3) SRA stem-loop-interacting RNA-binding protein, mitochondrial OS=Homo sapiens 
GN=SLIRP PE=1 SV=1
SLIRP_HUMAN 4 54.10%
ID11123 (nsP3) 60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 RL31_HUMAN 3 24.80%
ID11123 (nsP3) Translational activator GCN1 OS=Homo sapiens GN=GCN1L1 PE=1 SV=6 GCN1L_HUMAN 26 12.70%
ID11123 (nsP3) Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A PE=1 SV=2 RS27A_HUMAN 6 42.90%
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ID11123 (nsP3) Medium-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Homo sapiens 
GN=ACADM PE=1 SV=1
ACADM_HUMAN 7 20.00%
ID11123 (nsP3) Nicalin OS=Homo sapiens GN=NCLN PE=1 SV=2 NCLN_HUMAN 5 11.20%
ID11123 (nsP3) Four and a half LIM domains protein 1 OS=Homo sapiens GN=FHL1 PE=1 SV=4 FHL1_HUMAN 8 32.80%
ID11123 (nsP3) CAD protein OS=Homo sapiens GN=CAD PE=1 SV=3 PYR1_HUMAN 51 34.80%
ID11123 (nsP3) Hydroxysteroid dehydrogenase-like protein 2 OS=Homo sapiens GN=HSDL2 PE=1 
SV=1
HSDL2_HUMAN 1 3.11%
ID11123 (nsP3) Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 IF4A1_HUMAN 5 35.50%
ID11123 (nsP3) ES1 protein homolog, mitochondrial OS=Homo sapiens GN=C21orf33 PE=1 SV=3 ES1_HUMAN 5 33.20%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNPC 
PE=1 SV=4
HNRPC_HUMAN 6 25.80%
ID11123 (nsP3) Double-stranded RNA-specific adenosine deaminase OS=Homo sapiens GN=ADAR 
PE=1 SV=3
DSRAD_HUMAN 8 8.73%
ID11123 (nsP3) Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 PRDX6_HUMAN 3 14.30%
ID11123 (nsP3) LanC-like protein 2 OS=Homo sapiens GN=LANCL2 PE=1 SV=1 LANC2_HUMAN 7 24.90%
ID11123 (nsP3) Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 PABP1_HUMAN 5 24.70%
ID11123 (nsP3) Gephyrin OS=Homo sapiens GN=GPHN PE=1 SV=1 GEPH_HUMAN 11 21.70%
ID11123 (nsP3) Succinyl-CoA ligase [GDP-forming] subunit alpha, mitochondrial OS=Homo sapiens 
GN=SUCLG1 PE=1 SV=4
SUCA_HUMAN 5 23.40%
ID11123 (nsP3) 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 GRP78_HUMAN 13 28.00%
ID11123 (nsP3) Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 OS=Homo 
sapiens GN=AIMP1 PE=1 SV=2
AIMP1_HUMAN 1 6.73%
ID11123 (nsP3) Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2
PAIRB_HUMAN 5 16.40%
ID11123 (nsP3) Myc box-dependent-interacting protein 1 OS=Homo sapiens GN=BIN1 PE=1 SV=1 BIN1_HUMAN 14 34.10%
ID11123 (nsP3) Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 RINI_HUMAN 7 24.50%
ID11123 (nsP3) Thioredoxin domain-containing protein 5 OS=Homo sapiens GN=TXNDC5 PE=1 
SV=2
TXND5_HUMAN 7 19.90%
ID11123 (nsP3) 60S ribosomal protein L27a OS=Homo sapiens GN=RPL27A PE=1 SV=2 RL27A_HUMAN 7 37.80%
ID11123 (nsP3) T-complex protein 1 subunit beta OS=Homo sapiens GN=CCT2 PE=1 SV=4 TCPB_HUMAN 10 26.90%
ID11123 (nsP3) Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 TBA1B_HUMAN 4 44.80%
ID11123 (nsP3) 40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 RS25_HUMAN 7 40.80%
ID11123 (nsP3) Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 IPO9_HUMAN 2 2.79%
ID11123 (nsP3) Phenylalanyl-tRNA synthetase alpha chain OS=Homo sapiens GN=FARSA PE=1 
SV=3
SYFA_HUMAN 4 14.60%
ID11123 (nsP3) Midline-1 OS=Homo sapiens GN=MID1 PE=1 SV=1 TRI18_HUMAN 7 13.20%
ID11123 (nsP3) 60S ribosomal protein L32 OS=Homo sapiens GN=RPL32 PE=1 SV=2 RL32_HUMAN 7 43.00%
ID11123 (nsP3) Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 FAS_HUMAN 27 16.60%
ID11123 (nsP3) Eukaryotic translation initiation factor 2 subunit 3 OS=Homo sapiens GN=EIF2S3 
PE=1 SV=3
IF2G_HUMAN 10 30.70%
ID11123 (nsP3) Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 PARP1_HUMAN 21 28.50%
ID11123 (nsP3) GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 RAN_HUMAN 4 22.20%
ID11123 (nsP3) Serine-threonine kinase receptor-associated protein OS=Homo sapiens GN=STRAP 
PE=1 SV=1
STRAP_HUMAN 1 4.57%
ID11123 (nsP3) Matrin-3 OS=Homo sapiens GN=MATR3 PE=1 SV=2 MATR3_HUMAN 2 3.78%
ID11123 (nsP3) SAM domain and HD domain-containing protein 1 OS=Homo sapiens GN=SAMHD1 
PE=1 SV=2
SAMH1_HUMAN 20 43.50%
ID11123 (nsP3) 60S ribosomal protein L10 OS=Homo sapiens GN=RPL10 PE=1 SV=4 RL10_HUMAN 11 46.70%
ID11123 (nsP3) Eukaryotic initiation factor 4A-II OS=Homo sapiens GN=EIF4A2 PE=1 SV=2 IF4A2_HUMAN 2 30.50%
ID11123 (nsP3) Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=3 EF1B_HUMAN 4 27.10%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein D0 OS=Homo sapiens GN=HNRNPD PE=1 
SV=1
HNRPD_HUMAN 5 17.50%
ID11123 (nsP3) Pre-mRNA-processing-splicing factor 8 OS=Homo sapiens GN=PRPF8 PE=1 SV=2 PRP8_HUMAN 6 3.68%
ID11123 (nsP3) Interferon-induced protein with tetratricopeptide repeats 2 OS=Homo sapiens 
GN=IFIT2 PE=1 SV=1
IFIT2_HUMAN 5 14.20%
ID11123 (nsP3) Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 TEBP_HUMAN 3 26.20%
ID11123 (nsP3) Guanine nucleotide-binding protein-like 3 OS=Homo sapiens GN=GNL3 PE=1 SV=2 GNL3_HUMAN 4 11.70%
ID11123 (nsP3) Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 HSP7C_HUMAN 18 44.60%
ID11123 (nsP3) Insulin-like growth factor 2 mRNA-binding protein 1 OS=Homo sapiens GN=IGF2BP1 
PE=1 SV=2
IF2B1_HUMAN 12 30.00%
ID11123 (nsP3) Poly(U)-binding-splicing factor PUF60 OS=Homo sapiens GN=PUF60 PE=1 SV=1 PUF60_HUMAN 6 17.50%
ID11123 (nsP3) 26S proteasome non-ATPase regulatory subunit 12 OS=Homo sapiens GN=PSMD12 
PE=1 SV=3
PSD12_HUMAN 0 0.00%
ID11123 (nsP3) Proteasome subunit alpha type-6 OS=Homo sapiens GN=PSMA6 PE=1 SV=1 PSA6_HUMAN 1 5.28%
ID11123 (nsP3) Far upstream element-binding protein 3 OS=Homo sapiens GN=FUBP3 PE=1 SV=2 FUBP3_HUMAN 0 0.00%
ID11123 (nsP3) ATP-binding cassette sub-family E member 1 OS=Homo sapiens GN=ABCE1 PE=1 
SV=1
ABCE1_HUMAN 3 7.85%
ID11123 (nsP3) Far upstream element-binding protein 2 OS=Homo sapiens GN=KHSRP PE=1 SV=3 FUBP2_HUMAN 7 13.90%
ID11123 (nsP3) 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1433Z_HUMAN 4 33.10%
ID11123 (nsP3) 40S ribosomal protein S27 OS=Homo sapiens GN=RPS27 PE=1 SV=3 RS27_HUMAN 3 40.50%
ID11123 (nsP3) Tubulin beta-2B chain OS=Homo sapiens GN=TUBB2B PE=1 SV=1 TBB2B_HUMAN 3 53.90%
ID11123 (nsP3) Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1 TBA1C_HUMAN 4 45.00%
ID11123 (nsP3) 40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 RS26_HUMAN 4 44.30%
ID11123 (nsP3) Peptidyl-prolyl cis-trans isomerase FKBP8 OS=Homo sapiens GN=FKBP8 PE=1 
SV=2
FKBP8_HUMAN 1 3.88%
ID11123 (nsP3) Protein RCC2 OS=Homo sapiens GN=RCC2 PE=1 SV=2 RCC2_HUMAN 16 39.50%
ID11123 (nsP3) Phenylalanyl-tRNA synthetase beta chain OS=Homo sapiens GN=FARSB PE=1 SV=3 SYFB_HUMAN 7
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ID11123 (nsP3) T-complex protein 1 subunit zeta OS=Homo sapiens GN=CCT6A PE=1 SV=3 TCPZ_HUMAN 7 25.20%
ID11123 (nsP3) ATP-binding cassette sub-family F member 1 OS=Homo sapiens GN=ABCF1 PE=1 
SV=2
ABCF1_HUMAN 17 26.90%
ID11123 (nsP3) RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE=1 SV=1 RUVB1_HUMAN 13 40.80%
ID11123 (nsP3) Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 ACTB_HUMAN 1 51.20%
ID11123 (nsP3) Nucleoside diphosphate kinase A OS=Homo sapiens GN=NME1 PE=1 SV=1 NDKA_HUMAN 2 34.20%
ID11123 (nsP3) Zinc finger CCCH-type antiviral protein 1-like OS=Homo sapiens GN=ZC3HAV1L 
PE=1 SV=2
ZCCHL_HUMAN 7 44.70%
ID11123 (nsP3) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 
OS=Homo sapiens GN=DDOST PE=1 SV=4
OST48_HUMAN 4 9.87%
ID11123 (nsP3) Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1 TBB1_HUMAN 2 14.00%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein G OS=Homo sapiens GN=RBMX PE=1 
SV=3
HNRPG_HUMAN 5 14.10%
ID11123 (nsP3) 60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 RL11_HUMAN 5 29.20%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens GN=HNRNPF PE=1 
SV=3
HNRPF_HUMAN 5 26.30%
ID11123 (nsP3) Eukaryotic initiation factor 4A-III OS=Homo sapiens GN=EIF4A3 PE=1 SV=4 IF4A3_HUMAN 4 15.60%
ID11123 (nsP3) FACT complex subunit SSRP1 OS=Homo sapiens GN=SSRP1 PE=1 SV=1 SSRP1_HUMAN 7 13.00%
ID11123 (nsP3) Exosome complex exonuclease RRP45 OS=Homo sapiens GN=EXOSC9 PE=1 SV=3 EXOS9_HUMAN 4 11.40%
ID11123 (nsP3) Insulin-like growth factor 2 mRNA-binding protein 3 OS=Homo sapiens GN=IGF2BP3 
PE=1 SV=2
IF2B3_HUMAN 6 20.20%
ID11123 (nsP3) Methionyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=MARS PE=1 SV=2 SYMC_HUMAN 13 25.00%
ID11123 (nsP3) Isocitrate dehydrogenase [NADP], mitochondrial OS=Homo sapiens GN=IDH2 PE=1 
SV=2
IDHP_HUMAN 9 22.60%
ID11123 (nsP3) Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2 IMB1_HUMAN 4 6.96%
ID11123 (nsP3) Glutaryl-CoA dehydrogenase, mitochondrial OS=Homo sapiens GN=GCDH PE=1 
SV=1
GCDH_HUMAN 3 12.80%
ID11123 (nsP3) Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens 
GN=GNB2L1 PE=1 SV=3
GBLP_HUMAN 16 74.10%
ID11123 (nsP3) Polyadenylate-binding protein 4 OS=Homo sapiens GN=PABPC4 PE=1 SV=1 PABP4_HUMAN 3 15.70%
ID11123 (nsP3) Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial OS=Homo sapiens 
GN=IDH3G PE=1 SV=1
IDH3G_HUMAN 4 19.30%
ID11123 (nsP3) Proteasome subunit alpha type-4 OS=Homo sapiens GN=PSMA4 PE=1 SV=1 PSA4_HUMAN 1 3.83%
ID11123 (nsP3) 2'-5'-oligoadenylate synthase 3 OS=Homo sapiens GN=OAS3 PE=1 SV=2 OAS3_HUMAN 6 7.82%
ID11123 (nsP3) 40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 SV=1 RS20_HUMAN 4 29.40%
ID11123 (nsP3) Hypoxanthine-guanine phosphoribosyltransferase OS=Homo sapiens GN=HPRT1 
PE=1 SV=2
HPRT_HUMAN 5 28.90%
ID11123 (nsP3) Nascent polypeptide-associated complex subunit alpha OS=Homo sapiens GN=NACA 
PE=1 SV=1
NACA_HUMAN 6 33.50%
ID11123 (nsP3) NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial 
OS=Homo sapiens GN=NDUFA9 PE=1 SV=2
NDUA9_HUMAN 4 12.70%
ID11123 (nsP3) Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 SV=2 GRP75_HUMAN 7 14.60%
ID11123 (nsP3) ATP synthase subunit d, mitochondrial OS=Homo sapiens GN=ATP5H PE=1 SV=3 ATP5H_HUMAN 3 22.40%
ID11123 (nsP3) Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 K2C1_HUMAN 16 31.40%
ID11123 (nsP3) 40S ribosomal protein S29 OS=Homo sapiens GN=RPS29 PE=1 SV=2 RS29_HUMAN 4 58.90%
ID11123 (nsP3) Macrophage migration inhibitory factor OS=Homo sapiens GN=MIF PE=1 SV=4 MIF_HUMAN 6 89.60%
ID11123 (nsP3) 60S ribosomal protein L13a OS=Homo sapiens GN=RPL13A PE=1 SV=2 RL13A_HUMAN 6 28.60%
ID11123 (nsP3) T-complex protein 1 subunit epsilon OS=Homo sapiens GN=CCT5 PE=1 SV=1 TCPE_HUMAN 3 10.90%
ID11123 (nsP3) Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 
SV=3
G3P_HUMAN 5 34.30%
ID11123 (nsP3) Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 PPIA_HUMAN 10 66.70%
ID11123 (nsP3) Small nuclear ribonucleoprotein Sm D1 OS=Homo sapiens GN=SNRPD1 PE=1 SV=1 SMD1_HUMAN 4 54.60%
ID11123 (nsP3) FAS-associated factor 2 OS=Homo sapiens GN=FAF2 PE=1 SV=2 FAF2_HUMAN 3 11.50%
ID11123 (nsP3) X-ray repair cross-complementing protein 6 OS=Homo sapiens GN=XRCC6 PE=1 
SV=2
XRCC6_HUMAN 13 28.20%
ID11123 (nsP3) Putative RNA-binding protein Luc7-like 2 OS=Homo sapiens GN=LUC7L2 PE=1 SV=2 LC7L2_HUMAN 5 24.20%
ID11123 (nsP3) General transcription factor 3C polypeptide 4 OS=Homo sapiens GN=GTF3C4 PE=1 
SV=2
TF3C4_HUMAN 22 42.80%
ID11123 (nsP3) 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 1433B_HUMAN 4 33.70%
ID11123 (nsP3) mRNA turnover protein 4 homolog OS=Homo sapiens GN=MRTO4 PE=1 SV=2 MRT4_HUMAN 6 34.70%
ID11123 (nsP3) 60S ribosomal protein L36 OS=Homo sapiens GN=RPL36 PE=1 SV=3 RL36_HUMAN 4 30.50%
ID11123 (nsP3) Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=1 SV=2 PCBP1_HUMAN 4 25.80%
ID11123 (nsP3) Arginyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=RARS PE=1 SV=2 SYRC_HUMAN 10 17.70%
ID11123 (nsP3) 60S ribosomal export protein NMD3 OS=Homo sapiens GN=NMD3 PE=1 SV=1 NMD3_HUMAN 8 30.40%
ID11123 (nsP3) ATP synthase subunit O, mitochondrial OS=Homo sapiens GN=ATP5O PE=1 SV=1 ATPO_HUMAN 4 22.50%
ID11123 (nsP3) ATP-binding cassette sub-family F member 2 OS=Homo sapiens GN=ABCF2 PE=1 
SV=2
ABCF2_HUMAN 11 21.00%
ID11123 (nsP3) Keratin, type II cytoskeletal 75 OS=Homo sapiens GN=KRT75 PE=1 SV=2 K2C75_HUMAN 3 16.50%
ID11123 (nsP3) 40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 RS3A_HUMAN 12 43.60%
ID11123 (nsP3) RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=1 SV=3 RUVB2_HUMAN 14 35.40%
ID11123 (nsP3) 60S ribosomal protein L14 OS=Homo sapiens GN=RPL14 PE=1 SV=4 RL14_HUMAN 4 20.90%
ID11123 (nsP3) 60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 RL13_HUMAN 8 37.40%
ID11123 (nsP3) Crk-like protein OS=Homo sapiens GN=CRKL PE=1 SV=1 CRKL_HUMAN 13 52.80%
ID11123 (nsP3) 60S ribosomal protein L37a OS=Homo sapiens GN=RPL37A PE=1 SV=2 RL37A_HUMAN 4 42.40%
ID11123 (nsP3) Proteasome subunit alpha type-5 OS=Homo sapiens GN=PSMA5 PE=1 SV=3 PSA5_HUMAN 1 4.98%
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ID11123 (nsP3) Dynamin-like 120 kDa protein, mitochondrial OS=Homo sapiens GN=OPA1 PE=1 
SV=3
OPA1_HUMAN 0 0.00%
ID11123 (nsP3) Radixin OS=Homo sapiens GN=RDX PE=1 SV=1 RADI_HUMAN 2 3.26%
ID11123 (nsP3) Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 PARK7_HUMAN 4 38.10%
ID11123 (nsP3) Putative ATP-dependent RNA helicase DHX30 OS=Homo sapiens GN=DHX30 PE=1 
SV=1
DHX30_HUMAN 18 20.50%
ID11123 (nsP3) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 OS=Homo 
sapiens GN=RPN2 PE=1 SV=3
RPN2_HUMAN 9 23.80%
ID11123 (nsP3) Uncharacterized protein C7orf50 OS=Homo sapiens GN=C7orf50 PE=1 SV=1 CG050_HUMAN 4 35.60%
ID11123 (nsP3) Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial OS=Homo sapiens 
GN=DUT PE=1 SV=3
DUT_HUMAN 3 19.40%
ID11123 (nsP3) Profilin-2 OS=Homo sapiens GN=PFN2 PE=1 SV=3 PROF2_HUMAN 4 41.40%
ID11123 (nsP3) Trifunctional purine biosynthetic protein adenosine-3 OS=Homo sapiens GN=GART 
PE=1 SV=1
PUR2_HUMAN 16 24.10%
ID11123 (nsP3) Protein C20orf11 OS=Homo sapiens GN=C20orf11 PE=1 SV=1 CT011_HUMAN 4 32.50%
ID11123 (nsP3) Keratin, type II cytoskeletal 3 OS=Homo sapiens GN=KRT3 PE=1 SV=2 K2C3_HUMAN 1 6.04%
ID11123 (nsP3) RNA-binding protein 4 OS=Homo sapiens GN=RBM4 PE=1 SV=1 RBM4_HUMAN 1 2.20%
ID11123 (nsP3) Small nuclear ribonucleoprotein Sm D3 OS=Homo sapiens GN=SNRPD3 PE=1 SV=1 SMD3_HUMAN 4 38.10%
ID11123 (nsP3) Serine/arginine-rich splicing factor 1 OS=Homo sapiens GN=SRSF1 PE=1 SV=2 SRSF1_HUMAN 6 27.80%
ID11123 (nsP3) Small nuclear ribonucleoprotein Sm D2 OS=Homo sapiens GN=SNRPD2 PE=1 SV=1 SMD2_HUMAN 8 65.30%
ID11123 (nsP3) Acylglycerol kinase, mitochondrial OS=Homo sapiens GN=AGK PE=1 SV=2 AGK_HUMAN 10 32.50%
ID11123 (nsP3) 60S ribosomal protein L38 OS=Homo sapiens GN=RPL38 PE=1 SV=2 RL38_HUMAN 3 35.70%
ID11123 (nsP3) Leucine-rich repeat-containing protein 59 OS=Homo sapiens GN=LRRC59 PE=1 
SV=1
LRC59_HUMAN 5 26.70%
ID11123 (nsP3) Flap endonuclease 1 OS=Homo sapiens GN=FEN1 PE=1 SV=1 FEN1_HUMAN 8 35.30%
ID11123 (nsP3) L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 LDHB_HUMAN 2 8.08%
ID11123 (nsP3) Dolichol-phosphate mannosyltransferase OS=Homo sapiens GN=DPM1 PE=1 SV=1 DPM1_HUMAN 4 21.50%
ID11123 (nsP3) Coatomer subunit alpha OS=Homo sapiens GN=COPA PE=1 SV=2 COPA_HUMAN 34 39.90%
ID11123 (nsP3) RNA 3'-terminal phosphate cyclase OS=Homo sapiens GN=RTCD1 PE=1 SV=1 RTC1_HUMAN 5 22.10%
ID11123 (nsP3) Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 K1C9_HUMAN 15 37.20%
ID11123 (nsP3) ATP-dependent RNA helicase DDX39 OS=Homo sapiens GN=DDX39 PE=1 SV=2 DDX39_HUMAN 14 39.10%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein D-like OS=Homo sapiens GN=HNRPDL 
PE=1 SV=3
HNRDL_HUMAN 3 13.10%
ID11123 (nsP3) Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 TBB5_HUMAN 2 61.30%
ID11123 (nsP3) 60S ribosomal protein L15 OS=Homo sapiens GN=RPL15 PE=1 SV=2 RL15_HUMAN 5 26.00%
ID11123 (nsP3) Aspartyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=DARS PE=1 SV=2 SYDC_HUMAN 11 27.90%
ID11123 (nsP3) Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 ENOA_HUMAN 14 56.00%
ID11123 (nsP3) Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 SV=3 EF1G_HUMAN 9 24.70%
ID11123 (nsP3) 26S proteasome non-ATPase regulatory subunit 3 OS=Homo sapiens GN=PSMD3 
PE=1 SV=2
PSMD3_HUMAN 3 6.55%
ID11123 (nsP3) Trifunctional enzyme subunit beta, mitochondrial OS=Homo sapiens GN=HADHB 
PE=1 SV=3
ECHB_HUMAN 7 18.80%
ID11123 (nsP3) Trifunctional enzyme subunit alpha, mitochondrial OS=Homo sapiens GN=HADHA 
PE=1 SV=2
ECHA_HUMAN 11 24.50%
ID11123 (nsP3) T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 PE=1 SV=4 TCPG_HUMAN 14 34.90%
ID11123 (nsP3) Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase 
OS=Homo sapiens GN=GNE PE=1 SV=1
GLCNE_HUMAN 4 9.42%
ID11123 (nsP3) DNA polymerase delta catalytic subunit OS=Homo sapiens GN=POLD1 PE=1 SV=2 DPOD1_HUMAN 7 7.68%
ID11123 (nsP3) 2',3'-cyclic-nucleotide 3'-phosphodiesterase OS=Homo sapiens GN=CNP PE=1 SV=2 CN37_HUMAN 10 33.00%
ID11123 (nsP3) 3-hydroxyacyl-CoA dehydrogenase type-2 OS=Homo sapiens GN=HSD17B10 PE=1 
SV=3
HCD2_HUMAN 5 32.20%
ID11123 (nsP3) DNA replication licensing factor MCM3 OS=Homo sapiens GN=MCM3 PE=1 SV=3 MCM3_HUMAN 25 41.70%
ID11123 (nsP3) 60S ribosomal protein L18a OS=Homo sapiens GN=RPL18A PE=1 SV=2 RL18A_HUMAN 7 42.00%
ID11123 (nsP3) Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 COF1_HUMAN 7 62.00%
ID11123 (nsP3) T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 SV=4 TCPD_HUMAN 15 39.30%
ID11123 (nsP3) Cell division protein kinase 1 OS=Homo sapiens GN=CDK1 PE=1 SV=2 CDK1_HUMAN 5 23.90%
ID11123 (nsP3) GTP-binding protein 1 OS=Homo sapiens GN=GTPBP1 PE=1 SV=3 GTPB1_HUMAN 3 5.98%
ID11123 (nsP3) Estradiol 17-beta-dehydrogenase 12 OS=Homo sapiens GN=HSD17B12 PE=1 SV=2 DHB12_HUMAN 11 28.50%
ID11123 (nsP3) Delta-1-pyrroline-5-carboxylate synthase OS=Homo sapiens GN=ALDH18A1 PE=1 
SV=2
P5CS_HUMAN 14 21.90%
ID11123 (nsP3) Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 K2C5_HUMAN 6 25.80%
ID11123 (nsP3) Bifunctional aminoacyl-tRNA synthetase OS=Homo sapiens GN=EPRS PE=1 SV=5 SYEP_HUMAN 25 22.40%
ID11123 (nsP3) T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=1 SV=2 TCPH_HUMAN 4 9.76%
ID11123 (nsP3) Tricarboxylate transport protein, mitochondrial OS=Homo sapiens GN=SLC25A1 
PE=1 SV=2
TXTP_HUMAN 6 26.00%
ID11123 (nsP3) Serine/arginine-rich splicing factor 3 OS=Homo sapiens GN=SRSF3 PE=1 SV=1 SRSF3_HUMAN 3 25.60%
ID11123 (nsP3) GMP synthase [glutamine-hydrolyzing] OS=Homo sapiens GN=GMPS PE=1 SV=1 GUAA_HUMAN 1 1.88%
ID11123 (nsP3) 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 1433E_HUMAN 8 42.70%
ID11123 (nsP3) D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 SERA_HUMAN 9 21.60%
ID11123 (nsP3) Phosphoglycolate phosphatase OS=Homo sapiens GN=PGP PE=1 SV=1 PGP_HUMAN 6 24.60%
ID11123 (nsP3) TNF receptor-associated factor 2 OS=Homo sapiens GN=TRAF2 PE=1 SV=2 TRAF2_HUMAN 6 14.40%
ID11123 (nsP3) Pre-mRNA-processing factor 19 OS=Homo sapiens GN=PRPF19 PE=1 SV=1 PRP19_HUMAN 5 13.30%
ID11123 (nsP3) Retinol dehydrogenase 11 OS=Homo sapiens GN=RDH11 PE=1 SV=2 RDH11_HUMAN 4 18.90%
ID11123 (nsP3) RING finger protein 114 OS=Homo sapiens GN=RNF114 PE=1 SV=1 RN114_HUMAN 4 26.80%
ID11123 (nsP3) Coatomer subunit beta OS=Homo sapiens GN=COPB1 PE=1 SV=3 COPB_HUMAN 19 30.80%
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ID11123 (nsP3) Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 K1C17_HUMAN 2 13.00%
ID11123 (nsP3) 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 CH60_HUMAN 9 24.30%
ID11123 (nsP3) Cullin-associated NEDD8-dissociated protein 1 OS=Homo sapiens GN=CAND1 PE=1 
SV=2
CAND1_HUMAN 2 2.44%
ID11123 (nsP3) 60S ribosomal protein L17 OS=Homo sapiens GN=RPL17 PE=1 SV=3 RL17_HUMAN 7 38.00%
ID11123 (nsP3) Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens GN=AIFM1 PE=1 SV=1 AIFM1_HUMAN 14 32.60%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1 
SV=1
HNRPK_HUMAN 10 32.40%
ID11123 (nsP3) Mitochondrial dicarboxylate carrier OS=Homo sapiens GN=SLC25A10 PE=1 SV=2 DIC_HUMAN 11 55.40%
ID11123 (nsP3) 60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 RL23A_HUMAN 7 34.00%
ID11123 (nsP3) 60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=1 SV=2 RL7A_HUMAN 14 41.70%
ID11123 (nsP3) Complement component 1 Q subcomponent-binding protein, mitochondrial OS=Homo 
sapiens GN=C1QBP PE=1 SV=1
C1QBP_HUMAN 4 20.90%
ID11123 (nsP3) Mitochondrial 2-oxoglutarate/malate carrier protein OS=Homo sapiens GN=SLC25A11 
PE=1 SV=3
M2OM_HUMAN 8 28.30%
ID11123 (nsP3) Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM2 PE=1 SV=4 KPYM_HUMAN 13 36.70%
ID11123 (nsP3) Mitochondrial inner membrane protein OS=Homo sapiens GN=IMMT PE=1 SV=1 IMMT_HUMAN 8 14.50%
ID11123 (nsP3) DNA replication licensing factor MCM5 OS=Homo sapiens GN=MCM5 PE=1 SV=5 MCM5_HUMAN 24 43.50%
ID11123 (nsP3) Probable ATP-dependent RNA helicase DDX17 OS=Homo sapiens GN=DDX17 PE=1 
SV=1
DDX17_HUMAN 16 39.70%
ID11123 (nsP3) DNA replication licensing factor MCM4 OS=Homo sapiens GN=MCM4 PE=1 SV=5 MCM4_HUMAN 17 27.80%
ID11123 (nsP3) Protein FAM98A OS=Homo sapiens GN=FAM98A PE=1 SV=1 FA98A_HUMAN 4 12.50%
ID11123 (nsP3) Activated RNA polymerase II transcriptional coactivator p15 OS=Homo sapiens 
GN=SUB1 PE=1 SV=3
TCP4_HUMAN 5 52.00%
ID11123 (nsP3) Zinc finger CCCH-type antiviral protein 1 OS=Homo sapiens GN=ZC3HAV1 PE=1 
SV=3
ZCCHV_HUMAN 13 24.70%
ID11123 (nsP3) Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 NUCL_HUMAN 18 25.50%
ID11123 (nsP3) WD repeat-containing protein 11 OS=Homo sapiens GN=WDR11 PE=1 SV=1 WDR11_HUMAN 5 7.03%
ID11123 (nsP3) Testin OS=Homo sapiens GN=TES PE=1 SV=1 TES_HUMAN 4 14.00%
ID11123 (nsP3) DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC 
PE=1 SV=3
PRKDC_HUMAN 64 20.60%
ID11123 (nsP3) Isoleucyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=IARS PE=1 SV=2 SYIC_HUMAN 11 11.90%
ID11123 (nsP3) 6-phosphofructokinase, muscle type OS=Homo sapiens GN=PFKM PE=1 SV=2 K6PF_HUMAN 11 23.50%
ID11123 (nsP3) Serine hydroxymethyltransferase, mitochondrial OS=Homo sapiens GN=SHMT2 
PE=1 SV=3
GLYM_HUMAN 3 7.54%
ID11123 (nsP3) Serine/arginine-rich splicing factor 5 OS=Homo sapiens GN=SRSF5 PE=1 SV=1 SRSF5_HUMAN 4 23.20%
ID11123 (nsP3) 40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 RS2_HUMAN 12 49.50%
ID11123 (nsP3) Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 K2C6B_HUMAN 6 34.00%
ID11123 (nsP3) 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 1433G_HUMAN 2 19.00%
ID11123 (nsP3) Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens 
GN=ATP1A1 PE=1 SV=1
AT1A1_HUMAN 11 19.30%
ID11123 (nsP3) 14-3-3 protein eta OS=Homo sapiens GN=YWHAH PE=1 SV=4 1433F_HUMAN 5 35.00%
ID11123 (nsP3) Monocarboxylate transporter 1 OS=Homo sapiens GN=SLC16A1 PE=1 SV=2 MOT1_HUMAN 4 9.00%
ID11123 (nsP3) Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 H4_HUMAN 8 53.40%
ID11123 (nsP3) Coatomer subunit epsilon OS=Homo sapiens GN=COPE PE=1 SV=3 COPE_HUMAN 6 25.30%
ID11123 (nsP3) ATPase WRNIP1 OS=Homo sapiens GN=WRNIP1 PE=1 SV=2 WRIP1_HUMAN 6 9.92%
ID11123 (nsP3) 60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 SV=1 RL12_HUMAN 6 54.50%
ID11123 (nsP3) Protein arginine N-methyltransferase 1 OS=Homo sapiens GN=PRMT1 PE=1 SV=2 ANM1_HUMAN 2 7.76%
ID11123 (nsP3) Histone H2B type F-S OS=Homo sapiens GN=H2BFS PE=1 SV=2 H2BFS_HUMAN 2 35.70%
ID11123 (nsP3) Coatomer subunit delta OS=Homo sapiens GN=ARCN1 PE=1 SV=1 COPD_HUMAN 10 25.40%
ID11123 (nsP3) Insulin receptor substrate 4 OS=Homo sapiens GN=IRS4 PE=1 SV=1 IRS4_HUMAN 19 19.90%
ID11123 (nsP3) 60S ribosomal protein L19 OS=Homo sapiens GN=RPL19 PE=1 SV=1 RL19_HUMAN 4 21.90%
ID11123 (nsP3) Tubulin beta-8 chain OS=Homo sapiens GN=TUBB8 PE=1 SV=2 TBB8_HUMAN 4 40.10%
ID11123 (nsP3) 60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 RL18_HUMAN 6 38.30%
ID11123 (nsP3) Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens GN=HNRNPM PE=1 
SV=3
HNRPM_HUMAN 12 21.50%
ID11123 (nsP3) Inorganic pyrophosphatase OS=Homo sapiens GN=PPA1 PE=1 SV=2 IPYR_HUMAN 6 35.60%
ID11123 (nsP3) 2,4-dienoyl-CoA reductase, mitochondrial OS=Homo sapiens GN=DECR1 PE=1 SV=1 DECR_HUMAN 7 24.80%
ID11124 (GFP) Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1 CSK21_HUMAN 4 12.30%
ID11124 (GFP) POTE ankyrin domain family member E OS=Homo sapiens GN=POTEE PE=1 SV=3 POTEE_HUMAN 3 13.30%
ID11124 (GFP) Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 H4_HUMAN 8 52.40%
ID11124 (GFP) Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 TBA1B_HUMAN 3 35.90%
ID11124 (GFP) Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens 
GN=HNRNPA2B1 PE=1 SV=2
ROA2_HUMAN 2 7.08%
ID11124 (GFP) Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 TBB5_HUMAN 3 53.40%
ID11124 (GFP) Cellular nucleic acid-binding protein OS=Homo sapiens GN=CNBP PE=1 SV=1 CNBP_HUMAN 0 0.00%
ID11124 (GFP) 40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 RS16_HUMAN 2 14.40%
ID11124 (GFP) Elongation factor Tu, mitochondrial OS=Homo sapiens GN=TUFM PE=1 SV=2 EFTU_HUMAN 2 6.86%
ID11124 (GFP) 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 RS3_HUMAN 6 32.50%
ID11124 (GFP) Ketosamine-3-kinase OS=Homo sapiens GN=FN3KRP PE=1 SV=2 KT3K_HUMAN 2 10.70%
ID11124 (GFP) Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 TEBP_HUMAN 1 7.50%
ID11124 (GFP) 60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 SV=1 RLA2_HUMAN 3 57.40%
ID11124 (GFP) 40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 RS4X_HUMAN 2 12.90%
ID11124 (GFP) Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 K1C10_HUMAN 22 51.70%
	   282	  
 
ID11124 (GFP) Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens 
GN=GNB2L1 PE=1 SV=3
GBLP_HUMAN 8 43.80%
ID11124 (GFP) Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 HS90B_HUMAN 2 8.84%
ID11124 (GFP) 40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 SV=3 RS11_HUMAN 1 11.40%
ID11124 (GFP) Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 HSP71_HUMAN 5 17.80%
ID11124 (GFP) ES1 protein homolog, mitochondrial OS=Homo sapiens GN=C21orf33 PE=1 SV=3 ES1_HUMAN 2 17.50%
ID11124 (GFP) Trifunctional purine biosynthetic protein adenosine-3 OS=Homo sapiens GN=GART 
PE=1 SV=1
PUR2_HUMAN 11 19.10%
ID11124 (GFP) Macrophage migration inhibitory factor OS=Homo sapiens GN=MIF PE=1 SV=4 MIF_HUMAN 5 84.30%
ID11124 (GFP) Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 CYTB_HUMAN 4 55.10%
ID11124 (GFP) Glutaredoxin-3 OS=Homo sapiens GN=GLRX3 PE=1 SV=2 GLRX3_HUMAN 5 17.00%
ID11124 (GFP) 40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 RS25_HUMAN 3 16.80%
ID11124 (GFP) 60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 RL11_HUMAN 1 7.87%
ID11124 (GFP) Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 K1C14_HUMAN 2 16.10%
ID11124 (GFP) Profilin-2 OS=Homo sapiens GN=PFN2 PE=1 SV=3 PROF2_HUMAN 3 20.70%
ID11124 (GFP) Phenylalanyl-tRNA synthetase beta chain OS=Homo sapiens GN=FARSB PE=1 SV=3 SYFB_HUMAN 2 3.57%
ID11124 (GFP) DNA replication licensing factor MCM3 OS=Homo sapiens GN=MCM3 PE=1 SV=3 MCM3_HUMAN 0 0.00%
ID11124 (GFP) Ubiquitin/ISG15-conjugating enzyme E2 L6 OS=Homo sapiens GN=UBE2L6 PE=1 
SV=4
UB2L6_HUMAN 3 46.40%
ID11124 (GFP) Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 K1C9_HUMAN 18 35.80%
ID11124 (GFP) Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 PARP1_HUMAN 4 5.62%
ID11124 (GFP) Actin, gamma-enteric smooth muscle OS=Homo sapiens GN=ACTG2 PE=1 SV=1 ACTH_HUMAN 0 17.30%
ID11124 (GFP) Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 PRDX1_HUMAN 11 66.30%
ID11124 (GFP) 60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 SV=1 RL12_HUMAN 2 21.20%
ID11124 (GFP) Beta-enolase OS=Homo sapiens GN=ENO3 PE=1 SV=4 ENOB_HUMAN 1 7.60%
ID11124 (GFP) Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 PARK7_HUMAN 3 29.60%
ID11124 (GFP) Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 COF1_HUMAN 7 57.20%
ID11124 (GFP) Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 K22E_HUMAN 14 42.40%
ID11124 (GFP) Carbonyl reductase [NADPH] 1 OS=Homo sapiens GN=CBR1 PE=1 SV=3 CBR1_HUMAN 8 35.70%
ID11124 (GFP) Protein disulfide-isomerase A6 OS=Homo sapiens GN=PDIA6 PE=1 SV=1 PDIA6_HUMAN 12 39.80%
ID11124 (GFP) Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 EF2_HUMAN 8 9.79%
ID11124 (GFP) 60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 SV=3 RL5_HUMAN 3 11.80%
ID11124 (GFP) 60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE=1 SV=1 RL23_HUMAN 2 25.00%
ID11124 (GFP) Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 EF1A1_HUMAN 13 51.10%
ID11124 (GFP) Protein-L-isoaspartate(D-aspartate) O-methyltransferase OS=Homo sapiens 
GN=PCMT1 PE=1 SV=3
PIMT_HUMAN 3 17.60%
ID11124 (GFP) Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 HSP7C_HUMAN 9 23.70%
ID11124 (GFP) Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2
PAIRB_HUMAN 2 7.60%
ID11124 (GFP) Inorganic pyrophosphatase OS=Homo sapiens GN=PPA1 PE=1 SV=2 IPYR_HUMAN 5 38.10%
ID11124 (GFP) F-actin-capping protein subunit beta OS=Homo sapiens GN=CAPZB PE=1 SV=4 CAPZB_HUMAN 2 8.66%
ID11124 (GFP) Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 
SV=6
HNRPU_HUMAN 4 8.12%
ID11124 (GFP) Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 VIME_HUMAN 7 18.70%
ID11124 (GFP) Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 TBB3_HUMAN 0 25.10%
ID11124 (GFP) 40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 RS14_HUMAN 1 13.90%
ID11124 (GFP) Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=1 SV=2 PCBP1_HUMAN 2 15.70%
ID11124 (GFP) Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 PRDX2_HUMAN 1 14.60%
ID11124 (GFP) 60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 SV=1 RLA0_HUMAN 5 27.80%
ID11124 (GFP) Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform 
OS=Homo sapiens GN=PPP2R2A PE=1 SV=1
2ABA_HUMAN 4 15.20%
ID11124 (GFP) Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 PPIA_HUMAN 11 66.70%
ID11124 (GFP) CTP synthase 1 OS=Homo sapiens GN=CTPS PE=1 SV=2 PYRG1_HUMAN 10 25.50%
ID11124 (GFP) Thioredoxin-dependent peroxide reductase, mitochondrial OS=Homo sapiens 
GN=PRDX3 PE=1 SV=3
PRDX3_HUMAN 3 14.50%
ID11124 (GFP) 60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 RL31_HUMAN 1 11.20%
ID11124 (GFP) 60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 PE=1 SV=2 RL30_HUMAN 3 40.90%
ID11124 (GFP) Hypoxanthine-guanine phosphoribosyltransferase OS=Homo sapiens GN=HPRT1 
PE=1 SV=2
HPRT_HUMAN 4 21.10%
ID11124 (GFP) Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 K2C5_HUMAN 3 10.20%
ID11124 (GFP) Far upstream element-binding protein 2 OS=Homo sapiens GN=KHSRP PE=1 SV=3 FUBP2_HUMAN 2 3.38%
ID11124 (GFP) ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=6 ADT2_HUMAN 3 16.10%
ID11124 (GFP) C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens GN=MTHFD1 PE=1 
SV=3
C1TC_HUMAN 6 8.98%
ID11124 (GFP) Isochorismatase domain-containing protein 2, mitochondrial OS=Homo sapiens 
GN=ISOC2 PE=1 SV=1
ISOC2_HUMAN 4 35.60%
ID11124 (GFP) 40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 RSSA_HUMAN 6 27.80%
ID11124 (GFP) BolA-like protein 2 OS=Homo sapiens GN=BOLA2 PE=1 SV=1 BOLA2_HUMAN 4 61.60%
ID11124 (GFP) ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1 
SV=1
ATPA_HUMAN 3 7.41%
ID11124 (GFP) 40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 RS7_HUMAN 2 26.80%
ID11124 (GFP) GFP|GFP GFP|GFP 20 78.20%
ID11124 (GFP) Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 K2C1_HUMAN 19 33.10%
ID11124 (GFP) Tubulin beta-2C chain OS=Homo sapiens GN=TUBB2C PE=1 SV=1 TBB2C_HUMAN 3 56.00%
ID11124 (GFP) Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 FAS_HUMAN 3 1.39%
ID11124 (GFP) Thioredoxin domain-containing protein 5 OS=Homo sapiens GN=TXNDC5 PE=1 
SV=2
TXND5_HUMAN 3 9.26%







ID11124 (GFP) Crk-like protein OS=Homo sapiens GN=CRKL PE=1 SV=1 CRKL_HUMAN 13 51.50%
ID11124 (GFP) Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 THIO_HUMAN 4 48.60%
ID11124 (GFP) 3-hydroxyacyl-CoA dehydrogenase type-2 OS=Homo sapiens GN=HSD17B10 PE=1 
SV=3
HCD2_HUMAN 2 13.40%
ID11124 (GFP) Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 ENOA_HUMAN 9 39.60%
ID11124 (GFP) F-actin-capping protein subunit alpha-1 OS=Homo sapiens GN=CAPZA1 PE=1 SV=3 CAZA1_HUMAN 2 15.00%
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Myosin-14 OS=Homo sapiens GN=MYH14 PE=1 SV=1 MYH14_HUMAN 28 22.20%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L3 OS=Homo sapiens GN=RPL3 PE=1 SV=2 RL3_HUMAN 13 34.20%
ID12190 
(Abhay_nsP1)





Glycogen phosphorylase, liver form OS=Homo sapiens GN=PYGL PE=1 SV=4 PYGL_HUMAN 5 6.73%
ID12190 
(Abhay_nsP1)
Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 NUCL_HUMAN 5 10.80%
ID12190 
(Abhay_nsP1)
Importin-7 OS=Homo sapiens GN=IPO7 PE=1 SV=1 IPO7_HUMAN 11 17.00%
ID12190 
(Abhay_nsP1)
Myosin regulatory light chain 12A OS=Homo sapiens GN=MYL12A PE=1 SV=2 ML12A_HUMAN 5 36.80%
ID12190 
(Abhay_nsP1)










Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 EF2_HUMAN 24 33.40%
ID12190 
(Abhay_nsP1)










Serine/arginine-rich splicing factor 7 OS=Homo sapiens GN=SRSF7 PE=1 SV=1 SRSF7_HUMAN 5 24.80%
ID12190 
(Abhay_nsP1)
Coatomer subunit beta' OS=Homo sapiens GN=COPB2 PE=1 SV=2 COPB2_HUMAN 15 20.20%
ID12190 
(Abhay_nsP1)
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial 




40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 RS3_HUMAN 15 62.10%
ID12190 
(Abhay_nsP1)
S-formylglutathione hydrolase OS=Homo sapiens GN=ESD PE=1 SV=2 ESTD_HUMAN 5 34.00%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L27a OS=Homo sapiens GN=RPL27A PE=1 SV=2 RL27A_HUMAN 6 37.80%
ID12190 
(Abhay_nsP1)










FACT complex subunit SPT16 OS=Homo sapiens GN=SUPT16H PE=1 SV=1 SP16H_HUMAN 11 14.00%















DnaJ homolog subfamily A member 2 OS=Homo sapiens GN=DNAJA2 PE=1 SV=1 DNJA2_HUMAN 5 17.20%
ID12190 
(Abhay_nsP1)
DnaJ homolog subfamily A member 1 OS=Homo sapiens GN=DNAJA1 PE=1 SV=2 DNJA1_HUMAN 6 24.40%
ID12190 
(Abhay_nsP1)










Actin-related protein 3 OS=Homo sapiens GN=ACTR3 PE=1 SV=3 ARP3_HUMAN 12 38.30%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 RL4_HUMAN 17 37.20%
ID12190 
(Abhay_nsP1)
Actin-related protein 2 OS=Homo sapiens GN=ACTR2 PE=1 SV=1 ARP2_HUMAN 5 15.70%
ID12190 
(Abhay_nsP1)
THO complex subunit 3 OS=Homo sapiens GN=THOC3 PE=1 SV=1 THOC3_HUMAN 4 16.00%
ID12190 
(Abhay_nsP1)
Glutaredoxin-3 OS=Homo sapiens GN=GLRX3 PE=1 SV=2 GLRX3_HUMAN 6 21.20%
ID12190 
(Abhay_nsP1)
Protein flightless-1 homolog OS=Homo sapiens GN=FLII PE=1 SV=2 FLII_HUMAN 7 6.86%
ID12190 
(Abhay_nsP1)
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial OS=Homo 









Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1 SV=5 DDX21_HUMAN 7 10.60%
ID12190 
(Abhay_nsP1)
RNA-binding protein FUS OS=Homo sapiens GN=FUS PE=1 SV=1 FUS_HUMAN 6 9.32%
ID12190 
(Abhay_nsP1)
Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 PE=1 SV=3 PGK1_HUMAN 13 40.00%
ID12190 
(Abhay_nsP1)
40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 RS5_HUMAN 9 37.30%
ID12190 
(Abhay_nsP1)
Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 MYH9_HUMAN 97 49.60%
ID12190 
(Abhay_nsP1)
D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 SERA_HUMAN 11 23.80%
ID12190 
(Abhay_nsP1)
Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 CLH1_HUMAN 26 21.10%
ID12190 
(Abhay_nsP1)
Protein arginine N-methyltransferase 5 OS=Homo sapiens GN=PRMT5 PE=1 SV=4 ANM5_HUMAN 15 32.50%
ID12190 
(Abhay_nsP1)










Gamma-enolase OS=Homo sapiens GN=ENO2 PE=1 SV=3 ENOG_HUMAN 4 25.60%
ID12190 
(Abhay_nsP1)
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 K1C10_HUMAN 7 11.30%
ID12190 
(Abhay_nsP1)





Heat shock protein 75 kDa, mitochondrial OS=Homo sapiens GN=TRAP1 PE=1 SV=3 TRAP1_HUMAN 4 6.68%
ID12190 
(Abhay_nsP1)
ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=6 ADT2_HUMAN 14 46.30%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 RL6_HUMAN 12 35.80%
ID12190 
(Abhay_nsP1)
Coronin-7 OS=Homo sapiens GN=CORO7 PE=1 SV=2 CORO7_HUMAN 4 6.70%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 SV=3 RL5_HUMAN 7 32.00%




















Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 IPO9_HUMAN 4 6.44%
ID12190 
(Abhay_nsP1)
Electron transfer flavoprotein subunit beta OS=Homo sapiens GN=ETFB PE=1 SV=3 ETFB_HUMAN 4 18.80%
ID12190 
(Abhay_nsP1)
Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 NPM_HUMAN 7 28.90%
ID12190 
(Abhay_nsP1)
6-phosphofructokinase, liver type OS=Homo sapiens GN=PFKL PE=1 SV=6 K6PL_HUMAN 6 12.60%
ID12190 
(Abhay_nsP1)
Leucyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=LARS PE=1 SV=2 SYLC_HUMAN 5 5.61%
ID12190 
(Abhay_nsP1)
TAR DNA-binding protein 43 OS=Homo sapiens GN=TARDBP PE=1 SV=1 TADBP_HUMAN 6 23.40%
ID12190 
(Abhay_nsP1)
Serine/arginine-rich splicing factor 9 OS=Homo sapiens GN=SRSF9 PE=1 SV=1 SRSF9_HUMAN 6 25.30%
ID12190 
(Abhay_nsP1)
40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 RS7_HUMAN 9 56.20%
ID12190 
(Abhay_nsP1)
40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 RS6_HUMAN 5 22.10%
ID12190 
(Abhay_nsP1)
Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 ILF2_HUMAN 9 32.80%
ID12190 
(Abhay_nsP1)
Adenosylhomocysteinase OS=Homo sapiens GN=AHCY PE=1 SV=4 SAHH_HUMAN 14 35.20%
ID12190 
(Abhay_nsP1)
Fascin OS=Homo sapiens GN=FSCN1 PE=1 SV=3 FSCN1_HUMAN 9 24.90%
ID12190 
(Abhay_nsP1)
UPF0027 protein C22orf28 OS=Homo sapiens GN=C22orf28 PE=1 SV=1 CV028_HUMAN 11 30.30%
ID12190 
(Abhay_nsP1)










Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform OS=Homo 




60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 RL8_HUMAN 6 35.80%
ID12190 
(Abhay_nsP1)
ATP-dependent RNA helicase DDX1 OS=Homo sapiens GN=DDX1 PE=1 SV=2 DDX1_HUMAN 14 27.00%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 SV=1 RL7_HUMAN 11 35.10%
ID12190 
(Abhay_nsP1)
Ribosome maturation protein SBDS OS=Homo sapiens GN=SBDS PE=1 SV=4 SBDS_HUMAN 5 21.20%
ID12190 
(Abhay_nsP1)
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 EF1A1_HUMAN 13 39.60%
ID12190 
(Abhay_nsP1)










Tubulin beta-2C chain OS=Homo sapiens GN=TUBB2C PE=1 SV=1 TBB2C_HUMAN 4 61.10%
ID12190 
(Abhay_nsP1)
Transportin-1 OS=Homo sapiens GN=TNPO1 PE=1 SV=2 TNPO1_HUMAN 4 5.79%
ID12190 
(Abhay_nsP1)
Transcription intermediary factor 1-beta OS=Homo sapiens GN=TRIM28 PE=1 SV=5 TIF1B_HUMAN 7 13.10%
ID12190 
(Abhay_nsP1)





40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 RS9_HUMAN 12 48.50%
ID12190 
(Abhay_nsP1)
Exosome complex exonuclease RRP44 OS=Homo sapiens GN=DIS3 PE=1 SV=2 RRP44_HUMAN 12 18.60%
ID12190 
(Abhay_nsP1)
40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 RS8_HUMAN 8 44.20%




Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform 




Interleukin enhancer-binding factor 3 OS=Homo sapiens GN=ILF3 PE=1 SV=3 ILF3_HUMAN 14 18.90%
ID12190 
(Abhay_nsP1)
40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 P62701|RS4X_HU
MAN 
40Sribosomal 


















Ornithine aminotransferase, mitochondrial OS=Homo sapiens GN=OAT PE=1 SV=1 OAT_HUMAN 6 14.80%
ID12190 
(Abhay_nsP1)
Splicing factor 3B subunit 3 OS=Homo sapiens GN=SF3B3 PE=1 SV=4 SF3B3_HUMAN 11 11.30%
ID12190 
(Abhay_nsP1)
40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 RS15A_HUMAN 4 31.50%
ID12190 
(Abhay_nsP1)
ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X PE=1 SV=3 DDX3X_HUMAN 13 25.10%
ID12190 
(Abhay_nsP1)





Argininosuccinate synthase OS=Homo sapiens GN=ASS1 PE=1 SV=2 ASSY_HUMAN 6 22.10%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=1 RL9_HUMAN 7 46.40%
ID12190 
(Abhay_nsP1)
Hexokinase-1 OS=Homo sapiens GN=HK1 PE=1 SV=3 HXK1_HUMAN 6 7.09%
ID12190 
(Abhay_nsP1)
Reticulocalbin-1 OS=Homo sapiens GN=RCN1 PE=1 SV=1 RCN1_HUMAN 6 20.80%
ID12190 
(Abhay_nsP1)
Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A PE=1 SV=2 RS27A_HUMAN 6 48.10%
ID12190 
(Abhay_nsP1)











Coatomer subunit delta OS=Homo sapiens GN=ARCN1 PE=1 SV=1 COPD_HUMAN 10 26.80%
ID12190 
(Abhay_nsP1)
6-phosphofructokinase type C OS=Homo sapiens GN=PFKP PE=1 SV=2 K6PP_HUMAN 4 5.48%
ID12190 
(Abhay_nsP1)





ATP-dependent RNA helicase A OS=Homo sapiens GN=DHX9 PE=1 SV=4 DHX9_HUMAN 20 18.30%
ID12190 
(Abhay_nsP1)
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 K22E_HUMAN 5 14.40%
ID12190 
(Abhay_nsP1)
Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2 IMB1_HUMAN 17 27.70%
ID12190 
(Abhay_nsP1)
Threonyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=TARS PE=1 SV=3 SYTC_HUMAN 10 17.70%
ID12190 
(Abhay_nsP1)
Transforming protein RhoA OS=Homo sapiens GN=RHOA PE=1 SV=1 RHOA_HUMAN 7 49.70%
ID12190 
(Abhay_nsP1)





Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 














Elongation factor Tu, mitochondrial OS=Homo sapiens GN=TUFM PE=1 SV=2 EFTU_HUMAN 18 46.90%









Enoyl-CoA hydratase, mitochondrial OS=Homo sapiens GN=ECHS1 PE=1 SV=4 ECHM_HUMAN 10 43.80%
ID12190 
(Abhay_nsP1)
Calumenin OS=Homo sapiens GN=CALU PE=1 SV=2 CALU_HUMAN 7 30.50%
ID12190 
(Abhay_nsP1)





Ribose-phosphate pyrophosphokinase 1 OS=Homo sapiens GN=PRPS1 PE=1 SV=2 PRPS1_HUMAN 6 25.80%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 SV=2 RL10A_HUMAN 6 29.00%
ID12190 
(Abhay_nsP1)
26S protease regulatory subunit 6B OS=Homo sapiens GN=PSMC4 PE=1 SV=2 PRS6B_HUMAN 7 21.50%
ID12190 
(Abhay_nsP1)
Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 PCNA_HUMAN 7 31.40%
ID12190 
(Abhay_nsP1)
26S protease regulatory subunit 6A OS=Homo sapiens GN=PSMC3 PE=1 SV=3 PRS6A_HUMAN 10 32.10%
ID12190 
(Abhay_nsP1)
CTP synthase 1 OS=Homo sapiens GN=CTPS PE=1 SV=2 PYRG1_HUMAN 9 16.20%
ID12190 
(Abhay_nsP1)










Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 PHB_HUMAN 6 25.70%
ID12190 
(Abhay_nsP1)
GFP|GFP GFP|GFP 9 58.80%
ID12190 
(Abhay_nsP1)










F-actin-capping protein subunit beta OS=Homo sapiens GN=CAPZB PE=1 SV=4 CAPZB_HUMAN 7 30.00%
ID12190 
(Abhay_nsP1)





2',5'-phosphodiesterase 12 OS=Homo sapiens GN=PDE12 PE=1 SV=2 PDE12_HUMAN 4 8.05%
ID12190 
(Abhay_nsP1)





GTP-binding protein SAR1a OS=Homo sapiens GN=SAR1A PE=1 SV=1 SAR1A_HUMAN 4 33.30%
ID12190 
(Abhay_nsP1)





Cystathionine beta-synthase OS=Homo sapiens GN=CBS PE=1 SV=2 CBS_HUMAN 4 8.17%
ID12190 
(Abhay_nsP1)













Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens GN=AIFM1 PE=1 SV=1 AIFM1_HUMAN 6 14.20%
ID12190 
(Abhay_nsP1)





26S protease regulatory subunit 10B OS=Homo sapiens GN=PSMC6 PE=1 SV=1 PRS10_HUMAN 5 17.50%
ID12190 
(Abhay_nsP1)
Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 HSPB1_HUMAN 5 33.20%
ID12190 
(Abhay_nsP1)
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Homo sapiens 
GN=ACADM PE=1 SV=1
ACADM_HUMAN 9 27.80%





Four and a half LIM domains protein 1 OS=Homo sapiens GN=FHL1 PE=1 SV=4 FHL1_HUMAN 4 13.30%
ID12190 
(Abhay_nsP1)
Mitotic checkpoint protein BUB3 OS=Homo sapiens GN=BUB3 PE=1 SV=1 BUB3_HUMAN 4 14.30%
ID12190 
(Abhay_nsP1)















Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 IF4A1_HUMAN 16 48.50%
ID12190 
(Abhay_nsP1)





Alanyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=AARS PE=1 SV=2 SYAC_HUMAN 10 14.60%
ID12190 
(Abhay_nsP1)
















Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 PABP1_HUMAN 15 28.10%
ID12190 
(Abhay_nsP1)
Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2 PHB2_HUMAN 5 19.10%
ID12190 
(Abhay_nsP1)










Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2 CALX_HUMAN 5 9.80%
ID12190 
(Abhay_nsP1)
Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 RINI_HUMAN 8 24.10%
ID12190 
(Abhay_nsP1)










T-complex protein 1 subunit beta OS=Homo sapiens GN=CCT2 PE=1 SV=4 TCPB_HUMAN 18 48.80%
ID12190 
(Abhay_nsP1)
Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 TBA1B_HUMAN 18 59.00%
ID12190 
(Abhay_nsP1)
Regulator of chromosome condensation OS=Homo sapiens GN=RCC1 PE=1 SV=1 RCC1_HUMAN 6 23.50%
ID12190 
(Abhay_nsP1)
Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 FAS_HUMAN 41 23.40%
ID12190 
(Abhay_nsP1)





Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 SV=1 MEP50_HUMAN 7 31.00%
ID12190 
(Abhay_nsP1)
Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 PARP1_HUMAN 31 36.40%
ID12190 
(Abhay_nsP1)










GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 RAN_HUMAN 7 31.50%




Poly(rC)-binding protein 2 OS=Homo sapiens GN=PCBP2 PE=1 SV=1 PCBP2_HUMAN 5 24.10%
ID12190 
(Abhay_nsP1)
14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1 1433T_HUMAN 4 32.20%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 RL23A_HUMAN 6 32.70%
ID12190 
(Abhay_nsP1)
Sideroflexin-1 OS=Homo sapiens GN=SFXN1 PE=1 SV=4 SFXN1_HUMAN 6 29.20%
ID12190 
(Abhay_nsP1)
Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=3 EF1B_HUMAN 5 44.00%
ID12190 
(Abhay_nsP1)





Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 TEBP_HUMAN 6 44.40%
ID12190 
(Abhay_nsP1)
Chloride intracellular channel protein 1 OS=Homo sapiens GN=CLIC1 PE=1 SV=4 CLIC1_HUMAN 8 37.80%
ID12190 
(Abhay_nsP1)
Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 HSP7C_HUMAN 23 47.80%
ID12190 
(Abhay_nsP1)





Pyruvate dehydrogenase E1 component subunit beta, mitochondrial OS=Homo 




Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial OS=Homo 




NEDD8-conjugating enzyme Ubc12 OS=Homo sapiens GN=UBE2M PE=1 SV=1 UBC12_HUMAN 5 32.20%
ID12190 
(Abhay_nsP1)
T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 SV=4 TCPD_HUMAN 20 44.50%
ID12190 
(Abhay_nsP1)
60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 CH60_HUMAN 15 36.10%
ID12190 
(Abhay_nsP1)
Glycyl-tRNA synthetase OS=Homo sapiens GN=GARS PE=1 SV=2 SYG_HUMAN 8 13.70%
ID12190 
(Abhay_nsP1)
Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1 TBA1C_HUMAN 4 55.20%
ID12190 
(Abhay_nsP1)















Protein RCC2 OS=Homo sapiens GN=RCC2 PE=1 SV=2 RCC2_HUMAN 6 16.90%
ID12190 
(Abhay_nsP1)
Phenylalanyl-tRNA synthetase beta chain OS=Homo sapiens GN=FARSB PE=1 SV=3 SYFB_HUMAN 8 14.60%
ID12190 
(Abhay_nsP1)
T-complex protein 1 subunit zeta OS=Homo sapiens GN=CCT6A PE=1 SV=3 TCPZ_HUMAN 13 36.20%
ID12190 
(Abhay_nsP1)
Serpin B6 OS=Homo sapiens GN=SERPINB6 PE=1 SV=3 SPB6_HUMAN 4 13.00%
ID12190 
(Abhay_nsP1)
















Regulator of nonsense transcripts 1 OS=Homo sapiens GN=UPF1 PE=1 SV=2 RENT1_HUMAN 6 6.73%
ID12190 
(Abhay_nsP1)





Spermidine synthase OS=Homo sapiens GN=SRM PE=1 SV=1 SPEE_HUMAN 8 25.80%




Eukaryotic initiation factor 4A-III OS=Homo sapiens GN=EIF4A3 PE=1 SV=4 IF4A3_HUMAN 11 33.30%
ID12190 
(Abhay_nsP1)
FACT complex subunit SSRP1 OS=Homo sapiens GN=SSRP1 PE=1 SV=1 SSRP1_HUMAN 7 13.80%
ID12190 
(Abhay_nsP1)
T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=1 SV=4 TCPQ_HUMAN 25 53.10%
ID12190 
(Abhay_nsP1)
Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 MYL6_HUMAN 7 47.70%
ID12190 
(Abhay_nsP1)
Methionyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=MARS PE=1 SV=2 SYMC_HUMAN 4 6.89%
ID12190 
(Abhay_nsP1)





Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 COF1_HUMAN 9 57.20%
ID12190 
(Abhay_nsP1)





Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Homo 














LIM domain and actin-binding protein 1 OS=Homo sapiens GN=LIMA1 PE=1 SV=1 LIMA1_HUMAN 4 6.19%
ID12190 
(Abhay_nsP1)
Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 PROF1_HUMAN 10 70.70%
ID12190 
(Abhay_nsP1)
Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 SV=2 GRP75_HUMAN 5 9.57%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L13a OS=Homo sapiens GN=RPL13A PE=1 SV=2 RL13A_HUMAN 4 19.20%
ID12190 
(Abhay_nsP1)
T-complex protein 1 subunit epsilon OS=Homo sapiens GN=CCT5 PE=1 SV=1 TCPE_HUMAN 22 50.60%
ID12190 
(Abhay_nsP1)





Putative RNA-binding protein Luc7-like 2 OS=Homo sapiens GN=LUC7L2 PE=1 SV=2 LC7L2_HUMAN 9 27.00%
ID12190 
(Abhay_nsP1)










L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 LDHA_HUMAN 7 28.00%
ID12190 
(Abhay_nsP1)
Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=1 SV=2 PCBP1_HUMAN 5 15.70%
ID12190 
(Abhay_nsP1)
Arginyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=RARS PE=1 SV=2 SYRC_HUMAN 4 6.97%
ID12190 
(Abhay_nsP1)





Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 HSP71_HUMAN 15 37.10%
ID12190 
(Abhay_nsP1)





RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=1 SV=3 RUVB2_HUMAN 17 39.10%
ID12190 
(Abhay_nsP1)
Copine-3 OS=Homo sapiens GN=CPNE3 PE=1 SV=1 CPNE3_HUMAN 6 15.30%
ID12190 
(Abhay_nsP1)
Elongation factor 1-delta OS=Homo sapiens GN=EEF1D PE=1 SV=5 EF1D_HUMAN 10 42.00%
ID12190 
(Abhay_nsP1)
Alpha-centractin OS=Homo sapiens GN=ACTR1A PE=1 SV=1 ACTZ_HUMAN 4 17.60%
ID12190 
(Abhay_nsP1)
Eukaryotic translation initiation factor 3 subunit I OS=Homo sapiens GN=EIF3I PE=1 
SV=1
EIF3I_HUMAN 5 15.70%




Tyrosyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=YARS PE=1 SV=4 SYYC_HUMAN 12 22.70%
ID12190 
(Abhay_nsP1)
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 OS=Homo 









Signal recognition particle 68 kDa protein OS=Homo sapiens GN=SRP68 PE=1 SV=2 SRP68_HUMAN 4 9.41%
ID12190 
(Abhay_nsP1)





Pyrroline-5-carboxylate reductase 2 OS=Homo sapiens GN=PYCR2 PE=1 SV=1 P5CR2_HUMAN 6 23.40%
ID12190 
(Abhay_nsP1)















Serine/arginine-rich splicing factor 1 OS=Homo sapiens GN=SRSF1 PE=1 SV=2 SRSF1_HUMAN 9 33.90%
ID12190 
(Abhay_nsP1)





Flap endonuclease 1 OS=Homo sapiens GN=FEN1 PE=1 SV=1 FEN1_HUMAN 4 13.20%
ID12190 
(Abhay_nsP1)
L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 LDHB_HUMAN 4 19.50%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L36a-like OS=Homo sapiens GN=RPL36AL PE=1 SV=3 RL36L_HUMAN 4 25.50%
ID12190 
(Abhay_nsP1)
Coatomer subunit alpha OS=Homo sapiens GN=COPA PE=1 SV=2 COPA_HUMAN 13 13.30%
ID12190 
(Abhay_nsP1)





Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 K1C9_HUMAN 8 17.20%
ID12190 
(Abhay_nsP1)
ATP-dependent RNA helicase DDX39 OS=Homo sapiens GN=DDX39 PE=1 SV=2 DDX39_HUMAN 11 31.60%
ID12190 
(Abhay_nsP1)
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1433Z_HUMAN 7 42.40%
ID12190 
(Abhay_nsP1)





Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 TBB5_HUMAN 23 63.50%
ID12190 
(Abhay_nsP1)
Polypyrimidine tract-binding protein 1 OS=Homo sapiens GN=PTBP1 PE=1 SV=1 PTBP1_HUMAN 6 17.70%
ID12190 
(Abhay_nsP1)
Aspartyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=DARS PE=1 SV=2 SYDC_HUMAN 11 25.50%
ID12190 
(Abhay_nsP1)
Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 ENOA_HUMAN 14 46.50%
ID12190 
(Abhay_nsP1)
Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 SV=3 EF1G_HUMAN 15 34.80%
ID12190 
(Abhay_nsP1)
Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 FLNA_HUMAN 4 2.12%
ID12190 
(Abhay_nsP1)










T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 PE=1 SV=4 TCPG_HUMAN 21 41.50%
ID12190 
(Abhay_nsP1)
Myosin-11 OS=Homo sapiens GN=MYH11 PE=1 SV=3 MYH11_HUMAN 7 13.50%
ID12190 
(Abhay_nsP1)
60S ribosomal protein L18a OS=Homo sapiens GN=RPL18A PE=1 SV=2 RL18A_HUMAN 7 39.80%
ID12190 
(Abhay_nsP1)
Myosin-10 OS=Homo sapiens GN=MYH10 PE=1 SV=3 MYH10_HUMAN 74 45.20%
ID12190 
(Abhay_nsP1)
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 K2C1_HUMAN 16 23.80%






Cell division protein kinase 1 OS=Homo sapiens GN=CDK1 PE=1 SV=2 CDK1_HUMAN 8 30.60%
ID12190 
(Abhay_nsP1)
T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 SV=1 TCPA_HUMAN 24 50.40%
ID12190 
(Abhay_nsP1)















Bifunctional aminoacyl-tRNA synthetase OS=Homo sapiens GN=EPRS PE=1 SV=5 SYEP_HUMAN 10 8.13%
ID12190 
(Abhay_nsP1)
Proliferation-associated protein 2G4 OS=Homo sapiens GN=PA2G4 PE=1 SV=3 PA2G4_HUMAN 16 48.70%
ID12190 
(Abhay_nsP1)











T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=1 SV=2 TCPH_HUMAN 15 35.90%
ID12190 
(Abhay_nsP1)
Serine/arginine-rich splicing factor 3 OS=Homo sapiens GN=SRSF3 PE=1 SV=1 SRSF3_HUMAN 5 29.30%
ID12190 
(Abhay_nsP1)
Lysyl-tRNA synthetase OS=Homo sapiens GN=KARS PE=1 SV=3 SYK_HUMAN 11 23.80%
ID12190 
(Abhay_nsP1)
Cytosolic non-specific dipeptidase OS=Homo sapiens GN=CNDP2 PE=1 SV=2 CNDP2_HUMAN 4 14.50%
ID12190 
(Abhay_nsP1)
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 1433E_HUMAN 12 42.40%
ID12190 
(Abhay_nsP1)
Pre-mRNA-processing factor 19 OS=Homo sapiens GN=PRPF19 PE=1 SV=1 PRP19_HUMAN 6 13.10%
ID12190 
(Abhay_nsP1)
ADP-ribosylation factor 5 OS=Homo sapiens GN=ARF5 PE=1 SV=2 ARF5_HUMAN 6 38.90%
ID12190 
(Abhay_nsP1)
Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 ACTG_HUMAN 18 61.90%
ID12190 
(Abhay_nsP1)




















Beta-enolase OS=Homo sapiens GN=ENO3 PE=1 SV=4 ENOB_HUMAN 4 19.60%
ID12190 
(Abhay_nsP1)










F-actin-capping protein subunit alpha-1 OS=Homo sapiens GN=CAPZA1 PE=1 SV=3 CAZA1_HUMAN 5 27.60%
ID12190 
(Abhay_nsP1)
Creatine kinase U-type, mitochondrial OS=Homo sapiens GN=CKMT1A PE=1 SV=1 KCRU_HUMAN 7 22.10%
ID12190 
(Abhay_nsP1)
Coronin-1C OS=Homo sapiens GN=CORO1C PE=1 SV=1 COR1C_HUMAN 15 34.40%
ID12190 
(Abhay_nsP1)





Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM2 PE=1 SV=4 KPYM_HUMAN 30 71.60%
ID12190 
(Abhay_nsP1)





Stomatin-like protein 2 OS=Homo sapiens GN=STOML2 PE=1 SV=1 STML2_HUMAN 6 26.40%

























40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 RS2_HUMAN 9 35.20%
ID12190 
(Abhay_nsP1)





14-3-3 protein eta OS=Homo sapiens GN=YWHAH PE=1 SV=4 1433F_HUMAN 5 37.00%
ID12190 
(Abhay_nsP1)










Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 H4_HUMAN 6 52.40%
ID12190 
(Abhay_nsP1)
Drebrin OS=Homo sapiens GN=DBN1 PE=1 SV=4 DREB_HUMAN 11 26.20%
ID12190 
(Abhay_nsP1)
Splicing factor, proline- and glutamine-rich OS=Homo sapiens GN=SFPQ PE=1 SV=2 SFPQ_HUMAN 11 21.90%
ID12190 
(Abhay_nsP1)
Asparaginyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=NARS PE=1 SV=1 SYNC_HUMAN 5 10.90%
ID12190 
(Abhay_nsP1)











6-phosphogluconolactonase OS=Homo sapiens GN=PGLS PE=1 SV=2 6PGL_HUMAN 7 42.60%
ID12190 
(Abhay_nsP1)











Basigin OS=Homo sapiens GN=BSG PE=1 SV=2 BASI_HUMAN 5 17.90%
ID12190 
(Abhay_nsP1)
Eukaryotic translation initiation factor 6 OS=Homo sapiens GN=EIF6 PE=1 SV=1 IF6_HUMAN 4 24.10%
ID12190 
(Abhay_nsP1)
RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE=1 SV=1 RUVB1_HUMAN 11 32.70%
ID12191 
(Abhay_nsP2)

























Myosin-14 OS=Homo sapiens GN=MYH14 PE=1 SV=1 MYH14_HUMAN 26 21.00%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L3 OS=Homo sapiens GN=RPL3 PE=1 SV=2 RL3_HUMAN 14 34.50%
ID12191 
(Abhay_nsP2)
Leucine-rich repeat-containing protein 40 OS=Homo sapiens GN=LRRC40 PE=1 
SV=1
LRC40_HUMAN 8 15.90%






Protein FAM98B OS=Homo sapiens GN=FAM98B PE=1 SV=1 FA98B_HUMAN 7 29.10%
ID12191 
(Abhay_nsP2)





Myosin regulatory light chain 12A OS=Homo sapiens GN=MYL12A PE=1 SV=2 ML12A_HUMAN 8 62.60%
ID12191 
(Abhay_nsP2)
Kinectin OS=Homo sapiens GN=KTN1 PE=1 SV=1 KTN1_HUMAN 6 6.34%
ID12191 
(Abhay_nsP2)

















Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 EF2_HUMAN 25 38.70%
ID12191 
(Abhay_nsP2)
Adenylosuccinate lyase OS=Homo sapiens GN=ADSL PE=1 SV=2 PUR8_HUMAN 4 14.50%
ID12191 
(Abhay_nsP2)





Adenine phosphoribosyltransferase OS=Homo sapiens GN=APRT PE=1 SV=2 APT_HUMAN 5 35.60%
ID12191 
(Abhay_nsP2)
Serine/arginine-rich splicing factor 7 OS=Homo sapiens GN=SRSF7 PE=1 SV=1 SRSF7_HUMAN 4 21.40%
ID12191 
(Abhay_nsP2)
Myosin-Ic OS=Homo sapiens GN=MYO1C PE=1 SV=3 MYO1C_HUMAN 4 5.17%
ID12191 
(Abhay_nsP2)
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Homo 




40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 RS3_HUMAN 19 74.50%
ID12191 
(Abhay_nsP2)
S-formylglutathione hydrolase OS=Homo sapiens GN=ESD PE=1 SV=2 ESTD_HUMAN 4 23.00%
ID12191 
(Abhay_nsP2)
Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2 PHB2_HUMAN 5 20.10%
ID12191 
(Abhay_nsP2)















5'-3' exoribonuclease 2 OS=Homo sapiens GN=XRN2 PE=1 SV=1 XRN2_HUMAN 6 9.79%
ID12191 
(Abhay_nsP2)
FACT complex subunit SPT16 OS=Homo sapiens GN=SUPT16H PE=1 SV=1 SP16H_HUMAN 25 31.20%
ID12191 
(Abhay_nsP2)
E3 ubiquitin-protein ligase CHIP OS=Homo sapiens GN=STUB1 PE=1 SV=2 CHIP_HUMAN 4 16.20%
ID12191 
(Abhay_nsP2)










Creatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=1 KCRB_HUMAN 4 12.30%
ID12191 
(Abhay_nsP2)
DnaJ homolog subfamily A member 2 OS=Homo sapiens GN=DNAJA2 PE=1 SV=1 DNJA2_HUMAN 5 17.20%
ID12191 
(Abhay_nsP2)





Nucleolysin TIAR OS=Homo sapiens GN=TIAL1 PE=1 SV=1 TIAR_HUMAN 4 17.10%










Splicing factor U2AF 65 kDa subunit OS=Homo sapiens GN=U2AF2 PE=1 SV=4 U2AF2_HUMAN 4 11.80%
ID12191 
(Abhay_nsP2)





Splicing factor U2AF 35 kDa subunit OS=Homo sapiens GN=U2AF1 PE=1 SV=3 U2AF1_HUMAN 5 25.00%
ID12191 
(Abhay_nsP2)
Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 CALM_HUMAN 4 28.90%
ID12191 
(Abhay_nsP2)
Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM2 PE=1 SV=4 KPYM_HUMAN 31 68.00%
ID12191 
(Abhay_nsP2)
Actin-related protein 3 OS=Homo sapiens GN=ACTR3 PE=1 SV=3 ARP3_HUMAN 6 26.10%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 RL4_HUMAN 21 35.60%
ID12191 
(Abhay_nsP2)
Glutaredoxin-3 OS=Homo sapiens GN=GLRX3 PE=1 SV=2 GLRX3_HUMAN 4 14.30%
ID12191 
(Abhay_nsP2)
Nucleosome assembly protein 1-like 1 OS=Homo sapiens GN=NAP1L1 PE=1 SV=1 NP1L1_HUMAN 4 17.40%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L13a OS=Homo sapiens GN=RPL13A PE=1 SV=2 RL13A_HUMAN 6 30.00%
ID12191 
(Abhay_nsP2)
Protein flightless-1 homolog OS=Homo sapiens GN=FLII PE=1 SV=2 FLII_HUMAN 5 5.20%
ID12191 
(Abhay_nsP2)
ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=1 SV=4 ADT3_HUMAN 6 45.00%
ID12191 
(Abhay_nsP2)
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Homo 









14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 1433G_HUMAN 5 32.40%
ID12191 
(Abhay_nsP2)
Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1 SV=5 DDX21_HUMAN 7 11.90%
ID12191 
(Abhay_nsP2)





RNA-binding protein FUS OS=Homo sapiens GN=FUS PE=1 SV=1 FUS_HUMAN 8 20.50%
ID12191 
(Abhay_nsP2)
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 1433E_HUMAN 10 43.10%
ID12191 
(Abhay_nsP2)
Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 PE=1 SV=3 PGK1_HUMAN 13 47.20%
ID12191 
(Abhay_nsP2)
Glutaminyl-tRNA synthetase OS=Homo sapiens GN=QARS PE=1 SV=1 SYQ_HUMAN 9 16.30%
ID12191 
(Abhay_nsP2)





Lamin-B receptor OS=Homo sapiens GN=LBR PE=1 SV=2 LBR_HUMAN 4 9.11%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L18a OS=Homo sapiens GN=RPL18A PE=1 SV=2 RL18A_HUMAN 7 42.00%
ID12191 
(Abhay_nsP2)
Bifunctional aminoacyl-tRNA synthetase OS=Homo sapiens GN=EPRS PE=1 SV=5 SYEP_HUMAN 34 29.20%
ID12191 
(Abhay_nsP2)
Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 MYH9_HUMAN 108 52.20%
ID12191 
(Abhay_nsP2)
D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 SERA_HUMAN 11 27.80%
ID12191 
(Abhay_nsP2)













Coatomer subunit gamma OS=Homo sapiens GN=COPG PE=1 SV=1 COPG_HUMAN 9 14.40%
ID12191 
(Abhay_nsP2)
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform OS=Homo 




Eukaryotic translation initiation factor 4 gamma 2 OS=Homo sapiens GN=EIF4G2 
PE=1 SV=1
IF4G2_HUMAN 4 4.30%
	   297	  
ID12191 
(Abhay_nsP2)















Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 CLH1_HUMAN 35 25.60%
ID12191 
(Abhay_nsP2)















Cell division cycle 5-like protein OS=Homo sapiens GN=CDC5L PE=1 SV=2 CDC5L_HUMAN 7 11.20%
ID12191 
(Abhay_nsP2)
ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=6 ADT2_HUMAN 11 32.90%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 RL6_HUMAN 15 42.40%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 SV=3 RL5_HUMAN 12 44.10%
ID12191 
(Abhay_nsP2)





Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 NPM_HUMAN 8 29.30%
ID12191 
(Abhay_nsP2)
6-phosphofructokinase, liver type OS=Homo sapiens GN=PFKL PE=1 SV=6 K6PL_HUMAN 9 21.50%
ID12191 
(Abhay_nsP2)










Fermitin family homolog 2 OS=Homo sapiens GN=FERMT2 PE=1 SV=1 FERM2_HUMAN 6 11.20%
ID12191 
(Abhay_nsP2)
Leucyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=LARS PE=1 SV=2 SYLC_HUMAN 21 24.60%
ID12191 
(Abhay_nsP2)
TAR DNA-binding protein 43 OS=Homo sapiens GN=TARDBP PE=1 SV=1 TADBP_HUMAN 8 30.00%
ID12191 
(Abhay_nsP2)
F-actin-capping protein subunit alpha-1 OS=Homo sapiens GN=CAPZA1 PE=1 SV=3 CAZA1_HUMAN 4 24.10%
ID12191 
(Abhay_nsP2)
Serine/arginine-rich splicing factor 9 OS=Homo sapiens GN=SRSF9 PE=1 SV=1 SRSF9_HUMAN 4 21.70%
ID12191 
(Abhay_nsP2)
40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 RS7_HUMAN 10 60.30%
ID12191 
(Abhay_nsP2)





40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 RS6_HUMAN 5 25.70%
ID12191 
(Abhay_nsP2)
Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 ILF2_HUMAN 10 42.60%
ID12191 
(Abhay_nsP2)
Biliverdin reductase A OS=Homo sapiens GN=BLVRA PE=1 SV=2 BIEA_HUMAN 6 24.30%
ID12191 
(Abhay_nsP2)
Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB PE=1 SV=3 GANAB_HUMAN 8 9.53%
ID12191 
(Abhay_nsP2)
ATP-dependent RNA helicase DDX1 OS=Homo sapiens GN=DDX1 PE=1 SV=2 DDX1_HUMAN 25 45.50%
ID12191 
(Abhay_nsP2)
Adenosylhomocysteinase OS=Homo sapiens GN=AHCY PE=1 SV=4 SAHH_HUMAN 19 44.90%
ID12191 
(Abhay_nsP2)
Protein disulfide-isomerase A6 OS=Homo sapiens GN=PDIA6 PE=1 SV=1 PDIA6_HUMAN 7 27.30%
ID12191 
(Abhay_nsP2)
Splicing factor 3B subunit 1 OS=Homo sapiens GN=SF3B1 PE=1 SV=3 SF3B1_HUMAN 11 13.00%
ID12191 
(Abhay_nsP2)
UPF0027 protein C22orf28 OS=Homo sapiens GN=C22orf28 PE=1 SV=1 CV028_HUMAN 13 32.90%
ID12191 
(Abhay_nsP2)
Heterogeneous nuclear ribonucleoprotein R OS=Homo sapiens GN=HNRNPR PE=1 
SV=1
HNRPR_HUMAN 16 35.90%












Exosome complex exonuclease RRP4 OS=Homo sapiens GN=EXOSC2 PE=1 SV=2 EXOS2_HUMAN 4 20.80%
ID12191 
(Abhay_nsP2)





60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 RL8_HUMAN 7 38.90%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 SV=1 RL7_HUMAN 14 42.70%
ID12191 
(Abhay_nsP2)
Ribosome maturation protein SBDS OS=Homo sapiens GN=SBDS PE=1 SV=4 SBDS_HUMAN 4 18.40%
ID12191 
(Abhay_nsP2)
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 EF1A1_HUMAN 16 47.20%
ID12191 
(Abhay_nsP2)
Fascin OS=Homo sapiens GN=FSCN1 PE=1 SV=3 FSCN1_HUMAN 8 19.70%
ID12191 
(Abhay_nsP2)















Transcription intermediary factor 1-beta OS=Homo sapiens GN=TRIM28 PE=1 SV=5 TIF1B_HUMAN 9 14.60%
ID12191 
(Abhay_nsP2)











T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=1 SV=4 TCPQ_HUMAN 27 54.60%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 RL23A_HUMAN 8 34.60%
ID12191 
(Abhay_nsP2)
40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 RS9_HUMAN 10 34.00%
ID12191 
(Abhay_nsP2)
Exosome complex exonuclease RRP44 OS=Homo sapiens GN=DIS3 PE=1 SV=2 RRP44_HUMAN 16 24.20%
ID12191 
(Abhay_nsP2)
40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 RS8_HUMAN 11 53.40%
ID12191 
(Abhay_nsP2)
Serrate RNA effector molecule homolog OS=Homo sapiens GN=SRRT PE=1 SV=1 SRRT_HUMAN 5 5.48%
ID12191 
(Abhay_nsP2)
Interleukin enhancer-binding factor 3 OS=Homo sapiens GN=ILF3 PE=1 SV=3 ILF3_HUMAN 25 31.10%
ID12191 
(Abhay_nsP2)
Galactokinase OS=Homo sapiens GN=GALK1 PE=1 SV=1 GALK1_HUMAN 7 25.00%
ID12191 
(Abhay_nsP2)
40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 P62701|RS4X_HU
MAN 
40Sribosomal 


















Ornithine aminotransferase, mitochondrial OS=Homo sapiens GN=OAT PE=1 SV=1 OAT_HUMAN 7 20.70%
ID12191 
(Abhay_nsP2)
Splicing factor 3B subunit 3 OS=Homo sapiens GN=SF3B3 PE=1 SV=4 SF3B3_HUMAN 16 16.60%
ID12191 
(Abhay_nsP2)
Aspartyl-tRNA synthetase, mitochondrial OS=Homo sapiens GN=DARS2 PE=1 SV=1 SYDM_HUMAN 8 14.90%




Splicing factor 3B subunit 2 OS=Homo sapiens GN=SF3B2 PE=1 SV=2 SF3B2_HUMAN 8 10.80%
ID12191 
(Abhay_nsP2)
40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 RS15A_HUMAN 4 30.80%
ID12191 
(Abhay_nsP2)
ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X PE=1 SV=3 DDX3X_HUMAN 13 28.90%
ID12191 
(Abhay_nsP2)
WD repeat-containing protein 1 OS=Homo sapiens GN=WDR1 PE=1 SV=4 WDR1_HUMAN 7 14.90%
ID12191 
(Abhay_nsP2)





ATP-citrate synthase OS=Homo sapiens GN=ACLY PE=1 SV=3 ACLY_HUMAN 10 10.40%
ID12191 
(Abhay_nsP2)
Argininosuccinate synthase OS=Homo sapiens GN=ASS1 PE=1 SV=2 ASSY_HUMAN 4 8.50%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=1 RL9_HUMAN 8 61.50%
ID12191 
(Abhay_nsP2)
Protein SEC13 homolog OS=Homo sapiens GN=SEC13 PE=1 SV=3 SEC13_HUMAN 4 16.80%
ID12191 
(Abhay_nsP2)
Reticulocalbin-1 OS=Homo sapiens GN=RCN1 PE=1 SV=1 RCN1_HUMAN 5 19.60%
ID12191 
(Abhay_nsP2)
Proteasome subunit alpha type-5 OS=Homo sapiens GN=PSMA5 PE=1 SV=3 PSA5_HUMAN 4 22.40%
ID12191 
(Abhay_nsP2)
Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A PE=1 SV=2 RS27A_HUMAN 7 48.70%
ID12191 
(Abhay_nsP2)











Coatomer subunit delta OS=Homo sapiens GN=ARCN1 PE=1 SV=1 COPD_HUMAN 12 36.40%
ID12191 
(Abhay_nsP2)
Cytosol aminopeptidase OS=Homo sapiens GN=LAP3 PE=1 SV=3 AMPL_HUMAN 11 29.30%
ID12191 
(Abhay_nsP2)
6-phosphofructokinase type C OS=Homo sapiens GN=PFKP PE=1 SV=2 K6PP_HUMAN 11 15.30%
ID12191 
(Abhay_nsP2)
Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 UBA1_HUMAN 5 6.71%
ID12191 
(Abhay_nsP2)
Long-chain-fatty-acid--CoA ligase 3 OS=Homo sapiens GN=ACSL3 PE=1 SV=3 ACSL3_HUMAN 5 10.10%
ID12191 
(Abhay_nsP2)





Ubiquitin thioesterase OTUB1 OS=Homo sapiens GN=OTUB1 PE=1 SV=2 OTUB1_HUMAN 4 21.00%
ID12191 
(Abhay_nsP2)
Threonyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=TARS PE=1 SV=3 SYTC_HUMAN 16 28.40%
ID12191 
(Abhay_nsP2)





BolA-like protein 2 OS=Homo sapiens GN=BOLA2 PE=1 SV=1 BOLA2_HUMAN 5 70.90%
ID12191 
(Abhay_nsP2)
Transforming protein RhoA OS=Homo sapiens GN=RHOA PE=1 SV=1 RHOA_HUMAN 8 56.00%
ID12191 
(Abhay_nsP2)






























Elongation factor Tu, mitochondrial OS=Homo sapiens GN=TUFM PE=1 SV=2 EFTU_HUMAN 18 44.00%
ID12191 
(Abhay_nsP2)
Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 
SV=6
HNRPU_HUMAN 27 39.20%






Enoyl-CoA hydratase, mitochondrial OS=Homo sapiens GN=ECHS1 PE=1 SV=4 ECHM_HUMAN 9 40.30%
ID12191 
(Abhay_nsP2)
Nicotinamide phosphoribosyltransferase OS=Homo sapiens GN=NAMPT PE=1 SV=1 NAMPT_HUMAN 8 24.80%
ID12191 
(Abhay_nsP2)










ATP-dependent DNA helicase Q1 OS=Homo sapiens GN=RECQL PE=1 SV=3 RECQ1_HUMAN 8 14.20%
ID12191 
(Abhay_nsP2)





Ribose-phosphate pyrophosphokinase 1 OS=Homo sapiens GN=PRPS1 PE=1 SV=2 PRPS1_HUMAN 6 31.10%
ID12191 
(Abhay_nsP2)
DnaJ homolog subfamily B member 11 OS=Homo sapiens GN=DNAJB11 PE=1 SV=1 DJB11_HUMAN 5 20.90%
ID12191 
(Abhay_nsP2)
Uncharacterized protein C7orf50 OS=Homo sapiens GN=C7orf50 PE=1 SV=1 CG050_HUMAN 4 30.40%
ID12191 
(Abhay_nsP2)
60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 SV=2 RL10A_HUMAN 11 44.70%
ID12191 
(Abhay_nsP2)
26S protease regulatory subunit 6B OS=Homo sapiens GN=PSMC4 PE=1 SV=2 PRS6B_HUMAN 7 19.60%
ID12191 
(Abhay_nsP2)
Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 PCNA_HUMAN 7 35.20%
ID12191 
(Abhay_nsP2)
26S protease regulatory subunit 6A OS=Homo sapiens GN=PSMC3 PE=1 SV=3 PRS6A_HUMAN 7 17.80%
ID12191 
(Abhay_nsP2)
CTP synthase 1 OS=Homo sapiens GN=CTPS PE=1 SV=2 PYRG1_HUMAN 11 25.70%
ID12191 
(Abhay_nsP2)










Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 ENOA_HUMAN 16 53.00%
ID12191 
(Abhay_nsP2)





GFP|GFP GFP|GFP 8 54.20%
ID12191 
(Abhay_nsP2)
Histone-binding protein RBBP4 OS=Homo sapiens GN=RBBP4 PE=1 SV=3 RBBP4_HUMAN 4 22.60%
ID12191 
(Abhay_nsP2)





Replication protein A 14 kDa subunit OS=Homo sapiens GN=RPA3 PE=1 SV=1 RFA3_HUMAN 4 51.20%
ID12191 
(Abhay_nsP2)
Isoleucyl-tRNA synthetase, mitochondrial OS=Homo sapiens GN=IARS2 PE=1 SV=2 SYIM_HUMAN 11 12.70%
ID12191 
(Abhay_nsP2)





Catechol O-methyltransferase OS=Homo sapiens GN=COMT PE=1 SV=2 COMT_HUMAN 4 26.60%
ID12191 
(Abhay_nsP2)















Valyl-tRNA synthetase OS=Homo sapiens GN=VARS PE=1 SV=4 SYVC_HUMAN 18 17.60%
ID12191 
(Abhay_nsP2)










Signal recognition particle 54 kDa protein OS=Homo sapiens GN=SRP54 PE=1 SV=1 SRP54_HUMAN 5 12.10%
ID12191 
(Abhay_nsP2)
GTP-binding protein SAR1a OS=Homo sapiens GN=SAR1A PE=1 SV=1 SAR1A_HUMAN 4 21.70%












T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 SV=1 TCPA_HUMAN 27 59.90%
ID12191 
(Abhay_nsP2)








Carbonyl reductase [NADPH] 1 OS=Homo sapiens GN=CBR1 PE=1 SV=3 CBR1_HUMAN 4 27.40%
ID12191 
(Abhay_nsP2)





26S protease regulatory subunit 10B OS=Homo sapiens GN=PSMC6 PE=1 SV=1 PRS10_HUMAN 11 33.90%
ID12191 
(Abhay_nsP2)





Four and a half LIM domains protein 1 OS=Homo sapiens GN=FHL1 PE=1 SV=4 FHL1_HUMAN 6 21.40%
ID12191 
(Abhay_nsP2)
ADP-ribosylation factor-like protein 2 OS=Homo sapiens GN=ARL2 PE=1 SV=4 ARL2_HUMAN 6 43.50%
ID12191 
(Abhay_nsP2)
Mitotic checkpoint protein BUB3 OS=Homo sapiens GN=BUB3 PE=1 SV=1 BUB3_HUMAN 7 34.50%
ID12191 
(Abhay_nsP2)
Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 FLNA_HUMAN 40 24.00%
ID12191 
(Abhay_nsP2)
Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 IF4A1_HUMAN 15 43.10%
ID12191 
(Abhay_nsP2)
Alanyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=AARS PE=1 SV=2 SYAC_HUMAN 11 15.10%
ID12191 
(Abhay_nsP2)





Small nuclear ribonucleoprotein Sm D2 OS=Homo sapiens GN=SNRPD2 PE=1 SV=1 SMD2_HUMAN 4 33.10%
ID12191 
(Abhay_nsP2)
















Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 PABP1_HUMAN 11 21.50%
ID12191 
(Abhay_nsP2)
Glucose-6-phosphate 1-dehydrogenase OS=Homo sapiens GN=G6PD PE=1 SV=4 G6PD_HUMAN 10 21.90%
ID12191 
(Abhay_nsP2)
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 OS=Homo 














Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 OS=Homo 









Histone-binding protein RBBP7 OS=Homo sapiens GN=RBBP7 PE=1 SV=1 RBBP7_HUMAN 7 19.50%
ID12191 
(Abhay_nsP2)





Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 RINI_HUMAN 11 30.20%
ID12191 
(Abhay_nsP2)










60S ribosomal protein L27a OS=Homo sapiens GN=RPL27A PE=1 SV=2 RL27A_HUMAN 7 37.80%
ID12191 
(Abhay_nsP2)
T-complex protein 1 subunit beta OS=Homo sapiens GN=CCT2 PE=1 SV=4 TCPB_HUMAN 24 55.50%




Myosin light chain 6B OS=Homo sapiens GN=MYL6B PE=1 SV=1 MYL6B_HUMAN 4 39.40%
ID12191 
(Abhay_nsP2)
Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 FAS_HUMAN 57 34.80%
ID12191 
(Abhay_nsP2)
Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 SV=1 MEP50_HUMAN 5 27.80%
ID12191 
(Abhay_nsP2)
Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 PARP1_HUMAN 38 45.00%
ID12191 
(Abhay_nsP2)















GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 RAN_HUMAN 10 51.40%
ID12191 
(Abhay_nsP2)





Poly(rC)-binding protein 2 OS=Homo sapiens GN=PCBP2 PE=1 SV=1 PCBP2_HUMAN 5 37.30%
ID12191 
(Abhay_nsP2)
14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1 1433T_HUMAN 6 41.20%
ID12191 
(Abhay_nsP2)
Sideroflexin-1 OS=Homo sapiens GN=SFXN1 PE=1 SV=4 SFXN1_HUMAN 8 34.50%
ID12191 
(Abhay_nsP2)
Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=3 EF1B_HUMAN 5 35.10%
ID12191 
(Abhay_nsP2)
Pre-mRNA-processing-splicing factor 8 OS=Homo sapiens GN=PRPF8 PE=1 SV=2 PRP8_HUMAN 8 4.24%
ID12191 
(Abhay_nsP2)
Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 TEBP_HUMAN 7 48.10%
ID12191 
(Abhay_nsP2)
Chloride intracellular channel protein 1 OS=Homo sapiens GN=CLIC1 PE=1 SV=4 CLIC1_HUMAN 5 31.50%
ID12191 
(Abhay_nsP2)
Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 HSP7C_HUMAN 18 37.80%
ID12191 
(Abhay_nsP2)










Pyruvate dehydrogenase E1 component subunit beta, mitochondrial OS=Homo 









L-xylulose reductase OS=Homo sapiens GN=DCXR PE=1 SV=2 DCXR_HUMAN 4 25.00%
ID12191 
(Abhay_nsP2)
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial 




Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial OS=Homo 





















NEDD8-conjugating enzyme Ubc12 OS=Homo sapiens GN=UBE2M PE=1 SV=1 UBC12_HUMAN 6 35.50%
ID12191 
(Abhay_nsP2)
T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 SV=4 TCPD_HUMAN 22 52.90%














Tubulin beta-2B chain OS=Homo sapiens GN=TUBB2B PE=1 SV=1 TBB2B_HUMAN 6 56.20%
ID12191 
(Abhay_nsP2)
60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 CH60_HUMAN 21 47.80%
ID12191 
(Abhay_nsP2)
Glycyl-tRNA synthetase OS=Homo sapiens GN=GARS PE=1 SV=2 SYG_HUMAN 4 7.31%
ID12191 
(Abhay_nsP2)
Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1 TBA1C_HUMAN 4 67.90%
ID12191 
(Abhay_nsP2)















Protein RCC2 OS=Homo sapiens GN=RCC2 PE=1 SV=2 RCC2_HUMAN 12 28.20%
ID12191 
(Abhay_nsP2)
T-complex protein 1 subunit zeta OS=Homo sapiens GN=CCT6A PE=1 SV=3 TCPZ_HUMAN 19 47.60%
ID12191 
(Abhay_nsP2)
Serpin B6 OS=Homo sapiens GN=SERPINB6 PE=1 SV=3 SPB6_HUMAN 5 14.40%
ID12191 
(Abhay_nsP2)


























Regulator of nonsense transcripts 1 OS=Homo sapiens GN=UPF1 PE=1 SV=2 RENT1_HUMAN 10 13.50%
ID12191 
(Abhay_nsP2)
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 














Spermidine synthase OS=Homo sapiens GN=SRM PE=1 SV=1 SPEE_HUMAN 4 14.60%
ID12191 
(Abhay_nsP2)
Eukaryotic initiation factor 4A-III OS=Homo sapiens GN=EIF4A3 PE=1 SV=4 IF4A3_HUMAN 13 42.10%
ID12191 
(Abhay_nsP2)
FACT complex subunit SSRP1 OS=Homo sapiens GN=SSRP1 PE=1 SV=1 SSRP1_HUMAN 15 29.80%
ID12191 
(Abhay_nsP2)
Exosome complex exonuclease RRP45 OS=Homo sapiens GN=EXOSC9 PE=1 SV=3 EXOS9_HUMAN 5 12.30%
ID12191 
(Abhay_nsP2)
Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 MYL6_HUMAN 8 55.60%
ID12191 
(Abhay_nsP2)
Methionyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=MARS PE=1 SV=2 SYMC_HUMAN 13 21.60%
ID12191 
(Abhay_nsP2)
Isocitrate dehydrogenase [NADP], mitochondrial OS=Homo sapiens GN=IDH2 PE=1 
SV=2
IDHP_HUMAN 5 13.70%














Serine/arginine-rich splicing factor 3 OS=Homo sapiens GN=SRSF3 PE=1 SV=1 SRSF3_HUMAN 8 40.20%
ID12191 
(Abhay_nsP2)
Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 COF1_HUMAN 10 54.80%
ID12191 
(Abhay_nsP2)





Polyadenylate-binding protein 4 OS=Homo sapiens GN=PABPC4 PE=1 SV=1 PABP4_HUMAN 4 16.90%
ID12191 
(Abhay_nsP2)










Tubulin beta-2C chain OS=Homo sapiens GN=TUBB2C PE=1 SV=1 TBB2C_HUMAN 5 67.40%
ID12191 
(Abhay_nsP2)





RNA-binding protein EWS OS=Homo sapiens GN=EWSR1 PE=1 SV=1 EWS_HUMAN 4 6.25%
ID12191 
(Abhay_nsP2)
Amidophosphoribosyltransferase OS=Homo sapiens GN=PPAT PE=1 SV=1 PUR1_HUMAN 6 15.70%
ID12191 
(Abhay_nsP2)
AP-1 complex subunit mu-1 OS=Homo sapiens GN=AP1M1 PE=1 SV=3 AP1M1_HUMAN 13 36.90%
ID12191 
(Abhay_nsP2)
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 K2C1_HUMAN 7 11.30%
ID12191 
(Abhay_nsP2)
Macrophage migration inhibitory factor OS=Homo sapiens GN=MIF PE=1 SV=4 MIF_HUMAN 4 83.50%
ID12191 
(Abhay_nsP2)
Eukaryotic translation initiation factor 5A-1 OS=Homo sapiens GN=EIF5A PE=1 SV=2 IF5A1_HUMAN 4 35.70%
ID12191 
(Abhay_nsP2)
T-complex protein 1 subunit epsilon OS=Homo sapiens GN=CCT5 PE=1 SV=1 TCPE_HUMAN 23 55.60%
ID12191 
(Abhay_nsP2)





Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 PPIA_HUMAN 10 66.70%
ID12191 
(Abhay_nsP2)





Putative RNA-binding protein Luc7-like 2 OS=Homo sapiens GN=LUC7L2 PE=1 SV=2 LC7L2_HUMAN 8 23.00%
ID12191 
(Abhay_nsP2)










14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 1433B_HUMAN 5 35.80%
ID12191 
(Abhay_nsP2)
mRNA turnover protein 4 homolog OS=Homo sapiens GN=MRTO4 PE=1 SV=2 MRT4_HUMAN 5 26.40%
ID12191 
(Abhay_nsP2)
L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 LDHA_HUMAN 11 46.10%
ID12191 
(Abhay_nsP2)
Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=1 SV=2 PCBP1_HUMAN 7 30.60%
ID12191 
(Abhay_nsP2)
40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 RS2_HUMAN 15 51.50%
ID12191 
(Abhay_nsP2)
Arginyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=RARS PE=1 SV=2 SYRC_HUMAN 9 17.30%






















Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 HSP71_HUMAN 22 51.30%
ID12191 
(Abhay_nsP2)
Coatomer subunit beta' OS=Homo sapiens GN=COPB2 PE=1 SV=2 COPB2_HUMAN 17 23.10%
ID12191 
(Abhay_nsP2)
RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=1 SV=3 RUVB2_HUMAN 17 42.30%
ID12191 
(Abhay_nsP2)
Copine-3 OS=Homo sapiens GN=CPNE3 PE=1 SV=1 CPNE3_HUMAN 8 23.50%
ID12191 
(Abhay_nsP2)
Elongation factor 1-delta OS=Homo sapiens GN=EEF1D PE=1 SV=5 EF1D_HUMAN 12 52.00%
ID12191 
(Abhay_nsP2)
Alpha-centractin OS=Homo sapiens GN=ACTR1A PE=1 SV=1 ACTZ_HUMAN 4 18.10%
ID12191 
(Abhay_nsP2)





Tyrosyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=YARS PE=1 SV=4 SYYC_HUMAN 21 45.10%
ID12191 
(Abhay_nsP2)
Calumenin OS=Homo sapiens GN=CALU PE=1 SV=2 CALU_HUMAN 8 30.20%
ID12191 
(Abhay_nsP2)
Hexokinase-1 OS=Homo sapiens GN=HK1 PE=1 SV=3 HXK1_HUMAN 12 16.10%
ID12191 
(Abhay_nsP2)
Glycogen phosphorylase, liver form OS=Homo sapiens GN=PYGL PE=1 SV=4 PYGL_HUMAN 18 22.70%
ID12191 
(Abhay_nsP2)
Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 TBA1B_HUMAN 20 69.20%
ID12191 
(Abhay_nsP2)
ATP-dependent RNA helicase DDX39 OS=Homo sapiens GN=DDX39 PE=1 SV=2 DDX39_HUMAN 12 38.20%
ID12191 
(Abhay_nsP2)





Signal recognition particle 68 kDa protein OS=Homo sapiens GN=SRP68 PE=1 SV=2 SRP68_HUMAN 7 14.80%
ID12191 
(Abhay_nsP2)





Pyrroline-5-carboxylate reductase 2 OS=Homo sapiens GN=PYCR2 PE=1 SV=1 P5CR2_HUMAN 7 32.80%
ID12191 
(Abhay_nsP2)















Serine/arginine-rich splicing factor 1 OS=Homo sapiens GN=SRSF1 PE=1 SV=2 SRSF1_HUMAN 9 35.90%
ID12191 
(Abhay_nsP2)










Flap endonuclease 1 OS=Homo sapiens GN=FEN1 PE=1 SV=1 FEN1_HUMAN 10 36.10%
ID12191 
(Abhay_nsP2)
L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 LDHB_HUMAN 6 28.10%
ID12191 
(Abhay_nsP2)
Coatomer subunit alpha OS=Homo sapiens GN=COPA PE=1 SV=2 COPA_HUMAN 24 26.20%
ID12191 
(Abhay_nsP2)
Small nuclear ribonucleoprotein E OS=Homo sapiens GN=SNRPE PE=1 SV=1 RUXE_HUMAN 4 59.80%



















14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1433Z_HUMAN 6 39.20%
ID12191 
(Abhay_nsP2)





Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 TBB5_HUMAN 20 57.70%
ID12191 
(Abhay_nsP2)
AP-2 complex subunit alpha-1 OS=Homo sapiens GN=AP2A1 PE=1 SV=3 AP2A1_HUMAN 5 8.50%
ID12191 
(Abhay_nsP2)
Aspartyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=DARS PE=1 SV=2 SYDC_HUMAN 12 27.30%
ID12191 
(Abhay_nsP2)
Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 SV=3 EF1G_HUMAN 15 41.00%
ID12191 
(Abhay_nsP2)
40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 RS5_HUMAN 9 32.40%
ID12191 
(Abhay_nsP2)
Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 PHB_HUMAN 5 23.20%
ID12191 
(Abhay_nsP2)
T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 PE=1 SV=4 TCPG_HUMAN 25 52.80%
ID12191 
(Abhay_nsP2)
Myosin-11 OS=Homo sapiens GN=MYH11 PE=1 SV=3 MYH11_HUMAN 11 15.70%
ID12191 
(Abhay_nsP2)
Cofilin-2 OS=Homo sapiens GN=CFL2 PE=1 SV=1 COF2_HUMAN 4 33.70%
ID12191 
(Abhay_nsP2)
Myosin-10 OS=Homo sapiens GN=MYH10 PE=1 SV=3 MYH10_HUMAN 89 50.80%
ID12191 
(Abhay_nsP2)
Asparaginyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=NARS PE=1 SV=1 SYNC_HUMAN 10 22.60%
ID12191 
(Abhay_nsP2)
Cell division protein kinase 1 OS=Homo sapiens GN=CDK1 PE=1 SV=2 CDK1_HUMAN 9 35.40%
ID12191 
(Abhay_nsP2)
GTP-binding protein 1 OS=Homo sapiens GN=GTPBP1 PE=1 SV=3 GTPB1_HUMAN 5 8.52%
ID12191 
(Abhay_nsP2)
Estradiol 17-beta-dehydrogenase 12 OS=Homo sapiens GN=HSD17B12 PE=1 SV=2 DHB12_HUMAN 8 23.70%
ID12191 
(Abhay_nsP2)





Protein arginine N-methyltransferase 5 OS=Homo sapiens GN=PRMT5 PE=1 SV=4 ANM5_HUMAN 6 11.90%
ID12191 
(Abhay_nsP2)










Proliferation-associated protein 2G4 OS=Homo sapiens GN=PA2G4 PE=1 SV=3 PA2G4_HUMAN 20 61.90%
ID12191 
(Abhay_nsP2)











T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=1 SV=2 TCPH_HUMAN 18 42.90%
ID12191 
(Abhay_nsP2)
Lysyl-tRNA synthetase OS=Homo sapiens GN=KARS PE=1 SV=3 SYK_HUMAN 10 20.90%
ID12191 
(Abhay_nsP2)
Cytosolic non-specific dipeptidase OS=Homo sapiens GN=CNDP2 PE=1 SV=2 CNDP2_HUMAN 4 12.80%
ID12191 
(Abhay_nsP2)
Signal recognition particle 72 kDa protein OS=Homo sapiens GN=SRP72 PE=1 SV=3 SRP72_HUMAN 12 25.50%
ID12191 
(Abhay_nsP2)
DnaJ homolog subfamily C member 2 OS=Homo sapiens GN=DNAJC2 PE=1 SV=4 DNJC2_HUMAN 5 11.00%









Phosphoglycolate phosphatase OS=Homo sapiens GN=PGP PE=1 SV=1 PGP_HUMAN 4 16.20%
ID12191 
(Abhay_nsP2)





Pre-mRNA-processing factor 19 OS=Homo sapiens GN=PRPF19 PE=1 SV=1 PRP19_HUMAN 9 27.20%
ID12191 
(Abhay_nsP2)
Coatomer subunit beta OS=Homo sapiens GN=COPB1 PE=1 SV=3 COPB_HUMAN 7 10.20%
ID12191 
(Abhay_nsP2)
ADP-ribosylation factor 5 OS=Homo sapiens GN=ARF5 PE=1 SV=2 ARF5_HUMAN 7 51.70%
ID12191 
(Abhay_nsP2)
Eukaryotic translation initiation factor 5 OS=Homo sapiens GN=EIF5 PE=1 SV=2 IF5_HUMAN 7 19.70%
ID12191 
(Abhay_nsP2)
Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 ACTG_HUMAN 17 57.30%
ID12191 
(Abhay_nsP2)










Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens GN=AIFM1 PE=1 SV=1 AIFM1_HUMAN 10 21.90%
ID12191 
(Abhay_nsP2)

























Cytoskeleton-associated protein 4 OS=Homo sapiens GN=CKAP4 PE=1 SV=2 CKAP4_HUMAN 6 13.50%
ID12191 
(Abhay_nsP2)
Creatine kinase U-type, mitochondrial OS=Homo sapiens GN=CKMT1A PE=1 SV=1 KCRU_HUMAN 14 47.70%
ID12191 
(Abhay_nsP2)





Coronin-1C OS=Homo sapiens GN=CORO1C PE=1 SV=1 COR1C_HUMAN 10 28.50%
ID12191 
(Abhay_nsP2)















Stomatin-like protein 2 OS=Homo sapiens GN=STOML2 PE=1 SV=1 STML2_HUMAN 6 21.10%
ID12191 
(Abhay_nsP2)
ATP-dependent RNA helicase A OS=Homo sapiens GN=DHX9 PE=1 SV=4 DHX9_HUMAN 33 33.00%
ID12191 
(Abhay_nsP2)
Phenylalanyl-tRNA synthetase beta chain OS=Homo sapiens GN=FARSB PE=1 SV=3 SYFB_HUMAN 11 19.40%
ID12191 
(Abhay_nsP2)
Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 PROF1_HUMAN 8 69.30%
ID12191 
(Abhay_nsP2)





Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 NUCL_HUMAN 5 9.30%
ID12191 
(Abhay_nsP2)
Testin OS=Homo sapiens GN=TES PE=1 SV=1 TES_HUMAN 4 10.20%
ID12191 
(Abhay_nsP2)










DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC 
PE=1 SV=3
PRKDC_HUMAN 55 17.30%










Isoleucyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=IARS PE=1 SV=2 SYIC_HUMAN 13 12.50%
ID12191 
(Abhay_nsP2)
Eukaryotic translation initiation factor 2A OS=Homo sapiens GN=EIF2A PE=1 SV=3 EIF2A_HUMAN 11 31.80%
ID12191 
(Abhay_nsP2)




















Protein transport protein Sec23A OS=Homo sapiens GN=SEC23A PE=1 SV=2 SC23A_HUMAN 7 14.50%
ID12191 
(Abhay_nsP2)
6-phosphogluconolactonase OS=Homo sapiens GN=PGLS PE=1 SV=2 6PGL_HUMAN 6 37.60%
ID12191 
(Abhay_nsP2)
















Regulator of chromosome condensation OS=Homo sapiens GN=RCC1 PE=1 SV=1 RCC1_HUMAN 6 20.90%
ID12191 
(Abhay_nsP2)





Eukaryotic translation initiation factor 6 OS=Homo sapiens GN=EIF6 PE=1 SV=1 IF6_HUMAN 4 25.70%
ID12191 
(Abhay_nsP2)
RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE=1 SV=1 RUVB1_HUMAN 15 45.40%
ID12191 
(Abhay_nsP2)















Inorganic pyrophosphatase OS=Homo sapiens GN=PPA1 PE=1 SV=2 IPYR_HUMAN 11 54.00%
ID12191 
(Abhay_nsP2)
Seryl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=SARS PE=1 SV=3 SYSC_HUMAN 4 10.50%
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4.1 Mass-spectrometry data analysis 
4.1.1 List of pathways enriched in nsP4 proteomic list analyzed using 
the online KEGG tool.  
hsa01100 Metabolic pathways - Homo sapiens (human) (60) 
hsa03010 Ribosome - Homo sapiens (human) (50) 
hsa05169 Epstein-Barr virus infection - Homo sapiens (human) (26) 
hsa03050 Proteasome - Homo sapiens (human) (21) 
hsa03040 Spliceosome - Homo sapiens (human) (20) 
hsa04141 Protein processing in endoplasmic reticulum - Homo sapiens 
(human) (17) 
hsa01200 Carbon metabolism - Homo sapiens (human) (17) 
hsa04110 Cell cycle - Homo sapiens (human) (16) 
hsa05203 Viral carcinogenesis - Homo sapiens (human) (15) 
hsa03013 RNA transport - Homo sapiens (human) (15) 
hsa01230 Biosynthesis of amino acids - Homo sapiens (human) (13) 
hsa05168 Herpes simplex infection - Homo sapiens (human) (13) 
hsa03030 DNA replication - Homo sapiens (human) (12) 
hsa05010 Alzheimer's disease - Homo sapiens (human) (12) 
hsa00970 Aminoacyl-tRNA biosynthesis - Homo sapiens (human) (12) 
hsa05012 Parkinson's disease - Homo sapiens (human) (11) 
hsa04114 Oocyte meiosis - Homo sapiens (human) (11) 
hsa00190 Oxidative phosphorylation - Homo sapiens (human) (11) 
hsa05016 Huntington's disease - Homo sapiens (human) (10) 
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human) (10) 
hsa00010 Glycolysis / Gluconeogenesis - Homo sapiens (human) (9) 
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hsa04932 Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human) 
(9) 
hsa03018 RNA degradation - Homo sapiens (human) (8) 
hsa00020 Citrate cycle (TCA cycle) - Homo sapiens (human) (8) 
hsa04390 Hippo signaling pathway - Homo sapiens (human) (8) 
hsa05164 Influenza A - Homo sapiens (human) (8) 
hsa05160 Hepatitis C - Homo sapiens (human) (8) 
hsa03008 Ribosome biogenesis in eukaryotes - Homo sapiens (human) (7) 
hsa01212 Fatty acid metabolism - Homo sapiens (human) (6) 
hsa00620 Pyruvate metabolism - Homo sapiens (human) (6) 
hsa05161 Hepatitis B - Homo sapiens (human) (6) 
hsa03430 Mismatch repair - Homo sapiens (human) (6) 
hsa00071 Fatty acid degradation - Homo sapiens (human) (6) 
hsa05162 Measles - Homo sapiens (human) (6) 
hsa04910 Insulin signaling pathway - Homo sapiens (human) (6) 
hsa04066 HIF-1 signaling pathway - Homo sapiens (human) (6) 
hsa00052 Galactose metabolism - Homo sapiens (human) (5) 
hsa04919 Thyroid hormone signaling pathway - Homo sapiens (human) (5) 
hsa05205 Proteoglycans in cancer - Homo sapiens (human) (5) 
hsa00510 N-Glycan biosynthesis - Homo sapiens (human) (5) 
hsa04120 Ubiquitin mediated proteolysis - Homo sapiens (human) (5) 
hsa04530 Tight junction - Homo sapiens (human) (5) 
hsa00051 Fructose and mannose metabolism - Homo sapiens (human) (5) 
hsa03015 mRNA surveillance pathway - Homo sapiens (human) (5) 
hsa05152 Tuberculosis - Homo sapiens (human) (5) 
hsa05130 Pathogenic Escherichia coli infection - Homo sapiens (human) (4) 
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hsa04310 Wnt signaling pathway - Homo sapiens (human) (4) 
hsa05166 HTLV-I infection - Homo sapiens (human) (4) 
hsa00280 Valine, leucine and isoleucine degradation - Homo sapiens 
(human) (4) 
hsa05206 MicroRNAs in cancer - Homo sapiens (human) (4) 
hsa00330 Arginine and proline metabolism - Homo sapiens (human) (4) 
hsa00640 Propanoate metabolism - Homo sapiens (human) (4) 
hsa00270 Cysteine and methionine metabolism - Homo sapiens (human) (4) 
hsa04261 Adrenergic signaling in cardiomyocytes - Homo sapiens (human) 
(4) 
hsa03450 Non-homologous end-joining - Homo sapiens (human) (4) 
hsa03420 Nucleotide excision repair - Homo sapiens (human) (4) 
hsa00480 Glutathione metabolism - Homo sapiens (human) (4) 
hsa03320 PPAR signaling pathway - Homo sapiens (human) (4) 
hsa05200 Pathways in cancer - Homo sapiens (human) (4) 
hsa04260 Cardiac muscle contraction - Homo sapiens (human) (4) 
hsa04920 Adipocytokine signaling pathway - Homo sapiens (human) (4) 
hsa04810 Regulation of actin cytoskeleton - Homo sapiens (human) (3) 
hsa04015 Rap1 signaling pathway - Homo sapiens (human) (3) 
hsa04964 Proximal tubule bicarbonate reclamation - Homo sapiens (human) 
(3) 
hsa04350 TGF-beta signaling pathway - Homo sapiens (human) (3) 
hsa00520 Amino sugar and nucleotide sugar metabolism - Homo sapiens 
(human) (3) 
hsa00030 Pentose phosphate pathway - Homo sapiens (human) (3) 
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hsa00260 Glycine, serine and threonine metabolism - Homo sapiens (human) 
(3) 
hsa00630 Glyoxylate and dicarboxylate metabolism - Homo sapiens (human) 
(3) 
hsa04918 Thyroid hormone synthesis - Homo sapiens (human) (3) 
hsa00230 Purine metabolism - Homo sapiens (human) (3) 
hsa00380 Tryptophan metabolism - Homo sapiens (human) (3) 
hsa04520 Adherens junction - Homo sapiens (human) (3) 
hsa04670 Leukocyte transendothelial migration - Homo sapiens (human) (3) 
hsa04064 NF-kappa B signaling pathway - Homo sapiens (human) (3) 
hsa00062 Fatty acid elongation - Homo sapiens (human) (3) 
hsa05134 Legionellosis - Homo sapiens (human) (3) 
hsa04972 Pancreatic secretion - Homo sapiens (human) (3) 
hsa04146 Peroxisome - Homo sapiens (human) (3) 
hsa03410 Base excision repair - Homo sapiens (human) (3) 
hsa00310 Lysine degradation - Homo sapiens (human) (3) 
hsa04622 RIG-I-like receptor signaling pathway - Homo sapiens (human) (3) 
hsa04930 Type II diabetes mellitus - Homo sapiens (human) (3) 
hsa05202 Transcriptional misregulation in cancer - Homo sapiens (human) 
(3) 
hsa03440 Homologous recombination - Homo sapiens (human) (3) 
hsa00410 beta-Alanine metabolism - Homo sapiens (human) (3) 
hsa00240 Pyrimidine metabolism - Homo sapiens (human) (2) 
hsa00670 One carbon pool by folate - Homo sapiens (human) (2) 
hsa05210 Colorectal cancer - Homo sapiens (human) (2) 
hsa04380 Osteoclast differentiation - Homo sapiens (human) (2) 
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hsa04973 Carbohydrate digestion and absorption - Homo sapiens (human) 
(2) 
hsa00650 Butanoate metabolism - Homo sapiens (human) (2) 
hsa04210 Apoptosis - Homo sapiens (human) (2) 
hsa04668 TNF signaling pathway - Homo sapiens (human) (2) 
hsa04010 MAPK signaling pathway - Homo sapiens (human) (2) 
hsa01040 Biosynthesis of unsaturated fatty acids - Homo sapiens (human) 
(2) 
hsa04612 Antigen processing and presentation - Homo sapiens (human) (2) 
hsa01210 2-Oxocarboxylic acid metabolism - Homo sapiens (human) (2) 
hsa04974 Protein digestion and absorption - Homo sapiens (human) (2) 
hsa04144 Endocytosis - Homo sapiens (human) (2) 
hsa00250 Alanine, aspartate and glutamate metabolism - Homo sapiens 
(human) (2) 
hsa04062 Chemokine signaling pathway - Homo sapiens (human) (2) 
hsa00500 Starch and sucrose metabolism - Homo sapiens (human) (2) 
hsa05140 Leishmaniasis - Homo sapiens (human) (2) 
hsa05133 Pertussis - Homo sapiens (human) (2) 
hsa04510 Focal adhesion - Homo sapiens (human) (2) 
hsa05020 Prion diseases - Homo sapiens (human) (2) 
hsa04730 Long-term depression - Homo sapiens (human) (2) 
hsa04971 Gastric acid secretion - Homo sapiens (human) (2) 
hsa04728 Dopaminergic synapse - Homo sapiens (human) (2) 
hsa05142 Chagas disease (American trypanosomiasis) - Homo sapiens 
(human) (2) 
hsa04020 Calcium signaling pathway - Homo sapiens (human) (2) 
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hsa04068 FoxO signaling pathway - Homo sapiens (human) (2) 
hsa04722 Neurotrophin signaling pathway - Homo sapiens (human) (2) 
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4.1.2 List of the top five canonical pathways enriched in nsP4 proteomic 
list analyzed using software tool, Ingenuity. 
 
Ingenuity Canonical Pathways    p-value Molecules 
 
EIF2 Signaling      1.47e-46  55/181 
RPL11, RPL22, RPL27A, RPS23, RPS11, RPS7, RPS3A, RPL7A, RPL36, 
RPS20, RPL8, PABPC1, RPL3, RPL27, RPL23A, RPL10A, RPS6, RPS29, 
RPL15, EIF4A3, RPL10, RPS15, RPS25, RPS15A, RPL13A, RPS27A, 
RPL24, RPS18, RPS13, RPS8, RPL26, RPL14, EIF2S1, RPS17/RPS17L, 
RPL35A, RPL7, RPL6, RPS27, RPL18A, RPS9, EIF2S3, RPS5, RPL18, 
RPL13, RPL4, RPS2, RPS19, RPL21, RPL9, RPS12, EIF2S2, RPL28, 
EIF4A1, RPL32, EIF2AK2 
 
Regulation of eIF4 and p70S6K Signaling  6.58e-19  29/15 
PPP2CA, RPS18, RPS13, RPS8, RPS17/RPS17L, EIF2S1, RPS23, RPS11, 
RPS7, RPS27, RPS3A, RPS9, EIF2S3, RPS20, RPS5, PABPC1, RPS2, 
RPS19, RPS12, RPS29, RPS6, EIF2S2, PPP2R1A, EIF4A3, EIF4A1, RPS15, 
RPS15A, RPS25, RPS27A 
 
mTOR Signaling     4.62e-14  27/189 
PPP2CA, RPS18, RPS13, RPS8, RPS17/RPS17L, RPS23, RPS11, RPS7, 
RPS27, RPS3A, RPS9, RPS20, GNB1L, RPS5, RPS2, RPS19, RPS12, 
RPS29, RPS6, PPP2R1A, RHOA, EIF4A3, EIF4A1, RPS15, RPS25, 
RPS15A, RPS27A 
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Protein Ubiquitination Pathway   8.23e-13  30/263 
PSMA7, HSPA5, DNAJA1, PSMC5, USP10, PSMD14, PSMC2, PSMB4, 
PSMA6, PSMB5, PSMD13, HSPH1, HSPA9, USP9X, PSMC4, PSMD6, 
PSMD3, HSPD1, PSMD11, PSMC1, PSMD2, PSMD12, PSMA5, PSMA4, 
PSMB1, PSMD1, PSMD4, UBA1, PSMC3, DNAJC7 
 
tRNA Charging     5.66e-11  12/38 
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6.0 List of phosphatases uniquely interacted to CHIKV nsP4 
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Differential unfolded protein response during
Chikungunya and Sindbis virus infection: CHIKV
nsP4 suppresses eIF2α phosphorylation
Abhay P S Rathore1,2, Mah-Lee Ng2 and Subhash G Vasudevan1,2*
Abstract
Chikungunya (CHIKV) and Sindbis (SINV) are arboviruses belonging to the alphavirus genus within the Togaviridae
family. They cause frequent epidemics of febrile illness and long-term arthralgic sequelae that affect millions of
people each year. Both viruses replicate prodigiously in infected patients and in vitro in mammalian cells,
suggesting some level of control over the host cellular translational machinery that senses and appropriately directs
the cell’s fate through the unfolded protein response (UPR). The mammalian UPR involves BIP (or GRP78), the
master sensor in the endoplasmic reticulum (ER) together with the three downstream effector branches:
inositol-requiring ser/thr protein kinase/endonuclease (IRE-1), PKR-like ER resident kinase (PERK) and activating
transcription factor 6 (ATF-6). Through careful analysis of CHIKV and SINV infections in cell culture we found that the
former selectively activates ATF-6 and IRE-1 branches of UPR and suppresses the PERK pathway. By separately
expressing each of the CHIKV proteins as GFP-fusion proteins, we found that non-structural protein 4 (nsP4), which
is a RNA-dependent-RNA polymerase, suppresses the serine-51 phosphorylation of eukaryotic translation initiation
factor, alpha subunit (eIF2α), which in turn regulates the PERK pathway. This study provides insight into a
mechanism by which CHIKV replication responds to overcome the host UPR machinery.
Introduction
Chikungunya virus (CHIKV) is a member of the alpha-
virus genus, which contains 26 known arboviruses with
a wide host range [1]. During the past 50 years, numer-
ous CHIKV epidemics have been documented in both
Africa and Asia [2]. Since, its discovery, CHIKV has
spread widely and currently Chikungunya fever has been
detected in nearly 40 countries with a potential to affect
millions of people worldwide [3]. In general, alphaviruses
are divided into viruses that cause human diseases char-
acterized by rash and arthritis, that are primarily found
in the “old world” such as CHIKV, O nyong nyong,
Sindbis (SINV), Ross River, Barmah Forest and Mayaro
virus [4] and viruses that cause encephalitis, which are
primarily found in the “new world”. The first clear asso-
ciation of an alphavirus with arthritic disease was made
in 1953 when CHIKV was isolated from the blood of
individuals in Tanzania with severe arthritis [5]. SINV
was first isolated in 1952, which causes similar disease to
CHIKV in humans known as sindbis fever and the
symptoms include arthralgia, rash and malaise [6]. These
arthritogenic alphaviruses share certain antigenic deter-
minants [4] and also considerable genome similarity that
makes them interesting for comparative responses to the
host. In humans, CHIKV infection is characterized by a
rapid onset of fever that is cleared in 5–7 days with long
lasting immunity [7]. The major pathology associated
with CHIKV infection is very high viremia and polyar-
thritis [8-11]. The mortality rate associated with CHIKV
infection has been estimated to be 1:1000 with most
deaths occurring in neonates, adults with underlying
conditions and the elderly [3]. The persistent detection
of viral RNA or antigen in the host has suggested the
long-term persistence of these viruses in humans
[12,13]. The alphavirus genome is a single-stranded
RNA genome of ~12 kb in size of positive polarity. It
encodes two polyproteins of which the first encodes
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nonstructural proteins (nsPs) 1–4: nsP1 contains methyl
transferase and guanyl transferase activities, nsP2 is a
helicase/protease, nsP3 is an accessory protein involved
in RNA synthesis and nsP4 is the RNA dependent RNA
polymerase. The second polypeptide, translated from a
subgenomic RNA codes for structural proteins, capsid
(C) and the envelope glycoproteins, E1 and E2 that con-
stitute the virion coat [4,14,15]. Several studies have
shown that alphavirus replication in mammalian cells
usually results in severe cytopathicity, mainly caused
by dramatic shutdown of host translation machinery
[16-20]. However, the mechanism by which CHIKV
maintains such a high replication rate in the infected
cells is poorly understood.
One host response mechanism that has the potential to
limit virus replication is the endoplasmic reticulum (ER)
stress response, also known as unfolded protein response
(UPR) which, maintains cellular protein homeostasis and
prevents the over-accumulation of unfolded proteins in the
lumen of the ER during normal and diseased states [21]. ER
chaperone immunoglobulin heavy chain binding protein
(BIP), also known as glucose regulated protein 78 (GRP78)
plays a central role in this process via a three-pronged regu-
latory pathway involving PKR-like ER kinases (PERK),
activating transcription factor 6 (ATF-6) and the ER trans-
membrane protein kinase/endoribonuclease (IRE-1). Under
stress conditions, BIP is sequestered to misfolded or
unfolded proteins in the ER whereupon it activates PERK,
ATF-6 and IRE-1 [22]. During UPR, PERK activates by self-
dimerization and phosphorylation. Activated PERK phos-
phorylates eIF2α at serine-51 and leads to an inhibition of
general protein synthesis. PERK activation also induces the
activation of C/EBP homologous protein (CHOP) and
growth arrest and DNA damage-inducible protein
GADD34 [23]. CHOP is responsible for apoptosis mediated
cell death when functions of ER are severely impaired to
protect the organism by eliminating the damaged cell
[24] whilst GADD34 and its binding partner protein
phosphatase-1 catalytic subunit (PP1c) are involved in
eIF2α de-phosphorylation that also modulates cell fate dur-
ing protein translational stress. The activation of IRE-1
branch of UPR pathway leads to transcription induction of
a subset of genes encoding protein degradation and
pro-survival enzymes such as components of ER associated
degradation (ERAD) including ER degradation-enhancing-
α-mannosidase like protein (EDEM) [25-27]. Autoproteoly-
tic activation of ATF-6 stimulates transcription of genes en-
coding chaperones that assist in the refolding of misfolded
proteins [28]. On balance, the UPR pathway in conjunction
with ERAD controls the survival vs apoptosis decision of
cells stressed by increased protein translation from external
stimulus [29].
To circumvent the host cellular translational response,
several viruses [respiratory syncytial virus, simian virus-5,
Tula virus, African swine fever virus, herpes simplex virus,
cytomegalovirus, dengue virus and hepatitis C virus [30-34]
have been shown to regulate UPR machinery. For example,
in the case of hepatitis C virus, the virus encoded NS5A
phosphoprotein, inhibits PKR activation by direct protein-
protein interaction [35]. Likewise, K3L gene product of vac-
cinia virus also binds to PERK and inhibits its activation
[36]. Others such as herpes simplex viruses encode proteins
that mimic host factors to regulate the protein synthesis
traffic [37]. In light of these various mechanisms by which
viruses modulate UPR pathway, we investigated the impact
of CHIKV replication on the various components of the
UPR machinery and compared it to another representative
alphavirus, SINV, in order to reveal differential host
responses to these unique but closely related pathogens.
Real-time RT-PCR monitoring of transcriptional changes
and Western blotting of infected cells were used to reveal
the UPR components during both CHIKV and SINV infec-
tions. By carefully examining the UPR pathway components
and by selectively inducing the ER stress using thapsigargin
or tunicamycin treatment, we identified the suppression of
eIF2α phosphorylation during CHIKV infection in the early
phase of virus replication that does not occur with SINV
infection. Subsequently, transfection of individual CHIKV-
encoded proteins as GFP-fusion proteins revealed a mech-
anistic basis for the phenomenon dependent on nsP4.
Materials and methods
Cells and viruses
Mosquito cells Aedes albopictus clone (C6/36) and baby
hamster kidney cells (BHK-21) were cultured in RPMI-
1640 medium (Gibco) supplemented with 10% fetal bo-
vine serum (FBS) (Gibco). Human embryonic kidney
cells (HEK293) and human lung fibroblast cells (MRC-5)
were cultured in DMEM (Gibco) supplemented with 10%
FBS. C6/36 cells were grown and maintained in 28°C
temperature incubator. BHK-21, MRC-5 and HEK293
cells were grown and maintained at 37°C in a humidified
incubator with 5% CO2 atmosphere. CHIKV strain ‘ROSS’
and a laboratory strain of SINV MRM-39 strain (isolated
in Australia [38]) was a generous gift from Dr. Ooi Eng
Eong (Duke-NUS GMS). Both the viruses were ampli-
fied in C6/36 cells supplemented with 5% FBS at 28°C
and titrated by plaque assay as described previously
[39]. Low passage number (below passage 5) was used
for performing all experiments. Tunicamycin (Sigma) or
thapsigargin (sigma) was used to induce UPR stress in
the cells.
In vitro virus quantification
Prior to their use, plaque assays were carried out to quan-
tify the number of infectious viral particles for CHIKV and
SINV viruses used in the study. Briefly, BHK-21 cells were
cultured to approximately 80% confluency in 24-well plates
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(NUNC). The virus stock was 10-fold serially diluted from
10−1 to 10−12 in RPMI 1640 (Gibco). BHK-21 monolayers
were infected with 200μl of each virus dilution. After incu-
bation at 37°C and 5% CO2 atmosphere for 1h with rocking
at 15 min intervals, the medium was decanted and 1ml of
1% (w/v) carboxymethyl cellulose in RPMI supplemented
with 2% FBS was added to each well. After 72h of incuba-
tion at 37°C in 5% CO2, the cells were fixed with 4% paraf-
ormaldehyde and stained for 30 min with 200 μl of 1%
crystal violet dissolved in 1X-PBS. After thorough rinsing
with water, the plates were dried and the plaques were
scored visually.
Primer sequences used in the study
Real-time PCR primer sequences: - CHIKV nsP1 (F-TAG
AGCAGGAAATTGATCCC, R- CTTTAATCGCCTGGT




TC, R- ACTGGGTCCAAGTTGTCCAG), CHOP (F-TCT
GATTGACCGAATGGTG, R- TCTGGGAAAGGTGGGT
AGTG), BIP (F-TAGTGCAAGCTGAAGGCTGA, R- GG
GCTGGAGTACAGTGGTGT), GADD34 (F-AACCTCTA
CTTCTGCCTTGTCT, R- CGCCTCTCCTGAACGATAC
TC), eIF2αK2 (F-TTTGGACAAAGCTTCCAACC, R- AC
TCCCTGCTTCTGACGGTA), 18s (F-TGTTCAAAGCAG
GCCCGAG, R-CGGAACTACGACGGTATCTGATC), GA
PDH (F- ACAGTCAGCCGCATCTTCTT, R- ACGACCA
AATCCGTTGACTC), Actin (F-CAGGGGAACCGCTCA
TTGCCAATGG, R-TCACCACACACTGTGCCCATCTA
CGA), XBP-1 splicing (F- AAACAGAGTAGCAGCTCAG
ACTGC, R- TCCTTCTGGGTAGACCTCTGGGAG).
CHIKV recombination cloning primer sequences: -
nsP1 (F- AGATCTCGAGCTCAAGCT TCGATGGAT
CCTGTGTACGTG, R- TTAACCGTCGACTGCAGAT
CCTGCACCCGCTCTGTC), nsP2 (F- TCCGGACTCA
GATCTCGAGCTATAATAGAGACTCCGAGAGGA,
R-GGATCCCGGGCCCGCGGTACCACATCCTGCTC





CCTATTTAGGACCGCCGTA), Capsid (F- TCCGGA
CTCAGATCTCGAGCTTGCATGAAAATCGAAAAT-
GAC, R- GGATCCCGGGCCCGCGGTACCCCACTCT






RNA extraction and real-time RT-PCR analysis
HEK293 cells (1×105) were infected with virus (CHIKV/
SINV) at a multiplicity of infection (MOI) of 1. At indi-
cated time intervals, total RNA was isolated using the
trizol (Invitrogen) extraction method and 1μg of total
RNA was used for cDNA synthesis using ImProm II re-
verse transcription system (Promega), with oligo dT as
primer. cDNA (50 ng) was used for real-time amplifica-
tion of specific genes using respective primers (Materials
and Methods) in Bio-Rad iQ-5 real time thermal cycler.
The expression of viral and host gene products was
normalized to Actin and GAPDH mRNA expression,
followed by normalization to expression levels at unin-
fected conditions.
XBP-1 splicing assay
The XBP-1 splicing assay was performed essentially as
described elsewhere [40]. Briefly, total RNA from the
mock or virus (CHIKV/SINV) infected cells was
extracted as described above and 1 μg each of the total
RNA was used for cDNA synthesis using ImProm II re-
verse transcription system (Promega), with oligo dT as
primer, followed by PCR amplification of XBP-1 spliced
genes using XBP-1 splicing specific primers (Materials
and Methods). Amplified products were run on 2.5%
Agarose gel and visualized under UV ImageQuant.
Western blotting
HEK293 cells (1×105) were infected with MOI of 1 with
CHIKV/SINV and total cell lysate was collected in NET
lysis buffer (20 mM Tris, 100 mM NaCl & 1 mM EDTA)
containing 0.1% Triton X-100 with protease inhibitor
cocktail (Roche) at indicated time points post infections.
After 30 min on ice, lysates were centrifuged at 13000
rpm for 10 min and supernatants were used to quanti-
tate the amount of total protein by BCA assay (Pierce).
Equal amount (2-5 μg each) of protein was loaded on
12% SDS PAGE followed by Western blotting. Blots
were blocked overnight with blocking solution [2% Fish
gelatin (sigma) in 1X PBS] and were probed using pri-
mary antibodies against various proteins: GFP (Abcam),
BIP (Abcam), ATF-6 (Abcam), HSP-90 (cell signaling),
p58IPK (cell signaling), CHOP (cell signaling), phospho
(Thr 980) PERK (cell signaling), eIF2α (cell signaling)
and phospho (Ser 51) eIF2α (cell signaling). Anti-
GAPDH antibody (cell signaling) and anti-Actin anti-
body (sigma) were used as the loading control
antibodies. All the antibodies used were diluted in block-
ing solution. After incubating with secondary HRP-
conjugated antibodies, blots were developed using ECL
detection reagent (GE healthcare) and exposed on
Amersham hyper films prior to development or visua-
lized using Image-quant chemiluminiscent machine.
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Where required, image quantification was done using
Image-J software.
Construction of CHIKV-pEGFP clones
Vector pEGFP-C1 (Clontech) was used to clone all the
four non-structural (nsP1-4) and three major structural
(C, E2 & E1) genes of CHIKV. Briefly, CHIKV RNA was
extracted using a viral RNA extraction kit (Qiagen). All
the genes were amplified using gene specific primers
(Materials and Methods) and superscript III one step RT
PCR with platinum Taq kit (Invitrogen) in a thermal
cycler (Applied Biosystem). Amplified genes were run on
1% agarose gel and amplicons were gel eluted using
QIA-quick gel extraction kit (Qiagen). Individual puri-
fied PCR products were then inserted in to the pEGFP-
C1 vector using cloneEZ PCR cloning kit (Genscript) as
per the manufacturer’s recommendations. For conveni-
ence of restriction digestion analysis for screening
positive clones, nsP1 was inserted in between HindIII-
PstI restriction sites and nsP2-4 and C were cloned
using XhoI-KpnI restriction sites. Similarly, E1 and E2
were cloned using HindIII-BamHI restriction sites. All
the positive clones were further confirmed by DNA
sequencing.
Transfection of plasmids
For transfection of plasmid DNA into HEK293 or MRC-
5 cells, cells were seeded to 70% confluency in a 24 well
plate (Nunc) and incubated overnight in 37°C incubator
supplemented with 5% CO2 atmosphere. One μg of each
of the plasmids (GFP vector, GFP-nsP1/2/3/4 or GFP-C/
E1/E2) was transfected using jet prime transfection re-
agent (Polypus BST scientific) as per the manufacturers
described protocol. Transfected cells were incubated for
48h for protein expression and then washed once with
1X-PBS (Gibco). Finally, cells were collected in TNET-
lysis buffer as described above and then subjected to
Western blotting. The transfection efficiencies by fluor-
escence microscopic visualization for each of the plas-
mids except GFP-nsp2 were measured to be around
~70% using polyplus jet prime transfection reagent,
strictly as per the manufacturer’s protocol. For GFP-
nsP2 transfection was done using 2 μg of the plasmid
and nearly 60% of transfection efficiency was achieved.
No cytotoxicity was observed upon transfection of
plasmids till 72h post transfection. However, with GFP-
nsP2 some cytotoxicity (less than 20% cell death) was
observed after 48h post transfection.
Immunofluorescence
HEK293 cells were seeded on coverslips at a density of
1×105 cells/well in a 12-well plate. Following incubation
for overnight at 37°C with 5% CO2, the cells were
infected with CHIKV or SINV at an MOI of 1. At
indicated time points after infection cells were fixed with
ice cold 80% acetone for 10 min followed by overnight
incubation with blocking buffer (5% BSA in 1X PBS) at
4°C. The CHIKV RNA was detected using monoclonal
dsRNA antibody (J2). The phosphorylated form of ER
resident protein eIF2α was detected using antibody against
phospho (Ser 51) eIF2α (cell signaling). Secondary anti-
bodies used were anti-mouse alexa 488 and anti-rabbit
alexa 594. All the antibodies used were diluted in blocking
buffer. The coverslips were mounted on glass slides using
prolong gold anti-fade mounting medium (Invitrogen) con-
taining DAPI. Immunofluorescence images were captured
using an inverted fluorescence microscope (Olympus IX71,
USA) or upright confocal microscope (Zeiss) and image
analysis was performed with Image-J software.
Statistics
Statistical comparison of results were performed using
unpaired Student’s t test on the GraphPad Prism 5.0
software with p<0.005 considered statistically significant.
Results
Growth kinetics of CHIKV and SINV in vitro
Since the study is primarily investigating CHIKV growth,
we first determined the infectivity and growth kinetics of
CHIKV in various cultured mammalian cell types in
order to align our data with others in the field. Virus in-
fection was achieved using MOI of 1 and at various time
points post infection, growth kinetics was measured
using standard plaque assay or by real time RT PCR
for viral RNA detection. Mammalian mesenchymal cell
types such as human lung fibroblast cells (MRC-5),
human cervical epithelial cells (HeLa), human embry-
onic kidney cells (HEK293) and rat basophilic mast cell
like cells (RBL-2H3) support prolific CHIKV replication
reaching viral RNA induction up to 104 fold in the
infected cells (Figure 1A, B). However, several key im-
mune cells like primary human peripheral blood mono-
nuclear cells (PBMC) (data not shown), peripheral blood
monocytic cells (THP-1 & K562) and T lymphocytic
cells (Jurkat) were found to be poorly infected with
CHIKV, suggesting that immune cells may not be the
primary targets for infection (Figure 1A). These findings
are in agreement with previous reports that immune
cells, including monocyte-derived macrophages and T
and B cells are poorly susceptible to CHIKV infection
[41,42]. Human embryonic kidney cells (HEK293) are
widely used in the study of molecular pathways as they
are robust with respect to transfection of foreign genes
or proteins [16,43,44]. Indeed HEK293 cells supported
CHIKV replication with plaque titers reaching ~1011
pfu/ml and up to 10,000-fold induction of viral RNA
(Figure 1B). Equally, SINV growth in HEK293 cells
under similar conditions was also robust with plaque
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assay titers of ~1012 pfu/ml and nearly 100,000-fold in-
duction of viral RNA (Figure 1C). These high viral titers
were also observed in other publications [45,46]. The
similarity in growth kinetics of CHIKV & SINV in
HEK293 cells made this a relevant model for further in-
vestigation into the mechanism by which these viruses
modulate the cellular UPR pathway to achieve the high
viral load that is often observed in patients [3,12,47].
The ATF-6 signaling branch of UPR pathway during CHIKV
and SINV infection
Overload of viral protein translation in the ER during
virus replication triggers the activation of the UPR path-
ways. We sought to investigate both the overall and spe-
cific impact of CHIKV and SINV replication on the UPR
pathway by dissecting the individual signature branches
of UPR: the ATF-6, IRE-1 and PERK. For this, HEK293
cells were infected with CHIKV or SINV at an MOI of 1
and at indicated time points (0, 3, 6, 12, 24 and 48 h)
post infection, cells were harvested, lysed and subjected
to protein and RNA analysis for the component genes of
ATF-6 pathway. We first confirmed by using immuno-
fluorescence microscopy that majority of the cells were
infected from 12 h post infection onwards, with >95%
staining positive for dsRNA for both CHIKV and SINV
infections from 24 h post infection (Figure 2A). In re-
sponse to ER stress BIP activates ATF-6 to auto-
proteolyse and induce the transcription of ER chaperone
genes such as BIP, HSP-90 and p58IPK [48,49]. During
CHIKV infection BIP was induced both at the transcrip-
tional (~12 fold) and translational level (~6 fold) at 48 h
post infection (Figure 2B, D). The protein levels of both
trans-membrane and cleaved cytosolic ATF-6 were
increased throughout the infection time course com-
pared to the uninfected control (0 h) (Figure 2B). The
protein levels of ER chaperones, HSP-90 (~2 fold) and
p58IPK (~1.5 fold) were also induced from 12 h post
infection (Figure 2B), however, transcription levels were
only induced at a statistically significant level (p-value
less than 0.05) at 24 h (~2.5 fold) and 48 h (~21fold)
time points for p58IPK, and at 48 h (~2 fold) for HSP-
90 (Figure 2D). In contrast to CHIKV, during SINV in-
fection, no change in the protein levels of BIP was
observed (Figure 2C), however the BIP transcript was
significantly induced (~22 fold) at 48 h post infection
(Figure 2E). No significant change was observed at the
protein levels of both trans-membrane and cytosolic
cleaved ATF-6 (Figure 2C). Also the protein levels of
both HSP-90 and p58IPK were not significantly altered
(Figure 2C). However, statistically significant induction
of the transcripts for p58IPK (2, 16 fold) and HSP-90
(2.5, 16 fold) were observed at 24 and 48 h post infec-
tion (Figure 2E). Taken together, the data here suggest
that the ATF-6 pathway signaling is significantly acti-
vated during CHIKV infection, whereas the SINV infec-
tion appears to not have a major modulatory effect on
this branch of the UPR pathway.
The IRE-1 signaling branch of UPR pathway during CHIKV
and SINV infection
Next the IRE1 branch was investigated by probing the
splicing in the XBP-1 gene, which is a characteristic
marker for activation of IRE-1 signaling [50-52]. The
spliced XBP-1 gene product acts as transcription factor
and activates the transcription of pro-survival genes such
as EDEM and BCL-2 family proteins [53,54]. To assess
the IRE-1 signaling, upon CHIKV/SINV infections, total
RNA was extracted from the infected cells, harvested at
various time points post infection and used for cDNA
synthesis. The XBP-1 gene-splicing event was detected
using a standard primer-based XBP-1 splicing assay [40].
For easier interpretation of data, the corresponding level
of viral RNA present at each time point post infection
was detected using virus gene specific detection primers
Figure 1 Growth kinetics of CHIKV and SINV in HEK293 cells. A) Real time RT-PCR analysis shows the growth kinetics of CHIKV in various
cultured mammalian cell types and are presented as fold change in virus RNA (CHIKV nsP1 gene) over 6h infection time point using nsP1 specific
primers (Materials and Methods) after normalization with Actin and GAPDH mRNA. The graph is representative of two independent repeats. B, C) HEK293
cells (1×105 cells) were infected with MOI-1 of CHIKV or SINV. At indicated time points post infection, infectious virus particles were quantified in the
supernatant using standard plaque assay method (left Y-axis in the graph) and real time viral RNA quantification was done on the total RNA extracted
from infected cells using specific primers (Materials and Methods) against nsP1 in CHIKV or E1 in SINV. Viral RNA is presented as fold change over 3h
infection time points after normalization with Actin and GAPDH mRNA (right Y-axis in the graph). The graphs are representative of three
independent repeats.
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for CHIKV (nsP1 gene) and SINV (E1 gene) (Figure 3A, B).
The data shows that CHIKV infection triggers moderate
XBP-1 splicing from 12 h post infection, which only
becomes prominent at 48 h post infection (Figure 3A).
Quantitative real time PCR analysis showed that the
transcription levels of both XBP-1 gene (~9 fold) and
EDEM-1 (~16 fold) increased at 48 h post infection
(Figure 3C). However in the case of SINV infection, the
spliced XBP-1 gene transcript was much more promin-
ent than was observed for CHIKV, starting from 12 h
post infection with dramatic increase in the spliced
product at 24 and 48 h post infection (Figure 3B). Real
time PCR analysis revealed the increase in transcription
of XBP-1 gene starting from 3 h post infection and sig-
nificant increase in the EDEM transcript at 24 h (~2.5
fold) and 48 h (~24 fold) post infection (Figure 3D).
Figure 2 (See legend on next page.)
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Together the data suggests that both CHIKV and SINV
activate the IRE-1 branch of UPR except that SINV in-
fection appears to have a more profound impact on
XBP-1 gene splicing from a very early time point.
The PERK signaling branch of UPR pathway during CHIKV
and SINV infection
To examine the effects of CHIKV and SINV replication
on the PERK pathway of UPR, antibodies against phso-
pho (thr 980) PERK and phospho (ser 51) eIF2α were
used to measure their respective phosphorylation levels.
HEK293 cells were infected with CHIKV or SINV at an
MOI of 1 and at 0, 3, 6, 12, 24 and 48h post infection
cells were harvested and lysed before being subjected to
protein and RNA analysis for PERK pathway component
genes. During CHIKV infection the increase in the phos-
phorylation of PERK was detected starting from 12 h
post infection (Figure 4A). Intriguingly, even when the
PERK was activated (as indicated by its phosphorylation)
no phosphorylation (ser 51) of eIF2α was observed over
total eIF2α until 24 h post infection (Figure 4A). How-
ever, at 48 h post infection an increase in phosphoryl-
ation (ser 51) of eIF2α was observed (Figure 4A)
suggesting a delayed cellular response to virus infection
and perhaps an implication for the possible role of virus
mediated suppression of eIF2α phosphorylation. Similar
results were also obtained using another cell type MRC-
5 (Additional file 1: Figure S1) thus excluding the possi-
bility that the delayed response is cell-type specific. The
transcript level of eIF2αK was not altered during CHIKV
infection (Figure 4C). Also, both the protein and tran-
script levels of downstream apoptosis marker, CHOP,
were almost undetectable and not altered at any time
points post CHIKV infection (Figure 4A, C). Interest-
ingly, GADD34 a negative regulator of PERK was tran-
scriptionally induced (~9 fold) at 48 h post infection
(Figure 4C). However, during SINV infection the PERK
signaling was in stark contrast to that observed for
CHIKV infection (Figure 4). SINV infection induced
phosphorylation of PERK (Figure 4B) and a dramatic
increase in the phosphorylation (ser 51) of eIF2α was
observed over the entire time course, starting 3h post in-
fection (Figure 4B). Indeed, the transcript levels of
eIF2αk were also significantly elevated at 24 (~5 fold)
and 48 h (~12 fold) post infection (Figure 4D). CHOP
activity was also dramatically increased during SINV in-
fection at both the protein and transcript levels (upto 4
fold) starting 6 h post infection (Figure 4B, D). Overall,
the data here suggest that CHIKV may modulate the
PERK pathway signaling by suppressing the phosphoryl-
ation (ser 51) of eIF2α in the early phase of infection (3-
24 h). SINV infection on the other hand leads to an un-
controlled UPR in the cell characterized by increased
phosphorylation (ser 51) of eIF2α and apoptosis.
CHIKV infection suppress phosphorylation (ser 51) of
eIF2α
To interrogate the delayed phosphorylation (ser 51) of
eIF2α during CHIKV infection, we first confirmed by
immunofluorescence microscopy that the phosphoryl-
ation (ser 51) of eIF2α at 24 h post infection was much
more reduced and perhaps even suppressed in compari-
son to SINV or uninfected controls (Figure 5A). Next,
we determined whether CHIKV infection could efficiently
suppress phosphorylation (ser 51) of eIF2α even in the
presence of thapsigargin or tunicamycin (Figure 5B,
Additional file 1: Figure S2A), the known chemical
inducers of ER stress [39,55,56]. For this we verified
that treatment of HEK293 cells with thapsigargin (0.1 μM)
or tunicamycin (0.5 μg/ml) for 6 h induced ER stress
resulting in increased protein phosphorylation (ser 51) of
eIF2α (Figure 5B, Additional file 1: Figure S2A). Based on
this thapsigargin/tunicamycin treatment time of 6 h was
selected for further experiments to avoid any undesired
toxicity effects of the drug. To examine the effect of
CHIKV or SINV replication on thapsigargin/tunicamycin
induced ER stress, HEK293 cells were infected with MOI
of 1 of CHIKV or SINV for 12 h (for sufficient translation
of virus encoded proteins), thoroughly washed twice with
FCS free DMEM to remove any traces of excess virus and
(See figure on previous page.)
Figure 2 The ATF-6 signaling during CHIKV and SINV infection. A) HEK293 cells (1×105 cells) were cultured on coverslips and either mock or
CHIKV/SINV infected at an MOI-1. At indicated time points post infection cells were fixed and immunofluorescence microscopy was performed to
probe the virus replication-using antibody against dsRNA (red). Uninfected cells were used as negative control and nuclear stain DAPI (blue) was
used as background control. From 12h post infection onwards ~90% of cells were infected with CHIKV/SINV and stained positive for dsRNA
antibody. B, C) HEK293 cells (1×105 cells) were infected with MOI-1 of CHIKV/SINV and at indicated time points post infection cells were lysed
using TNET lysis buffer. Lysed samples were run on 12% SDS PAGE followed by Western blotting. Antibodies against BIP, ATF-6, HSP-90 and
p58IPK were used to probe the ATF-6 pathway component protein levels during CHIKV/SINV infection. Anti-actin antibody was used to probe
loading control and uninfected cells (0h) were used as baseline protein level control. D, E) Under the similar experimental conditions and time
points stated above, real time RT PCR analysis of BIP, HSP-90 and p58IPK transcripts was done on total RNA extracted from CHIKV/SINV infected
cells using specific primers (Materials and Methods) against each of three genes. All three transcripts are presented as fold change over 0h
(uninfected cells) after normalization with Actin and GAPDH mRNA. The graphs were plot using graph-pad prism software and are representative
of three independent repeats. Any significant change over 0h was determined using student unpaired T test and considered significant (*) if p
value was less than 0.05.
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finally treated with thapsigargin (0.1μM)/ tunicamycin
(0.5 μg/ml) or mock treatment for another 6 h. The cells
were harvested and lysed for Western blotting analysis
and the media supernatants from the tests were used
for virus quantification by plaque assay. As expected,
the phosphorylation (ser 51) of eIF2α was enhanced
(100% eIF2α-P) over total eIF2α in uninfected but thapsi-
gargin or tunicamycin treated cells (Figure 5B, Additional
file 1: Figure S2A). At the same time dramatic reduction
in the levels of eIF2α (ser 51) phosphorylation (~8%
eIF2α-P) over total eIF2α was observed for cells infected
only with CHIKV even in the presence of thapsigargin
or tunicamycin (Figure 5B, Additional file 1: Figure S2A).
However, SINV infection induced massive phosphoryl-
ation of eIF2α in both mock and thapsigargin or tunicamy-
cin treated cells (Figure 5B, Additional file 1: Figure S2A).
Consistent with our earlier observation (see above in
Figure 4, 5A) CHIKV infection by itself (~5% eIF2α-P)
failed to phosphorylate (ser 51) eIF2α (Figure 5B). Plaque
assay data confirmed the significant reduction in both
CHIKV and SINV viral titers upon treatment with thapsi-
gargin for 6h (Figure 5B). Next in order to examine if cel-
lular phosphatases could be directly or indirectly
modulating the de-phosphorylation of eIF2α we used
‘salubrinal’ a specific inhibitor of ER phosphatase (PP1c)
which function together with GADD34. For this, cells
were infected with CHIKV/SINV at an MOI of 1 for 1h
followed by treatment with various concentrations of
salubrinal starting from 0.625 μM to 5 μM for 24 h.
After 24 h post infection and treatment, media super-
natant was collected for plaque assay and cells were
collected for Western blotting analysis. By plaque assay,
salubrinal treatment had no effect on the production
of either CHIKV or SINV infectious virus particles. Never-
theless, salubrinal treatment lead to the increased phosphor-
ylation of eIF2α only in CHIKV infected cells suggesting the
involvement of GADD34 in CHIKV mediated eIF2α de-
phosphorylation (Figure 5C). In SINV infection salubrinal
treatment had no significant increase in the phosphorylation
of eIF2α over untreated infected cells (Figure 5C).
CHIKV protein nsP4 suppresses phosphorylation (Ser 51)
of eIF2α
To understand mechanism by which CHIKV replication
suppresses eIF2α (Ser 51) phosphorylation and also to
explore the possibility of whether any of the CHIKV-
Figure 3 The IRE-1 signaling during CHIKV and SINV infection. A, B) HEK293 cells (1×105 cells) were infected with MOI-1 of CHIKV/SINV and at
indicated time points post infection total RNA was extracted to make the cDNA. Equal amounts (1μg each) of cDNA were used for PCR based XBP-1
splicing assay using specific primers against the spliced (s-XBP-1) and un-spliced (u-XBP-1) gene variants. Virus replications in the same samples (CHIKV/
SINV) are probed using nsP1 specific primer for CHIKV or E1 specific primer for SINV (Materials and Methods). Actin gene amplification was used as an
input RNA control and 0h (uninfected cells) was used as baseline control. C, D) Under similar experimental conditions and time points stated above,
real time RT PCR analysis of XBP-1 and EDEM was done on total RNA extracted from CHIKV/SINV infected cells using specific primers (Materials and
Methods) against each of the two genes. Both gene transcripts are presented as fold change over 0h (uninfected cells) after normalization with Actin
and GAPDH mRNA. The graphs were plot using graph-pad prism software and are representative of three independent repeats. Any significant change
over 0h was determined using student unpaired T test and considered significant (*) if p<0.05.
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encoded proteins could play a role in this process, we in-
dividually cloned all the major structural and non struc-
tural genes (Figure 6A) into a CMV promoter driven
GFP tagged vector. The primers listed in Materials and
Methods were used to amplify the CHIKV genes from
the cDNA obtained from viral RNA and the resulting
correct size fragments were cloned into pEGFP-C1 vec-
tor by recombination cloning as described in the Materi-
als and Methods section. The sequence verified clones
(1 μg of each of the plasmid) were used to transfect
HEK293 cells followed by incubation for 24 h to allow
sufficient translation of plasmid-encoded proteins. SDS
PAGE separation followed by Western blotting using
anti-GFP antibody confirmed that GFP-fused CHIKV
proteins were expressed and each migrated to the cor-
rect size (Figure 6B). In the case of GFP-E1 expression,
three other bands were observed in addition to the
expected size of 87 KDa (Figure 6B). We speculate that
being a surface glycoprotein, the higher band could be a
multimeric form of GFP-E1, while the lower bands may
be due to degradation product. To address the question
whether any of these individually transfected CHIKV
genes could suppress tunicamycin-induced eIF2α (Ser
51) phosphorylation we transfected the individual GFP-
fused CHIKV genes in HEK293 cells followed by an in-
cubation period of 24 h to allow the sufficient transla-
tion of cloned genes. This was followed by tunicamycin
(0.5 μg/ml) treatment and further incubation for 24h
prior to fixing and visualizing using confocal immuno-
fluorescence microscopy or harvesting cells and analysis
by Western blotting. Remarkably, of the eight CHIKV
gene constructs that were transfected, only the expres-
sion of CHIKV nsp4, which is the RNA-dependent-RNA
polymerase, efficiently suppressed the phosphorylation
(Ser 51) of eIF2α, even in the presence of tunicamycin
(Figure 6C, D). However, other CHIKV proteins such as
nsP1, nsP2, nsP3, C, E2, E1 and the control protein GFP
had no effect on the phosphorylation (Ser 51) of eIF2α
(Figure 6C, D and other representative data which is not
shown here. In order to negate the possibility that the
nsP4 mediated suppression of the phosphorylation (Ser
51) of eIF2α may be due to a cell-line artifact; CHIKV-
GFP constructs were also examined in MRC-5 fibroblast
cell line. The results showed the similar trend of
Figure 4 The PERK signaling during CHIKV and SINV infection. A, B) HEK293 cells (1×105 cells) were infected with MOI-1 of CHIKV/SINV and
at indicated time points post infection cells were lysed using TNET lysis buffer. Lysed samples were run on 12% SDS PAGE followed by Western
blotting. Antibodies against phospho (Thr 980) PERK, phospho (Ser 51) eIF2α, eIF2α and CHOP were used to probe the PERK pathway component
protein levels during CHIKV/SINV infection. Anti-actin antibody was used to probe loading control and uninfected cells (0h) were used as baseline
protein level control. C, D) Under similar experimental conditions and time points stated above, real time RT PCR analysis of eIF2αK, CHOP and
GADD34 transcripts was done on total RNA extracted from CHIKV/SINV infected cells using specific primers (Materials and Methods) against each
of three genes. All three transcripts are presented as fold change over 0h (uninfected cells) after normalization with Actin and GAPDH mRNA. The
graphs were plot using graph-pad prism software and are representative of at-least three independent repeats. Any significant change over 0h
was determined using student unpaired T test and considered significant (*) if p<0.05.
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suppression of eIF2α phosphorylation when MRC-5 cells
were transfected with CHIKV nsP4 (Additional file 1:
Figure S2B). Cumulatively, our data suggest that expres-
sion of CHIKV nsP4 significantly reduces the phosphor-
ylation (Ser 51) of eIF2α thus ensuring translation of
viral proteins.
Discussion
Virus infection in mammalian cells consists of a series of
events from entry to maturation and egress of virus. Re-
markably, as intracellular parasites, viruses rely on the
utilization of cellular machinery and resources to
complete their life cycle. In this complex process, RNA
viruses synthesize dsRNA intermediates and produce
viral proteins within host cells. Consequently, viral repli-
cation elicits cellular responses, such as ER stress and
the interferon response, as a first line of defense against
the invading pathogen. To overcome this natural resist-
ance, viruses have evolved various mechanisms to sub-
vert host responses that limit or inhibit viral replication.
Recently, several groups [44,57-59] have reported the
impact of CHIKV or SINV replication on host cellular
interferon and apoptotic machinery. In this study we
specifically examined the cellular UPR signaling during
CHIKV and SINV infections and show that the gene/
protein expression responses in the pathway are differ-
entially modulated although the two viruses are consid-
ered to be closely related to each other. We explored in
more detail the mechanistic basis for CHIKV modula-
tion of the UPR pathway.
The stimulation of transcription and translation of BIP
(the master regulator of UPR) has been observed for sev-
eral viruses [33,60]. Not surprisingly the massive replica-
tion of CHIKV resulted in the induction of ER resident
chaperones, such as BIP and HSP-90, which presumably
assists in the folding of unfolded proteins in order to re-
lieve the UPR stress within the cell. SINV infection, on
the other hand, did not show significant induction in the
expression of BIP and HSP-90, suggesting the possible
early buildup of ER stress, which may contribute to the
apoptosis and early cell death that was observed [61].
However SINV infection caused a more pronounced
IRE-1 mediated splicing of XBP-1 gene that resulted in
transcriptional induction of XBP-1 and EDEM, a pro-
survival gene-product. Although the induction of XBP-1
and EDEM was less prominent during CHIKV infection
in comparison to SINV infection, the present data is
consistent with the recently reported role of IRE-1 sig-
naling in delaying caspase-induced cell death [62]. In the
PERK branch of UPR pathway, the phosphorylation of
PERK was observed in both CHIKV and SINV infected
cells but intriguingly the kinetics of the concomitant
phosphorylation of eIF2α showed marked difference be-
tween the two. At the early time points following
CHIKV infection although increased PERK phosphoryl-
ation could be detected from 12 h post infection, the
phosphorylation of eIF2α was not detected until 48h
post infection whereas in SINV infected cells the eIF2α
phosphorylation could be detected from 3 h post infec-
tion. This discrepancy was addressed by treating CHIKV
infected cells with thapsigargin or tunicamycin, the well
known strong inducers of PERK and eIF2α phosphoryl-
ation. This clearly demonstrated that eIF2α phosphoryl-
ation in the cell was suppressed at the early stages of
CHIKV infection (3-24 h) even with thapsigargin or
tunicamycin treatment so as to allow high and sustained
viral protein production without building up the ER
stress. At 48 h post CHIKV infection the eIF2α phos-
phorylation was quite prominent and comparable to
the level observed at the same time point in SINV
infected cells. However at this time point GADD34,
a negative regulator of PERK, which mediates the
de-phosphorylation of phospho-eIF2α and p58IPK, a
chaperone, which suppresses the PERK mediated phos-
phorylation of eIF2α were also induced, suggesting that
even when the cell tries to overcome its control by
CHIKV infection, negative loop transcripts like GADD34
and p58IPK are activated in order to rescue viral
protein synthesis. To further explore the importance of
GADD34 in mediating CHIKV induced suppression of
eIF2α-phosphorylation we used a specific GADD34 in-
hibitor ‘salubrinal’. Interestingly salubrinal treatment
during CHIKV infection lead to an increased phosphor-
ylation of eIF2α suggesting the involvement of GADD34
in suppression of eIF2α-phosphorylation. Salubrinal
treatment during SINV infection however did not show
(See figure on previous page.)
Figure 5 CHIKV infection suppresses the phosphorylation of eIF2α. A) Immunofluorescence microscopy at 10X magnification on CHIKV/SINV
(MOI-1) or mock-infected HEK293 cells at 24 h. Unlike SINV, CHIKV infection failed to phosphorylate eIF2α (red). Virus infection was probed using
dsRNA antibody (green). B) HEK293 cells were mock or CHIKV/SINV infected (MOI-1) till 12h to allow the translation of CHIKV encoded proteins
followed by treatment with thapsigargin (0.1 μM) for 6h and Western blotting was performed on cell lysates using specific antibodies against
phospho (Ser 51) eIF2α and eIF2α. Anti-actin antibody was used to probe loading control and uninfected or untreated cells (CC) were used as
baseline control. Plaque assay titers in the presence of thapsigargin for 6h are presented as log pfu/ml. C) HEK293 cells were mock or CHIKV/SINV
infected (MOI-1) for 1h. Cells were washed twice with 1X PBS to remove any traces of unbound virus particles followed by treatment with
medium containing indicated concentrations of salubrinal for 24h. At 24 h media supernatant was used for plaque assay and cells were used for
Western blotting using antibodies against phospho (Ser 51) eIF2α and eIF2α. Anti-actin antibody was used to probe loading control and
uninfected or untreated cells (CC) were used as baseline control.
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any significant change in the phosphorylation of eIF2α
over untreated SINV infected cells. Also, interestingly
CHOP activity was not detected at both protein and
transcription levels throughout the CHIKV infection
time course. In stark contrast to CHIKV, SINV infection
leads to phosphorylation of PERK and a dramatic in-
crease in the phosphorylation of eIF2α starting from 3h
post infection. The enhanced expression of CHOP
detected as early as 3h suggests the signature cell death
by apoptosis during SINV infection. Although, GADD34
was transcriptionally induced during SINV infection the
heightened phosphorylation of eIF2α and further in-
crease in CHOP activity triggers massive cell death,
which could be observed starting from 12 h post infec-
tion (data not shown). Altogether, our data suggest that
the PERK branch of UPR pathway is regulated during
CHIKV infection as reflected by the suppression in the
phosphorylation of eIF2α during the early stage of infec-
tion and the reduced CHOP activity.
A mechanistic basis for the suppression in the phos-
phorylation of eIF2α during the early stage of CHIKV
infection was investigated using EGFP-tagged clones of
seven CHIKV proteins and we discovered that the
observed phenotype in the PERK pathway (i.e. suppres-
sion of the phosphorylation of eIF2α) is mediated by
CHIKV nsP4 protein, which contains the RNA-
dependent-RNA polymerase activity. An interesting
conjunction to our finding is that nsP4 protein of
alphavirus is the first non-structural protein to be
cleaved from the nsP1-4 polyprotein. and this cleavage
as well as its enzymatic activity play a critical role in the
synthesis of minus strand viral RNA [4]. Furthermore it
is also well known that the alphavirus nsP4 is unstable,
short-lived and degrades rapidly in the infected cell [63].
This instability of nsP4 could possibly explain why
infected cells recover some degree of eIF2α phosphoryl-
ation in the late phase of infection (48 h). Together, we
suspect that early suppression of the translation inhib-
ition involving nsP4 could permit the buildup of
template RNA for further translation and, thereby, sup-
port robust replication.
The question of how CHIKV regulates the host trans-
lational machinery to achieve a high level of replication
is important to examine in detail particularly in light of
seemingly contradictory reports on this topic. White et al.
[59], reported independence of CHIKV induced transla-
tional shut-off from the phosphorylation of eIF2α, an intri-
guing finding since eIF2α phosphorylation has a well
established role in the shut-off of the host translational
machinery [64]. However, in our detailed time course
experiments with HEK293 cells, we did not observe eIF2α
phosphorylation until 48 h post infection, which was also
consistently not observed in another cell type MRC-5 cells
until 48 h. We believe our detailed time course study pro-
vides advantage in understanding the complex early events
of virus-host interactions in the UPR pathways. That it
occurs, mechanistically, is interesting since the actions of
transiently stable nsP4 function correlate to viral RNA
replication and life cycle. Even at the late phase of infec-
tion induction of ER chaperones (BIP, HSP-90) along with
pro-survival gene-product (EDEM) could work synergis-
tically with negative regulators of eIF2α phosphorylation
(p58IPK, GADD34) to possibly support sustained CHIKV
replication. SINV infection, on the contrary, is character-
ized by uncontrolled UPR as reflected by its failure to in-
duce synthesis of ER chaperones followed by increased
phosphorylation of eIF2α and CHOP activity leading to
early cell death. Since both CHIKV and SINV infections
showed differential activation or modulation of the UPR,
further detailed studies on the effects of infection on host
cellular UPR machinery is required to better understand
their characteristic prolific replication profiles.
In conclusion, we show that the two closely linked
viruses CHIKV and SINV from the same family, responds
differently to the host cellular UPR machinery. Indeed,
CHIKV infection modulates the PERK branch of UPR
machinery and that it occurs mechanistically through
the involvement of the viral protein nsP4 in direct or
(See figure on previous page.)
Figure 6 CHIKV nsP4 suppresses the phosphorylation of eIF2α. A) Schematic diagram showing the organization of CHIKV genes in the viral
genome. CHIKV genes (nsP1-4, C, E1 &E2) were cloned in a CMV driven GFP tagged vector and restriction analysis in Figure 6A shows expected
size insert in respective positive clones. B) HEK293 cells were transfected with 1 μg each of the recombinant CHIKV-gene plasmids and incubated
for 24 h to permit protein translation. At 24 h, Western blotting was performed with anti-GFP antibody for the detection of the correct size
proteins. Cells treated with transfection reagent without plasmid were used as negative control (CC). C) HEK293 cells were transfected with 1μg
each of CHIKV-gene carrying plasmids or control GFP-gene plasmid for 24h and then treated with tunicamycin (0.5 μg/ml) for 24 h followed by
immunofluorescence detection using antibody against phospho (Ser 51) eIF2α (red) under the confocal microscope and images were captured at
63X magnification. Nuclear stain DAPI (blue) was used to differentiate single cells and individually expressed CHIKV proteins were visualized as
GFP-fused proteins (green). As indicated using red arrows staining of phospho (Ser 51) eIF2α (red) was dramatically reduced in cells expressing
CHIKV nsP4. Images were processed using Zen image software from Zeiss. D) Cells (HEK293) were transfected with C, nsP2 and nsP4 or a control
plasmid GFP for 24 h and then further treated with tunicamycin (0.5μg/ml) for 24 h followed by Western blotting using antibodies against
phospho (Ser 51) eIF2α, and eIF2α. Anti-GAPDH was used as loading control and anti-GFP was used to probe plasmid encoded protein
expressions. Change in band intensity of phospho (Ser 51) eIF2α in GFP and nsP4 transfected cells was calculated using image-J and presented as
% eIF2α-P over total eIF2α. The data is representative of two independent experiments. The symbol (*) denotes p < 0.05.
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indirect conjunction with host factors such as GADD34.
The early suppression of UPR provides a mechanism for
robust replication. Our observation opens up the possi-
bility to explore in detail the interplay of CHIKV nsP4
protein in establishing the infection and exploit possible
avenues to use this in identifying a suitable target for
antiviral intervention.
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a b s t r a c t
The global emergence of Chikungunya virus (CHIKV) infection is alarming and currently there is no
licensed vaccine or antiviral treatment available to mitigate this disease. CHIKV infection typically results
in high viral load with an outcome of high fever, skin rashes, muscle pain, and sequelae of prolonged
arthritis, which occurs in >90% of the infected cases. In this study, using biochemical pull-downs,
mass-spectrometry, and microscopic imaging techniques, we have identified novel interactions between
CHIKV nsP3 or nsP4 proteins with the host stress-pathway chaperone HSP-90 protein. Indeed, silencing of
HSP-90 transcripts using siRNA disrupts CHIKV replication in cultured cells. Furthermore, drugs targeting
HSP-90, such as commercially available geldanamycin, as well as other specific HSP-90 inhibitor drugs
that had been obtained from a purinome mining approach (HS-10 and SNX-2112) showed dramatic
reduction in viral titers and reduced inflammation in a CHIKV mouse model of severe infection and mus-
culopathy. The detailed study of the underlying molecular mechanism of these viral and host protein
interactions may provide a platform to develop novel therapeutics against CHIKV infection.
! 2013 Elsevier B.V. All rights reserved.
1. Introduction
Chikungunya virus (CHIKV) is an alphavirus that belongs to the
family Togaviridae and is responsible for a human disease known as
Chikungunya fever (Burt et al., 2012). Since its first isolation in
Tanzania in 1952, CHIKV has spread massively and at present sev-
eral millions of people living in Asia and Africa are at risk of con-
tracting the disease (Schwartz and Albert, 2010). Chikungunya
fever is typified by a very high viraemic load and associated abnor-
malities such as lymphopenia and thrombocytopenia (Borgherini
et al., 2007). The disease progression is rarely asymptomatic and
usually patients require medical attention, which constitutes a ma-
jor socioeconomic burden on society. The mortality rates associ-
ated with CHIKV infections are low (1:1000) and the disease
predominantly is self-limiting. However, in some instances pa-
tients experience a relapse with persistent arthralgia or musculo-
skeletal pains that can last from several months to years.
Newborns and elderly people are particularly vulnerable for devel-
oping severe complications during the disease (Schwartz and Al-
bert, 2010).
The CHIKV genome, like all alphaviruses, is a single stranded
RNA molecule of !12 kb in size and positive polarity with a
7 mG cap at the 50 end and a poly-A tail at the 30 end. The CHIKV
genome reads in two open reading frames (ORFs), where the 50
ORF is directly translated from the genomic RNA encodes for four
non-structural proteins (nsPs) that serve various functions essen-
tial for virus replication; nsP1 contains methyl transferase and
guanyl transferase activities; nsP2 is a helicase/protease enzyme;
nsP3 is an accessory protein involved in viral RNA synthesis and
nsP4 is the RNA dependent RNA polymerase enzyme. The 30 ORF
is translated from the 26S sub-genomic RNA and encodes for viral
structural proteins such as nucleocapsid C, viral glycoproteins E1
and E2 and small peptides E3 and 6k (Li et al., 2010; Lulla et al.,
2013; Strauss and Strauss, 1994; Voss et al., 2010).
0166-3542/$ - see front matter ! 2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.antiviral.2013.12.010
q Parts of the information have been presented at the Keystone Conference on
positive strand RNA viruses in Boston, Massachusetts, USA (April 28th–May 3rd,
2013).
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To fulfill various critical functions required for virus replication,
it is believed that viral non-structural proteins work in conjunction
with the numerous host cellular proteins. Detailed understanding
of these interactions between viral and host proteins are crucial
for unraveling the viral replication and pathogenesis mechanisms
and also help discover novel antiviral drug targets. In recent years
various antiviral strategies have been proposed to control CHIKV
infection, utilizing both viral and host targets (Kaur and Chu,
2013; Rashad et al., 2013). However, currently there is no safe anti-
viral treatment available to mitigate the disease. In our previous
study we investigated the role of Unfolded Protein Response
(UPR) machinery during CHIKV infection and showed that the
UPR signaling arms such as the PERK pathway was highly regu-
lated by viral nsP4 protein and the levels of protein folding chaper-
ones such as HSP-90 and p58IPK were significantly induced
(Rathore et al., 2013). HSP-90 has known functions in assisting
the key steps of virus replication during Influenza and HCV infec-
tions (Geller et al., 2012; Okamoto et al., 2006). However, the de-
tailed mechanism of HSP-90 involvement during CHIKV infection
is not known.
In mammalian cells, HSP-90s are a family of highly conserved
molecular chaperones. These include two cytoplasmic isoforms;
stress-induced HSP-90a and constitutively expressed HSP-90b,
the latter of which has an ER resident homologue, Grp94, and a
mitochondrial homologue, TRAP-1 (Chen et al., 2005). The HSP-
90 proteins form a homodimeric complex with each monomer con-
sisting of a C-terminal dimerization domain, a middle domain and
an N-terminal ATPase domain (Pearl and Prodromou, 2006). In
general, HSP-90 is involved in maturation, localization, and turn-
over of its client proteins in a cell (Chadli et al., 2000; Prodromou
et al., 2000). Viral proteins, like cellular proteins, also require fold-
ing and assembly for function and HSP-90 has been known to play
an important role in the replication of many DNA and RNA viruses.
For instance, HSP-90 stabilizes and stimulates the reverse tran-
scription reaction step during hepatitis-B virus replication (Hu
and Anselmo, 2000; Hu et al., 1997). Similarly, during influenza
virus replication, the polymerase complex comprising of PB1,
PB2, and PA is stabilized by HSP-90 protein, an essential step for
virus replication (Momose et al., 2002; Naito et al., 2007). Other
viruses which utilize HSP-90 proteins during their replication in-
clude alpha-herpes simplex virus-1, human cytomegalovirus, flock
house virus, vesicular stomatitis virus, human parainfluenza 2/3
virus, hepatitis C virus, simian virus 5/41, and bunyavirus (Geller
et al., 2012). The reliance of many viruses on HSP-90 for replication
makes it an interesting potential broad-spectrum antiviral drug
target. Inhibitors of HSP-90 such as geldanamycin and its deriva-
tives, 17-allyl-17-demethoxygeldanamycin (17AAG) and 17-des-
methoxy-17-N,N-dimethylaminoethylaminogeldanamycin
(17DMAG) have been shown to possess antiviral activity in cell cul-
ture against range of DNA and RNA viruses (Geller et al., 2012). In
this study, we evaluated both in vitro and in vivo activities of spe-
cific HSP-90 inhibitor drugs, HS-10 and SNX-2112 against CHIKV
infection. Moreover, using biochemical techniques and by over-
expressing individual CHIKV non-structural proteins we identified
novel interactions between the HSP-90 protein and CHIKV nsP3
and nsP4 proteins. This study suggests an important role for
HSP-90 during CHIKV infection and opens up the possibility of tar-
geting this specific interaction.
2. Materials and methods
2.1. Cells and viruses
Mosquito cells Aedesalbopictus clone (C6/36) and baby hamster
kidney cells (BHK-21) were cultured in RPMI-1640 medium (Gib-
co) supplemented with 10% fetal bovine serum (FBS) (Gibco). Hu-
man embryonic kidney cells expressing SV40 large T antigen
(HEK-293T) were cultured in DMEM (Gibco) supplemented with
10% FBS. C6/36 cells were used for making virus stocks, grown
and maintained in 28 !C temperature incubator. BHK-21 and
HEK-293T cells were grown and maintained at 37 !C in a humidi-
fied incubator with 5% CO2 atmosphere. CHIKV laboratory strain
‘ROSS’ and a human clinical isolate-CHIKV EAS (East African lineage
strain-DMERI09/08) was a generous gift from Dr. Ooi Eng Eong
(Duke-NUS reference laboratory). Viruses were amplified in C6/
36 cells supplemented with 5% FBS at 28 !C and titrated by plaque
assay as described previously (Rathore et al., 2011). Low passage
number virus (below passage 5) was used for performing all
experiments.
2.2. Therapeutic drugs
Geldanamycin was purchased from Sigma. HSP-90 inhibitor
drugs; HS-10 (HS-100010) and SNX-2112 were synthesized in
the laboratory of Dr. Timothy Haystead at Duke University as de-
scribed elsewhere (Huang et al., 2009; Hughes et al., 2012).
2.3. Anti-CHIKV antibodies
A rabbit anti-CHIKV E1 polyclonal serum was prepared in-
house. Anti-CHIKV-nsP3 and nsP4 polyclonal serum was raised
and characterized in the laboratory of Dr. Andres Merits.
2.4. Cell viability
The cytotoxicity of each test drug was separately measured on
BHK-21 or HEK-293T cells using the cell titer-Glo luminescent cell
viability assay, according to the manufacturer’s protocol (G7570;
Promega). The luminescence signals for cells treated with the test
drugs were compared to those for cells treated with the maximum
tolerated dimethyl sulfoxide (DMSO) to determine the 50% cyto-
toxic concentration (CC50). Furthermore, the cytotoxicity data pre-
sented in Fig. 1 was determined by counting the number of viable
cells in the presence of drugs or DMSO at 24 h post-infection/
treatment.
2.5. CHIKV infection of HEK-293T or BHK-21 cells
The infections of HEK-293T or BHK-21 cells were done using
multiplicity of infection (MOI) of 1 of CHIKV-ROSS strain at 37 !C
in a humidified incubator with 5% CO2 atmosphere for 1 h. Cells
were washed twice with non-serum containing growth media be-
fore mock or drug treatment for 12 or 24 h.
2.6. RNA extraction and real-time RT-PCR analysis
HEK-293T cells (1 ! 105) were infected with CHIKV at a MOI of
1. At indicated time intervals, total RNA was extracted using the
trizol (Invitrogen) extraction method and 1 lg of total RNA was
used for cDNA synthesis using ImProm II reverse transcription sys-
tem (Promega), with oligo-dT as primers. cDNA (50 ng) was used
for real-time amplification of specific genes using respective prim-
ers (Supplementary material) in a Bio-Rad iQ-5 real time thermal
cycler. The expression of viral and host gene products was normal-
ized to actin or 18S rRNA, followed by normalization to the expres-
sion levels at uninfected conditions.
2.7. Western blotting
HEK-293T cells (1 ! 105) were infected with MOI of 1 with
CHIKV and total cell lysate was collected in NET lysis buffer
8 A.P.S. Rathore et al. / Antiviral Research 103 (2014) 7–16
	   336	  
 
(20 mM Tris, 100 mM NaCl & 1 mM EDTA) containing 0.1% Triton
x-100 with protease inhibitor cocktail (Roche) at indicated time
points post infections. After 30 min on ice, lysates were centrifuged
at 13,000 rpm for 10 min and supernatants were used to quantitate
the amount of total protein by BCA assay (Pierce). Equal amounts
(2–5 lg each) of protein were loaded on 12% SDS–PAGE followed
by Western blotting. Blots were blocked overnight with blocking
solution [2% Fish gelatin (Sigma) in 1!-PBS] and were probed using
primary antibodies against various proteins: CHIKV-E protein (in-
house) anti-CHIKV-nsP3 serum, anti-CHIKV-nsP4 serum, total
HSP-90 protein (cell signaling), HSP-90a or HSP-90b subunit (Sin-
gapore Advanced Biologics (SABIO) Pte Ltd), anti-GFP (Abcam) and
anti-Actin antibody (Sigma) were used as the loading control anti-
bodies. All the antibodies used were diluted in blocking solution.
After incubating with secondary HRP-conjugated antibodies, blots
were developed using ECL detection reagent (GE healthcare) and
visualized using an Image-quant chemiluminescent machine.
2.8. Transfection of plasmids
For the transfection of plasmid DNA into HEK-293T cells, cells
were seeded to 70% confluency in a 24 well plate (Nunc) and incu-
bated overnight in a 37 !C incubator supplemented with 5% CO2
atmosphere. One or 2 lg of each of the plasmid (GFP vector, GFP-
CHIKV nsP1/2/3/4, described previously in (Rathore et al., 2013))
were transfected using the jet-prime transfection reagent (Polypus
BST scientific) as per the manufacturers described protocol. Trans-
fected cells were incubated for 24 h for protein expression and
then washed once with 1!-PBS (Gibco). Finally, cells were col-
lected in TNET-lysis buffer and then subjected to Western blotting
as described above. The transfection efficiencies were verified by
fluorescence microscopic visualization for each of the transfected
plasmids.
For siRNA transfections, 100 nM each of the non-targeted, si-
HSP-90(1) and si-HSP-90(2) (SABIO) were transfected in 24 well-
plates using jet-prime transfection reagent (Polypus BST scientific)
essentially following the manufacturers protocol. At 24 h post
silencing, cells were either mock or CHIKV infected for a further
24 h. The siRNA sequences are provided in the Supplemental
material.
2.9. Co-immunoprecipitation
HEK-293T cells (1 ! 105) were transfected with plasmids (GFP
vector, GFP-CHIKV nsP1/2/3/4) as described above or infected with
CHIKV-ROSS (MOI-1) and incubated for 24 h in a humidified CO2
incubator at 37 !C. At 24 h post-transfection, cells were washed
once with 1!-PBS and lysed using TNET lysis buffer containing
protease inhibitor cocktail. Lysis was continued on ice for a further
1 h with intermittent mixing at 15 min each. The cell lysates were
clarified at high speed (14,000 rpm and 4 !C) and the supernatants
were collected on ice. Two lg of the polyclonal anti-GFP antibody
(Abcam) or HSP-90a or HSP-90b antibody (SABIO) were added in
each of the clarified lysates with further incubation overnight at
4 !C with a constant mixing using an end-over-end rotor. Immune
complexes formed were pulled out using 50 ll/reaction of protein
A/G beads (Pierce). Finally, beads were washed 3-times with lysis
buffer followed by elution of immune complexes in 1!-SDS load-
Fig. 1. HSP-90 inhibitors reduce CHIKV infection. (A) Plaque assay quantification of CHIKV replication in HEK-293T cells infected with MOI-1 of CHIKV for 1 h followed by
mock or geldanamycin (1.5 lM) treatment for 24 h. At 24 h post treatment plaque assay was performed using media supernatants. (B) Toxicity test for specific HSP-90
inhibitors HS-10 or SNX-2112 in HEK-293T cells treated with increasing concentrations of drugs for 24 h followed by viable cell counting using trypan blue stain. (C and D)
Dose–response curve for HS-10 or SNX-2112 in HEK-293T cells infected with MOI-1 of CHIKV for 1 h followed by mock or drug treatments at indicated concentrations for
24 h. At 24 h post treatments plaque assay was performed using media supernatant from each condition tested. A sigmoidal dose–response curve was plot using GraphPad-
prism software, where dotted line represents the error range at each concentration tested.
A.P.S. Rathore et al. / Antiviral Research 103 (2014) 7–16 9




ing dye with 15 min boiling in a water bath. Eluted samples were
spun at high speed before being analyzed by SDS–PAGE and Wes-
tern blotting.
2.10. Sample preparation for mass-spectrometry
HEK-293T cells (5 ! 106) were transfected with 10 lg of each of
the plasmids (GFP, GFP-nsP3 or GFP-nsP4) for 24 h. All the steps
described below were performed at 4 !C. For each immunoprecip-
itation reaction, cells were suspended in 200 ll of lysis buffer
(10 mM Tris/Cl, pH 7.5; 150 mM NaCl; 0.5 mM EDTA; 0.5% NP-40
and complete protease inhibitor cocktail). Lysis was further contin-
ued for 30 min with extensive mixing, before lysates were being
clarified at 20,000g for 10 min. Supernatants were collected in a
pre-cooled tube and the final volume was adjusted to 0.5 ml with
dilution buffer (10 mM Tris/Cl, pH 7.5; 150 mM NaCl; 0.5 mM
EDTA and complete protease inhibitor cocktail). GFP-TrapA beads
(30 ll each) were equilibrated in 0.5 ml dilution buffer for
15 min. Clarified cell lysates were added to equilibrated GFP-TrapA
beads and were incubated under constant mixing for overnight.
Beads were spun down at 2500g for 2 min and washed once with
0.5 ml ice-cold wash buffer (10 mM Tris/Cl, pH 7.5; 150 mM NaCl;
0.5 mM EDTA) and one time with 0.5% NP-40 in PBS followed by a
final 2 washes with 50 mM ammonium bicarbonate. Elution was
done using 60 ll of mass-spectrometry compatible elution buffer
(0.25% RapiGest SF in 50 mM ammonium bicarbonate) and in-solu-
tion mass-spec analysis of the trypsin-digested protein samples
was done using LC/ESI/MS/MS mass-spectrometry at the Duke pro-
teomic facility, USA. Peptide sequences from the mass-spec analy-
sis were matched against Swiss-prot 2013x database using
‘Mascot’ database search algorithm and the data analysis was car-
ried out using ‘Scaffold’ version 4.0.7 software using peptide
threshold of min 97% and protein threshold of min 45% (minimum
two peptides) (Bodnar et al., 2003).
2.11. Immunofluorescence
HEK-293T cells or BHK-21 cells were seeded on glass coverslips
at a density of 1 ! 105 cells/well in a 12-well plate. Following incu-
bation overnight at 37 !C with 5% CO2, the cells were transfected
with plasmids (GFP vector, GFP-CHIKV nsP1/2/3/4) or infected with
CHIKV-ROSS (MOI-1). At 24 h post-transfection/infection, cells
were fixed with ice cold 80% acetone for 10 min followed by over-
night incubation with blocking buffer (5% BSA in 1!-PBS) at 4 !C.
The primary antibodies used were anti HSP-90-total (cell signal-
ing) or HSP-90a or HSP-90b (SABIO). The secondary antibody used
was anti-rabbit alexa-594 or anti mouse alexa-488. All the anti-
bodies used were diluted in blocking buffer. The coverslips were
mounted on glass slides using prolong gold anti-fade mounting
medium (Invitrogen) containing DAPI. Immunofluorescence
images were captured using an upright confocal microscope (Zeiss)
and image analysis was performed with Zeiss image analysis
software.
2.12. In vivo infection
Sv/129 mice deficient in type -I IFN receptors (A129), purchased
from B&K Universal (UK), were housed in the BSL-2 animal facility
at Duke-NUS, Singapore and all animal experiments were approved
by the Animal Care Committee at Singapore General Hospital. For
infection, mice (n = 6) were inoculated with CHIKV EAS (100 pfu/
20 ll) via the footpad route and the control groups were given
5% DMSO in saline as either vehicle control or mock treatment.
For treatment during infection, mice were either mock or HS-10/
SNX-2112 treated (10 mg/kg/twice a day) for 3 days, starting from
day 0. Blood was collected for viremia at day 2 ("48 h) and 3
("72 h) post infection/treatment. Animals were euthanized at hu-
mane end points and muscle tissues were collected for cryo-sec-
tioning, staining and microscopic visualizations.
Limb swelling measurements: For measuring swelling in the in-
fected limbs, animals were very briefly held in the restrainer and
the measurement was done using a standard surgical ruler.
Tissue processing: Muscle tissues were harvested and frozen in
OCT compound (Tissue-Tek), and frozen sectioned ("10 lm thick-
ness) using a cryostat (Leica). Sections were fixed with acetone at
4 !C and air dried before being stained with 0.1% Mayer’s Hematox-
ylin (Sigma) for 10 min followed by 5 min wash with water. Sec-
tions were further stained with 0.5% Eosin for 2 min, washed
with water and then sequentially dehydrated using 50%, 70%,
95%, and 100% ethanol followed by final dehydration step in xy-
lene. Slides were mounted with permount (Bio-world) before visu-
alization and image capturing using an inverted fluorescence
microscope (Olympus IX71, USA).
2.13. Serum cytokine levels
Equal volumes of serum from individual mice were pooled in
each of the experimental groups and the concentration of each
pro-inflammatory cytokines in the serum was measured using ELI-
SA kits (R&D systems), following the manufacturer’s described
protocol.
2.14. Statistics
Statistical comparison of results were performed using un-
paired Student’s t-test using GraphPad Prism 5.0 software or using
Microsoft Excel software with p < 0.005 considered statistically sig-
nificant. For more than two comparisons one-way ANOVA test was
used.
3. Results
3.1. Drugs targeting HSP-90 reduce CHIKV infection
To determine the role of HSP-90 during CHIKV infection we
firstly used a commercially available, HSP-90 inhibitor drug ‘gel-
danamycin’. Geldanamycin binds in the ATP binding site on HSP-
90 and renders the protein in an open conformation (Stebbins
et al., 1997). However, the ATP-driven closed conformation of
HSP-90 is required for its chaperone function (Ali et al., 2006).
HEK-293T cells were infected with CHIKV (MOI-1) for 1 h followed
by mock or geldanamycin treatment for 24 h and virus production
in the cells was monitored by plaque assay. We found that gel-
danamycin treatment reduced CHIKV infection by "2.5 log sug-
gesting a significant involvement of HSP-90 during CHIKV
infectionor replication (Fig. 1A). Indeed, to rule out the possibility
of any off-target effects of geldanamycin during CHIKV infection,
we employed two very specific synthetic inhibitors of HSP-90,
HS-10, and SNX-2112, that are close structural analogs of the clin-
ical candidate SNX-5422 (Fadden et al., 2010). First we confirmed
that the drug concentrations used in this study are not toxic to
the cells (Fig. 1B). Furthermore, no cytotoxicity was observed for
either of the test drugs up to 100 lM for 24 h post-drug treatments
(Fig. S1). Next, we measured the efficacy of HS-10 and SNX-2112
test drugs against CHIKV infection. For this, CHIKV infected HEK-
293T cells were treated at various concentrations of HS-10 or
SNX-2112 for 24 h and the virus infection was measured by plaque
assay. Both HS-10 and SNX-2112 showed a dose-dependent reduc-
tion in viral titers, further implicating a specific role of HSP-90 dur-
ing the CHIKV infection cycle (Fig. 1C and D).
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3.2. HSP-90 inhibitors affect CHIKV replication
Next, we sought to understand if the inhibitory effects seen
with HSP-90 inhibitors have any direct effect on CHIKV replication.
For this, HEK-293T cells were infected with MOI-1 of CHIKV fol-
lowed by mock treatment or drug treatment with 10 lM dose of
HS-10 or SNX-2112 for 12 h. At 12 h post infection/treatment,
the amount of viral RNA (nsP1 or E2 gene) or total HSP-90 mRNA
was measured by real time RT-PCR and the protein levels were
measured by Western blotting (Fig. 2). Interestingly, a significant
reduction (!50–100 fold) in the levels of viral RNA was observed
during both HS-10 and SNX-2112 treatments (Fig. 2A and C); how-
ever, the mRNA levels of HSP-90 were not altered (Fig. 2B and C).
Similarly, viral protein levels measured by Western blot detection
of the CHIKV-E1 protein were also dramatically reduced during
drug treatments with no significant change in the levels of total
HSP-90protein (Fig. 2D). Furthermore, using immunofluorescence
microscopy we observed a visually striking reduction in virus
infection upon HS-10 or SNX-2112 (2 lM) treatment for 12 h
(Fig. 2E). Together our data suggest that blocking the chaperone
function of HSP-90 does not affect its protein level or its transcrip-
tion, but, results in a marked, early (12 h) reduction in the levels of
both viral RNA and protein. This early inhibition of CHIKV infection
could be due to the effects of HS-10 or SNX-2112 at virus replica-
tion level.
3.3. siRNA silencing of HSP-90 has detrimental effects on CHIKV
replication
To better understand the importance of HSP-90 protein during
CHIKV replication, we silenced the HSP-90 transcripts using two
specific siRNAs targeting the HSP-90mRNA and measured the
CHIKV replication in HSP-90-knockdown cells. First, we confirmed
using real time PCR that the siRNAs successfully knocked-down the
transcription of HSP-90 at 24 h and noted that siRNA(2) showed
more pronounced knockdown of HSP-90 and also a greater reduc-
tion in HSP-90 protein level compared to siRNA(1) or non-targeted
siRNA control (Fig. 3B and C). Next, to assess the effects of HSP-90
knockdown on CHIKV replication, we infected HSP-90-knockdown
cells with CHIKV at an MOI of 1 for 24 h, collected the cell superna-
tant for plaque assay analysis and harvested the total cells for RNA
or protein analysis. Consistent with the drug inhibition of HSP-90,
siRNA silencing of HSP-90 transcript showed a dramatic reduction
in virus production (Fig. 3A), viral RNA (Fig. 3B) and viral protein
levels (Fig. 3C), compared to the non-targeted siRNA infection con-
trol (Fig. 3). Despite the differing levels of HSP-90 mRNA knock-
down with both specific siRNAs, a significant reduction in the
CHIKV replication was observed (Fig. 3). Overall siRNA knockdown
data here support the HSP-90 specific drug inhibition of CHIKV
infection and suggest that HSP-90 has a critical function in CHIKV
replication.
3.4. CHIKV nsP3 or nsP4 proteins interact with HSP-90b or HSP-90a
subunits
With an aim to explore the mechanism of HSP-90 function dur-
ing CHIKV replication, we used our previously described GFP-
tagged CHIKV protein expressing constructs (Rathore et al.,
2013). Based on the results shown above in Figs. 1 and 3, we
hypothesized that HSP-90 protein must interact with the CHIKV
non-structural proteins to help virus replication. To prove this,
we over-expressed each of the GFP-CHIKV non-structural proteins
for 24 h followed by fluorescent confocal microscopy imaging
using antibody against total HSP-90 protein. Interestingly, two of
the CHIKV nsPs (nsP3 and nsP4) showed strong co-localization
with HSP-90 protein (Fig. 4A). Visually, nsP2 also appeared to show
some degree of co-localization (Fig. 4A); however, this interaction
was not validated by the GFP-pull-down assay that we performed.
Indeed, despite the similar levels of expression of CHIKV nsP2 and
nsP4 in our pull-down experiment, we did not observe any bio-
chemical interaction between nsP2 and HSP-90. This suggests that
the observed interaction with nsP4 is specific (Fig. 4B). Moreover,
our data shows strong evidence of a novel, unreported, interaction
between CHIKV nsP3 and HSP-90 protein (Fig. 4A). To further con-
firm the visual association of HSP-90 with CHKV proteins, we ad-
dressed the question whether HSP-90 protein could be pulled
down along with the over-expressed GFP-CHIKV nsPs using an
anti-GFP antibody. Indeed, in our pull-down assay we show strong
and specific interactions between CHIKV nsP3 or nsP4 proteins and
HSP-90 (Fig. 4B). These studies investigated the role of total HSP-
90 protein during CHIKV infection; however, HSP-90 protein in a
mammalian cell exists in two isomeric forms; a cytoplasmic HSP-
90a subunit and an ER predominant HSP-90b subunit (Little
et al., 1994; Meng et al., 1996). Therefore, we sought to investigate
whether there is any specificity in interaction between CHIKV nsP3
or nsP4 proteins with HSP-90a or HSP-90b subunits. For this, we
over-expressed CHIKV nsP3, nsP4 or GFP-only in HEK-293T cells
for 24 h followed by GFP pull-downs using GFP-TrapA beads. The
pull-down samples were run on SDS–PAGE and silver stained.
We observed minimal background interaction with GFP, yet many
interacting bands were seen in CHIKV nsP3 or nsP4 pull-down
lanes (Fig. 4C). Further analysis of these pull-down samples using
LC/ESI/MS/MS mass-spectrometry revealed unique specific inter-
actions between CHIKV GFP-nsP3 with HSP-90b subunit (17 un-
ique peptides matched) or GFP-nsP4 with HSP-90a and HSP-90b
subunits, respectively (16 or 13 unique peptides matched, respec-
tively). GFP alone as a control did not show any significant interac-
tion with either HSP-90a or HSP-90b subunits (only 1 or 0 unique
peptides matched, respectively) (Figs. 4D and S2). This data sug-
gests that nsP3 may interact more specifically with HSP-90b while
nsP4 may interact with both HSP-90a and HSP-90b subunits
(Figs. 4D and S2). Next to further verify our mass-spectrometry
data we probed the GFP-pull-down samples with specific HSP-
90a and HSP-90b antibodies by Western blotting. Consistent with
our mass-spectrometry interaction data, we saw HSP-90a co-pre-
cipitated with over-expressed nsp4 while HSP-90b co-precipitated
with over-expressed nsP3. GFP as a control did not precipitate
either of the HSP-90 subunits (Fig. S3A). This specific interaction
between HSP-90a and CHIKV-nsP4 could also be visualized using
immunofluorescence confocal imaging (Fig. S3B). To address the
significance of these interactions in the context viral infection,
we did the reverse pull-downs using antibodies specific to HSP-
90a and HSP-90b subunits and probed the western blots with
anti-CHIKV-nsP3 and anti-CHIKV nsP4 polyclonal serum (Fig. 4E).
Indeed, our data show that CHIKV-nsP3 co-precipitated with
HSP-90b and CHIKV-nsP4 co-precipitated with HSP-90aproteins
(Fig. 4E), thus validating all of the data obtained above through
an over-expression system.
The importance of these specific interactions with unique HSP-
90 subunits was further studied by specifically amplifying both
HSP-90a and HSP-90b in the HSP-90 knockdown cells using siR-
NAs. By amplifying HSP-90a and HSP-90b transcripts separately
we observed that siRNA(1) moderately silenced both the HSP-
90a and HSP-90b subunits (Figs. 4F and S4). However, in the case
of siRNA(2), only HSP-90a transcript was suppressed and not the
HSP-90b, suggesting that siRNA(2) was specific to HSP-90a subunit
(Figs. 4F and S4). Next, we dissected the roles of each individual
HSP-90 subunit during CHIKV replication, using the specifically
targeting siRNAs. Interestingly the amount of viral RNA produced
was significantly reduced in the presence of siRNA(2) where
HSP-90a subunit was knocked-down; however, the levels of
HSP-90b subunit were not altered (Figs. 4F and S4). The data here
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Fig. 2. CHIKV replication is affected by HSP-90 inhibitors. (A) Real time PCR analysis of viral nsP1 or E2 and host HSP-90 (total) gene from the total RNA extracted from the
CHIKV-infected (MOI-1) cells, which were either mock or HS-10 or SNX-2112 treated at the dose of 10 lM for 12 h show reduction in the viral RNA after normalization to the
levels seen in the infected but untreated control and actin. The reduction in viral RNA is highly significant as determined by one-way ANOVA test (p = <0.0001). (B) Mean Ct
values from the Real time RT PCR are presented to show that drug treatments had no effects on the mRNA levels of total HSP-90. (C) Real time PCR products were run on 2%
agarose gel to verify the correct amplification sizes of each of the CHIKV E2, HSP-90 and actin transcripts. (D) Under similar experimental conditions as described above,
Western blotting was performed using antibodies specific for total HSP-90 and CHIKV E protein. Uninfected/untreated cells and mock-treated but infected (CHIKV) cells are
shown as endogenous controls and actin was used as the input RNA or loading control. (E) Immunofluorescence microscopy images show significant reduction in CHIKV
replication (CHIKV E protein-red) upon treatment with either HS-10 or SNX-2112. Endogenous levels of total HSP-90 are shown in green whereas the nucleus is stained blue.
HEK-293T cells were grown overnight on a tissue culture coverslip in a 24-well plate followed by 1 h infection with CHIKV at an MOI of 1. After infection, excess media was
removed and cells were either mock or HS-10 or SNX-2112 treated at a dose of 2 lM, for 12 h. (For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article.)
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shows for the first time that in addition to HSP-90b, HSP-90a plays
an essential role in CHIKV replication and that the interaction be-
tween CHIKV nsp4 and HSP-90a might be critical for assembly of
the viral replication complex.
3.5. HSP-90 inhibitors reduce CHIKV viremia and inflammation in vivo
The specificity of the action of HSP-90-targeted drugs and the
finding that specific biochemical interactions occur between HSP-
90 subunits and viral nsPs, prompted us to evaluate the efficacy
of these drugs in a CHIKV mouse model of lethal infection and
inflammation. Mice (SvA129) deficient in type-I interferons (IFN-
a and IFN-b) were infected with 100 pfu of a clinical isolate of
CHIKV via the footpad route and either mock or HS-10 or SNX-
2112 treated via i.p. injection at a dose of 10 mg/kg twice a day
for 3 days. Serum viremia levels on day 2 (!48 h) in the treated
group showed significant reduction in the virus titers compared
to the mock-treated group (Fig. 5A). Viral infection was also probed
in the limb muscle using RT-PCR at 24, 48, and 72 h from the ani-
mals that were either mock or SNX-2112 treated (Fig. S5). Consis-
tent with the viremia data we show that at 24 and 48 h post
infection, viral burden in the muscle of animals treated with
SNX-2112 was significantly reduced compared to the untreated
animals (Fig. S5). However since CHIKV infection of A129 mice is
lethal, no difference in the level of viral RNA was observed between
the mock and treated animals at 72 h post infection (Fig. S5). Next,
to determine the effects of the drug treatments on inflammation,
we harvested the muscle tissues from animals from each group
and processed them for cryo-sectioning followed by Hematoxylin
and Eosin (H&E) staining. The cross-sections stained with H&E
showed substantial infiltration of mononuclear cells and consider-
able tissue damage in mock-treated infected animals (Fig. 5B).
However, muscle cross-sections from mice treated with either
HS-10 or SNX2112 showed significant reduction in both the tissue
damage and infiltration of mononuclear cells (Fig. 5B). The mea-
surement of width and thickness of the limbs of infected animals
treated with HS-10 or SNX-2112 showed that CHIKV induced
inflammation is significantly reduced compared to the untreated
animals (Figs. 5C and S6). To explore further, we measured the ser-
um concentrations of selected cytokines such as IL-6, IL-12, IFN-c,
and TNF-a, which have been associated with inflammation during
CHIKV infection (Hoarau et al., 2010). Our data showed that the
serum cytokine levels of IL-12 and IFN- c were significantly re-
duced upon treatment with HS-10 or SNX-2112 when compared
to the levels in mock-treated infected animals (Fig. 5D). On the
other hand the levels of IL-6 and TNF-a, were higher in the SNX-
2112 treated animals compared to untreated or HS-10 treatment
(Fig. 5D).
4. Discussion
Small RNA viruses such as CHIKV must rely on the host cellular
machinery to complete the viral life cycle, which includes folding
and maturation of viral proteins by host chaperones. Drugs target-
ing these host cellular factors provide an added advantage over the
conventional approach of directly targeting viral proteins that usu-
ally results in rapid acquisition of drug resistance by viruses. The
protein homeostasis in a cell is monitored by the UPR that func-
tions through the use of several signaling and chaperone proteins,
including HSP-90. Our previous study has shown the relevance of
UPR during CHIKV infection and revealed the key interplay of viral
nsP4 in modulating the host UPR machinery (Rathore et al., 2013).
HSP-90 has been shown to facilitate various aspects of virus repli-
cation during many viral infections. In this study we show that the
drugs targeting HSP-90 have profound effects on CHIKV replica-
tion. HSP-90 is a highly druggable target and to date many struc-
turally diverse pharmacological inhibitors have been identified.
The majority of these inhibitors block the ATP binding site in the
HSP-90 protein. Both the inhibitors used in this study, HS-10 and
SNX-2112, reduced CHIKV infection in a dose-dependent manner.
Indeed, real time RT-PCR amplification of viral specific nsP1 or E2
genes confirmed the effect of these inhibitors on CHIKV replication.
Treatment of cells with HS-10 or SNX-2112 showed significant
reduction of viral RNA as early as 6 h post infection (data not
shown) or protein levels at 12 h post infection suggesting the ef-
fects of HS-10 and SNX-2112 at the virus replication level. To fur-
ther understand the importance of HSP-90 during CHIKV
replication, we silenced HSP-90 mRNA using two different siRNAs
targeting different sites in the gene. Interestingly, a dramatic
reduction in the virus replication both at the RNA and protein level
was observed upon siRNA knockdown of HSP-90 gene, implicating
the critical role of HSP-90 during CHIKV replication. Next, to
understand the detailed function of HSP-90 during CHIKV replica-
tion we hypothesized that viral non-structural proteins must inter-
act with the HSP-90 protein to complete its function in the viral
replication cycle. By over-expressing each of the CHIKV non-struc-
tural proteins followed by co-immunoprecipitation or by using
confocal microscopy we showed that CHIKV nsP4 physically inter-
Fig. 3. siRNA knockdown of HSP-90 has deleterious effects on CHIKV replication. (A and B) HEK-293T cells were transfected with 100 nM of each of the siRNAs for 24 h
followed by infection with CHIKV at MOI-1 for 24 h. At 24 h post infection, cells were harvested to check the efficiency of HSP-90 knockdowns and the media supernatants
were collected for plaque assay analysis. (A) Plaque assay data shows reduced CHIKV titers in HSP-90 knockdown cells. (B and C) RT-PCR or Western blotting shows the total
mRNA or protein levels of HSP-90 in each of the specific siRNA treated groups. During HSP-90 knockdown, the levels of both viral RNA (CHIKV-E2 gene) and protein (CHIKV-E
protein) was significantly reduced as compared to the infected but non-targeted siRNA control group.
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acts with HSP-90. Similar interaction has been shown for Sindbis
virus using Flag-tagged protein and also by yeast-2-hybrid interac-
tion analysis (Bourai et al., 2012; Cristea et al., 2010). Very interest-
ingly, using our co-immunoprecipitation system we identified
CHIKV nsP3 as a novel interacting partner of HSP-90 protein. The
specificity in interactions between nsp3 and HSP-90b or nsP4
and HSP-90a shown using over-expression system as well as in
viral infection system along with the mass-spectrometry data
and siRNA knockdown experiments, suggest an integral role for
these interactions during CHIKV replication. Since HSP-90a is pre-
dominantly cytosolic (Lees-Miller and Anderson, 1989), it may help
in stabilization of CHIKV nsP4 and formation of the CHIKV replica-
tion complex (Strauss and Strauss, 1994). This notion is supported
by the siRNA knockdown of HSP-90a subunit that resulted in
greater inhibition of viral replication than targeting theHSP-90b
subunit. Overall the current data implicates a pivotal role for
HSP-90a and a possible ancillary role for HSP-90b subunits in facil-
itating CHIKV replication. However, further detailed studies are
warranted to clearly show the involvement of HSP-90a or
HSP-90b in a CHIKV replication complex. Since, the alphavirus
Fig. 4. Interactions between CHIKV nsP3 and nsP4 with HSP-90 subunits. (A) Co-localization (yellow) of CHIKV nsP3 and nsP4 proteins (green) with the HSP-90 protein (red).
GFP alone, CHIKV nsP1 and nsP2 show some degree of laser channel bleed-through (orange) with no obvious co-localization with the HSP-90 protein. For co-localization
studies, HEK-293T cells were grown on tissue culture coverslips and transfected with 1 lg of each of the GFP-fused CHIKV non-structural gene plasmids. After 24 h post-
transfection cells were fixed with 80% acetone and blocked with 2% fish gelatin overnight at 4 !C, followed by staining with HSP-90 antibody. Images were captured using a
Zeiss Confocal Microscope at 63! magnification. (B) Pull-down of GFP-fused CHIKV non-structural proteins and detection of HSP-90 shows the co-immunoprecipitation of
HSP-90 protein together with CHIKV nsP3 and nsP4 proteins. Briefly, GFP only and GFP-fused CHIKV non-structural proteins were allowed to express in HEK-293T cells for
24 h. At 24 h post transfection cells were lysed in the TNET lysis buffer containing complete protease inhibitor cocktail and co-immunoprecipitations with 2 lg of anti-GFP
antibody was carried out as described in Section 2. (C) Silver stained gel of an aliquot after GFP-nsP3 or GFP-nsP4 pull-down using GFP-TrapA beads for mass-spectrometric
analysis shows several unique host protein bands. See Section 2. (D) Graphical illustration of the number of unique peptides matched for HSP-90a or bwith GFP only, nsP3 or
nsP4 pull-downs. LC/ESI/MS/MS mass-spectrometric analysis of GFP pull-down samples revealed specific interactions between nsP4 and HSP-90a/b subunit or GFP-nsP3 and
HSP-90b subunit. GFP on its own did not show any interaction with either of the HSP-90 subunits. See Section 2. (E) Western blot showing that CHIKV-nsP3 co-
immunoprecipitates with HSP-90b and CHIKV-nsP4 co-immunoprecipitates with HSP-90a. For immunoprecipitation, HEK-293T cells were infected with CHIKV-ROSS at MOI-
1 for 24 h followed by cell lysis and co-immunoprecipitation using antibodies specific to HSP-90a or b subunits as described in Materials and methods. Un-infected cell lysate
immunoprecipitation was used as negative control and the flow-through samples after co-immunoprecipitation (F.T.) were run as infection positive controls. (F) CHIKV
replication in HEK-293T cells following siRNA knockdown of HSP-90. The figure shows that the siRNA(1) moderately silenced both HSP-90a/b subunits and significantly
reduced CHIKV replication as compared to the NT-siRNA control. However, in case of siRNA(2) only HSP-90a transcript was suppressed and not the HSP-90b, suggesting that
siRNA(2) is specific to HSP-90a subunit. The amount of viral RNA produced in presence of siRNA(2) was much significantly reduced compared to both NT-siRNA control and
siRNA(1), suggesting the critical role of HSP-90a subunit during CHIKV replication. Briefly, HEK-293T cells were transfected with 100 nM each of the siRNAs for 24 h, followed
by infection of cells with CHIKV at an MOI-1 for 24 h. At 24 h post infection, total RNA was extracted using a Trizol extraction reagent and cDNA was synthesized using oligodT
as primers. Equal amounts of cDNA (50 ng) were used for PCR amplification of CHIKV E2 (305 bp) and individual HSP-90a (2196 bp) or HSP-90b (2172 bp) subunits. Actin was
used as an input RNA control. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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replication complex is shown to involve several host proteins as re-
vealed by extensive studies in Semliki Forest virus and Sindbis
virus infections (Cristea et al., 2010; Varjak et al., 2013), the role
of HSP-90 in CHIKV replication is firmly anticipated.
Having shown the effectiveness of HSP-90 targeting drugs in
cell culture and also understanding the mechanism of HSP-90 dur-
ing CHIKV replication, we sought to evaluate the efficacy of HSP-90
inhibitor drugs in an in vivo infection model. We chose to use the
IFN-deficient animals to facilitate maximal CHIKV replication
in vivo. Both the drugs HS-10 and SNX-2112 significantly reduced
viral titers on day 2 (!48 h). However, viremia in all the animals
further increased to the levels of untreated control group on day
3 (!72 h) (data not shown), likely due to the lack of any IFN re-
sponse in these animals. Nevertheless, unlike untreated CHIKV in-
fected mice, all the animals treated with either HS-10 or SNX-2112
never developed swelling or inflammation during the course of
infection. Further studies using microscopic visualizations of
cross-sections of muscle tissues and by measuring the serum con-
centrations of pro-inflammatory cytokines (IL-6, IL-12, IFN-c, and
TNF-a) clearly demonstrated the ability of these drugs to suppress
the CHIKV-induced inflammation in mice. Increased suppression in
the levels of some of these inflammatory cytokines in our severe
immune-compromised animals could also explain why the viral ti-
ters in the treated animals were increased at day 3, aside from the
direct role of IFN on viral clearance. All in all, in this study we have
shown the importance of HSP-90 protein during CHIKV replication
and, indeed, drugs targeting HSP-90 could significantly reduce
CHIKV infection or inflammation. The precise mechanism of inter-
action and the immuno modulatory mechanisms remain to be
teased out in detail in studies that are currently underway.
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Fig. 5. In vivo testing of HSP-90 inhibitors in a lethal mouse model of CHIKV infection. (A) The serum viral load in CHIKV infected mice (SvA129, n = 6) at 48 h post infection
was significantly reduced upon treatment with HS-10 or SNX-2112. Mice (SvA129, n = 6) were infected with 100 pfu of a clinical isolate of CHIKV via the footpad route and
either mock or HS-10 or SNX-2112 treated (10 mg/kg twice a day) for 3 days. (B) H&E stained cross-section of limb muscle obtained from CHIKV infected mice (as above) at
day 3. Muscle cross-section from mock treated but infected mice showed extensive infiltration of mononuclear cells and tissue damage, which is reflective of tissue
inflammation. Treatment with either HS-10 or SNX-2112 showed dramatic reduction in tissue damage as well as mononuclear cell infiltrations. (C) Measurement of swelling
(thickness and width of the limb, as depicted in Fig. S6) in infected limbs at 48 and 72 h with or without treatment with HS-10 or SNX-2112 indicates that the drugs reduce
swelling and inflammation caused by CHIKV infection in this mouse model. (D) ELISA quantification of pro-inflammatory cytokines such as IL-6, IL-12, IFN-c, and TNF-a in the
serum of CHIKV infected/treated mice. The levels of some of these pro-inflammatory cytokines such as IL-12 and IFN-cwere significantly reduced during HS-10 or SNX-2112
treatment.
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